Logo Jan Blom
Login

Oncologisch onderzoek.nl

rss icon

Nieuws

TitelCommentaren Datum Auteur
Gerandomiseerde fase 2-studie van endocriene therapieën voor mammacarcinoom in mannen (0)2021-02-05 15:00
Associatie tussen lymfadenectomie en risico van VTE na chirurgie voor vroeg-stadium endometriumcarcinoom (0)2021-02-05 14:00
Aneuploïdie drijvende kracht bij evolutie van kanker (0)2013-11-02 20:56 dr. Jan Blom
Alternatieve VEGF-liganden bij resistentie mCRC tegen anti-VEGF therapie (0)2013-11-01 20:42 dr. Jan Blom
Atypisch leeftijds-specifiek patroon HCC in Peru (1)2013-09-03 21:05 dr. Jan Blom
AML: geen depletie maar differentiatieremming van hematopoëtische stamcellen (0)2013-08-15 20:53 dr. Jan Blom
Nieuw werkingsmechanisme PTEN ontdekt (0)2013-07-31 20:59 dr. Jan Blom

Tags

'gunstig hoog-risico'  “one thousand HER2 patients” project  (chemo)endocrine therapy  [11C] docetaxel  [18F]paclitaxel  %FT  1-day multidisciplinary clinic  1-year versus shorter duration of adjuvant trastuzumab  10-year outcomes  10-year recurrence  15-hydroxyprostaglandinedehydrogenase  15-PGDH  16-gene POLAR molecular signature  16K PRIL  16q23  1703-studie  177-Lu-dotatate  177Lu-PSMA-617 plus maintenance pembrolizumab  18F-FDG opname  18F-FDG PET CT  18F-fluciclovine-PET CT  18F-PSMA-1007 PET CT versus multiparametric MRI  1975-2016  1980-2017  1988-2017  1990 to 2017  1990-2017  1997-2016  1999-2020  1p 19q co-deleted oligodendroglioma  1p 19q codeleted oligodendroglioma  1p 19q non-co-deleted anaplastic glioma  2 induction courses of bacillus Calmette-Guèrin  20-year follow-up  20-year mortality  2000-2014  2003-2007 versus 2013-2017  2006-2016  2006-2019  2008-2018  2010-2016  2010-2019  2010-2020  2018 FIGO stage IIIC SCC of the cervix  2020 UK post-polypectomy surveillance guidelines  2021 cancer mortality prediction in EU and UK  2022 cancer mortality predictions in EU and UK  21-gen recurrence score assay  21-gene assay  21-gene assay and breast cancer mortality  21-gene assay recurrence score  21-gene expression assay  21-gene recurrence score  21-gene recurrence score and BCSS  21-gene RS  21-gene RS and response to neoadjuvant chemotherapy  21-year follow-up  25-hydroxyvitamin D  25-OH-D  25-OH-D level at time of diagnosis  27-hydroxycholesterol  28-year risk of lung cancer  3 versus 1 year adjuvant imatinib  3 versus 6 cycles CEV chemotherapy  3 versus 6 months adjuvant chemotherapy  3 vs. 6 months oxaliplatin-based adjuvant chemotherapy  3-dose COVID-19 mRNA vaccination  321GO  3D brachytherapy  3D-conformal radiotherapy for breast cancer  3DCRT  4 Gy versus 24 Gy radiotherapy  45 and Up Study  4EVER trial  4L lymph node dissection  5-ARIs  5-fraction prone APB  5-fraction whole-breast radiotherapy  5-FU  5-gene peripheral blood signature  5-year final analysis  5-year follow-up  5α-reductase inhibitors  6-MP plus methotrexate  6.5-year outcomes  70-gene ST  70-GS  8-OHdG  8-year follow-up results of CheckMate 214  90-day outcomes  90101 CREATE-studie  90YIT  91-maands update van CALGB 100104-studie  9MW2821  A M ESCC  A M NSCLC  A M STS  A R EC  A R endometrial cancer  A R thymic carcinoma  A U HER2-negative breast cancer  A-RT  A.R.R.O.W-studie  A021501 trial  A041202 study  AA versus NHW patients  AAC  AACR  AACR 2015  AACR Academy  AACR Project GENIE  AALL1731 trial  AAML0531 trial  AAML1031 phase III trial  AAML1421 study  AAP  AAP for high-risk metastatic castration-sensitive prostate cancer  AAP with or without cabazitaxel  AAP with or without SBRT  AB  AB12005 study  abatacept for prevention of acute GVHD  ABBV-383  aBC  aBC in young women  ABC study  ABC-06 trial  ABCB1 genetic variants  ABCD trial  ABCD-study  ABCSG 8A trial  ABCSG-18  ABCSG-18 study  ABCSG-52 ATHENE trial  abdominal and gluteofemoral size  abdominal radiation for childhood cancer; subsequent risk of diabetes  abdominopelvic RT for childhood cancer  abemaciclib  abemaciclib for MBC  abemaciclib plus ET  abemaciclib plus fulvestrant for MBC  Abi Race studie  abirateron  abiraterone  abiraterone acetate  abiraterone acetate and prednisolone with or without enzalutamide  abiraterone for prostate cancer  abiraterone or enzalutamide  abiraterone plus olaparib  abivertinib  ablatieve behandeling  ablation  ablative radiation therapy  ablative therapy after TACE for HCC  abnormal FIT result  abnormale peritoneale cytologie  ABOUND.2L+ study  ABP plus gemcitabine  aBS  abscopal effect  ABSI  ABSOLUTE  absolute dense area  absolute lymphocyte count  absolute lymphocyte count at diagnosis  absolute OPC risk  absoluut neutrofielgetal  ABT-199  ABTC  ABVD  ABVD versus BEACOPP-escalated  AC after NAC and resection  acalabrutinib  acalabrutinib monotherapy  acalabrutinib versus ibrutinib  ACC  accelarated aging  accelerated cellular senescence after chemotherapy  accelerated FDA approval cancer drugs  accelerated partial breast irradiation  accelerated partial breast irradiation versus whole breast irradiation  ACCENT database analysis  access to anticancer medicines for children and adolescents in Europe  ACCorD trial  accRCC  accRCC after immunotherapy  ACCRU study SC-1603  accrual  accumulation of chronic disease  ACE  ACE inhibitors versus ARBs  ACE study  ACE-LY-004 studie  acellular dermal matrix in immediate implant-based breast reconstruction  ACES  acetaminophen  achalasia  ACHIEVE study  ACHILLES TORG 1834 trial  acid-suppressive medication  acimtamig  ACIS study  ACLD  acne  ACOSOG Z0011  ACOSOG Z11102 trial  ACP statement  acquired resistance to immune checkpoint inhibitors  acquired resistance to osimertinib  acraal melanoom  ACRIN 6686-studie  acromegaly  ACS guideline for cancer survivors  aCSCC  aCSCC in kidney transplant recipients  AcSé Pembrolizumab trial  AcSé phase 2 study  AcSé study  ACT  ACT for solid tumors  ACT-2 trial  Act.In.Sarc study  aCTCL  actieve surveillance  ACTIM  actinic keratosis  actinisch carcinoom  actinium-225-lintuzumab  actinium-225-PSMA  actionability  activated osteoarthritis after immune checkpoint inhibitor treatment  active cancer  active melanoma brain metastases  ACTIVE study  active surveillance  active surveillance for low-risk prostate cancer  active surveillance for prostate cancer  actively treated cancer patients  activering immuunsysteem  ACTs  actual and surrogate Oncotype DX RS distribution  acupuncture  acupuncture for aromatase inhibitor-related joint pain  acupuncture for hot flashes  acute cancer-associated venous thromboembolism  acute care use after initiation of systemic cancer therapy  acute graft-versus-host disease  acute GVHD  acute kidney injury  acute leukemia  acute leukemie  acute lymfoblastische leukemie  acute lymphoblastic leukemia  acute myeloid leukemia  acute myeloïde leukemie  acute promyelocytische leukemie  acute promyeolcytische leukemie  acute toxic effects of the skin  acute toxicity  AD  AD-risico  ADAGIO study  adagrasib  adagrasib with or without cetuximab  ADAM-studie  ADAM8  ADAMTS-mutaties  ADAPT-IT study  ADAPT-studie  adaptive immune resistance  adaptive randomization  ADAs  ADAURA study  ADAURA trial  adavosertib  ADC as response marker  ADC versus SCC  ADCs  adding 6 months of ADT to PORT  adding durvalumab and olaparib to chemotherapy  adding gemcitabine to adjuvant chemotherapy  adding immunotherapy to first-line chemotherapy  adding MRI and biomarkers  adding OFS to tamoxifen  adding pertuzumab to first-line trastuzumab-docetaxel  adding pertuzumab to trastuzumab and chemotherapy  adding systemic to local therapy for stage I pT1aN0M0 breast cancer  addition of adjuvant capecitabine to standard chemotherapy  addition of ADT or PLNRT to PBRT  addition of androgen deprivation therapy or brachytherapy boost  addition of arsenic trioxide to frontline treatment  addition of bortezomib to first-line dexamethasone-rituximab-cyclophosphamide  addition of bortezomib to melphalan and dexamethasone  addition of BV to chemotherapy  addition of carboplatin to neoadjuvant chemotherapy  addition of celecoxib to adjuvant FOLFOX for stage III colon cancer  addition of chemotherapy to local therapy  addition of chemotherapy to neoadjuvant radiotherapy  addition of concurrent hypo-fractionated RT to failing anti-PD-1 therapy  addition of COX inhibition to immune checkpoint blockade  addition of daratumumab to lenalidomide plus dexamethasone  addition of ibrutinib to first-line bendamustine-rituximab  addition of ICIs to first-line chemotherapy  addition of lenalidomide to R-CHOP  addition of metastasis-directed therapy to systemic therapy  addition of navitoclax to ruxolitinib  addition of pembrolizumab to CRT  addition of ramucirumab to docetaxel  addition of ruxolitinib to neoadjuvant therapy  addition of systemic therapy to definitive radiotherapy  additional cytogenetic abnormalities  additional immune modulators  additional medical expenditures  ADEBAR  adebrelimab  ademanalyse  ademtest  adenocarcinoma of the esophagus and esophagogastric junction  adenocarcinoma of the small intestine  adenocarcinoom  adenoma detection rate  ADH  adherence  adherence among cancer survivors  adherence to healthy lifestyle  adherene to adjuvant endocrine therapy  adherentie  adherentie AET  adherentie orale chemotherapie  ADI-PEG20  adipose tissue distribution  adipositas  adiposity and risk of YOBC subtypes  adiposity and survival  ADIUVO trial  adjunctive ultrasonography  adjuvant 3D-CRT versus image-guided IMRT for cervical cancer  adjuvant abemaciclib plus endocrine therapy  adjuvant abemaciclib plus endocrine treatment  adjuvant AIs  adjuvant alectinib versus chemotherapy  adjuvant anastrazole for 10 or 5 years  adjuvant and concurrent TMZ  adjuvant anlotinib  adjuvant anlotinib versus placebo  adjuvant anthracyclines  adjuvant anti-PD-1 therapy  adjuvant aromatase inhibitor  adjuvant aspirin  adjuvant aspirin for cancer  adjuvant atezolizumab after adjuvant chemotherapy  adjuvant atezolizumab plus bevacizumab  adjuvant bevacizumab  adjuvant camrelizumab  adjuvant capecitabine  adjuvant capecitabine following concurrent chemoradiotherapy  adjuvant carboplatin plus taxanes versus EC followed by taxanes  adjuvant care  adjuvant chemotherapy  adjuvant chemotherapy after cytoreductive surgery  adjuvant chemotherapy after pCR to neoadjuvant CRT  adjuvant chemotherapy after preoperative FOLFIRINOX  adjuvant chemotherapy after RNU  adjuvant chemotherapy for breast cancer  adjuvant chemotherapy for breast cancer in older women  adjuvant chemotherapy for prevention of colorectal liver metastasis  adjuvant chemotherapy regimens  adjuvant chemotherapy with or without radiotherapy  adjuvant CRT  adjuvant CRT versus RT  adjuvant Cs-131 brachytherapy  adjuvant CT after neoadjuvant ET  adjuvant dabrafenib plus trametinib  adjuvant dabrafenib plus trametinib for stage III melanoma  adjuvant dabrafenib plus trametinib versus placebo for BRAF V600-mutated stage III melanoma  adjuvant dabrafenib-trametinib versus anti-PD-1  adjuvant denosumab  adjuvant docetaxel-based chemotherapy for early breast cancer  adjuvant EGFR-TKIs  adjuvant endocrine therapy  adjuvant endocrine therapy in premenopausal breast cancer  adjuvant enzalutamide  adjuvant EP versus EC-P  adjuvant erlotinib for early-stage NSCLC  adjuvant erlotinib versus vinorelbine-cisplatin  adjuvant ET ± CT  adjuvant ET with or without abemaciclib  adjuvant etoposide plus cisplatin  adjuvant everolimus  adjuvant exemestane with OFS in premenopausal breast cancer  adjuvant fluoropyrimidine-oxaliplatin for early-onset CRC  adjuvant FOLFIRINOX versus gemcitabine  adjuvant FOLFOX FLOX  adjuvant GC or CCRT  adjuvant gefitinib versus chemotherapy  adjuvant GemCap versus gemcitabine  adjuvant gemcitabine sensitivity of resectable PDAC  adjuvant goserelin and tamoxifen  adjuvant icotinib  adjuvant icotinib versus chemotherapy  adjuvant imatinib  adjuvant ipilimumab  adjuvant ipilimumab versus IFNα-2b  adjuvant metronomic capecitabine  adjuvant mitotane  adjuvant multimodality therapy  adjuvant nab-paclitaxel plus gemcitabine  adjuvant neratinib  adjuvant nivolumab  adjuvant nivolumab after salvage resection  adjuvant nivolumab plus ipilimumab versus placebo  adjuvant nivolumab versus ipilimumab  adjuvant nivolumab versus placebo  adjuvant nivolumab vs ipilimumab  adjuvant olaparib  adjuvant olaparib for BRCA1 2-mutated breast cancer  adjuvant osimertinib  adjuvant paclitaxel and carboplatin versus CEF-T  adjuvant palbociclib  adjuvant pembrolizumab  adjuvant pemetrexed plus cisplatin versus vinorelbine plus cisplatin  adjuvant PemP versus NP  adjuvant pertuzumab  adjuvant phosphoinositide 3-kinase inhibitors  adjuvant platinum-based chemotherapy  adjuvant radiation  adjuvant radiation therapy  adjuvant radiotherapy  adjuvant RT  adjuvant RT for breast cancer  adjuvant RT for EEC  adjuvant S-1  adjuvant S-1 plus endocrine therapy  adjuvant S-1 with or without docetaxel  adjuvant SCRT versus CCRT or RT alone  adjuvant sintilimab  adjuvant sorafenib  adjuvant TACE after hepatectomy  adjuvant tamoxifen adherence  adjuvant tamoxifen for HR-positive early breast cancer  adjuvant tamoxifen or AI for breast cancer  adjuvant therapies  adjuvant therapy  adjuvant TLPLDC vaccine  adjuvant TMZ with or without IFNα  adjuvant transarterial FOLFOX infusion  adjuvant trastuzumab  adjuvant trastuzumab duration  adjuvant trastuzumab for HER2-positive breast cancer  adjuvant trastuzumab with or without chemotherapy  adjuvant treatment  adjuvant treatment for breast cancer  adjuvant treatment for stage III melanoma  adjuvant treatments  adjuvant versus early salvage radiotherapy  adjuvant versus early salvage radiotherapy after prostatectomy for prostate cancer  adjuvant versus salvage radiotherapy  adjuvant weekly docetaxel plus radiotherapy  adjuvant XT-XEC versus T-FEC  ADJUVANT-studie  adjuvante chemotherapie  adjuvante CRT  adjuvante HER2-remming  adjuvante hormoontherapie  adjuvante systemische therapie  adjvant trastuzumab with or without chemotherapy  adjvuant chemotherapy versus chemoradiotherapy  ADMEC-O trial  ADMIRAL study  ADMIRAL trial  ADNEX  ado-trastuzumab emtansine  adolescent and young adult  adolescent and young adult cancer survivors  adolescent and young adult HL  adolescent overweigh or obesity  adolescents and young adults  adoptive T-cell therapy  ADORE trial  ADR  ADR and postcolonoscopy CRC risk  ADR improvement  ADRD  adrebrelimab  adrenal metastases  adrenocortical carcinoma  adrenocortical carcinoma cohort  ADRIATIC trial  ADRRAD study  ADRs  ADT  ADT for nmPCa  ADT for prostate cancer  ADT for prostate cancer in Canada  ADT plus pelvic RT plus radium-223  ADT risk of depression  ADT with or without docetaxel  adult alternative donor HCT  adult AML  adult cancers  adult childhood cancer survivors  adult chilhood cancer survivors  adult craniopharyngioma  adult glioma  adult glioma risk  adult glioma with LM  adult height  adult osteosarcoma patients  adult survivors of childhood ALL  adult survivors of childhood cancer  adult survivors of childhood cancer diagnosed between 1970 and 1999  adult survivors of neuroblastoma  adult T-cell leukemia lymphoma  adult type granulosa cell tumors of the ovary  adult weight gain  adults and children with cancer  advance uterine leiomyosarcoma  advanced acral melanoma  advanced adrenocortical carcinoma  advanced ALK-positive NSCLC  advanced ALK-positive or ROS1-positive NSCLC  advanced anal cancer  advanced anal squamous cell carcinoma  advanced anthracycline-naive sarcoma  advanced B-cell malignancies  advanced B-RAF- or K-RAS N-RAS-mutated solid tumors  advanced BCC  advanced biliary tract cancer  advanced biliary tract cancers  advanced BRAF V600-mutant melanoma  advanced BRAF-mutant melanoma  advanced BRAF-mutated melanoma  advanced BRAF-V600 mutated melanoma  advanced breast cancer  advanced BTC  advanced cancer  advanced cancer patients  advanced cancer-related chronic nausea and vomiting  advanced cancers  advanced carcinoid or pancreatic neuroendocrine tumor  advanced ccRCC  advanced cervical cancer  advanced cHL  advanced chondrosarcoma  advanced chordoma  advanced CLDN18.2 positive gastric cancer  advanced clear cell RCC  advanced colorectal liver metastases  advanced colorectal neoplasms at least ten years after negative coloscopy  advanced CRPC  advanced cutaneous squamous cell carcinoma  advanced dMMR solid tumors  advanced EGA  advanced EGFR T790M mutated non-small cell lung cancer  advanced EGFR-mutant NSCLC  advanced EGFR-mutated or ALK-rearranged NSCLC  advanced EGFR-positive non-squamous NSCLC  advanced endometrial cancer  advanced endometrial carcinoma  advanced ENKTL  advanced epithelial ovarian cancer  advanced epithelioid sarcoma with loss of INI1 SMARCB1  advanced ESCC  advanced esophageal cancer  advanced esophageal squamous cell carcinoma  advanced esophagogastric cancer  advanced extraskeletal myxoid chondrosarcoma  advanced FL  advanced G GEJ adenocarcinoma  advanced G GEJ cancer  advanced gastric cancer  advanced gastric or colorectal cancer  advanced gastric or gastroesophageal junction adenocarcinoma  advanced gastric or gastroesophageal junction and other solid tumors  advanced gastric or gastroesophageal junction cancer  advanced gastroenteropancreatic neuroendocrine carcinoma  advanced gastroesophageal cancer  advanced gastrointestinal cancer  advanced gastrointestinal stromal tumors  advanced germ cell tumors  advanced GIST  advanced GIST with heterogenous KIT PDGFRA mutations  advanced GIST with KIT or PDGFRA mutation  advanced HCC  advanced hepatocellu;ar carcinoma  advanced hepatocellular carcinoma  advanced hepatocellular carcinoma after progression on anti-PD-(L)1  advanced hepatocellular carcinoma in Asian patients  advanced hepatocellular carcinoma with MET overexpression  advanced HER2-negative breast cancer  advanced HER2-negative breast cancer in germline BRCA-mutated patients  advanced HER2-negative gastric or gastro-esophageal junction adenocarcinoma  advanced HER2-positive breast cancer  advanced HL with large nodal mass  advanced HN CSCC  advanced HNSCC  advanced Hodgkin lymphoma  advanced HR-positive breast cancer  advanced HR+ HER2- BC or TNBC  advanced IDH1-mutant cholangiocarcinoma  advanced indolent lymphoma  advanced leiomyosarcoma  advanced leiomyosarcoma liposarcoma  advanced liposarcoma or leiomyosarcoma  advanced liver cancer  advanced lung adenocarcinoma  advanced lung cancer  advanced malignancy  advanced malignant mesothelioma  advanced MDS in elderly patients  advanced melanoma  advanced melanoma in patients not represented in phase 3 trials  advanced melanoma with HR pathway gene mutations  advanced Merkel cell carcinoma  advanced metastatic esophageal squamous cell carcinoma  advanced metastatic medullary thyroid carcinoma  advanced microsatellite instability-high cancers  advanced microsatellite stable colorectal cancer  advanced MPM  advanced mucosal melanoma  advanced nccRCC  advanced non-clear cell RCC  advanced non-clear cell renal cell carcinoma  advanced non-clear-cell RCC  advanced non-small cell lung cancer  advanced non-small cell lung cancer in older adults  advanced non-small cell lung cancer with EGFR exon 20 insertion mutations  advanced non-small cell lung cancer with PD-L1<50% in elderly patients  advanced non-squamous non-small cell lung cancer  advanced non-squamous NSCLC  advanced noncolorectal gastrointestinal cancer  advanced nonsquamous non-small cell lung cancer  advanced nonsquamous NSCLC  advanced nonsquamous NSCLC in elderly patients  advanced NSCLC  advanced NSCLC harboring EGFR exon 20 insertion mutations or common EGFR mutations  advanced NSCLC harboring KRAS G12C mutation  advanced NSCLC in special populations  advanced NSCLC or CRC  advanced NSCLC with EGFR ex19del or L858R alterations  advanced NSCLC with high blood-based TMB  advanced NSCLC with T790M mutated EGFR  advanced or metaastatic colorectal cancer  advanced or metastatic colorectal cancer  advanced or metastatic CRC  advanced or metastatic esophageal squamous cell carcinoma  advanced or metastatic RCC  advanced or metastatic thymic carcinoma  advanced or metastatic urothelial carcinoma  advanced or recurrent endometrial cancer  advanced or recurrent endometrioid endometrial cancer  advanced or refractory desmoid tumors  advanced ovarian cancer  advanced ovarian cancer in patients with BRCA-mutation  advanced ovarian carcinoma  advanced ovarian tubal-peritoneal cancer  advanced ovarium neoplasms  advanced pancreas cancer  advanced pancreatic cancer  advanced pancreatic neuroendocrine tumor  advanced papillary renal cell carcinoma  advanced PDAC  advanced penile cancer  advanced phyllodes tumor of the breast  advanced prostate cancer  advanced pulmonary sarcomatoid carcinoma  advanced rare cancers  advanced rare genitourinary malignancies  advanced RCC  advanced recurrent ovarian cancer  advanced recurrent type B3 thymoma or thymic carcinoma  advanced refractory biliary tract cancer  advanced refractory CRC  advanced refractory esophageal squamous cell carcinoma  advanced renal cell carcinoma  advanced renal-cell carcinoma  advanced RET-mutant medullary thryoid cancer  advanced ROS1 fusion-positive non-small cell lung cancer  advanced salivary gland cancer  advanced salivary gland carcinoma  advanced sarcoma  advanced sarcomas  advanced soft tissue and bone sarcomas  advanced soft-tissue sarcoma  advanced solid cancer  advanced solid cancer in trial-ineligible patients  advanced solid cancers  advanced solid HER2-positive tumors  advanced solid KRAS G12C-mutated tumors  advanced solid malignancies  advanced solid tumors  advanced solid tumors or tenosynovial giant cell tumor  advanced solid tumors with KRAS-G12C mutation  advanced solid tumors with KRAS-G12C mutations  advanced squamous cell carcinoma of the anus  advanced squamous non-small cell lung cancer  advanced squamous non-small-cell lung cancer  advanced squamous NSCLC  advanced stage as end point  advanced stage EOC  advanced stage iNHL  advanced stage mantle cell lymphoma  advanced stage serous borderline ovarian tumor  advanced STS  advanced systemic mastocytosis  advanced thymic carcinoma  advanced thymoma  advanced thyroid cancer  advanced TNBC  advanced triple-negative breast cancer  advanced tumors  advanced UC  advanced urological cancers with pre-existing autoimmune disorders  advanced urothelial cancer  advanced urothelial carcinoma  advanced urothelial carcinoma with FGFR1 3 expression  advanced USC with HER2 overexpression  advanced wild-type BRAF melanoma  advanced-stage cancer  advanced-stage Hodgkin lymphoma  advanced-stage Hodgkin’s lymphoma  advanced-stage melanoma  advanced-stage orophryngeal squamous cell carcinoma  Adventist cohort compared with a US Census popiulation  adverse events  adverse events of oral azicitidine  adverse mental health outcomes  adverse pediatric outcomes  ADVL1412 study  AEG  AEGEAN trial  AENEAS trial  aEOC  AERAS trial  aerobe inspanning  aerobic and muscle-strengthening activity combinations  aerobic and resistance exercise  aerobic exercise during chemotherapy  aerobic physical activity and depression among cancer patients  AET adherence  Af  afami-cel  afatinib  afatinib versus methotrexaat  AFFIRM  AFFIRM-studie  aflibercept  AFP  AFT-01  AFUGEM GERCOR  aG GEJ adenocarcinoma  AG221-AML-005 trial  AGC  AGC with or without liver metastases  age  age at diagnosis  age at diagnosis of colorectal cancer  age at first breast cancer diagnosis  age at initiation of breast cancer screening  age at menarche  age at onset of lung adenocarcinoma  age at ovarian cancer onset  age dependence of modern clinical risk groups  age disparities  age-related disease risks in youger versus older B-NHL survivors  age-specific BMI  agent orange  Agent Orange exposure  AGES-Reykjavik study  aggressive B-cell lymphoma  aggressive lymphoma  aggressive prostate cancer  aggressive versus non-aggressive prostate cancer  AGILE study  AGITG MAX study  AGO-OVAR 16-studie  AGOC  agressieve fibromatose  agressive squamous cell carcinoma  AGRICAN-studie  aGVHD  AH use  aHCC  aHCC in Japan  aHCC refractory to hepatic arterial infusion chemotherapy  AHELP study  AHEP0731 study  AHL2011 study  aHNSCC  AHOD1221 study  AHOD1331 trial  AI  AI with or without palbociclib  AI-induced arthralgia  AI-therapie  AIC  AIDI  AIM trial  AIN3  AIO INTEGA trial  AIO-FLOT3 studie  air pollution and breast cancer incidence  airport-related ultrafine particles  AIs  AIs for HR-positive breast cancer  AIT for EBC in postmenopausal patients  AJCC 8th edition stage III melanoma  AJCC CSM-8  AJCC eighth edition staging  AK treatments  AK105-302  AL amyloidosis  AL-amyloïdose  ALBI  albumin-bilirubin grade  ALCANZA-studie  ALCL  aLCNEC  alcohol  alcohol and tobacco consumption  alcohol consumption  alcohol consumption and cancer risk in Australia  alcohol intake  alcoholconsumptie  alcoholgebruik  ALCYONE  ALCYONE trial OS analysis  ALCYONE-studie  aldoxorubicine  alectinib  alectinib for crizotinib-resistant ALK-positive NSCLC  alectinib versus crizotinib  ALEK-B trial  ALEX study  ALEX study PRO analysis  ALEX-studie  ALEXANDRA IMpassion030  ALFA-0701 trial  ALFA0701 trial  ALGONQUIN trial  ALiCCS studie  ALiCCS study  ALiCCS-studie  ALICE study  ALINA trial  alisertib  alisertib plus induction chemotherapy  alisertib with or without fulvestrant  ALK inhibitors  ALK inhibitors for NSCLC with ALK-rearrangement  ALK positive advanced NSCLC  ALK rearranged or ROS1 rearranged NSCLC  ALK-positive advanced NSCLC  ALK-positive ALCL  ALK-positive ALCL in pediatric patients  ALK-positive non-small cell lung cancer  ALK-positive NSCLC  ALK-rearranged nonlung solid tumors  ALK-rearranged NSCLC  ALK-remmer  ALK(+) and ROS1(+) NSCLC  ALK1  alkaline phosphatase  ALKi  alkylating chemotherapy  alkylating CRT versus RT  alkylerende chemotherapie  ALL  ALL in children  ALL in children and AYAs  all-cause and cancer-specific death  all-cause and cancer-specific mortality  all-cause and cardiovascular disease mortality  all-cause mortality  ALLCAR study  Alliance A011502  Alliance A071401 trial  Alliance A091401-studie  Alliance N0572-studie  ALLIVE-studie  ALLO-501 or cema-cel  allo-BMT  allo-HSCT  allo-HST  allogene hematopoïetische stamceltransplantatie  allogene stamceltransplantatie  allogeneic BCMA-targeting CAR T cells  allogeneic blood or marrow transplantation  allogeneic BMT in childhood  allogeneic hematopietic cell transplantation  allogeneic hematopoietic cell transplant  allogeneic hematopoietic cell transplantation  allogeneic hematopoietic cell transplantation outcomes  allogeneic HSCT  allogeneic stem cell transplantation  allogeneic stem cell transplantation for AML or ALL  allogeneic stem cell transplantion  allogeneic transplantation  allogeneic transplantation for myelodysplastic syndrome  allogenic transplant for NHL  alloHCT  alloHCT after PD-1 blockade  alloHCT for AML not in remission  alloHCT for early-stage leukemia or MDS  alloHCT for myelofibrosis  alloHCT recipients  alloHCT versus standard consolidation chemotherapy  alloHCT with CB versus MMUD with PTCy  alloHCT without first achieving complete remission  alloHSCT  alloHSCT for myelofibrosis  alloHSCT for pediatric ALL  alloHSCT in women  alloHSCT recipients  alloSCT  allostatic load  almonertinib  aLMS  ALND  alopecie  ALP and LDH prognostic potential  ALPACA trial  alpelisib  alpelisib plus fulvestrant  alpelisib plus nab-paclitaxel  alpelisib plus olaparib  alpelisib-associated hyperglycemia  alpha-fetoprotein  alpha-lipoic acid  ALPHA2 ALPHA clinical studies  ALPINE trial  ALTA-1L  ALTA-1L second interim analysis  ALTA-studie  ALTER 01031 study  ALTER 0303 study  ALTER-H-003 trial  ALTER-S006 trial  alternative cisplatin schedule  ALTERNATIVE study updated results  ALTERNATIVE-studie  ALTTO study sub-analysis  ALUR-studie  alveolar soft-part sarcoma  alvleesklierkanker  ALYCANTE trial  AM  Amara West  AMAROS trial  AMATERASU trial subgroup analysis  AMBASSADOR trial  ambient air pollution  ambulatory function and mortality among cancer survivors  aMCC  amcenestrant  AMD  AMEERA-3 randomized phase 2 trial  American Association for Cancer Research  American Cancer Society nutriton and physical activity guidelines  American Cancer Society richtljnen  AMG 337  AMH  amivantamab  amivantamab plus lazertinib  AML  AML and ALL in AYAs  AML in adult patients  AML in elderly nonfit patients  AML in elderly patients  AML in first relapse  AML in older adults  AML in patients aged 70 years and older  AML in remission  AML MDS  AML MDS in older patients  AML or high-risk MDS  AML or MDS  AML survival  AML with FLT3-ITD mutation  AML with genomic evidence of residual disease  AML with internal tandem duplication of Fms-like tyrosine kinase 3  AML-relapse after allo-HCT  AML-risico  AML17-studie  AML19 trial  AMLSG 09-09 study  aMM  AMPECT study  AMPK variant  AMPK-route  AMPLCaRE study  AMPLE-2 study  AMPLIFY trial  AMR  amrubicine  anal cancer  analgesic use  analgesics  analgetica  analyse AZURE-studie  analyse binnen PICCOLO-studie  analyse CheckMate 205-studie  analyse COG AAML 1031  analyse CROSS-studie  analyse fase 3-studie CALGB 40503  analyse fase 3-studie GeparQuinto  analyse MA.27-studie  analyse NORDIC-VII studie  analyse STAMPEDE-studie  Analyse van CheckMate 066 en CheckMate 067  analyse van fase 3-studie CAO ARO AIO-04  analyse van STAMPEDE-studie  anamorelin  anaplastic astrocytoma or glioblastoma  anaplastic large-cell lymphoma  anaplastic thyroid carcinoma  anaplastisch grootcellig lymfoom  anaplastisch schildkliercarcinoom  anastrazole with or without fulvestrant  anastrozol  anastrozole  anatomic locations of KCs  anatomic stage  and HIV infection  and rituximab  and time already survived  and triennial mammography screening  androgeendeprivatie  androgeenreceptor  androgeensuppressie  androgen concentrations in prepubertal girls  androgen deprivation for FIR versus UIR prostate cancer  androgen deprivation therapy  androgen deprivation therapy for prostate cancer  androgen receptor expression  androgen receptor signaling inhibitor  androgen-ablative therapy for advanced prostate cancer  aNENs  anesthesia  anesthesiologist volume  anetumab ravtansine  aneuploïdie  ANG1005  angiogenese  Angiome  angiosarcoma  angiosarcomen  angiosarcoom  angiotensin converting enzyme inhibitors  angiotensin II receptor blockers  ANGPT2  ANGPT2 and NOS3 polymorphisms  ANHL12P1 trial  animal and plant protein intake  anlotinib  anlotinib combined with PD-1 PD-L1 inhibitors  anlotinib maintenance therapy  anlotinib plus PD-1 inhibitor  anlotinib plus penpulimab  anlotinib plus temozolomide  anlotinib plus TQB2450  anlotinib versus placebo as third- or further-line treatment  anlotinib versus sunitinib  ANNIE study  ANNOUNCE trial  anoikis-resistentie  anorexia nervosa  anorexie  anosmin-1  ANS  aNSCLC  aNSCLC harboring c-Metex14 alterations  aNSCLC in elderly patients  aNSCLC in three countries  aNSCLC with CNS metastases  aNSCLC with EGFR ex19del or ex21 L858R  aNSCLC with EGFR exon 20 insertions  aNSCLC with EGFR exon 20ins  aNSCLC with KRAS G12C mutation  aNSCLC with PD-L1 ≥ 1%  aNSCLC with PD-L1 at least 50%  aNSCLC with PD-L1 TPS ≥ 1%  aNSLCL  ansqNSCLC  antacida  anterior temporal lobotomy  anthracycline chemotherapie  anthracyclines  anthracyclines for breast cancer  anthracyclines for breast cancer or lymphoma  anthracyclines for childhood cancer  anthracylcines  anthracyline-containing and taxane-containing chemotherapy  anti GPRC5D CAR T cell therapy  anti-angiogene middelen  anti-angiogenese  anti-angiogenic therapy  anti-B-cell maturation antigen BiTE molecule AMG 420  anti-BCMA GPRC5D bispecific CAR T cell therapy  anti-CD19 and anti-BCMA CAR T-cells  anti-CD19 CAR T-cell therapy  anti-CD19 CAR T-cells  anti-CD22 CAR T-cells  anti-CD30 CAR-T cell therapy  anti-CD7 CAR T cells with anti-CD7 PEBL  anti-CLL based CAR-T therapy  anti-CTLA-4 plus anti-PD-1 blockade  anti-diarrheal strategies  anti-EGFR  anti-EGFR rechallenge therapy  anti-EGFR therapy for metastatic colorectal cancer  anti-GPRC5D CAR-T after anti-BCMA CAR-T  anti-HER2 therapy  anti-HER2 therapy for MBC  anti-Hu  anti-humaan T-lymfocyt immunoglobuline  anti-inflammatory mouthwashes  anti-PD-(L)1 for advanced NSCLC  anti-PD-(L)1 monotherapy resistant metastatic melanoma  anti-PD-(L)1 therapy  anti-PD-(L)1 treatment for NSCLC  anti-PD-(L)1 with or without chemotherapy  anti-PD-1  anti-PD-1 antibodies plus RT  anti-PD-1 consolidation  anti-PD-1 immunotherapy for MSS solid tumors  anti-PD-1 L1  anti-PD-1 monotherapy  anti-PD-1 PD-L1 based regimes in advanced solid tumors  anti-PD-1 plus CRT  anti-PD-1 related pneumonitis  anti-PD-1 resistant advanced melanoma  anti-PD-1 therapy  anti-PD-1 therapy for advanced melanoma  anti-PD-1 therapy for solid tumors  anti-PD-1 therapy with or without chemotherapy  anti-PD-1 vs anti-PD-L1 for cancer  anti-PD1 with or without anti-CTLA4  anti-programmed cell death 1 therapy  Anti-T-lymfocten globuline  anti-thymocyte globulin  anti-TNF for steroid refractory toxicity  anti-VEGF therapie  anti-VGEF therapie  antiangiogenese  antiangiogenic therapy  antibiotic use and risk of colorectal cancer  antibiotics  antibiotics before immune checkpoint inhibitors  antibiotics use and subsequent risk of colorectal cancer  antibodies  antibody drug conjugate MRG003  antibody drug conjugates  antibody-drug-conjugates  anticancer immune checkpoint inhibitors  anticoagulants and breast cancer survival  anticoagulatie  antidepressant use and mortality  antihypertensive drugs  antiogeneseresistentie  antioxidant supplements  antioxidanten  antioxidants  antithymocyte globulin  antithymocytenglobuline  antitumor-werkzaamheid van bisfosfonaten  antiviral treatment  anus squameus celcarcinoom  anuscarcinoom  anuskanker  anxiety and depression symptoms  AO AOA  aOC  aOC or aTNBC  AOM  AON  AOTs  aPaC  APACT trial  apalutamide  apalutamide for nmCRPC  apalutamide versus placebo for nmCRPC  aPASC  apatinib  apatinib after failure of chemotherapy  apatinib plus oral etoposide  apatinib plus pemetrexed-platinum chemotherapy  APBI versus WBI  aPBSCT for HL  aPC  aPDAC  aPDAC progressing on rucaparib  APHINITY study post-hoc analysis  APHINITY trial 6-year follow-up  APHINITY-studie  API-AI  APICAL-RST trial  apixaban  apixaban versus aspirin  APL  APL in older patients  aPM  apocrine breast cancer  APOLLO study  APOLLO trial  apoptose  appendiceal adenocarcinoma  appendiceal cancer  appendiceal neuroendocrine tumors  appendixcarcinoom  appropriate use criteria for radiation therapy  APPROVE trial  aPRCC  aprepitant  aPSC  APT trial  APT trial 10-year analysis  AQUILA trial  AR  AR expression in breast cancer  AR-expression  AR-positive advanced breast cancer  AR-positive triple-negative breast cancer  AR-remming  AR-V7  ARAMIS study  ARANOTE trial  ARASENS trial  ARCAD  ARCAD database individual patients analysis  ARCAD-NADEGE cohort study  ARCADIA trial  ARCAGE-studie  aRCC  aRCC progressing after IO therapy  aRCC with brain metastases  ARCHER 1050  ARCHER 1050-studie  ARCHES secondary analysis  ARCHES study  ARCTIC study  ARD in breast or head and neck cancer patients  ARET0321 trial  ARI0002h  ARIC-studie  ARIEL3-studie  ARIEL4 study  ARIES trial  ARIs  ARIs for prostate cancer  Aristotle study  ARMANI trial  ARMD  armodafinil for CRF  aRMS  aromatase inhibitor-resistant HR+ HER2- ABC  aromatase inhibitors  aromatase inhibitors versus tamoxifen  aromatase inibitor-induced adverse effects  aromataseremmer  aromataseremmers  ARON-1 study  ARPIs  array comparative genomic hybridization  ARROW study  ARROW trial  ARRY-380  arseentrioxide  arsenic trioxide plus ATRA  arsenicum  ARST1321 study  ART  ART versus ALND after positive SN biopsy  ART-gerichte behandeling  arterial chemotherapy versus sorafenib  arterial thromboembolism preceding cancer diagnosis  artificial intelligence  artificial intelligence algorithms  ARTIS study  ARTIST 2 study  ARTIST 2 trial  ARTO trial  artralgie  ARTSCAN III study  ARv567es  AS for PCa  AS04-adjuvanted HPV-16 18 vaccine  ASAP trial  ASCC  ASCEMBL study  ASCEND study  ASCEND-2  ASCEND-3 final results  ASCEND-5  ASCEND-5 studie  ASCENT final results  ASCENT study  ASCENT trial  ASCERTAIN trial  asciminib  asciminib versus bosutinib  ascites  ASCO  ASCO 2016  ASCT  ASCT versus maintenance chemotherapy consolidation  ASH 2015  Ashkenazi Jewish ancestry  Asian versus non-Asian patients  ASILs  asparaginase-associated pancreatitis  ASPECCT  AspECT study  ASPEN study  ASPIRE-studie  aspirin  aspirin NSAID use  aspirin use  aspirin use and CRC incidence according to lifestyle risk  aspirin use and CRC risk in older adults  aspirin use and ovarian cancer risk  aspirine  aspirine NSAIDs  aspirineprofylaxe  ASPREE study  ASPREE trial  ASPS  asqNSCLC  assessment of lung cancer risk  assessment of screening mammograms  Assisted reproduction  assisted reproductive technologies after breast cancer  assisted reproductive technology  associatie diabetes en kanker  association between age and survival trends after adoption of immunotherapy  association between alcohol consumption and BTC risk  association between Alzheimer disease and cancer  association between meningioma and breast cancer  association between PFS and QOL  association between prediabetes and breast cancer  association between previous infection and cancer risk  association between weight change and breast cancer prognosis  association of adjuvant chemotherapy with overall survival  association of age with efficacy of immunotherapy  association of age with TRAEs and survival  association of BMI with efficacy of ICIs  association of BMI with outcomes  association of BMI with safety profile of nivolumab with or without ipilimumab  association of breast cancer risk with type 2 diabetes and metformin use  association of coffee intake and survival  association of ctDNA and CTCs after NAC with disease recurrence  association of cutaneous toxic effects with outcomes  association of depression and anxiety with mortality  association of diabetes with risk of SAEs during chemotherapy  association of DM with first-line pembrolizumab efficacy  association of endothelial dysfunction and thromboembolism  association of ethnicity and prostate cancer after raised PSA test result  association of extent of tumor resection and survival  association of familial burden of cancer with outcomes of immunotherapy  association of fatigue and outcomes in advanced cancer  association of fiber intake and breast cancer incidence  association of gut microbiome and response to anti-PD-1 therapy  association of hearing impairment with neurocognition  association of height and survival of resectable lung cancer  association of HPV status with survival  association of intensity and duration of alcohol use and risk of head and neck cancer  association of intrinsic subtype with PFS  association of marital status with cancer-specific survival  association of measurable residual disease with DFS and OS  association of MHT with breast cancer subtypes  association of molecular characteristics with OS benefit  association of multifocality with prognosis  association of nativity with survival  association of neoadjuvant chemotherapy with survival  association of neuronal autoantibodies and cognitive impairment  association of obesity with outcomes of breast cancer subtypes  association of obesity with survival outcomes in patients with cancer  association of obesity with toxicity  association of pCR with outcomes in breast cancer  association of PD-L1 expression status with efficacy of PD-1 PD-L1 inhibitors  association of performance status with survival  association of periodontal disease and edentulism with cancer mortality  association of physical activity with cognitive function  association of physical activity with survival  Association of postmenopausal overweight obesitas and subtype-specific breast cancer risk  association of PR status with RS and survival  association of prediagnosis smoking cessation and overall survival  association of preoperative chemosensitivity with survival  association of procedure volume and in-house mortality  association of race and socioeconomic factors with OS  association of recent oncologic treatment with mortality  association of residual DCIS after NAC with breast cancer recurrence  association of response and event-free survival with overall survival  association of RRSO with breast cancer risk  association of sarcopenia with short-term outcomes  association of sedentary behaviors with survival  association of time-to-treatment initiation and survival  association of tumor site with prognosis  association of use of PET-CT with mortality  association with breakthrough infections and complications in cancer patients  association with cancer  association with cancer outcomes  association with cancer risk  association with hepatic malignancy  association with long-term survival  association with lung cancer risk  association with management  association with multiple diseases  association with other cancers  association with other types of tumors  association with rate of treatment for recurrence  association with relapse  association with site-specific cancers  association with survival  association with type of treatment  associations between circulating eosinophils and cancer risk  associations of irAEs with clinical outcomes  associations with mortality  associations with outcomes  associations with prostate cancer risk  associations with season of birth  AST  astma  ASTRO 2015  ASTRO 2016  ASTRRA trial  ASTRUM-005 trial  aSTS  asunercept  ASXL1 mutations  asymptomatic brain metastases  asymptomatic early-stage CLL  asymptomatic mCRPC  asymptomatic WM  ASyMS  AT RT  ATBC Study  ATC  ATC of TILs  ATE  ATEMPT trial  ATEMPT trial 5-year results  atezo-bev  atezo-bev for HCC  Atezo-Brain trial  atezolimuab plus bevacizumab  atezolizumab  atezolizumab for aHCC  atezolizumab for NSCLC  atezolizumab for urothelial carcinoma  atezolizumab plus bevacizumab  atezolizumab plus carboplatin  atezolizumab plus chemotherapy  atezolizumab plus chemotherapy with or without bevacizumab  atezolizumab plus nab-paclitaxel  atezolizumab plus targeted therapy  atezolizumab versus chemotherapy  atezolizumab versus durvalumab  atezolizumab versus nivolumab versus docetaxel  atezolizumab with or without bevacizumab  atezolizumab with or without CMB305  atezolizumab with or without human recombinant IL-7  atezolizumab-bevacizumab for HCC  atezolizumab-vemurafenib-cobimetinib  AtezoTRIBE trial  ATG  ATHENA study  ATHENA-MONO trial  atherosclerosis  ATL  ATLANTIC-studie  ATLANTIS trial  ATLAS trial  ATM  ATM gene PVs  ATM mutations in cancer  aTNBC  ATOM study  ATOM trial  ATOMIC-Meso trial  atopic dermatitis  atopic eczema and cancer risk  atopie  ATR-blockers  atrial fibrillation  atriumfibrilleren  ATRTs  AtTEnd trial  ATTRACTION-2 studie  ATTRACTION-3 study  ATTRACTION-4 trial  attrition between lines of therapy  atypical breast lesions  atypical bronchopulmonary carcinoids  atypical chronic myeloid leukemia  atypical squamous cell of undetermined signifance  atypical squamous cells of undetermined significance  atypisch meningioom  atypische ductale hyperplasie  atypische hyperplasie  Atypische teratoïde rhabdoïde tumor  atypische teratoïde rhabdoïde tumoren  aUC  AUGMENT study  AUGMENT-101  aumolertinib  AURA  AURA studies  AURA-studie  AURA-substudie  AURA2  AURA3  AURA3 overall survival analysis  AURA3 study  AURA3-studie  AURELIA  AURELIA-studie  AURELIA-substudie  AURIGA study  Aurora A  aurora kinase A inhibition  Australian Melanoma Family Study  auto-immuunziekten  autofagie  autoHCT  autoHSCT  autoimmune disease  autologe stamceltransplantatie  autologous dendritic cell therapy  autologous stem cell transplantation  automated classification  automated opt-out versus opt-in outreach strategy  autoSCT after complete response to first-line treatment  AVAglio  avapritinib  AVAST-M study  AVAST-M trial  AVAST-M trial analysis  avastin  AVATAR trial  avelumab  avelumab maintenance  avelumab plus axitinib  avelumab plus cabozantinib  avelumab versus chemotherapy  avelumab versus chemotherapy maintenance  avelumab-palbociclib-axitinib  AveNEC trial  average risk B-ALL in children  AVERT study  AVERT trial  AVO  avoidable cancer deaths by diagnosis prior to metastasis  avoiding peg-filgrastim  avoiding unnessecary surgery  AvR-CHOP study  axatilimab  axi-cel  axi-cel in the non-trial setting  axicabtagene ciloleucel  axillaire lymfeklierdissectie  axillaire radiotherapie  axillaire status  axillaire ultrasound  axillary dissection  axillary lymph node dissection  axillary response  axillary soft tissue pathology  axillary surgery and nodal irradiation  axitinib  axitinib plus avelumab  axitinib plus pembrolizumab  axitinib versus observation  AYA cancer  AYA cancer survivors  AYA-maligniteiten  AYAs  AYAs at end of life  AYAs versus older adults  AYAs with cancer  AZ9291  AZA-MDS-003 study  azacitidine  AZD4547  B-43 trial  B-ALL  B-ALL in CAYAs  B-ALL in patients aged 1-24 years  B-ALL in pediatric and young adult patients  B-cel activering  B-cel lymfoom  B-cel maligniteiten  B-cel precursor-ALL  B-cell ALL  B-cell ALL in children and young adults  B-cell ALL resistant to CD19 immunotherapy  B-cell hematological malignancies  B-cell infiltration  B-cell lymphoma  B-cell lymphomas after CD19-directed CAR T-cell therapy  B-cell malignancies  B-cell non-Hodgkin lymphoma  B-cell precursor acute lymphoblastic leukemia  B-cellymfoom  B-F1RST trial  B-precursos ALL  B-progenitor acute lymphoblastic leukemia  baarmoederhalskanker  BACCI study  BALLET-studie  BAP1 pathogenic variant carriers  BARCODE1 trial  bariatric surgery  bariatric surgery after age 60  bariatric surgery and cancer risk in obese adults  bariatric surgery in French obese patients  bariatrische chirurgie  Barrett esophagus  Barrett slokdarm  Barrett-slokdarm  Barrett's esophagus  Barrett's slokdarm  Barrett’s oesophagus  barriers  BArT study  basaalcelcarcinoom  basal-like mammacarcinoom  base-edited CAR7 T cells  Baselga  baseline anxiety or depression  baseline CTC count  baseline factors associated with response  baseline metabolic tumor volume as predictive and prognostic biomarker  baseline QOL  baseline tumor burden and overall survival  baseline US and FDG-PET CT  basline plasma tumor mutational burden  bassi  BAT  BAY1436032  BAYOU trial  bazedoxifene plus palbociclib  bb2121  BBB  BBD  BBD-BC  BC  BC characteristics and outcomes related to race ethnicity in Canada  BC risk  BC stage at diagnosis  BC survivors  BC with three or more SLNs  BC-LMD  BCa  BCBM  BCC  BCCs  BCCSS  BCG  BCG vaccination in childhood  BCG-unresponsive non-muscle-invasive bladder cancer  BCI  BCIN+  BCIS  Bcl-2  BCL-2 dependence  BCL2 expression  BCLC B2 HCC  BCMA CAR-T cell therapy  BCMA-directed CAR-T  BCMA-targeted CAR-T cell therapy for MM  BCNU  BCP-ALL  BCR  BCR after RT or RP  BCRA-mutated advanced breast cancer  BCRC trial 022  BCRL after ALND  BCS  BCS among women with intellectual disability  BCS for N2 N3 disease  BCS versus mastectomy after neoadjuvant chemotherapy  BCS versus mastectomy for DCIS  BCS with or without RT  BCS with or without RT for large DCIS lesions  BCT  BCT versus mastectomie  BCT versus mastectomy  BCT vs MAST  Be-Well Study  BEACON CRC study  BEACON-studie subgroep-analyse  Beamion LUNG-1  BEAT Cancer interventie  BEATcc trial  BEB trial  BEBYP-studie  Beckwith-Wiedemann syndrome  BECOME randomized trial  beeld-geleide brachytherapie  beeldvorming  beenmergevaluatie  BEFLICO study  beha  belamaf  belangenconflicten  belantamab mafodotin  belantamab mafodotin for advanced multiple myeloma  belantamab mafodotin plus pomalidomide and dexamethasone  BELIEVE trial  belinostat  BELIS study  BELLE-2 studie  BELLINI trial  BELOB  belotecan versus topotecan  belumosudil  belzutifan  belzutifan plus cabozantinib  bemarituzumab  bempegaldesleukin plus nivolumab  bendamustine  bendamustine lymphodepletion before lisocabtagene maraleucel  bendamustine plus dexamethasone  benefit of healthy lifestyle  benefits and harms of annual  benign biopsy rate  benign ovarian tumor  benign ovarian tumors  benign solid tumors  benigne borstziekte  benmelstobart  benzeen  benzodiazepine  BEP  berberine versus placebo for the prevention of recurrence of colorectal adenoma  BERIL-1  BERT trial  bestraling  BET inhibitor RO6870810  beta-arrestin-1  beta-blocker use  beta-blocker use at time of prostatectomy  beta-blockers  BETA-Text  bètablokkers  BETINA trial  between-hospital variation  BEV  BEV1L study  bevaciumzab  bevacizumab  bevacizumab and platinum-based combinations  bevacizumab biosimilar  bevacizumab plus chemotherapy  bevacizumab plus CRT  bevacizumab preconditionering voor chemotherapie  bevacizumab versus cetuximab  bevacizumab with or without reirradiation  bevacizumab-etoposide-cisplatin before whole-brain radiotherapy  bevacizumab-resistant high-grade glioma  BEVERLY trial  BEVZ92  BFAST cohort C  BFAST trial  BFM 2009 ALL trial  BFORE trial 5 year follow-up  BFORE-studie  BFR14 trial  BGJ398  bhatia  BI-ALCL  BIA ALCL  biallelic pathogenic CHEK2 variants  BIDOC-studie  biennial  BIG 1-01  BIG 1-98  BIG 1-98 trial analysis  BIG 3-07 TROG 07.01 study  BIG-RENAPE study  bijnierschorscarcinoom  bijniertumoren  bijwerkingen  bilateral and contralateral risk-reducing mastectomy  bilateral breast cancer  bilateral oophorectomy  bilateral oophorectomy and all-cause mortality  bilaterale risicoreducerende mastectomie  BILCAP study  BILCAP study long term outcomes  BILCAP-studie  biliary tract cancer  binatumomab  BIND-014  Bing-Neel syndrome  binimetinib  binimetinib for NRAS-mutated cancers  bintrafusp alfa  biochemical recurrence of prostate cancer  biochemically detected nonadherence to adjuvant tamoxifen  biochemically recurrent prostate cancer  biochemisch recidief  BioItaLEE trial  biologic subtype  biological aging  biological disease-modifying antirheumatic drugs  biologische beschikbaarheid  biomarker  biomarker for response to MET inhibitors  biomarker testing disparities  biomarker voor respons op bevacizumab  biomarker vs MRI-enhanced strategies for prostate cancer screening  biomarker-driven therapies  biomarkeranalyse ASPECCT-studie  biomarkers  biomarkers for detection  biomarkers for nivolumab efficacy  biomarkers for surveillance  biomarkers of activity  biomarkers of breast cancer risk  biomarkers of response to adjuvant chemotherapy  biomarkers of response to ICIs  biomarkers of treatment benefit  biomarkers predicting survival  BioPER trial  biopsie schildwachtklier  biopsy preceding resection  bipolar androgen therapy  BIRC3 mutations  BIRCH-studie  birinapant  birth defects  birth order  birth weight  BIS versus circumference assesements  bisfosfonaat  bisfosfonaten  bispecific CAR-T cell targeting both CD19 and CD22  bispecific CS1-BCMA CAR-T cells  bisphosphonate use and breast cancer risk among women with DCIS  bisphosphonates and risk of cancers  bivalent HPV vaccination  bivalent HPV vaccine  biweekly docetaxel plus ADT  biweekly versus triweekly cabazitaxel  BL-B01D1  blaascarcinoom  blaaskanker  black race  Black versus non-Black patients  black versus nonblack men  Black versus White breast cancer patients  black versus white patients  black versus white women  Black Women's Health Study  Black Women’s Health Study  bladder cancer  bladder cancer in postmenopausal women  bladder cancer progression  bladder cancer risk  bladder cancer VI-RADS score  bladder-preserving trimodality treatment  bladder-sparing TMT  BladderPath trial  blast-phase CML  blastic plasmacytoïd dendritic cell neoplasm  BLC2001 study  bleeding after ACS  bleeding risk  BLEND study  bleomycin-related pulmonary toxicity  bleomycine  blinatumomab  blinatumomab and POMP maintenance  blinatumomab nonresponse  blinded double reading  bloedgluocse  bloeding  bloedkanker  bloedlipiden  bloedtest colorectaalcarcinoom  blood arsenic levels  blood cholesterol  Blood ICT  blood markers of oxidative stress  blood or marrow transplant  Blood or Marrow Transplant Survivor Study-2  blood pressure  blood tests  blood triglycerides  blood tumor mutational burden  blood-based genomic mutation signature  blood-based test for the detection of multiple cancer types  blood-based tests for multicancer early detection  bloodstream infections  bloodstream infections after curative-intent radiotherapy  BLOOM study  BLOSSOM trial  BLU-667  BLV DNA  BM  BM from BC and NSCLC  BM versus PB  BMAs  BMAs for bone loss in prostate cancer patients receiving androgen deprivation therapy  BMBC  bmCRPC without significant PSA response under enzalutamide  BMD  BMI  BMI and molecular subtypes of premenopausal breast cancer  BMI and outcomes of systemic therapy for metastatic melanoma  BMI and prognosis  BMI and T2D as determinants of response  BMI during maintenance therapy  BMI in early and middle adulthood  BMI surgical treatment  BMM  BMs  BMs from EGFR-mutant NSCLC  BMS-096299  BMS-986156  BMT  BMT CTN 1501 study  BMT survivor study  BMTSS  BNT162b2 vaccination in patients undergoing treatment for cancer  BO  body composition  body composition and cardiovascular events  body composition features  body composition phenotypes  body fat  body fat distribution  body fat mass  body fat percentage  body mass index  body mass index and risk of second cancer  body shape trajectory  Boekel  BOLERO-1  BOLERO-2  bone loss in younger breast cancer patients  bone marrow biopsy  bone marrow donor registration  bone marrow plasma cell level  bone marrow versus blood stem cell graft  bone metabolism  bone metastases  bone metastasis in stage IV NSCLC  bone metastatic melanoma  bone modifying agents  bone sarcoma survivors  bone-metastatic castration-resistant prostate cancer  bone-only metastasis  bone-targeted agents  BONSAI trial  BOOG 2019-01 TIBET trial  BOOSTER trial  borderline ovarian tumor  borderline ovariumtumor  borderline resectable or locally advanced unresectable pancreatic cancer  borderline resectable pancreatic cancer  borderline resectable PDAC  Borealis-1 studie  Borealis-2 studie  borstbiopsie  borstchirurgie  borstdichtheid  borstimplantaat  borstkanker  borstkanker bij mannen  borstkankerpreventie  borstkankerscreening  borstkankerscreening oudere vrouwen  borstkankersterfte  borstparende chirurgie  borstreconstructie  borstreconstructie na mastectomie  borstsparende chirurgie  borsttomosynthese  borstvoeding  bortezomib  bortezomib induction for NDMM  bortezomib plus chemotherapy  bortezomib plus rituximab maintenance  BOS chordomas  BOSS cohort  BOSTON study  bosutinib  bosutinib for previously treated chronic myeloid leukemia  bosutinib versus imatinib  BOT  BOT plus BAL  bot-SPNs  boteffect  botensilimab plus balstilimab  botmetastasen  botmetastasen van mammacarcinoom  botmetastasering  botmicrometastasen  botox  botpijn  botsarcoom  bovenste-luchtwegkanker  BP-RMS  BPd versus PVd  BPDCN  bPFS  BPH  BPM  BPs  BR  BR-ESCC  BR.36 trial  BRAC1 2-mutation  brachytherapie  brachytherapy for glioblastoma  BRAF  BRAF 594 en 596 mutaties  BRAF 600 wild type melanoom  BRAF HER2 MET RET-alterations  BRAF mutated advanced solid tumors  BRAF mutation  BRAF non-V600-mutant mCRC  BRAF plus MEK inhibition  BRAF plus MEK inhibitors  BRAF V600 mutated metastatic melanoma  BRAF V600-mutated mNSCLC  BRAF V600-mutated NSCLC  BRAF V600-mutated pediatric LGG  BRAF V600-mutated stage III melanoma  BRAF V600E  BRAF V600E mCRC  BRAF V600E mutated CRC  BRAF V600E-mutant mNSCLC  BRAF V600E-mutated biliary tract cancer  BRAF V600E-mutated CRC  BRAF variants  BRAF wild-type advanced melanoma  BRAF-genfusies  BRAF-mutant CRC  BRAF-mutant mCRC  BRAF-mutant melanoma  BRAF-mutant mNSCLC  BRAF-mutated aCRC  BRAF-mutated malignancies  BRAF-mutated melanoma  BRAF-mutated metastatic melanoma  BRAF-remmer  BRAF-remmers  BRAF-remming  BRAF-V600 mutation-positive melanoma  BRAF-V600 or BRAF-nonV600 mutated NSCLC  BRAF-V600E  BRAF-V600E mutant mCRC  BRAF-V600E mutated tumors  BRAF-V600E mutation  BRAF-wt advanced melanoma  BRAFV600-mutant melanoma  BRAFV600-mutant stage III melanoma  BRAID randomized trial  brain cancer  brain imaging  brain metastases  brain metastases from melanoma  brain metastases in older patients  brain metastases nivolumab plus ipilimumab  brain metastases of gastroesophageal adenocarcinoma  brain metastases or leptomeningeal disease  brain metastasis  brain metastasis and survival outcomes  brain metastasis outcomes  brain metastasis resection  brain MRI surveillance  brain radiotherapy plus pyrotinib and capecitabine  brain tumors  brain volume  brain white matter microstructure  brain-metastatic lung cancer  brain-only mBC  brainstem metastases  BRCA  BRCA mutation carriers  BRCA mutation carriers with breast cancer  BRCA mutational status  BRCA PVs  BRCA testing  BRCA-altered uterine sarcoma  BRCA-defective tumors  BRCA-mutatie  BRCA-related cancer  BRCA1  BRCA1 2 germline mutation in women  BRCA1 2 germline mutations  BRCA1 2 mtuation. risk of contralateral disease  BRCA1 2 mutation  BRCA1 2 mutation carriers  BRCA1 2 mutations  BRCA1 2 mutations and endometrial cancer  BRCA1 2 pathogenic variants  BRCA1 2 pathogenic variants carriers  BRCA1 2 pathogenic variants in women aged 50-75 years  BRCA1 2 PV  BRCA1 2 PV carriers  BRCA1 2 PVs  BRCA1 2 variants  BRCA1 2-associated pT1 breast cancer  BRCA1 2-mutatie  BRCA1 2-mutaties  BRCA1 2-mutations  BRCA1 2-negative Chinese breast cancer patients  BRCA1 and BRCA2 germline pathogenic variants  BRCA1 and BRCA2 mutations  BRCA1 mutation  BRCA1 pathogenic variant  BRCA1- or BRCA2-mutated breast cancer  BRCA1-mutatie  BRCA1-versus BRCA2-altered mCRPC  BRCA2  BRCA2-associated breast cancer  BRCA2-mutaties  BRCAAway trial  BRCP  BREACH study  breakthrough COVID-19 infections in cancer patients  breakthrough infections after COVID-19 vaccination in patients with cancer  breakthrough SARS-CoV-2 infections in vaccinated patients with cancer  BREAKWATER study  breast and lung cancer mortality in women  breast and prostate cancer  breast angiosarcoma  breast cancer  breast cancer –related lymphedema  breast cancer after radiotherapy for HL  breast cancer and other cancers  breast cancer before age 45  breast cancer bone metastasis  breast cancer brain metastases  breast cancer brain metastasis  breast cancer central nervous system metastases  breast cancer chemotherapy  breast cancer chemotherapy dose reduction  breast cancer CMs  breast cancer conservation surgery  breast cancer diagnosis  breast cancer family history  Breast Cancer Family Registry  breast cancer in BRCA PV carriers  breast cancer in BRCA1 2 PV carriers  breast cancer in childhood cancer survivors  breast cancer in high-risk women  breast cancer in HL survivors  breast cancer in men  breast cancer in older women  breast cancer in patients with BRCA variants  breast cancer in sub-Saharan Africa  breast cancer in women  breast cancer in young women  breast cancer incidence after a false-positive mammography result  breast cancer incidence before age 40  Breast Cancer Index  breast cancer leptomeningeal disease  breast cancer lymph node metastases  breast cancer metastases  breast cancer metastatic recurrence  breast cancer molecular subtypes  breast cancer mortality  breast cancer mortality by comorbidty and age  breast cancer mortality rates in U.S. women  breast cancer outcomes  breast cancer ovarium cancer predisposition genes  breast cancer patients  breast cancer patients aged 35 years or younger  breast cancer patients over age 50  breast cancer preventive effects of anastrozole  breast cancer prior to age 45 years  breast cancer PRS  breast cancer radiation therapy  breast cancer radiotherapy planning CT scans  breast cancer rate after oophorectomy in the general population  breast cancer recurrence  breast cancer risk  breast cancer risk after age 60  breast cancer risk after bariatric surgery  breast cancer risk before age 40 years  breast cancer risk estimation model  breast cancer risk in women ≥50 years  breast cancer screening  breast cancer screening among women with dense breasts  breast cancer screening in average-risk women  breast cancer screening interval  breast cancer screening participation  breast cancer second recurrences afte mastectomy  breast cancer subtype  breast cancer subtype incidence  breast cancer subtypes  breast cancer surgery  breast cancer survival  breast cancer survivors  breast cancer survivorship  breast cancer treated in neoadjuvant setting  breast cancer treatment  breast cancer treatment quality  breast cancer treatments  breast cancer with sentinel-node metastases  breast cancer-related fatigue  breast cancer-related lymphedema  breast cancer-specific mortality  breast cancer-specific survival  breast compression  breast conservation  breast conservation vs mastectomy and reconstruction  breast consevation versus mastectomy  breast desmoid tumor management in France  breast ductal carcinoma in situ  breast feeding experiences  breast intraepithelial neoplasia recurrence  breast milk paclitaxel excretion  breast MRI versus digital tomosynthesis  breast non-invasive disease  breast or ovarian cancer  breast radiotherapy  breast surgery after NAC  breast symptoms  breast tumors  breast-conserving surgery  breast-conserving surgery versus mastectomy for EBC  breast-conserving therapy  breast-conserving therapy in women over 70  breastfeeding  BreastScreen Norway  BRENDA-score  brentuximab vedotin  brentuximab vedotin and risk-adapted node radiation  brentuximab verdotin  brexu-cel as standard therapy  brigatinib  brigatinib after failure of BV  BrighTNess study  BRIM-3 studie  BRIM7 study  BRIM8-studie  BRIs  British Childhood Cancer Survivor Study  BrMs  Broad-based genomic sequencing  BROCADE3 trial  BROCADE3 trial exploratory analysis  bronchopulmonary carcinoids  BRPC  BRRM  BRUIN study  BRUIN trial  bruton's tyrosine kinase  BS  BTC  BTC in patients aged ≥ 70 years  BTC with ERBB2 3 alterations  BTCRC-GU14-003 study  BTCRC-LUN15-029 trial  BTCRT LUN 16-081  BTCs  BTK  BTK inhibition  BTK inhibitor therapy  bTMB as biomarker for atezolizumab activity  bulky stage I-II cHL  burden of pancreatic cancer in Europe between 1990 and 2019  Burkitt lymphoma  Burkitt's lymfoom  burnout in cancer care physicians  busulfan plus fludarabine  busulfan plus melphalan conditioning  busulfan-fludarabine versus busulfan-cyclophosphamide  BV  BV plus AVD  BV plus nivolumab  BV+pembrolizumab  BVd versus DVd  BVD-523  BYLieve study cohort A  BYLieve trial  BZD  C reactive protein flare  C SCANS studie  C-144-01 study  C-486  C-ALCL  C-Brain study  C-CAR066  C-ETACs as hallmarks of cancer  C-ion RT  c-Met protein-expressing NSCLC  c-Met protein-overexpressing EGFR-wildtype NSCLC  C-reactive protein  C-reactive protein trajectories  C-TASK FORCE studie  CA 125  CA 209-678 trial  CA-125  CA-125 KELIM  CA125  CA180-226 studie  CA19-9  CA209-003 studie  CA209-003 trial  CA209-9JC trial  CA301 study  CABARET-studie  CABASTY trial  cabazitaxel  cabazitaxel plus carboplatin  cabazitaxel versus abiraterone or enzalutamide  CABINET trial  CABIR study  CABONE study  CABOSUN  cabozantanib  cabozantinb  cabozantinib  cabozantinib plus ADT  cabozantinib plus atezolizumab  cabozantinib plus atezolizumab versus sorafenib  cabozantinib plus nivolumab  cabozantinib plus nivolumab and ipilimumab  cabozantinib plus nivolumab with or without ipilimumab  cabozantinib versus everolimus  cabozantinib with or without atezolizumab  cabozantinib-nivolumab sequence  cachexia  CAD  CADC  CADM1 MAL-methylering  cadmium and lead in erythrocytes  cadonilimab  cafeïne  caffeïne  CAG-repeat  CAIRO3  CAIRO4 trial  CAIRO5 post hoc analysis  calcifications and cystic morphology on preoperative imaging  calcitonin receptor-like  calcium  calcium and magnesium intake  calcium intake and CRC risk  calcium supplementation  calciuminname  calculated tumor area  CALGB 30160 RTOG 0538  CALGB 40601 follow-up  CALGB 40903 study  CALGB 50604  CALGB 50801  CALGB 70702  CALGB 80405 exploratory analysis  CALGB 80803  CALGB 89803-studie  CALGB Alliance 140503  CALGB SWOG 80405  CALGB SWOG 80405 study  CALGB SWOG 80702  CALGB SWOG 80702 analysis  CALGB SWOG 80702 post hoc analysis  CALGB SWOG 80702 study  CALLA trial  CALM trial  CALOR-studie  caloric restriction  CALYPSO trial  CAM  CameL study  CameL trial  CameL trial 5-year outcomes  Camel-sq trial  camizestrant  CamRelief trial  camrelizumab  camrelizumab plus apatinib  camrelizumab plus apatinib and fuzuloparib  camrelizumab plus apatinib for advanced cervical cancer  camrelizumab plus chemotherapy  camrelizumab plus famitinib  camrelizumab plus famitinib after PD-1 blockade  camrelizumab plus gemcitabine plus oxaliplatin  camrelizumab plus GEMOX  camrelizumab plus GVD chemotherapy  camrelizumab plus pemetrexed and carboplatin  camrelizumab plus rivoceranib  camrelizumab plus rivoceranib versus sorafenib  camrelizumab with or without decitabine  camrelizumab-apatinib-temozolomide  CanAssist Breast test  cancer  Cancer and Aging Research Group score  cancer and cardiovascular disease intensity an mortality  cancer and cardiovascular risk with tofacitinib in rheumatoid arthritis  cancer and risk of COVID-19 diagnosis and severity  cancer burden in patients with sleep apnea  cancer burden in the oldest-old in The Netherlands 1990 to 2019  cancer cachexia  cancer case trends  cancer cases attributable to modifiable lifestyle risk factors in Switzerland  cancer chemotherapy during pregnancy  cancer clinical trial participants  cancer clinical trials  cancer deaths due to delays in diagnosis in England  cancer detection rate  cancer diagnoses after recent weight loss  cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible  cancer diagnosis  cancer diagnosis during adolescence  cancer diagnosis in primary care  cancer driver genes  cancer drugs approved based on response rate  cancer drugs receiving FDA accelerated approval  cancer emergency presentation  cancer history  cancer immunotherapy  cancer immunotherapy trials  cancer in older adults  cancer in solid organ transplantation recipients  cancer in the prison population in England  cancer incidence  cancer incidence among children and young adults by single year of age  cancer incidence and mortality  cancer incidence and spectrum in children  cancer incidence and survival in older adults  cancer incidence in World Trade Center rescue and recovery workers  Cancer Moonshot goal  cancer mortality  cancer mortality in Europe  cancer of unknown primary  Cancer of unknown rimary  cancer outcomes  cancer patients  cancer patients aged 70 years or older  cancer patients and matched norm population perceived care and well-being  cancer patients treated with anticoagulation  cancer patients undergoing systemic treatment  cancer predisposition screening tool  cancer prevalence  cancer prevalence in medieval Cambridge (UK)  cancer prevention  cancer prevention recommendations  Cancer Prevention Study-3  Cancer READMIT Score  cancer recurrence  cancer risk  cancer risk after hematuria diagnosis  cancer risk in children  cancer risk in children and adolescents  cancer risk in individuals with major birth defects  cancer risk in patients with bipolar disorder and unaffected siblings  cancer risk in South Korean GERD patients  cancer risk in women  cancer risks  cancer risks among men  cancer screening  cancer screening in people with mental illness  cancer screening tests  cancer spectrum  cancer surgery in older adults  cancer surgical procedures  cancer survival in Germany  cancer survivors  cancer susceptibility genes  cancer therapy approval timings in the US and Europe  cancer trials  cancer types and risk of delirium  cancer-associated isolated DVT  cancer-associated venous thromboembolism  cancer-related cognitive impairment  cancer-related fatigue  cancer-specific mortality  cancer-testis antigens  cancers attributable to infections  cancers of unknown primary origin  cancers with MUC16-variants  CANDOR study  CANDOR study updated outcomes  canine lung cancer detection  cannabidiol for relief of symptoms in advanced cancer  cannabigerol  cannabinoids for symptom management  cannabis  cannabis use  cannabis use and lung cancer susceptibilty  CanSaRCC study  CanSNET-studie  CANTO prospective cohort study  CANTO skin  CANTO trial  CANVAS trial  CAO ARO AIO-04 study  CAO ARO AIO-04 trial post hoc analysis  CAO ARO AIO-12 trial long-term results  CAO ARO AIO-16 trial  CAP 01 study  CAP 02 trial  CAP 03 trial  CAP trial  CAP-BRAIN study  CAP-studie  CAPability-01 trial  CAPAP-Lung trial  capecitabine  capecitabine maintenance after first-line induction chemotherapy  capecitabine maintenance therapy  capecitabine versus observation  capecitabine-associated hand-foot syndrome  CAPFISH-3 randomized trial  CAPITAL study  CAPItello-291  CAPItello-291 trial  capivaserib for AKT1 E17K-mutated tumors  capivasertib  capivasertib for tumors with AKT mutations  capmatinib  capmatinib plus nivolumab  CAPP-Seq  CAPP2 study  CAPRI trial  CAPRI-GOIM  CAPRICE  CAPSTONE-1 trial  CaPSURE trial  CAPTAIN-1st study  CAPTIVATE study MRD-cohort  CAR T cell therapy  CAR T cells and T-cell therapies for cancer  CAR T cells and TCE  CAR T-cell therapy  CAR T-cell therapy for relapsed refractory large B-cell lymphoma  CAR T-cellen voor solide tumoren  CAR T-cells for B-cell lymphoma  CAR T-celtherapie  CAR-HEMATOTOX model  CAR-macrophage therapy  CAR-T  CAR-T celtherapie  CAR-T CRS  CAR-T for lymphomas  CAR-T for pediatric ALL  CAR-T therapy  CAR-T-cell therapy in patients with advanced B-cell cancers and HBV-infection  CAR-transduced natural killer cells  CAR19 22 T-cell therapy  Caravaggio study  carbazitaxel  carbon ion RT  carbon nanoparticle suspension lymphografy guided distal gastrectomy  carboplatin  carboplatin dose capping  carboplatin plus nab-paclitaxel  carboplatin plus pemetrexed  carboplatin with or without atezolizumab  carboplatin with radiotherapy  carboplatin-etoposide with or without atezolizumab  carboplatin-paclitaxel with or without trastuzumab  carboplatine  carcinoïd tumoren  CARD study  cardiac dysfunction  cardiac events  cardiac impact of cytokine release syndrome  cardiac outcomes  cardiac safety  cardiac substructure radiation dose and risk of late cardiac disease  cardiale disfunctie  cardiale toxiciteit  cardiale veiligheid  cardiometabolic risk factors  cardiometabolic risk factors and survival after cancer  cardiomyopathy in CCSs  cardioprotective strategies  cardiopulmonary complications  cardiorespiratorische fitheid  cardiorespiratory fitness  cardiotoxiciteit  cardiotoxiciteit anthracylines  cardiotoxiciteit chemotherapie  cardiotoxicity  cardiotoxicity of doxorubicin  cardiotoxicity with encorafenib and binimetinib  cardiovasculair risico  cardiovasculaire toxiciteit  cardiovascular adverse events  cardiovascular disease  cardiovascular disease risk  cardiovascular diseasse  cardiovascular events  cardiovascular events and chronic kidney disease  cardiovascular fitness and muscular strength  cardiovascular mortality  cardiovascular outocmes  cardiovascular risk  cardiovascular risk factors  cardiovascular surveillance  cardiovascular toxicity  CARE study  CareMin650  CARES-310  carfilzomib  carfilzomib for myeloma  carfilzomib-bendamustine-dexamethasone  carfilzomib-lenalidomide-dexamethasone followed by lenalidomide maintenance  carfilzomib-lenalidomide-dexamethasone-daratumumab  CARG tool  CARMENA study  CARMENA-studie  carmustine  Carolina Breast Cancer Study  carotenoïden  carpaal-tunnelsyndroom  CARRIERS consortium  CART-19  CART-SIE study  CARTBCMA-HCB-01 trial  CARTIFAN-1 study  CARTITUDE-1 study  CARTITUDE-1 trial  CARTITUDE-4  CARTITUDE-4 trial  CARTS study  CARTTAS study  cascade genetic testing  case-control analysis within IBIS-II  case-mix adjusted comparison of Dutch hospital perfomances  CASPIAN study  CASPIAN study follow-up  CASPS study  CASR  CASSINI study  CASSIOPEIA part 2  CASSIOPEIA study  CASTOR and POLLUX age subgroup analysis  CASTOR subgroup analysis  castratieresistent prostaatcarcinoom  castration-resistant AR-expressing salivary gland cancer  castration-resistant prostate cancer  CATCH  CATCH program  catch-up HPV-vaccination  CATNON study  CATNON trial post-hoc analysis  CATNON-studie  catumaxomab  caudate lobe solitary HCC  cause of death  cause-specific mortality  cause-specific mortality after initial chemotherapy  causes of death  causes of death after breast cancer diagnosis  causes of death among Finnish women with breast cancer  CAVE trial  CB307  CBC  CBC prediction  CBC risk  CBC-risico  CBCSG010 study  CBD for scan-related anxiety  CBT-I  CBTRUS  CBTS  cc mRCC  CC-220-MM-001 trial  CC-223  CC-486  CC-92480-MM-001 Study  ccA and ccB molecular subtypes  CCEC  CCGCs  CCNE1 expression  CCR7  ccRCC  ccRCC brain metastases  CCRT  CCRT versus IC plus IMRT  CCRT with or without nimotuzumab  CCSS  CCSS cohort  CCTG BR.34 trial  CCTG HE1 study  CD103+ immune cells  CD123 surface expression  CD19 CAR-T cell therapy  CD19 CAR-T cell therapy in children and young adults  CD19 CAR-T for large B-cell lymphoma  CD19-1XX CAR  CD19-directed CAR T cell therapy  CD19-directed CAR T-cell therapy  CD19-positive lymphoid tumors  CD20-positive diffuse large B-cell lymphoma  CD22-directed CAR T-cell therapy  CD22-targeted CAR T-cell therapy  CD30-positive R R PTCL  CD4  CD4 CD8 ratio  CD4+ percentage  CD45-targeted antibody-radionuclide conjugate  CD47 blockade plus rituximab  CD8+ T cell infiltration  CDG  CDH1 mutation carriers  CDK12-mutated prostate cancer  CDK4 6 inhibition  CDK4 6 inhibitor plus AI  CDK4 6 inhibitor plus fulvestrant  CDK4 6 inhibitors  CDK4 6-inhibitors for breast cancer  CDK4 6-remming  CDK4 6i  CDKN2A alterations in solid tumors  CDKN2A homozygous deletion  CDKN2C  CDS  CDX-110  CDX2  CE  CEA  CEA-specifieke T-cel respons  cediranib  cediranib plus olaparib  cediranib with or without lenalidomide  CEGT  celecoxib  CELESTIAL trial  celiac plexus radiosurgery  cell nest size  cell-free circulating tumor DNA variant allele frequency  cell-free DNA multicancer early detection test  cell-free Epstein-Barr virus DNA  cell-free urine  cellulaire immuuntherapie  cellular immune activation  CelTIL score  CelTIL-score  celvrij circulerend tumor DNA  cemiplab versus investigator’s choice chemotherapy  cemiplimab  cemiplimab after HHIs  cemiplimab plus chemotherapy  cemiplimab Q4W  central adiposity  central adiposity and risk of subsequent breast cancer by menopause status  central obesity and CRC risk  centrale adipositas  centralized CRC screening in FQHCs  centrally located HCC  CEPHEUS study  ceralasertib (AZD6738)  ceralasertib plus durvalumab  cerebellopontine angle tumors  cerebrospinal fluid microRNA signatures  cerebrospinal fluid tumor DNA genotyping  cerebrospinale vloeistof  ceritinib  cervical cancer  cervical cancer and CIN3+  cervical cancer and precancer risk  cervical cancer incidence  cervical cancer patients with or without mental disorder  cervical cancer screening  cervical cancer survivors  cervical chordomas  cervical conization  cervical dysplasia after HPV vaccination  cervical HPV-testing  cervical neoplasia  cervical screening  cervical screening self-collection method  cervicale glandulaire neoplasie  cervicale intra-epitheliale neoplasie graad 3  cervicale intraepitheliale neoplasie  cervicale-slokdarmkanker  cervixcarcinoom  cervixcarcinoomscreening  cervixconisatie  cervixkanker  cervixkankerscreening  cervixlaesies  cesarean delivery  cesium-131 brachytherapy  CESM  CeTeG NOA-09 study  CETSA  cetuximab  cetuximab maintenance  cetuximab plus nivolumab  cetuximab-IRDye800  cetuximab-related infusion reactions  cetuximab-resistant recurrent metastatic HNSCC  cetuximab-resistentie  CEVOREM trial  CF-WBI  cfDNA  cfDNA blood-based test for CRC screening  cfDNA genotyping  cfDNA in CSF  cfDNA methylation signatures  CFS  CGC  CGT  cGVHD  cGVHD in pediatric patients  ch  CH and subsequent lung cancer risk  CH and t-MN  CH in long-term pediatric cancer survivors  CHAARTED trial eight-year survival  CHAARTED-analyse  CHAARTED-studie  CHANCE2201 study  change in mammographic density  change in PD-L1 expression  change in serum uric acid level  change in trust in US government health agencies  change of breast cancer subtype during neoadjuvant chemotherapy  changes from 1993-2015  changes in alcohol consumption  changes in cancer diagnoses and stage distribution  changes in length and complexity of oncology guidelines since 1996  changes in survival since 1995  changes in taste and smell of food  changes in urological cancer surgical volume and length of stay  changes in weight and waist circumference during menopause  changes of body mass index or waist circumference  changes of diet after cancer diagnosis  characteristics and outcomes  characteristics and prognosis  characteristics and prognosis of luminal and basal subtypes  characteristics in young versus old patients  characteristics of high-volume lung segmentectomy hospitals  Charlson-score  CHART trial  CHB  ChcekMate 066 five-year results  CHD  CheckMate & HW trial  CheckMate 012  CheckMate 016-studie  CheckMate 017 and 057 trials  CheckMate 017 en 057  CheckMate 017 en CheckMate 057  CheckMate 017-studie  CheckMate 025  CheckMate 026-studie  CheckMate 032 study  CheckMate 037  CheckMate 040  CheckMate 040 cohort 6  CheckMate 040 five year follow-up  CheckMate 040 study  CheckMate 064  CheckMate 066  CheckMate 066 study  CheckMate 067  CheckMate 067 five-year survival  CheckMate 067 trial  CheckMate 069  CheckMate 069 066 en 067  CheckMate 078  CheckMate 141  CheckMate 141-studie  CheckMate 142  CheckMate 142 first-line therapy cohort  CheckMate 143 study  CheckMate 153  CheckMate 204  CheckMate 204 study  CheckMate 205 study  CheckMate 214  CheckMate 214 long-term follow-up  CheckMate 214 study  CheckMate 214 trial  CheckMate 214 trial 42-months results  CheckMate 227  CheckMate 227 part 1 three-year update  CheckMate 227 study  CheckMate 227-studie  CheckMate 238 and EORTC 18071  CheckMate 238 five-year follow-up  CheckMate 238 four-year results  CheckMate 238-studie  CheckMate 274  CheckMate 275  CheckMate 358  CheckMate 358 trial  CheckMate 370-studie  CheckMate 384 study  CheckMate 401  CheckMate 436 study  CheckMate 459 trial  CheckMate 511 trial  CheckMate 568  CheckMate 577 study  CheckMate 648  CheckMate 648 study  CheckMate 649  CheckMate 649 3-year follow-up  CheckMate 649 HRQOL analysis  CheckMate 743 trial  CheckMate 744  CheckMate 76K trial  CheckMate 77T  CheckMate 7FL  CheckMate 816 study  CheckMate 816 trial  CheckMate 817  CheckMate 8HW  CheckMate 901  CheckMate 908  CheckMate 914 trial part A  CheckMate 920 study  CheckMate 9DW  CheckMate 9ER long-term follow-up analysis  CheckMate 9ER study  CheckMate 9ER trial  CheckMate 9KD  CheckMate 9LA study  CheckMate studies  CheckMate-032 study  CheckMate-067  CheckMate-142  CheckPAC trial  checkpoint blockade  checkpoint blockade immunotherapy  checkpoint inhibitor therapy  checkpoint inhibitor-resistant metastatic melanoma  checkpoint inhibitors for various types of melanoma  checkpoint kinases  CHEERS  CHEK2 1100delC  CHEK2 germline pathogenic variants  CHEK2-mutaties  CHEK2*1100delC  chemerin plasma concentration  chemo-immunotherapy for advanced NSCLC  chemobrain  chemoimmunotherapy  chemoimmunotherapy in patients with a poor performance status  chemopreventie mammacarcinoom  chemopreventie van mammacarcinoom  chemoprevention of CRC  chemoprevention of recurrence  chemoprevention with low-dose aspirin  chemoradiation plus durvalumab  chemoradiotherapie  chemoradiotherapy  chemoradiotherapy versus radiotherapy  chemoradiotherapy with proton versus photon therapy  chemorefractory BTC  chemorefractory metastatic colorectal cancer  chemorefractory or relapsed gestational trophoblastic neoplasia  chemoresection  Chemoresistentie  chemosensitizatie  chemotherapie  chemotherapie tijdens zwangerschap  chemotherapie-geïnduceerd ovariumfalen  chemotherapie-geïnduceerd POF  chemotherapie-geïnduceerde febriele neutropenie  chemotherapie-geïnduceerde misselijkheid en braken  chemotherapy  chemotherapy adherence  chemotherapy after colorectal cancer liver metastasectomy  chemotherapy after progression on EGFR-TKIs  chemotherapy alone versus combined modality therapy  chemotherapy and ICU admission in last phase of life  chemotherapy and radiotherapy long-term adverse impact on dental health  chemotherapy benefit  chemotherapy demands  chemotherapy for breast and prostate cancer  chemotherapy for breast cancer  chemotherapy for childhood cancer  chemotherapy for CRC  chemotherapy for early-stage breast cancer in older women  chemotherapy for EBC  chemotherapy for nonmetastatic breast cancer  chemotherapy for pediatric AML  chemotherapy free treatment  chemotherapy plus atezolizumab for NSCLC  chemotherapy plus immunotherapy  chemotherapy plus pembrolizumab versus chemotherapy  chemotherapy plus ponatinib  chemotherapy regimens  chemotherapy response  chemotherapy response score  chemotherapy timing in pregnancy  chemotherapy use  chemotherapy versus observation  chemotherapy with bevacizumab or temsirolimus  chemotherapy with or without cetuximab  chemotherapy with or without pembrolizumab  chemotherapy with versus without bevacizumab  chemotherapy with versus without total hysterectomy  chemotherapy-associated cognitive fatigue and evening physical fatigue  chemotherapy-free treatment  chemotherapy-induced alopecia  chemotherapy-induced amenorrhea  chemotherapy-induced anemia  chemotherapy-induced cardiotoxicity  chemotherapy-induced nausea and vomiting  chemotherapy-induced neutropenia  chemotherapy-induced neutropenia in adult NSCLC-patients  chemotherapy-induced ovarian dysfunction in breast cancer patients  chemotherapy-induced peripheral neuropathy  chemotherapy-induced thrombocytopenia  chemotherapy-induced toxicities  chemotherapy-ineligible HL patients  chemotherapy-naïve non-squamous NSCLC  chemotherapy-related amenorrhea  chemotherapy-related cognitive impairment  chemotherapy-related hematological toxicity  chemotherapy-related toxicities  chemotherapy-related vomiting in children and adolescents  chest CT plus x-ray versus x-ray follow-up  chest radiation for childhood cancer  chest-irradiated cancer survivors  CHF  CHHiP-studie  chiauranib  child and adolescent survivors of malignancies  child self-report versus caregiver report  Child-Pugh class B  childbearing potential  childbirth  childhood ALL  childhood ALL survivors  childhood AML  childhood and adolescent ALL in The Netherlands 1990-2015  childhood and AYA cancer survivors  childhood and young adult ALL  childhood B-ALL  childhood B-cell ALL  childhood brain tumors  childhood cancer  childhood cancer survival in immigrants  Childhood Cancer Survivor Study  childhood cancer survivors  childhood central nervous system tumors  childhood leukemia  childhood leukemia among offspring  childhood leukemia and lymphoma survivors  childhood leukemia risk  childhood leukemia; maternal hormonal contraception use  childhood medulloblastoma survivors  childhood nasopharyngeal carcinoma  childhood neuroblastoma epidemiology  childhood ovarian non-seminomatous germ cell tumors  children  children and adolescents with cancer  children and AYAs with cancer  children with cancer  children with cancer at home  children with FA or AT  Children’s Oncology Group  Children’s Oncology Group AALL0434 study  Children’s Oncology Group study  Children’s Oncology Group Study AALL03N1  chimeric antigen receptor  China Kadoorie Biobank cohort  China Kadoorie Biobank study  Chinese Alliance for Research in Thymomas database  CHIP  CHIPOR trial  chirurgie  cHL  cHL after PD-1 blockade monotherapy  cHL in older adults  cHL in young patients  cHL survivors  CHM  choice between first-line endocrine versus chemotherapy  CHOICE-01 trial  cholangiocarcinoma  cholangiocarcinoom  cholecystitis  cholesterol lowering drug use and breast cancer survival  chondrosarcoma  chondrosarcoom  CHOP  CHOP with or without alemtuzumab  chordoma  chordoom  chromische lymfocytische leukemie  chromocolonoscopy versus white-light colonoscopy  chromosoom 21  chromosoominstabiliteit  chromothripisis  chronic comorbidities  chronic conditions  chronic fatigue in long-term survivors  chronic health conditions  chronic hepatitis B  chronic irAEs  chronic liver disease mortality  chronic lymphocytic leukemia  chronic musculosketal pain in cancer survivors  chronic myeloid leukemia  chronic myeloid leukemia in chronic phase  chronic myelomonocytic leukemia  chronic neutrophilic leukemia  chronic pain  chronic phase CML  chronic radiation-induced xerostomia  chronic skin toxicities  chronical medical conditions and late effects in survivors  chronisch graft-versus-host disease  chronische fase CML  Chronische fase-CML  chronische lymfatische leukemie  chronische lymfocytische leukemie  chronische lymfoide leukemie  chronische myelomonocytische leukemie  CHRONOS trial  Chronos-1  CHRONOS-1 study two-year follow-up  CHRONOS-3 study  CHRYALIS-2 cohort A  CHRYSALIS cohort E  CHRYSALIS study  chubb  chyleuze ascites  chylothorax and chylous ascites  CI versus CE  CIA  cigarette type  CIK therapy  cilengitide  cilta-cel  cilta-cel for RRMM in Chinese patients  ciltacabtagene autoleucel  CIMBA  cimetropium bromide  CIMP  CIN  CIN 3  CIN2 3  CIN2 3 spontaneous regression  CIN2+ detection  CINP  cinrebafusp alfa  CINV  CIO  CIOD  CIP  CIPN  CIPN in breast cancer survivors  cirAEs  circadiaan ritme  CIRCULATE-Japan GALAXY  circulating AR-status and resistance to Lu-177-PSMA-617  circulating biomarkers  circulating breast cancer risk factors in normal weight postmenopausal women  circulating cytokines  circulating DNA  circulating estradiol level  circulating HPV DNA  circulating immune cells  circulating immune markers  circulating levels of specific lipid groups  circulating lipids and breast cancer prognosis  circulating protein biomarkers for CRC risk  circulating proteins  circulating sex hormone levels  circulating tumor cell-count driven therapy  circulating tumor cells  circulating tumor DNA  circulating tumor DNA analysis  circulating tumor DNA kinetics predict outcomes  circulerend DNA  circulerend tumor-DNA  circulerende tumorcellen  circulerende tumorcellen; detectie nieuwe mutaties  circulerende vetzuren  CIRT  CIRT for unresectable pelvic bone sarcoma  CIRT versus en bloc resection  CISIG  cisplatin  cisplatin and fluorouracil versus carboplatin and paclitaxel  cisplatin for cancer in children  cisplatin-induced hearing loss in children and AYAs  cisplatin-ineligible operable high-risk UC  cisplatin-related hearing loss and tinnitus  cisplatin-unfit NSCLC patients  cisplatine  cisplatine plus gemcitabine and IMRT  CITADEL-203  CITN-10 study  CITN-14 trial  citrusfruit  CITYSCAPE trial  cixutumumab  CKD  CL versus cBCS  cladribine  cladribine and low-dose cytarabine-based regimens  CLAP study  ClarIDHy study  ClarIDHy trial  CLARITY study  CLASS-01 trial  CLASS02 trial  classic and variant hairy cell leukemia  classic Hodgkin lymphoma  classic or endemic KS  classical Kaposi sarcoma  CLASSICAL-Lung clinical trial  claudine 18.2  CLDN18.2-positive gastric or gastroesophageal adenocarcinoma  CLDN18.2-redirected CAR T cells for gastrointestinal cancers  CLEAR  clear cell renal cell carcinoma  CLEAR study  CLEAR trial  clearance of driver mutations after transplantation for myelofibrosis  CLEOPATRA study final results  Clevers  clinical actionability of cancers  clinical and genetic risk factors  clinical and genomic risk  clinical and lifestyle characteristics  clinical and molecular features  clinical and molecular predictors of very late recurrence  clinical benefit and regulatory outcomes  clinical benefit of genomicprofiling  clinical calculator for prediction of recurrence  clinical characteristics  clinical characteristics and outcomes  clinical features  clinical features and outcomes  clinical features for prediction of survival  clinical impact of tumor burden  clinical management  clinical meaningful outcomes  clinical models to predict response and survival  clinical outcomes  clinical outcomes and prognostic factors  clinical prognostic stage group system  clinical significance of adult T-cell leukemia lymphoma  clinical stage I gastric cancer  clinical stage I nonseminoma  clinical stage I NSCLC  clinical stage I seminoma  Clinical Treatment Score at 5 years  clinical trial effect  clinical trial enrollment  clinical trial evidence  clinical trial participation  clinical trials  clinical utility of qPCR plasma EGFR mutation detection in advanced lung cancer  clinical value  clinically N2 non-small cell lung cancer  clinically node-positive breast cancer  clinically node-positive breast cancer with downstaging to ypN0 after NACT  clinician-level knowledge  clinicogenomic classifier  clinicopathologic characteristics  clinicopathologic features  clinicopathologic phenotype  clinicopathological characteristics  clinicopathological features and prognosis after RO resection  clinicopathological predictors of outcomes  CLL  CLL 2007 SA-studie  CLL in patients intolerant to BTK inhibitor or PI3K inhibitor  CLL in younger patients  CLL resistant to venetoclax  CLL SLL  CLL therapies after venetoclax discontinuation  CLL therapy guided by MRD  CLL with coexisting conditions  CLL with comorbidities  CLL with TP53 aberration  CLL with TP53 aberrations  CLL-IPI  CLL10  CLL12 trial  CLL14 study  CLL14 trial  CLL2-BAG study  CLLM1-studie  CLM  CLND  clofarabine  clofarabine plus total body irradiation conditioning  CLOG1302-studie  CLOLE  clomid  clomifeen  clomifeencitraat  clonal hematopoiesis of indeterminate potential  Clozel  CLUE II cohort  CME  CML  CML after ABL kinase inhibitor failure  CML in chronic phase  CML in chronic phase in older patients  CML with T351I mutation  CML without MMR after 2 years of TKI  CML-BP  CML-CP  CML-CP after 2 or more TKIs  CML-studie IV  CMM  CMML  CMML and sAML  CMS risk  CMSs  CMV  CMV viremia after hematopoietic stem cell transplant  CMV-viremie  CN-AML  cN+ M0 BCa  CNAs  CNBSS  CNF  CNS disease  CNS disease control with cranial radiotherapy and ICIs versus chemotherapy  CNS efficacy  CNS efficacy analysis  CNS lymphoma  CNS metastases  CNS metastases of breast ancer  CNS metastasis  CNS NGGCTs  CNS outcomes  CNS relapsed or refractory B-ALL  CNS response  CNS tumors  CNS tumors in children  CNS tumors in young adult patients  CNS-DLBCL  CNS-lymfoom  CNS-metastasen  CNS-recidief HER2-tumoren  CNS-tumoren  CNS-tumoren; impact van behandelcentrum  CNSL  CNV signature  co-occuring MET amplification  co-occuring NOTCH and HR mutations  CO.26 study  CO.26 trial post hoc analysis  coadministration of CD19- and CD22-directed CAR T-cell therapy  COBALT-LYM trial  cobas  cobimetinib  cobimetinib plus vemurafenib  COBRA KAI Study  COBRA study  COBRA-score  coBRIM-studie  cochlear radiation dose  CodeBreaK 101 substudy  CodeBreaK 200  CodeBreaK 200 trial  CodeBreaK100 trial  codon 12 13 versus codon 61 mutation  Cofe-P  coffee and tea consumption  coffee intake  COG AALL0232 study  COG AALL0434  COG AALL0622-studie  COG AALL0932 study  COG AALL1231 trial  COG AALL1331 study  COG AALL1621  COG AAML0631-studie  COG AAML1331 trial  COG AEWS0031 trial  COG ARAR0331 study  COG AREN0533-studie  COG trial ACNS0333  COG-studie AAML0531  COG-studie AREN0532  cognitief functioneren  cognitieve disfunctie  cognitieve klachten  cognitieve veranderingen na chemotherapie  cognition  cognition after endocrine versus chemoendocrine therapy  cognitive and behavioral development of 9-year-old children  cognitive and functional toxicities  cognitive and neurobehavioral impairment  cognitive decline  cognitive functioning  cognitive performance  cohabitation and breast cancer risk  cohesin mutations  COIN colorectal trial  colectomie  colitis-associated CRC risk prediction  collider stratification bias  COLLISION trial  COLOFOL-studie  Cologuard  colon and rectal cancer  colon cancer  colon cancer drug metabolism  Colon Cancer Family Registry  colon cancer peritoneal recurrence  colon cancer risk  colon cancer surgery  colon surgery  colon-NET  coloncarcinogenese  coloncarcinoom  colonkanker  colonoscopic diagnosis of early-onset versus average-onset CRC  colonoscopie  colonoscopy after positive FIT  colonoscopy bowel preparation  colonoscopy in individuals older than 75 years  colonoscopy screening  colonoscopy screening intervals  colonoscopy-based CRC screening  COLONPREV trial  COLOPEC trial  colorectaakanker  colorectaaladenomen  colorectaaladenoom  colorectaalcarcinoom  colorectaalkanker  colorectaalkankerscreening  colorectaalneoplasie  colorectaalpoliepen  colorectal  colorectal adenomas  colorectal cancer  colorectal cancer incidence in Americans approaching screening age  colorectal cancer lever metastasis  colorectal cancer molecular subtypes  colorectal cancer mortality  colorectal cancer precursors  colorectal cancer risk  colorectal cancer screening  colorectal cancer survival models  colorectal carcinogenesis  colorectal liver metastases  colorectal neoplastic polyps  colorectal peritoneal metastasis  colorectale chirurgie  colorectale levermetastasen  colorectale neoplasie  coloscopie  COLUMBA study  COLUMBUS trial  COLUMBUS trial 5-year update  COMBI-AD  COMBI-AD studie  COMBI-AD study  COMBI-d studie  COMBI-MB studie  COMBI-v  CombiDT  combination antiemetics  combination immunotherapy  combination of genetic and environmental risk scores  combination of HAI and systemic chemotherapy  combination of HDAC and mTOR inhibition  combination of ICI and TKI  combination of ICIs  combination of osimertinib and bevacizumab  combination strategy  combined analysis of N9831 and NSABP B-31  combined BRAF- and MEK-inhibition plus PD-1 blockade  combined CTLA-4 and PD-1 inhibition  combined effect of breast density and BMI  combined inhibition of CD38 and PD1  combined inhibition of PD-1 and BRAF and MEK  combined lifestyle factors  combined modality treatment  combined nivolumab and bevacizumab  combined PD-1 blockade and VEGF inhibition  combined risk factors score  combined surgical approach  combined-modality therapy  COMET randomized clinical trial  COMET trial  COMFORT-studies  COMMAND study TP53-mutated AML  COMMANDS trial  commercial gene expression tests  commercial tisagenlecleucel  common cancers  common medications  CoMMpass study  community jury  comorbid depression  comorbiditeiten  comorbidities  comorbidity prevalence in cancer  comparative safety of ICIs  comparison between men and women  comparison Hong Kong and USA  comparison of 5-aza and HSCT  comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing HSCT  comparison of black and white patients  comparison of CBT and MRDT  comparison of clinical studies and real-world outcomes  comparison of early-onset and average-onset colorectal cancers  comparison of first-line treatments  comparison of five guidlelines  comparison of outcomes across neoadjuvant and adjuvant treatments  comparison of PD-L1 protein expression between primary and metastic lesions  comparison of survival by treatment type  comparison of systemic treatments  comparison of three MIBG regimens  comparison of two induction therapies  comparison of two RT fractionation schedules  COMPASS study  COMPASS trial  COMPASSION-03 trial  COMPASSION-04 trial  COMPASSION-16 trial  CompLEEment-1 trial subgroup analysis  complementaire en alternatieve behandelingen  complementary and alternative medications  complementary medicine  complete mesocolic excision  complete remission with vismodegib  complete response to neoadjuvant CRT  COMPLETE study  completion of chemotherapy for breast cancer  complex cancer surgery  complex gastrointestinal cancer surgery  complex karyotype  complication rate and outcomes  complication risk  complications after cancer surgery  complications after surgery for colorectal cancer  complications of axillary surgery  COMPOSE-studies  composite GRFS and CRFS outcomes  compromised immune microenvironment  computationele pathologie  computed tomography screening  computer-assisted colorectal adenoma detection  Computer-geassisteerde chirurgie  CONCERTO trial  CONCERVE Study  conclusions of publcations  concomitant discontinuation of adjuvant hormone therapy and cardiovascular therapy  concomitant mutations  concomitant PPIs  concomitant PPIs and CDK4 6 inhibitors  concomitant use  CONCORD-2  CONCORD-3  CONCORD-3 study  concurrent capecitabine and stereotactic radiation  concurrent cetuximab and nivolumab  concurrent chemoradiotherapy  concurrent chemoradiotherapy with IMRT versus IMPT  concurrent chemoradiotherapy with or without neoadjuvant chemotherapy  concurrent CRT followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil  concurrent intrathecal and intravenous nivolumab  concurrent olaparib and radiotherapy  concurrent tissue and ctDNA profiling in a multicancer cohort  concurrent use of anticoagulants and ibrutinib  conditional cancer-specific survival  conditional immune toxicity rate  conditional local recurrence risk  conditional recurrence-free survival  conditional relative survival  conditional risks of BF and PCSD  conditional survival  conditional survival after five recurrence-free years  conditional survival after resection  conditionele ziektevrije overleving  conditioning after autoHCT  conditioning with G-CSF and decitabine  CONDOR trial  CONFIRM trial  congenital heart disease  congenital tooth agenesis  congestive heart failure  conjunctival melanoma  CONKO-004  connexine 30  consecutive mammography screening examinations  consensus definitions  consensus molecular subtypes  consequences of negative confirmatory trials  conservative management  CONSIGN  consistent physical activity  CONSOLE study  consolidation radiotherapy  consolidation with WBRT or stem-cell transplantation  consoliderende radiotherapie  Consomic Xenograft Model  constitutional mismatch repair deficiency syndrome  consumption of red meat or poultry or fish  CONTACT-01 trial  CONTACT-03 trial  contemporary hormonal contraception  contemporary immuno-oncology combination therapy  contemporary lenalidomide-based regimens  contemporary radiation therapy for ESFHL  CONTESSA 2 study  continuation of lorlatinib beyond progressive disease  continuation of screening after age 70 years  continuous growth model  continuous lenalidomide maintenance for MM  continuous tumor-size-based end points  continuous versus 1-year nivolumab  continuous versus intermittent dosing of dabrafenb-trametinib  CONTINUUM trial  CONTINUUM-studie  contralateraal mammacarcinoom  contralateral breast cancer  contralaterale borstkanker  contralaterale mastectomie  contralaterale profylactische mastectomie  convalescent plasma therapy  conventional versus hypofractionation  conventional versus moderate hypofractionated RT  conversion surgery  CONVERT-studie  CONVINCE-studie  coopERA Breast Cancer trial  copanlisib  copanlisib for tumors with PIK3CA mutations  copanlisib plus gemcitabine  COPD  COPD and lung cancer  copy number alteration screening  copy number loss  CORE-001 trial  coronary artery calcifications  corpus uteri cancer  correlation between RFS and OS after resection of CLM  correlation between surrogate end points and overall survival  correlation of CTCs or DTCs with Oncotype DX recurrence score  correlation of IDFS and OS  correlation with overall survival  corticosteroid refractory ICI-induced enterocolitis  corticosteroïden  corticosteroids  corticosteroids for immune-related adverse events  cosibelimab  COSMIC-021  COSMIC-021 cohort 6  COSMIC-021 study  COSMIC-311 study  COSMIC-312 trial  COSMIC-313  COSMIC-313 trial  COSMOS trial  cost-effective global care for cancer in children  cost-effectiveness  cost-effectiveness of CAR T-cell therapy  cost-effectiveness of intraoperative MRI  cost-effectiveness of lung cancer screening  cost-effectiveness of nivolumab-ipilimumab combination therapy  cost-effectiveness of prostate RT  cost-effectiveness of surveillance  Costa RIca  Costa Rica HPV Vaccine Trial  cotinine  COVID-19  COVID-19 after CAR T-cell therapy for B-cell malignancies  COVID-19 among US cancer survivors  COVID-19 and rates of cancer diagnosis in the US  COVID-19 first wave  COVID-19 hospitalized patients  Covid-19 hospitalized patients with lymphoma  COVID-19 in patients with hematological malignancies  COVID-19 in patients with thoracic malignancies  COVID-19 incidence and mortality  COVID-19 lockdown  COVID-19 mortality in patients with various cancers  COVID-19 mortality risk  COVID-19 mRNA vaccine  COVID-19 outcomes  COVID-19 pandemic  COVID-19 sequelae  COVID-19 severity and outcomes in patients with cancer  COVID-19 vaccination  COVID-19 vaccine  COVID-19-infected cancer patients  COVID-CS  COVIDSurg Collaborative  COX-2 inhibition  coxibs  CP-AKI  CP-B uHCC  CP-CML  CP-genen  CPA use  CPG PVs  CpG-B  CPI-613  CPIs  CPM  CPPT  CPRC5D-targeted CAR T cells  CPX-351  CR after LRT plus IO  CR24  CRA  craniopharyngioma  craniopharyngioma in adults  craniotomie  CRB-401 phase 1 trial  CRBSI  crc  CRC and precursor lesions in adults younger than 50 years  CRC detection  CRC diagnosis  CRC in Taiwan  CRC incidence  CRC incidence and mortality  CRC incidence and mortality after polypectomy  CRC incidence and mortality after snigle negative screening colonoscopy  CRC incidence and mortality in Asia  CRC incidence in Canada  CRC intrinsic subtypes  CRC liver metastases  CRC lung metastasis patients  CRC prevention  CRC prognosis  CRC risk  CRC risk among survivors  CRC risk associated wiht lifetime excess weight  CRC risk following polypectomy  CRC risk in Lynch syndrome  CRC screening in European countries  CRC screening program  CRC stage at diagnosis before versus during the COVID-19 pandemic  CRC stage distribution  CRC surgery in older patients  CRC survival  CRC survivors  CRC with asymptomatic synchronous metastases  CRC with BRAF V600E mutation  CRC with ERBB2 amplification overexpression  CRC with G12C-mutation  CRC with high tumor mutaional burden  CRC-biomarkers  CRC-diagnose  CRC-PM  CRC-PREVENT trial  CRC-risico  CRC-screening  CRCD  CRCPM  CREATE-studie  crenigacestat  cretostimogene grenadenorepvec plus nivolumab  CRF  cribriform groeipatroon  CRICKET trial  crizotinb  crizotinib  crizotinib plus chemotherapy  crizotinib-resistant ALK-positive NSCLC  CRLM  CRLX101  CRN  crofelemer for CID  Crohn’s disease  CRONOS study  CROSS  CROSS trial ten-year outcomes  CROSS versus FLOT  CROSSFIRE trial  crossover or pembrolizumab rechallenge after recurrence  CROWN study  CROWN Trial  CRP  CRP flare-response  CRP-niveau  CRPC  CRPC with bone metastases  CRS  CRS + HIPEC  CRS for advanced-stage OC  CRS HIPEC  CRS plus chemotherapy versus chemotherapy alone  CRS plus HIPEC  CRS with or without HIPEC  CRS-207  CRS-HIPEC  CRS-HIPEC cost effectiveness  CRS-HIPEC for CRC PMs  CRS-HIPEC for CRPM  CRT  CRT and local excision versus TME for T2-T3ab N0 M0 rectal cancer  CRT as alternative for NSCLC surgery with predicted high risk of irradical resection  CRT for cervical cancer  CRT for esophageal cancer  CRT for HNC  CRT for LA HNC  CRT versus CT  CRT with cisplatin versus cetuximab  CRT with liposomal paclitaxel plus cisplatin  CRT with or without metformin  CRTCOESC trial  cryoablation  cryoablation for lung metastases  cryoablation with excision  cryotherapy  CS tumors  CS1002 with or without CS1003  CSCC  cSCC of head and neck  cSCC risk after diagnosis actinic keratosis  CSCC-HN  CSCCs  CSF penetration of anti-PD-1 antibodies  CSM  CT  CT examinations  ct HPV DNA for surveillance  CT imaging  CT lung cancer screening  CT radiation  CT radiation exposure before age 22 years  CT-based biomarkers  CT-guided high-dose-rate interstitial brachytherapy  CT-longkankerscreening  CT-P10  CT-P6 versus trastuzumab  CT-screening longkanker  CT041  cT1-2N0 breast cancer  cT1T2No OTSCC  cTACE  CTC clusters  CTCAE  CTCL  CTCs  CTCs and early relapse  ctDNA  ctDNA after NACT  ctDNA after neoadjuvant chemotherapy  ctDNA alterations  ctDNA analysis  ctDNA analysis to direct therapy  ctDNA analysis to guide adjuvant therapy  ctDNA and risk of progression after long-term response  ctDNA as a risk stratifying biomarker  ctDNA as biomarker of response to palbociclib-fulvestrant  ctDNA as marker of MRD  ctDNA as response indicator  ctDNA clearance  ctDNA detection after CRT  ctDNA dynamics  ctDNA for early detection of MRD and risk stratification  ctDNA for monitoring disease status  ctDNA in CSF and plasma  ctDNA markers for early progression  ctDNA methylation  ctDNA methylation haplotypes  ctDNA mutations  ctDNA predicts response and prognosis  ctDNA profiling  ctDNA reflects response and survival  ctDNA response  ctDNA sequencing  ctDNA TMB and response to first-line pembrolizumab  ctDNA-guided de-escalation of targeted therapy  ctDNA-guided therapy  ctHPV DNA  ctHPV DNA in saliva  ctHPVDNA after surgery for HPV-associated OPSCC  ctHPVDNA monitoring in recurrence surveillance  CTL019 for pediatric B-ALL  CTLA-4  CTLA-4 blokkade  CTLC  CTONG1104 study  CTP  CTRCD  CTS5 risk score  CTX130  CUDC-907  CUETO  cumulative burden of major surgical interventions  cumulative burden of psychiatric disorders and self-harm across 26 adult cancers  cumulative GRAS score  cumulative incidence of CIHL  cumulative incidence of CVD  cumulative risk of false-positive result  CUP  CUPISCO study  curatie  curative intent treatment for bladder cancer  curative-intent resection  CURB oligoprogression trial  current or former smoking  cutaan squameus celcarcinoom  cutaan squameus celcarcinoom van hoofd en hals  cutaan T-cel lymfoom  CUTALLO trial  cutane bijwerkingen  cutaneous adverse events  cutaneous basal cell carcinoma  cutaneous BCC  cutaneous HNSCC with regional lymph node metastasis  cutaneous malignant melanoma  cutaneous melanoma  cutaneous melanoma survivors  cutaneous SCC  cutaneous squamous cell carcinoma  cutaneous toxicities  cutaneous toxicity  CUX1-ALK rearrangement  CV risk  CVD  CVD and stroke following cancer in older adults  CVD risk  CVD risk after GnRH agonists versus GnRH antagonists  CVD risk factors  CVD risk factors and colorectal cancer  CVEs  CVSS-studie  CVT  CX.5 SHAPE trial  CXB  CXCL8-CXCR1 2 axis  CXCR4 expression in lung cancer  CXM  cycline D1  cyclofosfamide  cyclophosphamide  cyclophosphamide for prevention of aGVHD  cyclophosphamide-bortezomib-dexamethasone  cyclophosphamide-free chemotherapy for ovarian protection  CYP2D6 genotype  CYP3A  CYPIDES trial  cyproteronacetaat  cyramza  cystatin-C  cystectomie  cystectomy versus trimodality therapy  cytarabine  CYTO-CHIP study  CyTOF of peripheral blood  cytogenetically defined high-risk multiple myeloma  cytogenetisch normaal AML  cytokine levels  cytokine-induced killer cell therapy  cytokines  cytology testing  cytoreductive surgery  Cytosponge-trefoil factor 3  D plus TM  D-2-hydroxyglutaraat  D-index-guided early antifugal therapy  D-Rd  D-Rd versus Rd  D-TORCH trial  D-VCd  D-Vd versus Vd  D-VMP  D-VTd versus VTd  D-VTd versus VTd for newly diagnosed multiple myeloma  D3S-001  DA-EPOCH plus InO  DA-EPOCH-R versus R-CHOP  DAAs  DaBlaCa-13 study  dabrafenib  dabrafenib plus trametinib  dabrefenib plus trametinib  dacarbazine for metastatic melanoma  dacomitinib  DADI  DAFI  daily aspirin  daily insulin dose  daily sitting time  daily step counts  dairy intake during adolescence and risk of colorectal adenoma  DAISY trial  DALLT cohort  dalpiciclib  Danish Breast Cancer Group Internal Mammary Node study  Danish Breast Cancer Group Partial Breast Irradiation Trial  Danish cancer patients  DAOH  DAPHNe trial  daratumumab  daratumumab for AL amyloidosis  daratumumab plus lenalidomide maintenance after transplantation  daratumumab-based regimens  daratumumab-based treatment  daratumumab-bortezomib-dexamethasone  darm-microbioom  darm-stamcellen  darmflora  darmkanker  darolutamide  darolutamide maintenance  darolutamide plus ADT  DARPin drug candidate MP0250  DART S1609 neuroendocrine cohort  DART SWOG 1609  DART SWOG 1609 Cohort 47  DART SWOG S1609  DART-studie  dasatinib  dasatinib plus blinatumomab  dasatinib plus CAR T-cell therapy  dasatinib plus dendritic cell vaccines targeting TBVAs  dasatinib versus imatinib  DASCERN randomized study  DASFREE 5-year analysis  DAstop2 trial  DATA-studie  Dato-DXd  Dato-DXd versus docetaxel  David A. Karnofsky Memorial Award and Lecture  DAVLEC trial  davoli  DAWN-studie  DAWNA-2 trial  DAWT  DB  DB-020  DBCG 07-READ studie  DBCG HYPO trial  DBMS  DBT versus DM  DC-CIK  DCCSS-LATER 2 psycho-oncology study  DCCSS-LATER 3  DCd with or without P  DCE-MRI  DCF chemotherapy  DCIS  DCIS adjacent to IBC  DCIS and early stage HR-positive breast cancer  DCIS and node-negative breast cancer  DCIS before age 50 years  DCIS grading  DCIS in the male breast  DCIS of the breast  DCIS risk  DCIS size and margin status  DCOG-LATER cohort  DCOG-LATER cohort study  DCOG-LATER studie  dd BV plus ICE chemotherapy  dd-chemotherapie  DD-cxdl  DDCT  DDGP versus SMILE  DDLT  DDR gene aberrations  DDR gene mutations  DDR-HRR altered mCRPC  de novo HER2-positive metastatic breast cancer  de novo metastatic breast cancer  de novo metastatic nasopharyngeal carcinoma  de novo metastatic prostate cancer  de novo mHSPC  de novo stage IV breast cancer  de novo stage IV HER2-positive MBC  de novo stage IV versus distant metastatic recurrent NSCLC  De-ESCALaTE HPV study  de-escalation of axillary surgery  de-escalation of TKIs  DEAR study  death and dementia risk  death from unintentional injury among cancer patients  Debio 1143 plus high-dose cisplatin CRT  Debio0932  Decipher  decision support system  decision-making  decitabine  decitabine plus camrelizumab  dedifferentiated chordoma  deep learning  deep learning model  deep molecular response  deepening of response after completing therapy  defactinib  DeFi trial  deficient mismatch repair stage III colon cancer  definition of positive CRM  definitive local therapy  definitive radiotherapy  definitive RT  definitive stereotactic body radiotherapy  degarelix  DEL  delay of cancer surgery  delayed CINV in pediatric patients  delayed hearing loss  delayed immune-related adverse events  delayed surgical treatment  delirium  DeLLphi 300  DeLLphi-301 trial  dementia  demographic characteristics  dendritic cell-based immunotherapy  Denemarken  denosumab  denosumab or zoledronic acid in cancer patients  dense breast tissue  dentaal trauma  dental extractions and ORN risk  dental health and lung cancer risk  DEP KP80 study  depatux-M  depressie  depression  depression and suicidal ideation  depression risk  depth of response  dermatofibrosarcoma protuberans  DESKTOP III trial  desmoïd  desmoid tumors  DESMOPAZ study  DESTINY study  DESTINY-Breast01  DESTINY-Breast01 study  DESTINY-Breast02  DESTINY-Breast02 trial  DESTINY-Breast03  DESTINY-Breast03 subgroup analyses  DESTINY-Breast03 trial  DESTINY-Breast04  Destiny-Breast06 trial  DESTINY-CRC01 trial  DESTINY-CRC02  DESTINY-Gastric01 study  DESTINY-Lung01  DESTINY-Lung01 trial  DESTINY-Lung02 trial  DESTINY-PanTumor01  DESTINY-studie  detectie  Detectie borstkanker  detectie colorectaalkanker  detecting genomic biomarkers in plasma versus tissue  detection advanced neoplasia  detection bias  detection early-stage OPSCC  detection of circulating tumor DNA after surgery for nmCRC  detection of colon cancer recurrences  detection of CTCs during follow-up  detection of germline variants  detection of invasion of detrusor muscle  detection of microsatellite instability  detection of mutations in ctDNA  detection of non-index lesions  detection of prostate cancer  detection of relapse  determinants of breast cancer risk  determinants of optimal adjuvant therapy  determinants of outcomes  determinants of survival  determinants of tumor cell PD-L1 expression  determinants of uptake of active surveillance  determinants of xerostomia  development of 12- and 15-year old offspring  development of new drugs  devimistat in combination with gemcitabine and cisplatin  dexamethason  dexamethasone  dexanethasone  dexrazoxane  DFCI 11-001 study  DFF332  DFP-10917  DFS  DHA  DHAP  DHL  DHL and THL  diabetes  diabetes and cancer risk  diabetes in long-term cancer survivors  diabetes mellitus  diagnose longcarcinoom  diagnosis and treatment  diagnostic low-dose ionizing radiation in youth  diagnostic scrutiny  diagnostic value of FDG PET CT  diagnsotic performance of feacal immunochemical test  DICER1 pathogenic variants  diet and survival  diet qualiity  diet quality  diet quality and risk of prostate cancer grade reclassification during active surveillance  dietary carbohydrate quality and human health  dietary carbohydrates  dietary fat  dietary fiber  dietary fiber and yogurt  dietary intake  dietary intake of antioxidants  dietary modification and breast cancer mortality  dietary polyunsaturated fat  dietary sodium restriction  dietary supplement use  dietary supplement use and documentation  dietary supplement use during chemotherapy  differences in treatment outcomes  different cancer types  different types of plant-based dietary patterns and CRC risk  differential activity of PARP inhibitors  differential response to neoadjuvant endocrine therapy  differential ribosome measurements of codon reading  differentiated thyroid cancer  difficult patients  diffuse large B cell lymphoma  diffuse large B-cell lymphoma  diffuse large B-cell lymphoma-specific mortality  Diffuse midline H3K27-altered gliomas in the spinal cord  Diffuse optical spectroscopic imaging  diffuse type TGCT  diffuse-type giant cell tumor  diffusion-weighted MRI  diffuus grootcellig B-cel lymfoom  diffuus intrinsiek ponsglioom  difluoromethylornithine maintenance  digestive tract cancer  digital breast tomosynthesis  digital breast tomosythesis  digital remote monitoring  digital screening mammografie  DigniCap  digoxin  digoxine  DII  DIP  DIPG  DIPG patients ≥ 10 years of age  DIPG-BATS studie  DIPPER trial  direct-acting antivirals  direct-to-patient outreach  discontinuation imatinib for CML in children  discontinuation of anti-PD-1 antibody therapy  discontinuation of first-line dasatinib for CML  discontinuation of immune suppression  discontinuation of TKIs for de novo CP-CML  discontinuous SBRT  discordance between CA-125 progression and RECIST progression  discordance between primary and matched metastatic breast cancer  disease burden  disease control after radiotherapy  disease progression in cancer patients  disease trajectories and mortality after breast cancer  disease-free survival  diseases and deaths in middle-aged adults  disontinuation of trastuzumab  disparaties in cancer incidence by sexual orientation  disparities  disparities by race ethnicity and age  disparities in access to high-volume pancreatectomy centers  disparity between children and AYAs  dispositional optimism  disruption of FIT-screening programmes  distal cholangiocarcinoma  distal rectal cancer  distale pancreatectomie  distant disease-specific survival  distant metastasis of salivary gland cancer  distant metastatic breast cancer  distant recurrence of breast cancer  distant versus supraclavicular lymph node metastases  DisTinGuish trial  distress  Distress Thermometer  divarasib  divarasib plus cetuximab  DLBCL  DLBCL in elderly frail patients  DLBCL in patients aged 18-65 years  DLBCL survivors  DLBCL-RT  DLGG  DM  DMFS  dMMR CC  dMMR colon cancer  dMMR MSI mCRC  dMMR MSI metastatic gastrointestinal cancer  dMMR MSI-H GC  dMMR MSI-H PaC  dMMR MSI-H solid tumors  dMMR PDAC  dMMR subgroup analysis  DMPM  DN  DNA damage immune response  DNA Damage Immune Response signatrue  DNA damage repair mutations  DNA damage response targeting treatments  DNA next-generation sequencing  DNA promoter-hypermethylering  DNA repair gene aberrations. platinum-base chemotherapy  DNA-methylering  DNA-test  DNA-thioguanine concentration  DNMT3A-mutatie  DOACs versus LMWH for prevention of recurrent VTE in cancer patients  DOACs versus LMWHs  docetaxel  docetaxel and trametinib  docetaxel-based neoadjuvant chemotherapy and en bloc resection  docetaxel-cyclophosphamide for breast cancer  docetaxel-PM plus trastuzumab-pkrb  documentaire  doelgerichte behandeling  DOLPHIN phase 2 nonrandomized trial  dominant TCR clone  donor clonal hematopoiesis  donor-derived anti-CD19 CAR T cells  donor-derived CD7 CAR T-cells  donor-derived expanded NK-cells to prevent relapse  DoR  dordaviprone (ONC201)  DOREMY study  dormancy-genen  dose dense doxorubicin-cyclophosphamide and-paclitaxel  dose optimization  dose reduction of preoperative RT  dose-adjusted EPOCH-R  dose-dense adjuvant chemotherapy plus trastuzumab  dose-dense versus standard chemotherapy  dose-individualized FP therapy  dosisescalatie  DOSISPHERE-01 study  dostarlimab  dostarlimab for endometrial cancer  dostarlimab in doublet triplet combinations  DOT1L  double expressor DLBCL  doublet therapy for de novo mCSPC  DOVIGIST-studie  Down syndrome and ALL in children and AYAs  downstaging before liver transplant  doxorubicin delivery from ultrasound-triggered liposomes  doxorubicin for adolescent and adult HL  doxorubicin for sarcoma  doxorubicin plus pembrolizumab  doxorubicin with or without ICI  doxorubicine  dPFSors after PD-1 blockade for melanoma or NSCLC  DPP-4 inhibition for aGVHD proylaxis  DPYD genotyping  DPYD*2A variant carrying cancer patients  DRAGON IV CAP 05 trial  DRD-positive mUC  DREAM study  DREAMM-2 study  DREAMM-2 trial final analysis  DREAMM-7  DREAMM-8 trial  DREAMseq trial  driver-negative advanced non-small cell lung cancer  drivers of patients rating of cancer care in Switzerland  droge mond  droplet digital PCR  DRRD  DRUG Access Protocol  Drug Rediscovery Protocol  drug response predictor  drug-drug interactions  drug-funding reimbursement  DRUP trial  drye eye syndrome  DSMM XI-studie  DSRCT  DSTP30865  dt-GCT  DTC  DTCs  DTX3 copy number in breast cancer  dual ICI and radiosurgery for BMs  dual PD-1 and HER2 blockade for aGC  DUBLIN-3 trial  ductaal carcinoom in situ  ductal carcinoma in situ  DUD  dunne-darmadenocarcinoom  dunne-darmneoplasie  DUO Crossover Extension Study  DUO study  durability of response to SARS-CoV-2 BNT162b2 vaccine  duration of adjuvant trastuzumab  duration of ADT with postoperative radiotherapy  duration of androgen deprivation therapy added to RT for PCa  duration of immunotherapy  duration of response  DURIGAST trial  durvalumab  durvalumab after CRT  durvalumab and tremelimumab with definitive CCRT  durvalumab for NSCLC  durvalumab for solid tumors in HIV-1 infected patients  durvalumab or placebo after CRT for stage III NSCLC  durvalumab plus chemotherapy  durvalumab plus CRT  durvalumab plus gemcitabine and cisplatin  durvalumab plus olaparib  durvalumab plus olaparib plus cediranib  durvalumab plus radiotherapy  durvalumab plus targeted therapy  durvalumab plus tremelimumab  durvalumab with or without stereotactic body radiotherapy  durvalumab with or without tremelimumab  durvalumab-cisplatin-pemetrexed  DURVAST study  dutasteride  Dutch Bone Metastasis Study  Dutch MINDACT cohort analyis  Dutch trends in incidence and prognosis  duvelisib  duvelisib plus romidepsin  DV  DYNAMIC study  DYNAMIC trial  DYNAMIC trial 5-year outcomes  dynamics of ctDNA  DYNAMO study  DYPD genotyping  dysfagie  dyslipidemia  dyspnea in cancer patients  dyspnoe  E GEJ cancer  e-sigaretten  E1609 study  E1912 study  E1912 updated results  E2F8  E3805-studie  E3A06 study  E3N  E3N cohort  E4  E5103 study  E7389-EF plus nivolumab  E75  EA  EA2108 study  EAA  EAC  EAC and GEJ adenocarcinoma  EADC  EAGLE study  EAGLES study  early and locally advanced breast cancer  early AYAs  early breast cancer  early breast cancer or ductal carcinoma in situ  early breast cancer treatment  early cancer surveillance  early cervical cancer  early changes in ctDNA  early CRC  early CRP kinetics as predictive biomarker  early death  early detection and monitoring progression of gastric cancer  early detection and prognosis prediction  early diagnosis  early discontinuation of endocrine therapy  early donor identification  early experience  early HER2-positive BC  early HER2-positive breast cancer  early HR-positive breast cancer  early interdisicplinary supportive care  early intervention  early invasive breast cancer mortality  early liquid biopsy  early local therapy  early markers for cardiovascular disease  early melanoma recurrence despite adjuvant anti-PD-1 therapy  early metabolic response  early mortality  early multinodular HCC  early noninvasive detection of response  early onset CRC  early onset female cancer survivors  early palliative care use  early phase ICI-trials  early prediction of chemoradiotherapy-induced cardiotoxicity  early prediction of response  early prediction of response or progression  early predictors of pathologic complete response to neoadjuvant therapy  early rectal cancer  early recurrence  early recurrence after resection  early relapse detection  early rituximab versus WW  early stage breast cancer  early stage breast cancer in older women  early stage breast cancer outcome  early stage EGFR-mutated NSCLC  early stage ER-positive breast cancer  early stage ER-positive breast cancer in older women  early stage prostate cancer  early stage TNBC  early stage triple-negative breast cancer  early thymic precursor acuut lymfoblastische leukemie  early thymic precursor-like phenotype ALL  early TNBC  early trastuzumab interruption  early triple-negative breast cancer  early-life alcohol intake  early-onset cancers  early-onset colorectal cancer  early-onset colorectal cancer among women  early-onset CRC  early-onset familial breast cancer  early-onset pancreas cancer  early-onset pancreatic cancer  early-onset severe infections  early-onset versus late-onset CRC  early-stage breast cancer  early-stage breast cancer in elderly patients  early-stage breast cancer in the elderly  early-stage breast cancer in young women  early-stage breast cancer recurrence  early-stage cancers  early-stage cervical cancer  early-stage CLL  early-stage cutaneous T-cell lymphoma  early-stage endometrial cancer  early-stage gastric cancer  early-stage hepatocellular carcinoma  early-stage HER2-positive breast cancer  early-stage Hodgkin lymphoma  early-stage HR-positive breast cancer  early-stage lung cancer  early-stage lung cancer in octogenarians  early-stage MCC  early-stage melanoma micrometastases  early-stage non-small cell lung cancer  early-stage non-small lung cancer  early-stage NSCLC  early-stage or isolated lung parenchymal recurrent node-negative NSCLC  early-stage oropharyngeal squamous cell carcinoma  early-stage PaC  early-stage pediatric HL  early-stage primary cutaneous melanoma  early-stage TNBC  early-stage TNBC in older patients  early-stage unfavorable cHL  early-stage unfavorable classic Hodgkin lymphoma  early-stage unfavorable HL  EAST ENERGY trial  EBC  EBCC-12 postponed  EBMT ALWP study  EBRT for localized prostate cancer  EBRT for prostate cancer  EBV  EC  EC with ERBB2 3 alterations  EC with lymph node metastasis  EC-CRT-001  ECD  Echelon-1 studie  ECHELON-1 study  ECHELON-1 trial  ECHELON-2 study  ECHELON-3  ECHO trial  ECHO-202 KEYNOTE-037  ECLIPSE trial  ECOG PS  ECOG PS 2  ECOG-ACRIN 2511 study  ECOG-ACRIN 5508 study  ECOG-ACRIN E1412 study  ECOG-ACRIN E1609 study analysis  ECOG-ACRIN E1912 study  ECOG-ACRIN E2211  ECOG-ACRIN E2810  ECOG-ACRIN E3311 trial  ECOG-ACRIN EA3163  ECOG-ACRIN EA9131  ECOG-PS  economic evaluation  ECT  ECX)  ED  ED-SCLC  ED-SCLC in elderly patients  Edinburgh Pain Assessment and management Tool  education level related inequalities in cancer mortality in Europe  educational level  educational outcomes  EE2012 trial  één-maands mortaliteit  eenarmige versus gerandomiseerde fase 2-studies  eerdere kanker  EET  EF-14  efbemalenograstim alfa  effect modification  effect modifiers of low-dose tamoxifen  effect of immunotherapy time-of-day infusion  effect of racial concordance on patient trust  effect on early cancer detection  effectivity and safety of BNT162b2 vaccine in patients undergoing treatment for cancer  effects of GVHD on long-term outcomes  effects of HER2 alterations  efficacy of adjuvant chemotherapy  efficacy of BNT162b2 mRNA vaccine in patients with CLL  efficacy of ICIs  efficacy of immunotherapy  efficacy of medications for reduction of risk of primary breast cancer in women  EFVPTC  EGA  EGCG for prevention of postoperative RT-induced dermatitis in breast cancer patients  EGD for detection of gastric neoplasms  EGFR  EGFR amplification  EGFR amplified glioblastoma  EGFR copy number gain  EGFR ex20ins-mutant NSCLC  EGFR exon 20 insertion-mutated NSCLC  EGFR inhibition  EGFR inhibition resistance  EGFR mutant NSCLC  EGFR mutated advanced non-small cell lung cancer  EGFR mutated metastatic non-small cell lung cancer  EGFR mutated NSCLC  EGFR mutation status  EGFR mutation-positive advanced NSCLC  EGFR mutation-positive MET-amplified NSCLC after EGFR TKIs  EGFR mutation-positive NSCLC with leptomeningeal metastases  EGFR T790 mutated aNSCLC detected in plasma  EGFR T790M  EGFR T790M mutant NSCLC  EGFR T790M-positive advanced NSCLC with leptomeningeal metastases  EGFR T790M-positive NSCLC  EGFR T790M-positive NSCLC in elderly patients  EGFR therapy resistant NSCLC  EGFR wild-type aNSCLC  EGFR-amplified GEA  EGFR-amplified recurrent glioblastoma  EGFR-blokkade  EGFR-mutant and MET-amplified NSCLC  EGFR-mutant aNSCLC  EGFR-mutant lung adenocarcinoma  EGFR-mutant lung cancer  EGFR-mutant mNSCLC  EGFR-mutant non-small cell lung cancer  EGFR-mutant NSCLC  EGFR-mutant NSCLC in chemotherapy-ineligible patients  EGFR-mutant NSCLC with liver metastases  EGFR-mutant RET fusion-positive non-small cell lung cancer  EGFR-mutated advanced non-small cell lung cancer  EGFR-mutated advanced non-small-cell lung cancer  EGFR-mutated advanced NSCLC  EGFR-mutated aNSCLC  EGFR-mutated LA M NSCLC  EGFR-mutated lung adenocarcinoma  EGFR-mutated non-small cell lung cancer  EGFR-mutated nonsquamous NSCLC after EGFR-TKI therapy  EGFR-mutated NSCLC  EGFR-mutated NSCLC in elderly or frail patients  EGFR-mutated NSCLC with brain metastases  EGFR-mutated NSCLC with LMs  EGFR-mutatie  EGFR-mutaties  EGFR-TKI  EGFR-TKI with or without thoracic radiotherapy  EGFR-TKIs  EGFR-TKIs for stage IIIB IV EGFR-mutant NSCLC  EGFR-variant NSCLC  EGFR+ and ALK+ NSCLC  EGFRex20ins mutation-positive NSCLC  EGFRex20ins-positive mNSCLC  EGJ adenocarcinoma  EHCC  eHealth support  eierstokkanker  eiwitbiomarkers  elacestrant  elacestrant (RAD1901)  ELCC 2017  elderly cancer patients  elderly HR-positive breast cancer patients  elderly patients  elderly patients with advanced non-small cell lung cancer  electric power morcellation  electroacupuncture  electroacupuncture for postoperative ileus  electronic nose  electroporated plasmid IL-12  ELEVATE TN study  ELEVATE-TN 4-year follow-up  elevated CRP  elevated platelet count  elevated vitamin B12 levels  ELIANA study QOL analysis  ELIANA trial  Eliasof  eliminating surgery  ELM-1 study  ELM-2 trial  ELOQUENT-3 study  ELOQUENT-3 trial  elotuzumab  elranatamab  ELRP  ELSA  eltrombopag  ELTS-score  emactuzumab  EMBARK trial  EMBER-3 study  EMBRACA study  EMBRACA-studie  EMBRACE trial  EMBRACE-I study  EMBRACE-studie  embryonale hersentumoren  EMD  EMERALD trial  EMERALD-1 trial  emergency department use and unplanned hospitalization  EMERGING-CTONG 1103 study  emesis  emetogenic chemotherapy in pediatric patients  EMILIA  EMN09 study  emotionele uitputting  EMP of the head and neck  EMPIRE-1 study  EMPOWER-Cervical 1 trial  EMPOWER-Lung 1  EMPOWER-Lung 1 trial  EMPOWER-Lung 3  EMPOWER-Lung 3 part 2  EMPOWER-Lung 3 trial  EMT  EMVI  EMZL  ENACT trial  enasidenib plus azacitidine  encorafenib  encorafenib plus binimetinib  encorafenib-binimetinib-cetuximab  ENCORE-601 study  end of life use of systemic therapy  END versus observation  end-of-life care  end-of-life quality indicators  end-of-life zorg  ENDEAVOR-studie  ENDOANGEL system  endocriene behandeling  endocriene effecten  endocriene therapie  endocrine deficiency  endocrine diseases  endocrine pathways dysregulation  endocrine resistance  endocrine therapies  endocrine therapy  endocrine therapy adherence  endocrine therapy for breast cancer  endocrine therapy resistance  endocrine therapy response  endocrine treatment  endocrine treatment versus chemotherapy  endocrine-resistant ABC  endocrine-resistant mBC  endocrine-responsive lobular carcinoma of the breast  endometrial ancer  endometrial cancer  endometrial cancer prevention  endometrial cancer risk  endometrial cancer surgery  endometrial cancer survival  endometrioïd endometriumcarcinoom  endometrioïd epitheliaal ovariumcarcinoom  endometriosis  endometriosis typology and ovarian cancer risk  endometrium-adenocarcinoom  endometriumcarcinoom  endometriumkanker  EndoPredict  endoprosthetic reconstruction for lower extremity bone tumors  endoscopic or open resection  endoscopic surgery versus intensity-modulated radiotherapy  endoscopist ADR  endotheliaal ovariumcarcinoom  ENDS  ENDURANCE trial  ENEC  energetic capacity  ENESTfreedom  ENESTfreedom trial  enfortumab vedotin  ENGOT-EN5 GOG-3055 SIENDO  ENGOT-EN6 GOG-3031 RUBY  ENGOT-OV16 NOVA study  ENGOT-OV16 NOVA trial  ENHANCE 1 study  enhanced recovery after surgery  enhancer of zeste homolog 2  ENITEC consortium  ENKTL  ENLIVEN study  enobosarm  ENOC  enocrafnib  eNose  eNRGy trial  ensartinib  ensartinib versus crizotinib  entecavir  entecavir with or without interferon-α  enteropancreatic neuroendocrine tumors  enterovirus  enthusiasm hypothesis  entinostat with nivolumab and ipilimumab  entospletinib  ENTRATA trial  entrectinib  Environmental Quality Index  ENZ or ABI for mCRPC  ENZ vs AA  ENZA-p trial  enzalutamide  enzalutamide for castration-resistant prostate cancer  enzalutamide plus trastuzumab  enzalutamide versus bicalutamide  ENZAMET study  ENZAMET trial  enzastaurine  EOC  EOC in Black women  EOC in high income countries  EOC stage IC2 IC3  EOCRC  EOCRC versus LOCRC  EOPC  EOPM  EORTC  EORTC 10995  EORTC 1325 Keynote-054 studie  EORTC 1325 KEYNOTE-054 study  EORTC 1325 KEYNOTE-054 trial  EORTC 1325-MG KEYNOTE-054  EORTC 1325-MG KEYNOTE-054 3-year follow-up  EORTC 18071  EORTC 22922 10925 study  EORTC 22922 10925-studie  EORTC 22952-26001 trial exploratory analysis  EORTC 26101 analysis  EORTC 26951  EORTC LYSA FIL H10 and NCRI RAPID joint analysis  EORTC QLQ-C30 prognostic value for overall survival  EORTC study 22033-26033  EORTC-62092  EPA  epacadostat  EpCAM-positieve tumoren  EPCORE NHL-1  EPCORE NHL-1 trial  EPCORE NHL-2 trial  epcoritamab  epcoritamab plus GemOx  EPd versus Pd  ependymoom  epertinib  EPHOS-B  EPHOS-B trial long-term results  ephrinB2 inhibition plus pembrolizumab  EPI-CT cohort study  epi-drugs  Epi-R-CHOP trial  EPIC  EPIC and UK Biobank prospective cohort studies  EPIC cohort  EPIC trial  EPIC-analyse  EPIC-NL  EPICAL trial  EPICAP-studie  epichaperome-targeted positron emission tomography for tumor imaging  epidemiologic trends  epidemiological characteristics  epidemiology and outcomes  epidemiology of primary and metastatic brain tumors in children  epidemiology of VTE  epidural use  epidurale metastasen  epigenetic age acceleration  epigenetic editing  epigenetische stabiliteit  epigenetische veranderingen  epilepsy risk factors  epirubicin  epitheliaal ovariumcarcinoom  epithelial ovarian cancer  epithelial ovarian cancer risk  epithelial ovarian cancer survivors  epithelial ovarian carcinoma  epitinib  Epitopes-HPV02 ancillary study  Epitopes-HPV02 study  EPOC  EPOC1706 study. advanced gastric cancer  EPOC1802 trial  EPOCH study  eprenetapopt (APR-246) plus azacitidine  eprenetapopt plus azacitidine  eprenetapopt-azacitidine maintenance  eprenetapopt-venetoclax-azacitidine  EPSILoN  Epstein Barr virus-specific autologous cytotoxic T lymphocytes  Epstein-Barr virus serology-based screening  Epstein-Barr virus-geïnduceerde lymfoproliferatieve ziekte  EQoL-MDS  EQOL-MDS trial  eque-cel  ER low-positive breast cancer  ER positive breast cancer  ER status  ER status and breast cancer survival  ER- en PR-testen  ER-low positive breast cancer  ER-low-positive breast cancer  ER-negatief mammacarcinoom  ER-negatieve borstkanker  ER-negatieve tumoren  ER-positief HER2-negatief gevorderd mammacarcinoom  ER-positief mammacarcinoom  ER-positieve borstkanker  ER-positive advanced breast cancer  ER-positive advanced breast cancer after aromatase inhibitor failure  ER-positive BC  ER-positive breast cancer  ER-positive breast cancer in postmenopausal women  ER-positive early-stage breast cancer  ER-positive EBC  ER-positive HER2 negative ABC  ER-positive HER2 negative breast cancer  ER-positive HER2-negative aBC  ER-positive HER2-negative advanced breast cancer  ER-positive HER2-negative breast cancer  ER-positive HER2-negative breast cancer in elderly patients  ER-positive HER2-negative early breast cancer  ER-positive HER2-negative MBC  ER-positive HER2-negative primary breast cancer  ER-positive node-positive breast cancer in elderly patients with comorbidities  ER-specific CBC  ER-targeted PET  ER+ HER2-  ER+ HER2- BC  ER+ HER2- breast cancer  ER+ HER2- mBC  ER+ HER2- MBC after failure of AI  ERA 223 study  era-by-era analysis of survival  eRAPID intervention  ERAS  ERBB2 HER2-positive metastatic breast cancer  ERBB2 mRNA expression  ERBB2 mutations in solid tumors  ERBB2 plasma copy number  erdafitinib  erdafitinib versus chemotherapy  Erdheim-Chester disease  EREMISS trial  erfelijke borst- en eierstokkanker  erfelijke syndromen  erfelijkheid  ERG- and PTEN-defined prostate cancer  eribulin  eribulin plus cyclophosphamide  eribulin plus everolimus  eribulin plus gemcitabine  eribulin plus pembrolizumab  eribulin versus S-1  eribulin with or without pembrolizumab  eribuline  ErkentNIS  erlotinib  erlotinib for advanced EGFR-mutated NSCLC  erlotinib plus vemurafenib  ersatzdroge  Erβ1  Erβ2  ES  ES SCLC  ES-NSCLC  ES-SCLC  ES-SCLC after platinum-based chemotherapy  ES-SCLC in chemo-naïve patients  ESAS-scores  ESCC  ESCC detection by microRNA profiling  ESCC in older patients  ESCORT study  ESCORT-1st study  ESD  ESGC  ESHAP  eSMART study  ESME trial  ESMO  ESMO-MCBS H  ESO-Shanghai 13  esomeprazole  ESOPEC  esophageal adenocarcinoma  esophageal and esophagogastric junction adenocarcinoma  esophageal and gastric cancer  esophageal and GEJ adenocarcinoma  esophageal cancer  esophageal cancer in older patients  esophageal cancer risk  esophageal cancer surgery  esophageal Candida infection  esophageal gastroesophageal junction cancer  esophageal squamous cell carcinom  esophageal squamous cell carcinoma  esophagectomy  esophagectomy for cancer  esophagogastric adenocarcinoma  esophagogastric cancer surgery  ESPAC-4 secondary analysis  ESPAC4 trial  ESPAC5 trial  ESR1 mutations  ESR1 mutations in CTCs and ctDNA  ESR1-amplificatie  essential thrombocythenia and polycythemia vera  estetrol  ESTHER cohort study  esthesioneuroblastoom  esthetische uitkomst  ESTIMABL2 trial  estimated gained lifetime  estimated projection of US cancer incidence and deaths to 2040  estimates of overtreatment with adjuvant systemic therapy  estimating risk of pancreatic cancer in the general population  estimating survival  estimation of risk by HCPs  estradiol levels  estrogen monotherapy  estrogen receptor-positive recurrent endometrial cancer  estrogen therapy after breast cancer diagnosis  ET  ET outcomes  ET with or without ribociclib  ET with versus without CDK4 6 inhibitors  ETD EOD  ETER701 trial  ethnic disparities in ERBB2 amplification in gastric cancer  etirinotecan pegol  etnische diversiteit  ETP-ALL LBL  ETS  EU cancer mortality prediction for 2023  EU cancer mortality predictions for 2024  EU-regelgeving  EURECCA  Euro-E.W.I.N.G.99  Euro-Ski  EURO-SKI studie  EUROCARE-5  EUROCARE-6  EuroNet-PHL-C1  European cancer mortality  European cancer mortality prediction  European Code against Cancer  European Mantle Cell Lymphoma Elderly Trial  European trends in NST use for node-positive breast cancer  Europese kankermortaliteit  EURTAC  EUTOS  EV with or without pembrolizumab  EV-101 study  EV-201 study  EV-201 trial  EV-202 trial  EV-301 study  EV-302 trial  EV-assay  EV-pembrolizumab  evaluation of adjuvant chemotherapy after neoadjuvant FOLFIRINOX  evaluation of hematuria  evaluation of systemic treatments  EVAN study  event order  EVEREST trial  everolimus  everolimus plus ET  everolimus plus exemestane for postmenopausal HR+ HER2- advanced breast cancer  everolimus plus letrozole and metformin  everolimus plus octreotide  everolimus plus pazopanib  everyday clinical practice  EVICT  EVIDENCE study  evofosfamide  EWALL-INO trial  Ewing and Ewing-like sarcoma in adults  Ewing sarcoma  Ewing sarcoom  Ewing-2008  ex vivo IFNγ production  eXalt3 study  exceptional responder  exceptional response to RAI  excess body weight  excess long-term morbidity with modern treatment  excision margin size  EXCITE-studie  EXCLAIM-2 trial  exclusive breastfeeding duration  exemestaan  exemestaan plus everolimus  exemestane dose regimens  exemestane with or without enzalutaimde  exemstaan  exercise  exercise and nutrition intervention  exercise intervention in cancer patients  exercise versus usual care  exhaled breath tests  exogenous estrogen  exogenous hormone use  exome sequencing-based screening  exosomal lncRNA-GC1  exosomen  expansie van fase 1-studie PCD4989g  expansion of cancer risk profile  explaining risk factors  Exploratieve analyse MARQUEE-studie  exposoom  exposure to occupational carcinogens in 195 countries  expressie stromagenen in CRC  EXPRESSION III-studie  expression of biomarkers  expression of insulin-like growth factor-1 receptor on CTCs  EXTEND phase 2 randomized trial  EXTEND trial  extended adjuvant letrozole therapy  extended endocrine benefit  extended follow-up of PALOMA-2 study  extended postgastrectomy follow-up  EXteNET  ExteNET-studie  extension of aromatase inhibitor therapy  extensive stage  extensive stage small cell lung cancer  extensive-stage small cell lung cancer  extensive-stage small-cell lung cancer  extent of resection  EXTENTORCH trial  external beam radiation therapy  external validation of risk calculators  extracapsular extension in sentinel node  extracorporeal photopheresis  extracranial chondrosarcoma  extracranial disease control  extracranial oligometastasis  extracranial oligometastatic breast cancer  extrahepatic CCA  extrahepatic malignancies  extrahepatisch cholangiocarcinoom  extrameningeal primary SFT  extranodal natural killer T-cell lymphoma  extranodale extensie  extraocular retinoblastoma  extrapleural pneumonectomy  extrauterine disease  extremity cooling  EZH2  EZH2 inhibitor SHR2554  FACE  facial nerve function  facial-aging app  facility patient volume and survival  facility volume  facilty volume and mortality  FACT-HN-RAD  factors affecting recurrence and survival  factors affecting sentinel node metastasis  factors associated with duration of diagnostic interval  factors associated with response to ICIs  factors associated with risk of body image-related distress  factors associated with risk of progression  factors associated with vomiting control  factors explaining sex differences  factors influencing multidisciplinary tumor board recommendations  factors leading to alpelisib discontinuation  factors predicting invasive breast cancer recurrence  failure to rescue rates  FAK inhibition for meningiomas with somatic NF2 mutations  FAKTION study  FALCON  fall and fracture risk  false positive FIT  familair mammacarcinoom  familiaal colorectaalcarcinoom  familiaal risico  familiaire adenomateuze polyposis  familiaire adenomateuze popyposis  familial adenomatous polyposis  familial and hereditary cancer syndromes  familial platelet disorder  familiale adenomateuze polyposis  familiegeschiedenis  familiegeschiedenis prostaatkanker  family history  family history of breast cancer  family history of cancer  family history of OC and BC  family history of plasma cell disorders  family history-based screening  famitinib plus camrelizumab and nab-paclitaxel  FaMRIsc study  FAP-IL2v plus atezolizumab  fase 2-studie BOLERO-4  fase 2-studie BOLERO-6  fase 2-studie KEYNOTE-224  Fase 2-studie SWOG S0801  fase 3- studie DREAM  fase 3-studie AURA3  fase 3-studie BrighTNess  fase 3-studie COLUMBUS  Fase 3-studie CRITICS  fase 3-studie ETNA  fase 3-studie FATA-GIM3  fase 3-studie GEC-ESTRO  Fase 3-studie KEYNOTE-045  fase 3-studie METEOR  Fase 3-studie MONALEESA-3  fase 3-studie MONALEESA-7  fase 3-studie NETTER-1  Fase 3-studie PERSEPHONE  fase 3-studie PRODRIGE 9  Fase 3-studie SAKK 75 08  Fase 3-studie SWOG S9921  fase 3-studie TROG 05.01  fase 3-studies  FAST study  FAST-Foward noninferiority phase 3 study  fasting-mimicking diet  FASTRACK II trial  fatal ICI-associated toxic effects  fatalisme  fatigue  fatigue in cancer patients  favorable histology Wilms tumor  favorable-risk AML in patients younger than 60 years  FCR  FCT  FDA approval of novel cancer therapies between 2000 and 2016  FDA oncology drug approvals in 2018  FDA-approved novel oncology drugs  FDG PET CT after 1 week predicts response  FDG-PET  FDG-PET CT  FDG-PET scanning  feasibility  febriele neutropenie  fecal and plasma short-chain fatty acdis  fecale immunochemische test  fedratinib  FELIX study  female and male breast cancer. global trends 1990-2017  female breast cancer risk  female invasive breast cancer patients  female reproductive and hormonal factors  female survivors of childhood and adolescent cancer  FENIX  fentanyl  fentanyl sublinguale spray  fenylketonurie hyperfenylalaninemie  fermented dairy foods  fertiliteitspreservatie  fertility drugs  fertility preservation  fertility treatment  fertility-sparing surgery  FFCD-ANABASE  FGFR pathway alterations  FGFR2-rearranged ICC  FGFR2b-selected gastric or gastro-esophageal junction adenocarcinoma  FGFR3 mutation  FGFR4 alterations predict efficacy  FGFRs  FH02 study  FHBC  FHWT  FIA  ficlatuzumab with or without cetuximab  ficonalkib  fifteen-year results  FIGHT trial  FIGHT-207 trial  FIGHTDIGO-studie  FIGO score 5 or 6 gestational trophoblastic neoplasia  fijne motoriek  fijnstof  FIL MIRO trial  FIL_ReRi trial  FIL-HD0801 study  final OS analysis  Final OS results from SOLO2 study  final overall survival analysis of IMpassion130  final results of CheckMate 204  final survival outcomes  Finale analyse FIRST-studie  finale analyse van GOG 240-studie  finale overlevingsresultaten van KEYNOTE-006  financial links  financiële toxiciteit  finasteride  fine-needle biopsy  Finland Capecitabine Trial 15-year follow-up  finotonlimab  FinRSPC study  FinXX-studie  FIR prostate cancer  FIR-studie  FIRE-3  FIRE-4.5 trial  FIRE-SCLC Cohort Study  firefighters  FIREFLY-1 trial  FIRES  first cycle toxicity and survival  first line anlotinib  first line therapy  first relapse B-ALL in children and AYAs  first responders exposed to WTC disaster  first- versus second-line CDK4 6 inhibitor  first-degree relatives of pancreas cancer patients  First-iGAP study  first-in-human study of ivuxolimab-utomilumab combination  first-line abiraterone or enzalutamide  first-line abiraterone-prednisone for mCRPC with bone metastases  first-line afatinib  first-line afatinib combined with anti-EGF vaccination  first-line anlotinib plus platinum-etoposide  first-line anlotinib plus toripalimab  first-line anlotinib-oxaliplatin-capecitabine  first-line anti-PD-1 or targeted therapy  first-line apatinib plus gefitinib  first-line atezolizumab  first-line atezolizumab plus bevacizumab  first-line atezolizumab plus chemotherapy  first-line atezolizumab-bevacizumab versus sunitinib  first-line aUC treatment  first-line avelumab  first-line avelumab for mMCC  first-line axi-cel  first-line azacitidine plus venetoclax  first-line bavacizumab plus trebananib without chemotherapy  first-line befotertinib versus icotinib  first-line belzutifan plus cabozantinib  first-line BEMPEG plus NIVO  first-line bevacizumab-erlotinib  first-line blinatumomab  first-line BV plus AVD  first-line BV plus nivolumab  first-line cabozantib and nivolumab with or without CBM588  first-line cabozantinib  first-line cadonilimab plus anlotinib  first-line camrelizumab plus famitinib  first-line camrelizumab plus RT  first-line carboplatin versus cisplatin  first-line carboplatin-paclitaxel with or without bevacizumab  first-line CCRT  first-line cemiplimab  first-line chemo-immunotherapy for stage IV NSCLC  first-line chemotherapy plus PD-(L)1 blockade  first-line chemotherapy with or without bevacizumab  first-line chemotherapy with or without immunotherapy  first-line chemotherapy with or without pembrolizumab  first-line chemotherapy with sugemalimab versus placebo for mNSCLC  first-line CHOP or R-CHOP  first-line cisplatin-pemetrexed-nivolumab  first-line cladribine with concurrent or delayed rituximab  first-line CLL treatment  first-line combinations of immune checkpoint inhibitors and chemotherapy  first-line dacomitinib versus afatinib  first-line DADI trial  first-line donafenib versus sorafenib  first-line dose-dense early postoperative intraperitoneal chemotherapy  first-line everolimus plus bevacizumab  first-line FOLFIRINOX  first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel  first-line gemcitabine-trastuzumab-erlotinib combination  first-line ibrutinib  first-line ibrutinib plus rituximab  first-line ibrutinib plus venetoclax  first-line ibrutinib-venetoclax versus chlorambucil-obinutuzumab  first-line ICI  first-line ICI plus chemotherapy versus bevacizumab plus chemotherapy  first-line ICIs  first-line ICIs for mM  first-line ICIs with or without chemotherapy  first-line imatinib plus binimetinib  first-line immunotherapy for SCLC  first-line ipatasertib plus paclitaxel for advanced TNBC  first-line lenvatinib  first-line lenvatinib plus transarterial chemoembolization  first-line lenvatinib versus atezolizumab plus bevacizumab  first-line lorlatinib versus crizotinib  first-line mCRC  first-line mFOLFOX6 plus bevacizumab versus cetuximab  first-line N-AVD  first-line nab-paclitaxel plus carboplatin for aNSCLC in clinical practice  first-line niraparib plus pembrolizumab  first-line nivolumab  first-line nivolumab plus cabozantinib for advanced RCC  first-line nivolumab plus ipilimumab  first-line nivolumab plus ipilimumab and chemotherapy  first-line NSCLC treatment  first-line obinutuzumab plus lenalidomide  first-line options  first-line osimertinib  first-line osimertinib versus afatinib  first-line osimertinib versus afatinib or erlotinib  first-line pazopanib  first-line pembrolizumab  first-line pembrolizumab for advanced NSCLC with low PD-L1 expression  first-line pembrolizumab for NSCLC  first-line pembrolizumab monotherapy  first-line pembrolizumab plus lenvatinib  first-line pembrolizumab plus R-CHOP  first-line PLD-IFO  first-line PVAB  first-line quavonlimab (anti-CTLA-4) plus pembrolizumab  first-line R-CHOP plus roflumilast  first-line R-CODOX-M R-IVAC chemotherapy  first-line R2 versus rituximab-chemotherapy  first-line radioembolization plus chemotherapy  first-line regorafenib with nivolumab and chemotherapy  first-line S-1 versus anthracyclines  first-line selinexor plus R-CHOP  first-line selpercatinib  first-line serplulimab plus chemotherapy  first-line sintilimab plus decitabine  first-line sintilimab with pegaspargase-gemcitabine-oxaliplatin  first-line SRS versus WBRT  first-line sunitinib  first-line systemic treatment options  first-line systemic treatment strategies  first-line tebentafusp versus investigator’s choice  first-line tebentafusp versus nivolumab plus ipilimumab  first-line therapies  first-line therapy  first-line tislelizumab plus chemotherapy  first-line tislelizumab versus sorafenib  first-line TKIs  first-line toripalimab plus bevacizumab  first-line toripalimab plus chemotherapy  first-line TPEx versus EXTREME  first-line trastuzumab  first-line treatment  first-line treatment options  first-line Tumor Treating Fields plus chemotherapy  first-line vemurafenib plus obinutuzumab  first-line venetoclax combinations  first-line venetoclax plus 3 + 7 daunorubicin-cytarabine  first-line venetoclax plus azacitidine for AML  first-line venetoclax-obinutuzumab versus chlorambucil-obinutuzumab  first-line versus second line daratumumab  first-line zuberitamab plus CHOP  first-recurrence GBM  first-relapse rhabdomyosarcoma  FIRSTANA-studie  FIRSTMAPPP study  FIRSTMAPPP trial  fistula  FIT  FIT cohort  FIT implementation in guaiac-based screening program  FIT screening  FIT screening and risk of CRC death  FIT-detection of advanced colorectal neoplasia  FIT-screening  fitheid  fitness  five miRNA-model  five versus two years adjuvant zoledronate  five-miRNA based classifier  five-year analysis  five-year follow-up of CPX-351 versus 7+3 cytabine and daunorubicin  five-year outcome  five-year outcomes  five-year outcomes with cobimetinib plus vemurafenib  five-year PROs  five-year survival outcomes  five-year survivors of adolescent and young adult cancer  five-year survivors of chldhood cancer  fixed duration of venetoclax-rituximab  fixed-duration ibrutinib-venetoclax  fixed-duration MRD-guided approach  FKBPL  FL  FLAIR trial  FLAME trial  FLAMES trial  FLASH trial  FLAURA study  FLAURA-studie  FLAURA2 trial  flavonoïden  flexibele sigmoïdoscopie  flexibele-sigmoïdoscopie  FLIPPER trial  Florence Trial long-term results  FLOT4 study  FLOT4-studie  flow cytometry status  FLT3-internal tandem duplication mutated AML  FLT3-ITD AML  FLT3-ITD positive AML  FLT3-ITD-positive acute myeloid leukemia  FLT3-mutated R R AML  fluciclovine versus PSMA PET-CT  fludarabine  FLUOGLIO-studie  fluoropyrimidine  fluoropyrimidine therapy  fluoropyrimidines  fluoroscopie  fluorouracil-leucovorin  fluzoparib  FLYER study  FMD  FMT plus tislelizumab and fruquintinib  FN  FN after chemotherapy for breast cancer  FNMTC  focal adhesion kinase  focal boost  focal versus extended IRE  FOCUS-cohort  FOCUS4-C trial  FOCUS4-N trial  FOENIX-CCA2 Study  FOHAIC-1 trial  Fol-BRITe study  folate receptor α  FOLFIRI  FOLFIRI plus bevacizumab or aflibercept  FOLFIRI plus cetuximab or bevacizumab  FOLFIRI plus durvalumab with or without tremelimumab  FOLFIRINOX  FOLFIRINOX and chemoradiotherapy  FOLFIRINOX induction for LAPC  FOLFIRINOX salvage treatment  FOLFOX  FOLFOX hepatic arterial infusion  FOLFOX4  FOLFOXIRI  FOLFOXIRI plus bevacizumab  FOLFOXIRI plus panitumumab  FOLFOXIRI-bevacizumab  FOLFOXIRI-bevacizumab versus doublets-bevacizumab  FOLH1 expression  foliumzuur  FOLL05-studie  folliculair lymfoom  follicular and other CD20+ non-Hodgkin lymphoma  follicular lymphoma  follow-up adherence  follow-up after discontinuation  follow-up after resection  follow-up after treatment cessation  Follow-up analyse van CheckMate 067-studie  follow-up analyse van JFMC34-0601  follow-up of overdue abnormal cancer screening test results  follow-up van overlevers  food insecurity in cancer survivors  FOR46  forego medical care  foritinib  formaldehyde  FOrMAT-studie  FoRT trial  FORT-1 trial  FORT-2 multinational phase 1b trial  FORUM study  fosaprepitant  fosaprepitant meglumine  FosNTP versus FosAPR  fotofarmacologie  four-factor prognostic model  FOXA1-expressie  FOXA2  FOXC1  FOxTROT trial  FP  FP in BC patients  FP with or without oxaliplatin  FPD AML  FR  FRACTION-RCC trial  fractionated gamma knife radiosurgery  fractionated pre-operative SRS  fractionated stereotactic radiosurgery  fractionated stereotactic radiotherapy  fractionation schedule of CCTRT  fracture risk  fracture risk prediction in cancer patients  fracturen  fractures  fractuurrisico  fragiele ouderen  fragiliteit  fragmentation of surgery and chemotherapy  frailty and neurocognitive decline  frailty and survival  FRAX  FREEDOM2 trial  frequency and outcomes  frequency and outcomes of brain metastases  frequency and quantity of alcohol consumption  frequent aspirin use  frequent cystoscopy  FRESCO study  FRESCO-2  fresolimumab  front-line fludarabine-cyclophosphamide-rituximab  front-line ibrutinib for CLL patient populations not included in RESONATE-2  frontline acalabrutinib plus venetoclax and obinutuzumab  frontline dasatinib  frontline FCR  frontline hyper-CVAD plus ofatumumab  frontline hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab  frontline ibrutinib-rituximab followed by R-HCVAD  frontline low-dose versus standard dose dasatinib  frontline maintenance PARP inhibition  frontline ponatinib versus imatinib  frontline targeted therapy plus low-intensity chemotherapy  frontline therapies  frontline therapy for AML in elderly patients  frontline treatment for pediatric AML  frontline treatments  fruit  fruit and vegetable consumption  fruquintinib  fruquintinib in Chinese patients in clinical practice  FRUTIGA trial  FS118  FSRT  FSS versus RS  FTD versus HD-MA  FTD-TPI  FTD-TPI with or without bevacizumab  FTL3-mutatie  Fudan CUP-001  FUJI cohort  fulvestrant  fulvestrant plus capivasertib  fulvestrant plus palbociclib  fulvestrant versus AIs  FUMANBA-1 trial  functional outcomes  FURLONG study  FURLONG trial  furmonertinib  furmonertinib versus gefitinib  FUS-ERG and RUNX1-CBFA2T3  fusion gene  Fusobacterium nucleatum  futibatinib  future cancer risk  FUTURE-C-PLUS study  FUTURE-SUPER trial  fuzuloparib maintenance  fuzuloparib plus apatinib  fysieke activiteit  FZOCUS-2 trial  G GEJ adenocarcinoma  G GEJ cancer  G-CSF support  G-CSFs  g-NETs  G84E  GAIA CLL13 4-year follow-up  gain-of-function mutatie  gait speed  galactography  galblaascarcinoom  GALEN study  galeterone  GALGB 89803 and 80702  gallbladder cancer  GALLIUM study  gallium-68 labelled PSMA-11 PET  gallium-68 PET-MRI  GALLIUM-studie  galunisertib  galunisertinib plus neoadjuvant chemoradiotherapy  galwegcarcinoom  gamma knife radiosurgery  GammaTile brachytherapy  ganglioside vaccine for high-risk neuroblastoma  ganglioside-monosialic acid  ganitumab  GAP BRAIN phase 3 study  GARD  garlic  GARNET study  GARNET trial  garsorasib  GASTFOX trial  GASTO 1028 study  GASTO1003 trial  gastric adenocarcinoma  gastric and duodenal cancer  gastric cancer  gastric cancer detection one year after negative endoscopy  gastric cancer family history  gastric cancer in Helicobacter pylori-infected patients  gastric cancer prevention  gastric cancer risk  gastric cancer surgery  gastric cancer with synchronous peritoneal metastases  gastric gastroesophageal junction AC  gastric gastroesophageal junction adenocarcinoma  gastric or esophagastric junction adenocarcinoma  gastric or gastric-esophageal junction adenocarcinoma  gastric or gastro-esophageal junction cancer  gastric or gastroesophageal junction adenocarcinoma  gastric or gastroesophageal junction cancer  gastric or GEJ adenocarcinoma  GASTRIPEC-I trial  gastritis  gastro-intestinale mucositis  gastro-intestinale stromale tumoren  gastro-oesofagaal adenomcarcinoom  gastroenteropancreatic neuroendocrine neoplasms  gastroenteropancreatic neuroendocrine tumors  gastroesophageal adenocarcinoma  gastroesophageal cancer  gastroesophageal reflux disease  gastrointestinal bleeding  gastrointestinal cancer  gastrointestinal neuroendocrine carcinoma  gastrointestinal stromal tumor  gastrointestinal stromal tumors  gastroïntestinale kanker  gastroïntestinale stromale tumoren  Gattelli  GAUDI  GBC  GBCA  GBD 2019  GBM  GBM in elderly patients  gBRCAm breast cancer  gBRCAm HER2-negative mBC  GBS  GBSM  GBV-C  GC  GC GEJC  GC with synchronous PMs  GC012F  GC1008  GC4419  GCA  GCC  GCC19 CART  GCIG INTERLACE trial  GCPM  GCT  GCTB  GCTs  GD  GD2-CART01  GD2-directed CAR-T cell therapy  GDP  GEA  GEC  GECCOR-GB study  gedatolisib  gedatolisib plus paclitaxel and carboplatin  gedatolisib plus palbociclb and ET  GeDDiS-studie  gedifferentieerd schildkliercarcinoom  gedissemineerde tumorcellen  gefitinib  gefitinib alone or with chemotherapy  gefitinib and erlotinib  gefitinib continuation after progression  gefitinib plus chemotherapy  GEICAM 2003-11_CIBOMA 2004-01 study  GEICAM 2010-04 study  GELAD chemotherapy with sandwiched radiotherapy  GELATO trial  GELLC-7 trial  gelokaliseerd prostaatcarcinoom  GEM  GEM-1402 study  GEM20110714 study  gemcitabine  gemcitabine plus adavosertib  gemcitabine plus cisplatin induction chemotherapy  gemcitabine plus nab-paclitaxel and ficlatuzumab  gemcitabine with or without berzosertib  gemcitabine with or without ramucirumab  gemcitabine-eribulin combination  gemcitabine-trastuzumab-pertuzumab after pertuzumab-based therapy  gemcitabineresistentie  gemetastaseerd mammacarcinoom  gemetastaseerd melanoom  gemetastaseerde borstkanker  gemetastaseerde borstkanker; trastuzumab  gemetastaseerde colorectaalkanker  GEMPAX study  GemPred  GEMSTONE-201  GEMSTONE-301 trial  GEMSTONE-302  GEMSTONE-302 trial  GEMSTONE-303 trial  gemtuzumab ozogamicin  gemtuzumab ozogamicine  GEN501 and SIRIUS final results  gender differences  gene expression markers in peripheral blood  gene expression profiles  gene expression profiling assay  gene expression signature to predict response  gene signature for predicting lymph node status  gene variants and subsequent neoplasms  gene variants associated with increased cancer risk  gene-specific prevention strategies for OC and BC  geneesmiddelinteracties  generalizibilty among different ethnicities  Generations Study  genetic alterations  genetic and clinical predictors  genetic factors  genetic prognostic and predictive factors  genetic risk  genetic risk for overall cancer  genetic susceptibility  genetic testing  genetically defined renal tumors  genetically determined cutaneous nevi  genetically predicted low-density lipoprotein level  genetically proxied inhibition of HMG-CoA reductase  genexpressie  genito-urinaire maligniteiten  genmethylering  genome sequencing  genome-edited donor-derived anti-CD19 CAR T cells for pediatric and adult B- ALL  genome-wide association study  genome-wide diet-gene interaction  genome-wide variants  genomic alterations  genomic analysis in NRG Oncology RTOG 9802  genomic biomarkers predicting anti-PD-(L)1 response  genomic characterization  genomic classification and clinical outcome  genomic correlates  genomic correlates of progression or response  genomic determinants of clinical outcomes  genomic determinants of early recurrence  genomic determinants of outcomes  genomic identification of HRD  genomic landscape in never-smoking patients  genomic profiling  genomic profiling of prostate cancers from met with African and European ancestry  genomics and outcomes  genotoxic pks E. coli  genotyping before first-line therapy  genotyping lung adenocarcinoma  GENUINE trial  genvarianten  GEOMETRY mono-1 study  GEP-NETs  GeparNuevo analysis  GeparNuevo study  GeparOcto secondary analysis  GeparQuattro-studie  GeparSepto  GeparSepto long-term outcomes  GeparSixto trial  GeparX trial  gepegyleerd liposomaal doxorubicine  geptanolimab  geptanolimab (GB226)  gerandomiseerde fase 2-studie PrE0102  GERD treatment  Gerecke  geriatirc patients  geriatric assessment impairments  geriatric comanagement  Geriatric Prognostic Indicator  germ cell tumors  germline BARD1 gene variants  germline BRCA PALB2 mutation  germline BRCA pathogenic variant  germline BRCA PVs and ovarian reserve  germline BRCA-mutated metastatic pancreatic cancer  germline BRCA-mutated mPaC  germline BRCA1 2 mutation  germline BRCA1 2 pathogenic variants  germline BRCA2 mutations  germline CDH1 variants and lifetime cancer risk  germline CDH1 variants in HLBC  germline genetic testing  germline genetic testing after cancer diagnosis  germline mutaties  germline mutations  germline mutations in DNA repair genes  germline PALB2 pathogenic variants  germline pathogenic variants in 28 genes  germline predisposition gene mutations  germline PTEN variants in children and adults  germline PVs in cancer predisposition genes  germline sequencing analysis  germline variant status  germline variants in DNA repair genes  germline variants in natural killer cells  germline variations in drug transporters  geserreerde poliepen  geslachtshormonen  gestation and birthweight of offspring  gestational trophoblastic neoplasia  gestationele trofoblasttumor  GETNE-TRASGU study  GETUG-AFU 16 study 112-months follow-up  gevorderd cervixcarcinoom  gevorderd maag-adenocarcinoom  gevorderd melanoom  gevorderd niercelcarcinoom  gevorderde borstkanker  gevorderde maagkanker  geweichtsverlies  gezondheidsutiliteitsindex  gFOBT  GFPC 08-2015 ENERGY trial  GFR  GFR; niercelcarcinoom; urotheelcarcinoom  GGO lung adenocarcinoma  GHSG HD13-15 trials  GHSG HD17 study  GI adverse events  GI cancer  GI malignancies  GI malignant neoplasms  giant-cell tumor of bone  gilteritinib  gilteritinib as post-transplant maintenance  GIMEMA-MMY-3006 trail  GIST  GISTs  GK  GK-SRS with or without EGFR-TKIs  GKRS  GKRS for BMs of non-pulmonary primary tumors  GLARIUS-studie  glasdegib  GLASS study  Gleason score 10 prostate cancer  Gleason score 9-10 prostate cancer  glecirasib  glembatumumab vedotin  glioblastoma  glioblastoma in elderly patients  glioblastoma in patients aged 80 years and older  glioblastoma in poor perfomance status patients  glioblastoma multiforme  glioblastoma recurrence  glioblastoma with methylated MGMT promoter  glioblastoom  glioma  glioma risk  glioma with BRAF-V600E mutation  gliomas  gliomen  glioom  glitazonen  global burden in 2019  global burden of 30 cancers among men in 2022 and projections for 2050  global burden of breast cancer  Global Burden of Cancer  global burden of cancer attributable ro risk factors  global burden of cancer attributable to infections in 2018  global burden of cancer in 2020 attributable to alcohol consumption  Global Burden of Disease Study  Global Burden of Disease Study 2019  global burden of male breast cancer  global cancer incidence and mortality from 2010 to 2019  global expanded access program  global incidence and mortality for 29 cancer groups in 2019  global incidence and mortality trends  global longitudinal strain  global pediatric cancer care  global retinoblastoma presentation analysis by national income level  global trends  global variations in incidence by histological subtype  glofitamab  glofitamab plus GemOx versus rituximab plus GemOx  GLORY trial  glottic squamous cell carcinoma  GLOW study  GLOW trial  GLP-1RAs  glucocorticoid treatment  glucocorticoid-refractory cGVHD  glucose lowering drugs  GLUT-  GLUT-14  glutamine  glutathion-S-transferase P1  glycaan-gerelateerde genen  glypicaan-1  GM-CSF  GM1 for OIPN  GMMG-CONCEPT trial  GMMG-HD7 trial  GMMG-MM5 trial  GNAS variants in solid tumors  GNCC  GnHRa  GNOS-PV02 plus pembrolizumab  GnP or mFFX  GnRH-agonist  GnRHa  GO  GO30103 trial  GO30140 study  GO42144 trial  goals of care in last years of life  GOG 0212 study  GOG 281 LOGS  GOG Study 279  GOG-0213 studie  GOG-0213 study  GOG-0218 final OS-analysis  GOG-0218 studie  GOG-0277  Golestan Cohort Study  golidocitinib  gonadotropine  Google Translate  GORILLA-3004 study  GORTEC 2007-01 studie  GORTEC 2014-01 TPExtreme study  GOSAFE Study  gosereline  GÖTEBORG-2 ISRCTN study  GOYA-studie  GP-led versus surgeon-led colon cancer survivorship care  GPRC5D-targeted CAR T cells  grade 1-2 AEs  grade 2 oligodendroglioma  grade migration during the last decade  graded cardiac response criteria  graft failure  graft versus host disease  graft-versus-host disease  graft-versus-host disease prophylaxis  grain consumption and dietary fiber intake  GRASPA  GRAVITAS-301 trial  GRCCC cohort study  GRECCAR 2-studie  GREEN study subgroup analysis  GRIFFIN study  grijpkrachtverlies  grip strength  groeicurves naevi  groeisnelheid  groenten  groentenconsumptie  GROINSS-V-II  grootcellig granulair lymfocytaire leukemie  grootcellig neuro-endocrien longcarcinoom  grootte van lymfekliermetastasen  gross total versus subtotal resection  gross-total resection  grote-korrel lymfocyten leukemie  growth hormone deficiency  growth rate of untreated hemangioblastomas  growth rates  GSD  GSK2857916  GT-30  GT90001 plus nivolumab  GTN  GTT  GU-toxiciteit  guadecitabine  guanylaatcyclase  GUIDANCE-03 trial  gumarontinib  gut microbiota and metabolites  GVAX pancreas  GVHD  GVHD prevention after haploidentical HCT  GVHD prophylaxis  GWAS  GX-188E  Gxplore-002 study  Gxplore-005 study  gynecologic cancers  gynecologic oligometastatic and oligoprogressive tumors  gynecologic oncology  gynecological brain metastases  gynecological cancer  gynecologische maligniteiten  H-RT versus C-RT  H. pylori  H. pylori infection status  H. pylori screening  H3K27M+ diffuse midline glioma  HA-WBRT + SIB for brain metastases  HA-WBRT + SIB versus conventional WBRT  haarverlies  hafnium oxide nanoparticle  HAI  HAI chemotherapy  HAI pump chemotherapy plus systemic therapy  HAIC  HAIC with FOLFOX  HAIP floxuridine chemotherapy versus resection  hair dye use and prostate cancer risk  hair products  hairy cell leukemia  hairy-cell leukemie  hallmarks of cancer  HALO 202-studie  HALT-D trial  Ham-Wasserman lecture  Hamilton Fairley Award  hand cooling and compression  hand-voet huidreacties  hand-voet syndroom  hand-voetsyndroom  HannaH study final analysis  haplo versus UD transplantation  haplo-HSCT  haplo-HSCT versus chemotherapy  haplo-identieke HSCT  haplo-SCT  haploidentical HSCT  haploidentical versus unrelated cord blood transplantation  haploidentical versus unrelated SCT  haploidentical; sibling; matched unrelated donor  HARMONi-2 trial  HARMONi-A study  harms of exercise training  HART  hartfalen  hartfalen na auto-HCT  HAS  HBOC  HBOT for late local toxic effects  HBOT in breast cancer patients  HBV-related HCC  HBV-related HCC risk  HBV-vaccinatie  HC  hcc  HCC diagnosis  HCC expressing CD147  HCC in children compared to young adults  HCC in HBV- or HCV-infected patients  HCC mortality  HCC overall survival  HCC risk  HCC risk algorithm  HCC risk in patients with HBV and or HCV infection  HCC screening in a cohort of at-risk patients  HCC surveillance in cirrhosis patients  HCC with extrahepatic metastasis  HCC with MVI  HCC with portal vein tumor thrombus  HCC with PVTT  HCL  HCMV reactivation during radiochemotherapy  HCRN GU16-257 trial  HCT  HCV  HCV-associated indolent NHL  HD 0607 trial  HD IL-2  HD-MTX for prevention of CNS progression  HD12 study  HD16 trial  HD18-studie  HD201  HD21 trial  HD9 study  HDAC inhibition  HDCT plus autoHSCT  HDCT plus PBSCT  HDL-cholesterol level and risk of hematologic malignancy  HDR-brachytherapie  head and neck cancer  head and neck cancer risk after hematologic cancer  head and neck cancer surgery during COVID-19 pandemic  head and neck procedures  head and neck squamous cell carcinoma  head en neck cancer  Head Start III  health care contact days  health care contact days and outcomes in trials vs routine care  health care use  health consequences  health literacy  health maintenance practices  Health Professionals Follow-up Study  health promotion among cancer survivors  health-related quality of life  healthy eating patterns  healthy immigrant effect  healthy lifestyle  healthy lifestyle and liver cancer risk  healthy older adults  healthy postpolypectomy lifestyle  hearing impairment  hearing loss  heart failure  heart failure risk  heavily pretreated HR-positive HER2-negative metastatic breast cancer  heavily pretreated MBC  heavily pretreated PROC  heavy smokers  HECTOR model  hedgehog inhibitors  hedgehog-signaalroute  HEI-2010  heldercellig niercelcarcinoom  heldercellig ovariumcarcinoom  HELEN-001 trial  HELEN-006 trial  Helicobacter pylori  Helicobacter pylori treatment  HELIOS study  HeLiX randomized clinical trial  hematologic cancer patients  hematologic cancers and COVID-19  hematologic malignancies  hematologic malignancies in older patients  hematologic malignant neoplasms  hematological cancer  hematological disorders  hematologische maligniteiten  hematopoietic cell transplantation  hematopoietic score predicts outcomes  hematopoietic stem cell transplantation  hematopoietic stem cell transplation  hematopoïetische celtransplantatie  hemicolectomy versus appendectomy  hemispheric-specific clinical presentation  hemochromatosis HFE p.C282Y homozygosity  hemorrhagic cystitis following allotransplantation  hENT1 expression  HEPAR PluS study  hepatectomy in academic versus community cancer center  hepatectomy with or without adjuvant mFOLFOX6  hepatic arterial infusion chemotherapy  hepatic artery infusion pump chemotherapy  hepatitis B virus infection  hepatitis B-virus  hepatitis C  hepatobiliary cancers  hepatocallular carcinoma  hepatocellulair carcinoom  hepatocellular carcinoma  hepatocellular carcinoma and pancreatic ductal adenocarcinoma  hepatocellular carcinoma with portal vein invasion  hepatocellular carcinoma with preoperative portal vein tumor thrombus  HEPATORCH  hepatospleen T-cel lymfoom  hepatotoxiciteit  hepatotoxicity  HER2  HER2 amplification  HER2 exon 20 insertions  HER2 exon 20 mutant NSCLC  HER2 expressing UCS  HER2 expression discordance between primary and metastatic breast cancer  HER2 expression testing  HER2 gene expression levels  HER2 loss  HER2 mutated aNSCLC  HER2 negative advanced gastric gastroesophageal junction cancer  HER2 peptide vaccines for prevention of breast cancer recurrence  HER2 pro-oncogene signalering  HER2-0 and HER2-low mBC  HER2-altered advanced solid tumors  HER2-amplified LA M BTC  HER2-amplified mCRC  HER2-amplified non-breast gastroesophageal tumors  HER2-directed therapies  HER2-enriched EBC  HER2-expressie  HER2-expressing cancers  HER2-expressing mCRC  HER2-expressing or mutated advanced solid tumors  HER2-expressing prostate cancer  HER2-gedreven NSCLC  HER2-HER3 dimerization  HER2-low  HER2-low advanced breast cancer  HER2-low breast cancer  HER2-low expression  HER2-low mBC  HER2-low versus HER2-negative breast cancer  HER2-low versus HER2-negative mBC  HER2-low versus HER2-null  HER2-low versus HER2-zero MBC  HER2-low-positive breast cancer  HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy  HER2-mutant aNSCLC  HER2-mutant lung cancer  HER2-mutant metastatic cervical cancer  HER2-mutant mNSCLC  HER2-mutant NSCLC  HER2-negatief mammacarcinoom  HER2-negatieve borstkanker  HER2-negatieve MBC  HER2-negative  HER2-negative advanced G GEJ cancer  HER2-negative BC  HER2-negative BRCA mutated resectable breast cancer  HER2-negative breast cancer  HER2-negative early breast cancer  HER2-negative MBC  HER2-negative metastatic breast cancer  HER2-negative node-positive breast cancer  HER2-negative tumors  HER2-overexpressing advanced solid tumors  HER2-overexpressing breast cancer  HER2-overexpressing mGEA  HER2-overexpressing mNSCLC  HER2-positief mammacarcinoom  HER2-positief metastatisch mammacarcinoom  HER2-positieve borstkanker  HER2-positieve vroege borstkanker  HER2-positive ABC  HER2-positive ABC MBC  HER2-positive aCRC  HER2-positive advanced breast cancer  HER2-positive advanced G GEJ cancer  HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma  HER2-positive advanced gastric or gastroesophageal junction cancer  HER2-positive advanced solid malignancies  HER2-positive and AR-positive advanced breast cancer  HER2-positive and biopsy-proven node-positive breast cancer  HER2-positive BC with BMs  HER2-positive BCBM  HER2-positive BCBMs  HER2-positive biliary tract cancer  HER2-positive breast cancer  HER2-positive breast cancer and brain metastases  HER2-positive breast cancer brain metastases  HER2-positive breast cancer neoadjuvant lapatinib plus trastuzumab  HER2-positive breast cancer survivors  HER2-positive breast cancer with brain metastases  HER2-positive BTC  HER2-positive de novo metastatic breast cancer  HER2-positive EAC  HER2-positive early breast cancer  HER2-positive early breast cancer in elderly  HER2-positive early-stage breast cancer  HER2-positive EBC  HER2-positive esophagogastric adenocarcinoma  HER2-positive esophagogastric cancer  HER2-positive gastric cancer  HER2-positive gastro-esophageal adenocarcinoma  HER2-positive LA M UC  HER2-positive localized breast cancer  HER2-positive MBC  HER2-positive mBC in Europe  HER2-positive mBTC  HER2-positive metastatic breast cancer  HER2-positive metastatic breast cancer after ≥ 2 HER2-directed regimens  HER2-positive metastatic breast cancer and central nervous system disease  HER2-positive non-metastatic breast cancer  HER2-positive R MBC  HER2-positive salivary duct carcinoma  HER2-positive stage II or III breast cancer  HER2-scoringsysteem  HER2-screening  HER2-targeted ADCs  HER2-targeted CAR T cell therapy  HER2-targeted therapies  HER2-targeted therapy  HER2+ aBC  HER2+ BC  HER2+ breast cancer  HER2+ breast cancer brain metastases  HER2+ mCRC  HER2CLIMB  HER2CLIMB brain metastases subgroup analysis  HER2CLIMB randomized phase 2 study  HER2CLIMB study  HER2CLIMB study exploratory analyses  HER2DX  HER2DX model  HER2DX pCR-score  HER3 overexpression  HER3-DXd  HER3-mutant mammacarcinoom  HERA  HERA trial  HERALD EPOC 1806  herb and supplement use  HERBY-studie  herceptin  herceptin-biosimilar  herceptine  hereditary diffuse gastric cancer  Heritage  HERIZON-BTC-01  HERO study  heropname  herpes zoster after autologous stem cell tranplantation  hersenmetastasen  hersenmetastasen mammacarcinoom  hersenmetastasering  hersenmicrobloedingen  hersentumoren  HERTHENA-Lung01  Heterocephalus glaber  heterogeneity between SEER counties  heterogeneity of IHC  HF-WBI  HFSRT  HGG  HGGs  HGS OC  HGSC after risk-reducing salpingo-oophorectomy  HGSC at RRSO  HGSOC  HIDAC versus IDAC consolidation  hidden-genome classifier  hidradenitis suppurativa  HIFU  high burden of clonal hematopoiesis  high hereditary breast cancer risk  high PD-L1 expressing NSCLC  high risk early breast cancer  high risk locally advanced rectal cancer  high risk melanoma  high risk of colorectal peritoneal metastasis  high RS  high sensitivity C reactive protein  high TIL and pCR  high TMB tumors  high versus low dose lenalidomide maintenance after transplantation  high- or very high-risk localized prostate cancer in patients ≤ 65 years  high-dose carboplatin  high-dose chemotherapy  high-dose chemotherapy and 3D conformal radiation  high-dose cisplatin ototoxicity  high-dose cyproterone acetate  high-dose folic acid use during pregnancy in epilepsy patients  high-dose intensity-modulated chemoradiotherapy  high-dose once-daily RT  high-dose versus standard-dose twice daily thoracic RT  high-dose vitamin D  high-dose-rate brachytherapy  high-grade and low-grade glioma  high-grade brainstem gliomas  high-grade breast DCIS  high-grade cervical lesions  high-grade glioma  high-grade gliomas in children  high-grade gliomas in pediatric patients  high-grade mature B-cell NHL in children and adolescents  high-grade osteosarcoma of the extremities  high-grade ovarian cancer  high-grade prostate cancer  high-grade UTUC  high-intensity focused ultrasound  high-intermediate and high risk early stage EC  high-mobility group box 1  High-molecular-mass hyaluronan  high-PD-L1 expressing NSCLC with brain metastases  high-risk ALL in children  high-risk AML  high-risk AML in remission  high-risk asymptomatic bone metastases  high-risk B-ALL  high-risk biochemically recurrent prostate cancer  high-risk breast cancer  high-risk cancer surgery  high-risk CSPC  high-risk DCIS  high-risk DLBLC  high-risk early breast cancer  high-risk EBC  high-risk endometrial cancer  high-risk extremity trunk STS  high-risk factors and real-world outcomes  high-risk features  high-risk first-relapse B-ALL in children  high-risk HCC  high-risk HNC patients  high-risk LBCL  high-risk localized gastrointestinal stromal tumor  high-risk locally advanced rectal cancer  high-risk locally advanced squamous cell carcinoma of head and neck  high-risk low-grade glioma  high-risk luminal breast cancer  high-risk lymphoma  high-risk mature B-cell non-Hodgkin’s lymphoma in children  high-risk medulloblastoma  high-risk medulloblastoma in children  high-risk melanoma  high-risk MIUC  high-risk mNSCLC  high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia  high-risk neuroblastoma  high-risk non-muscle-invasive bladder cancer  high-risk nonmetastatic breast cancer  high-risk oral squamous cell carcinoma  high-risk pediatric HL  high-risk prostate cancer  high-risk resected melanoma  high-risk retinoblastoma  high-risk rhabdomyosarcoma  high-risk SM  high-risk smoldering multiple myeloma  high-risk smoldering myeloma  high-risk soft tissue sarcoma  high-risk stage 2 colon cancer  high-risk stage II melanoma  high-risk uveal melanoma  high-stage cSCC  high-volume metastatic hormone-sensitive prostate cancer  higher-risk MDS  higher-risk MDS or CMML  HIIT  HiLo trial  hilotherapy versus frozen gloves  HIMALAYA study  HIMALAYA trial  HIMRT versus CIMRT  HIPEC  HIPEC + CS  HIPEC after CRS  histologic regression  histological biomarkers  histologically rare triple-negative breast cancers  histologische regressie  histology-tailored versus standard neoadjuvant chemotherapy  histopathologic features  historical 90-day mortality  history of atopy  history of use of statins and COX-2 inhibitors  HIV  HIV AIDS  HIV infection  HIV infection in elderly patients  HIV RNA  HIV status and survival  HIV-associated Kaposi sarcoma  HIV-infection  HL  HL diagnosis during pregnancy  HL in elderly patients  HL survivors  HL with high risk of failure after autoHSCT  HL-behandeling  HLA antigen mismatch  HLA-A*03 and response to immune checkpoint blockade in cancer  HLA-matched or alternative donors  HLA-matched sibling donor transplantation  HLA-mismatched unrelated donor HCT  HMA plus venetoclax  HMAs for high-risk MDS or AML  HMAs plus venetoclax for HR-MDS  HMIE versus open esophagectomy  hMPV  HMR 2.0  HMT for BC  HNC  HNC risk  HNC survivors  HNC versus onther cancers  HNCs  HNMCC  HNSCC  HNSCC in older patients  HNSCC patients  HNSCC surgery  HNSS  Hodgkin and non-Hodgkin lymphoma  Hodgkin lymfoom  Hodgkin lymphoma  Hodgkin lymphoma in children and adolescents  Hodgkin lymphoma survivors  Hodgkin's lymfoom  Hodgkin’s lymphoma  hofd-hals Merkel celcarcinoom  hoge dosering chemotherapie  Hokusai VTE-Cancer studie  holmium-166 after lutetium-177-dotatate  home administration of trastuzumab  homeobox B13  homocysteïne  homologous recombination deficiency  hoofd hals squameus celcarcinoom  hoofd halscarcinoom  hoofd halskanker  hoofd-hals melanoom  hoofd-hals squameus celcarcinoom  hoofd-halscarcinoom  hoofd-halskanker  hoofdhuidkoeling  hoog-risico B-ALL  hoog-risico cervixcarcinoom  hoog-risico CML  hoog-risico melanoom  hooggradig sereus ovariumcarcinoom  HOPE trial  HORIZON-Lung  horizontale transfer  hormonal therapy  hormonal therapy resistance  hormone receptor low positive breast cancer  hormone-modulating breast cancer therapy  hormone-naïve metastatic prostate cancer  hormone-sensitive oligorecurrent prostate cancer  hormoonreceptor positieve borstkanker  hormoontherapie  hospital connectedness  hospital frailty risk score  hospital variation in treatment and survival in The Netherlands  hospital volume  hospital volume status  hospitalisatie  hospitalization  hospitalization after adolescent and young adult cancer  hospitalizations and ED visits after CAR T-cell therapy  hospitalized patients with active cancer  hot flashes  HOVON 105 ALLG NHL 24  HOVON 105 study  Hovon 143 study  HOVON-143 trial  HOVON124 ECMW-R2  HOVON141 VISION trial  How Long studie  HP SCC  HPC-SFT  HPD  HPTC  HPV  HPV circulating cell-free DNA kinetics  HPV ctDNA  HPV ctDNA after CRT  HPV DNA in penile cancer and intraepithelial neoplasia  HPV DNA persistence  HPV genotypes  HPV infection  HPV load and genotype analysis  HPV status  HPV status and HPV16 viral load  HPV types  HPV types 16 18 in cervical precancers  HPV vaccination  HPV vaccination and anal HSIL+ and cancer  HPV vaccine  HPV-16 18 vaccin  HPV-associated cancers  HPV-associated epithelial cancers  HPV-associated malignancies  HPV-associated OPSCC  HPV-associated oropharyngeal carcinoma  HPV-associated oropharyngeal squamous cell carcinoma  HPV-associated SNSCC  HPV-FOCAL trial  HPV-independent and HPV-associated vulvar SCC  HPV-infectie  HPV-negative head and neck squamous cell carcinoma  HPV-negative HNSCC  HPV-orofarynxcarcinoom  HPV-positive OPC  HPV-positive oropharyngeal cancer  HPV-positive oropharyngeal squamous cell cancer  HPV-positive oropharyngeal squamous cell carcinoma  HPV-related malignancies  HPV-related OPSCC  HPV-related oropharyngeal cancer and cancer of unknown primary  HPV-typen  HPV-unrelated locally advanced HNSCC  HPV-vaccinatie  HPV+ OPC  HPV+OPSCC  HPV16 18-positive advanced cervical cancer  HPV16- and or HPV18-positive recurrent of advanced cervical cancer  HPV16-associated CIN3  HPV16-E6 serology test  HPV16-related cancerISA101  HR-deficiëntie  HR-MDS  HR-NB  HR-NBL1 SIOPEN study  HR-NL81 SIOPEN  HR-NMPC  HR-positief mammacarcinoom  HR-positief metastatisch mammacarcinoom  HR-positive advanced breast cancer  HR-positive advanced postmenopausal breast cancer  HR-positive and HER2-negative T1a bN0M0 breast cancer  HR-positive BC  HR-positive breast cancer  HR-positive breast cancer brain metastases  HR-positive breast cancer in young women  HR-positive early breast cancer  HR-positive early-stage breast cancer  HR-positive EBC  HR-positive HER2 negative metastatic breast cancer  HR-positive HER2-negative aBC  HR-positive HER2-negative advanced breast cancer  HR-positive HER2-negative advanced or metastatic breast cancer  HR-positive HER2-negative breast cancer in older patients  HR-positive HER2-negative early breast cancer  HR-positive HER2-negative mBC  HR-positive HER2-negative metastatic breast cancer  HR-positive HER2-negative metastatic breast cancer in older women  HR-positive HER2-positive advanced breast cancer  HR-positive HER2-positive early-stage breast cancer  HR-positive metastatic breast cancer  HR-status  HR+ HER- ABC  HR+ HER- BC  HR+ HER2- ABC  HR+ HER2- aBC progressing beyond CDK4 6 inhibitor  HR+ HER2- breast cancer  HR+ HER2- breast cancer in real-world patients  HR+ HER2- breast cancer survival  HR+ HER2- EBC  HR+ HER2- MBC  HR+ HER2- vroeg-stadium mammacarcinoom  HR+ HER2-ABC  HR+ HER2+ breast cancer  HR+ MBC  HR20013  HRBOC  hrCT  HRD  HRGI cancers  HRP ovarian cancer  HRQoL  HRQOL impact  HRQOL in long-term survivors  HRQOL in prostate cancer  HRR-deficient metastatic castration-resistant prostate cancer  HRT  HRT and breast cancer risk  HRT versus CRT  hs-cTnT  HSC  HSCT  HSCT-bijwerkingen  HSCT-TMA in adults  Hsp70  HT  hTERT-DCs  hu14.18K322A  hu3F8  huCART19  huCART19-IL18  HUDSON trial  huidkanker  huidkankerscreening  huidmaligniteit  huidneoplasmen  huisartsenzorg  humaan papillomavirus  human equilibrative nucleoside transporter 1  human readers versus machine-learning algorithms  hyaluronic acid  hybrid minimally invasive esophagectomy  hyper-CVAD followed by blinatumomab  hyperbaric oxygen therapy  hypercalcaemia of malignancy  hypercalcemie  hyperemesis gravidarum  hyperfractionated versus standard fractionated IMRT  hyperleukocytosis  hyperprogression  hyperprogressive disease  hyperproliferatie van stamcellen  hypertensie  hypertension  hyperthermic intraperitoneal chemotherapy  hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery  hyperthermische intraperitoneale chemoperfusie  hypervascular intracranial tumors  HYPO-RT-PC study  hypodiploid ALL in children  hypofarynxcarcinoom  hypofractionated adjuvant radiotherapy  hypofractionated breast RT for 1 week versus 3 weeks  hypofractionated IMRT  hypofractionated postmastectomy radiation therapy  hypofractionated postmastectomy radiotherapy  hypofractionated preoperative radiotherapy  hypofractionated RT  hypofractionated SRS  hypofractionated SRT to the resection cavity  hypofractionated stereotactic radiotherapy  hypofractionated stereotactic radiotherapy after surgery for brain metastases  hypofractionated versus conventional RT  hypofractionated versus conventionally fractionated RT  hypofractionated versus conventionally fractionated whole-breast irradiation  hypolipidemic drugs  hypomethylating agents  hyponatremie  HYPOR  HYPORT-STS  HYPRO  hysterectomy  I CARE study secondary outcome  I CARE trial  I T DIN GM-CSF  I-131 labelled metuximab  i-ALCL  I-SPY 2 trial  I-SPY2 three-year follow-up analysis  I-SPY2 trial  I+V versus FCR  I2D  IAC versus IA induction  iadademstat plus azacitidine  iAMP21  IARC  IBC  IBC versus SBC  IBC with exceptional response to NST  IBCSG 23-01 trial  IBD  iberdomide plus dexamethasone  IBI318  IBI351  IBIS II  IBIS-I  IBIS-II trial 10 year follow-up  IBM Watson  IBR  ibrutinib  ibrutinib –bortezomib  ibrutinib discontinuation  ibrutinib followed by ofatumumab consolidation  ibrutinib for CLL  ibrutinib maintenanc  ibrutinib monotherapy  ibrutinib plus chemoimmunotherapy for CLL  ibrutinib plus fludarabine  ibrutinib plus palbociclib  ibrutinib plus rituximab  ibrutinib plus venetoclax  ibrutinib versus ofatumamab  ibrutinib with or without ublituximab  ibrutinib-obinutuzumab-venetoclax combination  ibrutinib-rituximab versus chemoimmunotherapy  ibrutinib-rituximab versus placebo-rituximab  ibuprofen  ICANS prophylaxis with anakinra  ICARIA-MM study  ICARIA-MM subgroep analysis  ICB  ICB for SCLC  ICBP SURVMARK-2 study  ICC  ICC versus STC  iCCA  ICd versus Id  ICE3 trial  ICI  ICI dosing strategy  ICI effectiveness  ICI efficacy  ICI for aNSCLC  ICI for GBM  ICI harm-benefit balance  ICI monotherapy  ICI plus VEGFR inhibitor therapy for aRCC  ICI rechallenge  ICI therapy  ICI therapy in IBD patients  ICI treated mUC  ICI treatment  ICI use during pregnancy  ICI use in real-life practice  ICI versus chemotherapy  ICI with or without chemotherapy followed by resection of primary tumor  ICI with or without SBRT  ICI with or without SRS  ICI-AKIs  ICI-associated irAEs terminology  ICI-associated neurotoxicities  ICI-induced autoimmunity  ICI-naïve A R NSCLC  ICI-pretreated stage IV NSCLC  ICI-refractory advanced melanoma  ICI-related multisystem immune-related adverse events  ICI-related myocarditis  ICIs  ICIs after EGFR TKIs  ICIs and chemotherapy  ICIs for advanced cSCCs  ICIs for advanced gastrointestinal cancers  ICIs for advanced non-small cell lung cancer  ICIs for advanced NSCLC  ICIs for advanced NSCLC in clinical practice  ICIs for advanced PLC  ICIs for advanced solid tumors  ICIs for aGEC  ICIs for aNSCLC  ICIs for cancer  ICIs for cancer in clinical practice  ICIs for cancer in patients with autoimmune disease  ICIs for HNSCC  ICIs for lung cancer or malignant melanoma  ICIs for mCRC  ICIs for melanoma  ICIs for melanoma in patients with preexisting autoimmune disease  ICIs for metastatic cancer  ICIs for metastatic cancers in solid organ transplant recipients  ICIs for metastatic melanoma. early prediction of pseudoprogression  ICIs for metastatic renal and urothelial cancer  ICIs for mNSCLC  ICIs for mRCC  ICIs for MSI-H metastatic colorectal cancer  ICIs for mUC  ICIs for non-small cell lung cancer  ICIs for NSCLC  ICIs for NSCLC in patients with pre-existing autoimmune disorders  ICIs for rare cancers  ICIs for solid malignancies  ICIs for solid tumors  ICIs plus anlotinib  ICIs plus anti-VEGF therapy with or without TACE  ICIs plus bevacizumab  ICIs plus chemotherapy  ICIs plus statins  ICIs with or without denosumab  ICLL-07 FILO trial  ICLL07 FILO study  ICON6-studie  ICON8 study  ICON8-studie  ICPi  ICs  ICU-opname  idarubicine plus cytarabine plus nivolumab  IDC versus ILC  iddEPC-studie  ide-cel  IDEA collaboration  IDEA database  IDEA-collaboration  IDEAL secondary analysis  idecabtagene vicleucel  idelalisib  identification of patients with high recurrence risk  identification of patients with underrecognized symptoms  IDH mutant and wildtype LGG  IDH mutation  IDH mutation status  IDH wildtype glioblastoma  IDH-mutant CNS WHO grades 2 or 3 astrocytoma  IDH-mutant diffuse glioma  IDH-mutant lower-grade glioma and glioblastoma  IDH-mutated acute myeloid leukemia myelodysplastic syndrome  IDH-wildtype GBM  IDH-wildtype supratentorial GBM  IDH1 2-mutant low-grade glioma  IDH1 IDH2-mutant solid tumors  IDH1 mutation  IDH1-expressie  IDH1-mutant glioma  IDH1-mutant LGG  IDH1-mutant solid tumors  IDH1-mutated AML  idiopathische membraneuze nefropathie  idiopatische MCD  IDO PD-L1 targeting peptide vaccine plus nivolumab  Idylla  IELSG-19 studie  IELSG32 trial 7-year results  IELSG32-studie  ieramilimab with or without spartalizumab  IES  IFCT-0302 trial  IFCT-2104 CAPMATU  IFD  IFG  IFM 2009  IFN-onderhoudsbehandeling  IFRT  IFTC-1703 R2D2 trial  Ig paraproteïn  IGBT  IGF-1  IGF-1R expressie  IGF2-AS  IgM MGUS  IGT  IHC  IHCA  IHCC  IHGV mutational status  IHP  IHT  iIC versus iC  IIIA-N2 NSCLC  ijzersuppletie  IKEMA trial  IKFZ1-deletie  IKFZ1-deletion  IKZF1-deletie  IL-12 plasmid transfection  IL-6  IL-8  ILC  ILC in premenopausal patients  illness perception and outcomes in cancer  iLLUMINATE study  image-guided intensity modulated radiation therapy  Imaging  imaging surveillance  imaging-based prostate cancer screening  IMAJEM-studie  imatinib  imatinib after other multi-kinase inbitors  imatinib plus binimetinib  iMATRIX study  IMbrave 150 study  IMbrave050  IMbrave150  IMbrave150 study  IMbrave151  IMbrella A trial  IMCL-2015 trial  IMD  IMDC  imetelstat  IMiDs  imiquimod  immediate vs deferred cytoreductive nephrectomy  IMmotion 151 trial  IMmotion 151-studie  IMmotion151 trial  immune cells in mesothelioma microenvironment  immune checkpoint blockade  immune checkpoint inbition for cancer  immune checkpoint inhibition  immune checkpoint inhibition for unresectable HCC  Immune Checkpoint Inhibitor  immune checkpoint inhibitor associated acute kidney injury  immune checkpoint inhibitor for NSCLC  immune checkpoint inhibitor induced pituitary dysfunction  immune checkpoint inhibitor rechallenge after irAE  immune checkpoint inhibitor therapy  immune checkpoint inhibitor trials  immune checkpoint inhibitor-induced colitis  immune checkpoint inhibitor-mediated diarrhea and colitis  immune checkpoint inhibitors  immune checkpoint inhibitors for AML  immune checkpoint inhibitors for metastatic cutaneous melanoma  immune effector cell-associated neurotoxity syndrome  immune effects of rituximab  immune health  immune infiltration  immune markers of nivolumab response  immune microenvironment  immune phenotype  immune response  immune status  immune-mediated diarrhea and colitis  immune-related adverse events  immune-related adverse events and efficacy of avelumab  immune-related enteritis  immune-related gene expression in osteosarcoma  immune-related meningitis  immune-related pneumonitis  IMMUNED study  immunocheckpoint blockade  immunochemottherapy  immunocompromised cancer patients  immunogenicity and safety in patients with solid cancer  immunogenicity of metastatic breast cancer  immunogenomic biomarker analysis  immunoglobuline lichte-keten amyloïdose  immunologically quiescent melanoma  immunomodulatory TNBC  immunophenotyping of TILs and PBLs  IMMUNOPRESERVE trial  IMMUNOSARC  Immunoscore  immunosuppression  immunosuppressive therapy for management of MDS  immunotherapeutic boost  immunotherapy  immunotherapy after chemotherapy and radiation for stage III NSCLC  immunotherapy after surgery of the primary tumor  immunotherapy for advanced cancers  immunotherapy for advanced non-small cell lung cancer  immunotherapy for advanced stage cancer  immunotherapy for EGFR ALK wild-type advanced NSCLC  immunotherapy for malignancies  immunotherapy for melanoma  immunotherapy for metastatic melanoma  immunotherapy for NSCLC  immunotherapy initiation at EOL  immunotherapy or chemoimmunotherapy  immunotherapy plus stereotactic radiotherapy  immunotherapy rechallenge  immunotherapy use  immunotherapy versus BSC  immunotherapy versus chemotherapy  immunotherapy with or without live bacterial supplementation  immunotherapy-based TNT  immunotherapy-related pruritus  immutherapy  immuuncheckpointremmers  immuunrespons  immuunsuppressie  immuuntherapie  IMPAC  IMPACT  impact of adjuvant regimes  impact of adjuvant therapies on outcomes  impact of advances in treatment  impact of age  impact of age and frailty  impact of age at diagnosis on survival  impact of age on melanoma response to bevacizumab  impact of age on outcomes  impact of age on outcomes of dual anti-HER2 therapy  impact of alcohol and smoking and FRP  impact of ancestry on frequency of actionable alterations  impact of antibiotics  impact of antiviral therapy for chronic hepatitis C  impact of asparaginase discontinuation on outcome  impact of attending surgeon  impact of baseline body mass index  impact of biopsy frequncy on metastasis and mortality  impact of BMI  impact of body composition factors  impact of bone metastases  impact of BRAF V600E K mutation status  impact of breast cancer treatment on employment  impact of breast screening programme on mortality in England  impact of calcium channel blocker use  impact of cancer on COVID-19 outcomes  impact of care fragmentation on outcomes  impact of celebrity’s disclosure of leukemia  impact of center volume on outcomes of adverse events  impact of centralization within hospital systems  impact of cisplatin-based chemotherapy on risk of metachronous contralateral disease  impact of Combined Positive Score  impact of comorbidities on overall survival  impact of concomitant antihypertensive medication  impact of concomitant PPIs on survival  impact of concurrent dexamethasone on clinical benefit  impact of conditioning intensity  impact of COVID-19 on treatment and short-term mortality  impact of COVID-19 pandemic  impact of cumulative excess body mass index  impact of cumulative exposure to premenopausal obesity  impact of detailed family history  impact of diet  impact of disease stage  impact of ECD  impact of EGFR mutation and ALK rearrangement  impact of epigenetics on association of aspirin use with mortality after breast cancer  impact of ER status on survival  impact of ET adherence  impact of experimental molecular-matched therapies on cancer outcomes  impact of facility caseload  impact of facility surgical caseload volume on survival  impact of FIT-screening on CRC incidence and outcomes in The Netherlands  impact of follow-up time  impact of germline BRCA1 or BRCA2 or PALB2 mutation on platinum response  impact of germline mutations  impact of glycemic status  impact of high TMB on response rates  impact of HIV infection  impact of hormone receptor status  impact of ILD on outcomes of lung cancer surgery  impact of imaging intensity on survival after systemic therapy  impact of intratumoral Escherichia  impact of low-dose aspirin  impact of lower airway dysbiosis on progression  impact of metabolic syndrome  impact of metastatic pattern  impact of moderate-to-vigorous intensity physical activity  impact of molecular subtype and race  impact of molecular subtypes on incidence and prognosis of CNS metastases  impact of NST on postoperative complications  impact of obesity  impact of oophorectomy on breast cancer survival in patients with CHEK2 mutations  impact of optimizing diagnostic workup and reducing time to treatment  impact of overweight and obesity  impact of overweignt and obesity  impact of patient age  impact of POD24 on survival  impact of polypharmacy on AI adherence  impact of poverty  impact of pre-existing CVD on mortality  impact of pregnancy on genomic landscape  impact of primary tumor surgery  impact of prior CT or RT on efficacy of durvalumab for NSCLC  impact of prior or concurrent antibiotic therapy  impact of prior ruxolitinib  impact of prior therapy  impact of prior treatment  impact of prior treatments  impact of probiotics use  impact of race  impact of race and age on response to NACT and long-term outcomes  impact of race ethnicity  impact of race ethnicity on OS  impact of race on outcomes  impact of race on outcomes of definitive RT  impact of radiation facility volume  impact of screening  impact of screening on OPE diagnosis  impact of solid cancer on in-hospital mortality  impact of stewardship program  impact of subtype on axillary pCR to neoadjuvant therapy  impact of subtype on GKS outcomes  impact of surveillance  impact of T2D  impact of the COVID-19 pandemic on new diagnoses of cancers  impact of TP53 genomic alterations on CD19 CAR T-cell therapy  impact of treatment modality on performance of prognostic factors  impact of tumor size and high-risk features on chemotherapy benefit  impact on antitumor immunity in cancer patients  impact on breast cancer incidence and mortality  impact on breast cancer risk  impact on cancer risk in men  impact on cancer stage at diagnosis  impact on COVID-19 survival  impact on CRC incidence and mortality  impact on CRC screening rate  impact on diagnosis and initial treatment of breast cancer in The Netherlands  impact on Dutch lung cancer care  impact on frequency of biopsy and tumor grade  impact on functional age and mortality  impact on long-term risk of morbidity  impact on memory  impact on metastatic behavior and outcome  impact on OC risk in African American and White women  impact on OS  impact on outcome  impact on outcomes  impact on outcomes of durvalumab for NSCLC  impact on patients’ treatment experience and treatment discontinuation  impact on recurrence and survival  impact on sexual function  impact on short-term mortality  impact on survival  impact on survival and recommended treatment intensity  impact on survival of cancer patients  impact on survival of patients with cancer  impact on treatment and survival of cancer patients  impact on treatments for metastatic solid cancer in the USA  IMPACT program  IMPACT study  Impact van timing van adjuvante chemotherapie voor vroeg-stadium mammacarcinoom  IMPACT-studie  IMPACT2  IMPARTER  IMpassion031 trial  IMpassion130 study  IMpassion130 study updated results  IMpassion130 trial  IMPATTO study  implementation of best practices in pancreatic care  implications of minimal residual disease detection  IMPORT LOW study  IMpower010  IMpower010 study  IMpower010 trial  IMpower110 study  IMpower130 trial  IMpower132 trial  IMpower133 Study  IMpower133 updated analyses  IMpower150 final overall survival analyses  IMpower150 regimen  IMpower150 study  IMpower150 trial safety and PROs  IMpower150-studie  IMPRESS-studie  IMPROVE study  IMPROVE trial  improvements in survival between 2009 and 2022  improvent over time in posttransplant outcomes  improving PCa diagnosis  IMPT  IMPT versus VMAT  IMQ  IMROZ trial  IMRT  IMRT alone  IMRT for HNC  IMRT versus 3D-CRT  IMRT versus 3DCRT for prostate cancer  IMRT versus SBRT  IMRT with or without cisplatin  IMspire150  IMspire150 second interim analysis  IMspire150 study  IMspire150 trial  IMT  IMvigor130 study  IMvigor211-studie  in situ mammacarcinoom  in utero chemotherapy exposure  in utero exposure to maternal cancer  in utero pembrolizumab exposure  in-breast tumor recurrence  in-field lung cancer recurrence after stereotactic ablative radiotherapy  in-hospital mortality  in-transit metastatic melanoma  INAVO120 trial  inavolisib  incidence  incidence and mortality in England  incidence and mortality of colon and lung and prostate cancer  incidence and mortality of second primary cancers  incidence and outcomes  incidence and outcomes of lung cancer  incidence and patterns of cancer  incidence and predictors of diabetes mellitus  incidence and predictors of SPCs  incidence and risk factors  incidence and survival among solid organ transplant recipients  incidence and survival in the USA 1973-2015  incidence and survival outcomes  incidence of adverse events with various therapies  incidence of and mortality from malignancies after CIN treatment  incidence of cancer  incidence of cancer and CVD  incidence of cancer diagnoses  incidence of hypothyroidism  incidence of pneumonitis  incidence of recurrence 10-32 years after primary diagnosis  incidence of recurrence and time to recurrence in Denmark  incidence of relapse  incidence of second primary melanoma  incidence of subtypes  incidence of T790M mutation in cfDNA  incidence of thyroid cancer in WTC-exposed rescue workers  incidence of vulvar precancerous lesions and cancer  incidence of young adult cancers in Canada  incidence trends  incidence trends in Finland  incidence trends of breast cancer molecular subtypes by age and race in the US  incidence trends of pancreatic adenocarcinoma and colorectal adenocarcinoma  incident breast cancer  incident cancer  incident cancer risk  incident cardiovascular events  incident comorbidities  incident type 2 diabetes duration  incidental pulmonary embolism in cancer patients  incidentally detected lung nodules  incidentally found pediatric brain tumors  incidentie  incidentie mammacarcinoom USA  Incidentie van cardiovasculaire gebeurtenissen in ICI-behandelde patiënten  incomplete pregnanacy  increase since 2017  increased α-fetoprotein  increasing dose intensity of chemotherapy  INDAR  indatuximab ravtansine  independence  independent roles  indeterminate pulmonary nodules  index lymph node  individual and neighborhood-level SES  individual oncogenic HPV types  individual patient data meta-analysis  individual patient-level analysis  individual patient-level data meta-analysis  individualised axitinib regimen  individualized prognostic model  indolent lymfoom  indolent mammacarcinoom  indolent MCL  indoor tanning  Indoor tanning industry  indoximod  indoximod plus pembrolizumab  iNDUCT trial  inductie-chemoradiatie  inductiechemotherapie  induction chemotherapy  induction chemotherapy for AML  induction chemotherapy for NPC  induction CRT with or without sintilimab  induction CT followed by CCRT  induction CT followed by RT versus CRT  induction CT followed by standard CRT  induction toripalimab and chemotherapy  infant lymphoblastic leukemia  infants  infectie  infertility and risk of breast cancer in men  infigratinib  INFINITY study  inflammatie  inflammation  inflammation and clinical decline  inflammation cascade  Inflammatoir mammacarcinoom  inflammatoire voeding  inflammatory and insulinemic dietary patterns  inflammatory biomarkers and survival  inflammatory blood markers  inflammatory bowel disease  inflammatory bowel disease and risk of adenocarcinoma and NETs in the small bowel  Inflammatory breast cancer  inflammatory markers  inflammory tongue conditions and risk of oral tongue cancer in elderly patients  infliximab  INFLUENCE 2.0 model for improved risk estimations  influenza vaccination  influenza vaccine effectiveness among cancer patients  influenzavaccinatie  infradiaphragmatic disease  infrared laser moxibustion  inhaled corticosteroids  INHANCE-consortium  iNHL  iniparib  initial FOLFIRINOX  INITIAL-1 trial  INITIATE study  inMIND trial  iNNOVATE  iNNOVATE-studie  innovations in therapy  InnovaTV 201 study  innovaTV 204 study  innovaTV 205 trial  innovaTV 301 ENGOT-cx12 GOG-3057  InO  INO-CD22 study  INO-VATE studie  inoperable endometrial cancer  inoperable pancreatic cancer  inoperable pleural mesothelioma immediate versus deferred systemic therapy  inoperable stage I NSCLC  inotuzumab ozogamicin  INOVA trial  inpatient care and outcomes  inpatient versus outpatient administration  INSEMA trial  INSIGHT 2 trial  INSIGHT-studie  insomnia  inspanning  INSPIRE study  Institute of Cancer Research  insulin resistance  insulin-like growth factor  insulin-like growth factor -1  insulinemie  insulineresistentie  intake of dietary fats  intake of one-carbon metabolism-related micronutrients  intake of whole grains and dietary fiber  INTEGRATE  INTEGRATE IIa study  integrated palliative and oncology care  INTELLANCE 2 study  intellectual functioning  intellectual outcomes  INTENS-studie  intense androgen deprivation before prostatectomy  intensieve chemotherapie  intensification of androgen blockade  intensity of diagnostic evaluation  intensity-modulated proton therapy versus intensity-modulated radiation therapy  intensity-modulated radiation therapy  intensity-modulated reirriation plus nivolumab  intensive chemotherapy versus HMAs  intensive therapy  inter- and intra-laboratory variation  Inter-B-NHL Ritux 2010 trial secondary analysis  InterAAct  interaction of Helicobacter pylori infection and HR genes  interaction of leisure-time physical activity with BMI  interaction of sexual orientation with race ethnicity  Intergroup Exemestane Study  interim OS analysis of MONARCH 2  interim PET  interim PET CT predicts PFS  intermediate endpoints  intermediate endpoints as surrogates for OS  intermediate recurrence score  intermediate stage recurrent hepatocellular carcinoma  intermediate- or high-risk GIST  intermediate-risk AML  intermediate-risk cervical cancer  intermediate-risk prostate cancer  intermediate-stage hepatocellular carcinoma  intermediate-stage uHCC  intermittent nivolumab  intermittent versus continous PEG-asparaginase  intermitterende claudicatie  internal mammary and medial supraclavicular irradiation  internal mammary node irradiation  International Breast Cancer Intervention Study I  International Childhood Cancer Cohort Consortium  International Male BC Program  International Prognostic Index  International Prognostic Score  international variation in radiation dose  international variation in survival  internet-steunprogramma's  interrupting endocrine therapy to attempt pregnancy after breast cancer  interruption of adjuvant endocrine therapy  interruption or noncompletion of chemoradiotherapy  interstitial lung disease induced by HER2-targeting therapy for MBC  interval and screen-detected breast cancers  interval breast cancer  interval cancers  interval CRC incidence  interval versus screening-detected breast cancers  interval-compressed VDC IE-chemotherapy  intervalcarcinomen  intervals to diagnosis  intra-tumor heterogeniteit  intra-tumoral genomic heterogeneity in rectal cancer  intracraniaal ependymoom  intracranial efficacy of lorlatinib  intracranial injection of NK cells engineered with a HER2-targeted CAR  intracranial meningioma  intracranial metastatic disease  intracranial SFTs  intractable serous ascites  intraductal papillary mucinous neoplasms  intraductale papillaire mucineuze neoplasie  intraductale papillaire mucineuze neoplasmen  intradural spinal hemangioblastoma  intrahepatic cholangiocarcinoma  intrahepatic cholangiocarcinoma risk  intrahepatisch cholangiocarcinoom  intraoperative frozen section analysis  intraoperative peritoneal lavage  intrapatient heterogeneity in enzalutamide response  intraperitoneale chemotherapie  intrathecal pemetrexed  intrathecal trastuzumab  intratumoral CD8  intratumoral dendritic cells before chemotherapy  intratumoral F. nucleatum  intratumoral immune infiltrate and prognosis  intratumoral injection of mRNA-2752 and pembrolizumab  intratumoral oncolytic herpes virus G47Δ  intratumoral PVSRIPO  intratumoral V937 plus ipilimumab  intratumorale genetische heterogeniteit  intratumorale genoomdiversiteit  intrauterine devices  intravenous and intracranial GD2-CAR T cell therapy  intravenous high-dose methotrexate based therapy  intravesical BCG vaccine  intravitale microscopie  INTRIGUE trial  intrinsic subtype analysis of BOLERO-2  intrinsiek subtype  intrinsieke subtypes  intrinsieke subtypes mammacarcinoom  INTUITT-NF2  invasieve borstkanker  invasive breast cancer  invasive breast cancer after non-screen detected DCIS  invasive breast cancer diagnosis  invasive breast cancer risk  invasive cervical cancer  invasive cSCC risk  invasive ductal carcinoma of the breast  invasive fungal infections  invasive lobular carcinoma of the breast  invasive lobular carinoma of the breast  invasive melanoma  invasve breast cancer and breast cancer mortality after screen-detected DCIS  INVICTUS trial  invitation letter in language of origin  invloed behandelcentrum op overleving  involvement of dentists  IO  IO plus bosutinib  iodine 131-refractory DTC  iodine-131 apamistamab  IOERT for early invasive ductal breast cancer  IOHDR-BT  IOLite trial  IONESCO trial  ioniserende straling  iontoforese  IORT  IORT versus adjuvant SRT  IOTA5 study  IOUS  IP  IP1-PROSTAGRAM study  iparomlimab (QL1604)  ipatasertib  ipatasertib plus abiraterone and prednisolone  IPATential150 trial  IPD meta-analysis  iPDT  IPH4102  ipilimumab  ipilimumab and nivolumab  ipilimumab every three versus twelve weeks plus nivolumab  ipilimumab plus nivolumab  ipilimumab plus nivolumab for desmoid tumors  ipilimumab versus pembrolizumab  ipilimumab with or without anti-PD-1  ipilimumab with or without T-VEC  IPMN  IPMNs  ipsilateral axillary lymph node reactivity on imaging  ipsilateral breast event  ipsilateral breast tumor recurrence  IPSS-M  IPTT  IR versus FCR  irAEs  irAEs and survival  irAEs with ICIs  IRd  IRE  irinotecan  irinotecan dose  irinotecan plus cetuximab with or without vemurafenib  irinotecan-based nCRT  IRIS  irradiation for breast cancer  iruplinalkib  IS in stage III CRC  Isa-Kd versus Kd  Isa-KRd  iSABR phase 2 trial  ISARIC-CCP-UK  isatuximab  isatuximab fixed-volume infusion  isatuximab-bortezomib-lenalidomide-dexamethasone  isatuximab-VRd  ISB  ischemic cardiotoxicity  iscocitraatdehydrogenase  ISM  isocitraatdehydrogenaseremmer  isocitrate dehydrogenase 1-mutated glioma  isocitrate dehydrogenase wild-type glioblastoma in young adults  isoflavone intake  isolated breast pain  isolated synchronous colorectal peritoneal metastases  isotretinoin  itacitinib  Italiaanse cultuur  ITCC-050 study  ITOMIC-001 studie  iuESCC  IV magnesium  IV versus IP chemotherapy plus bevacizumab  IVC filters  IVF  IVF utilization  IVIG for HG  IVMs  ivonescimab  ivonescimab plus etoposide and carboplatin  ivosidenib  ivosidenib plus azacitidine  ivosidenib plus azacitidine versus placebo plus azacitidine  IVY study  IWDD  ixazomib  ixazomib maintenance  ixazomib of placebo toegevoegd aan lenalidomide-dexamethason  J-ALEX studie  J-FAPP Study IV  JACC-studie  JACCRO CC-08 study  JACCRO GC-07 study  JACKPOT8 Part B  JACOB study  JAKARTA-2 studie  jandus  Janus Cohort  JASPER study  JAVELIN Bladder 100  JAVELIN Bladder 100 study  JAVELIN Lung 100  JAVELIN Lung 200 study  JAVELIN Merkel 200 study  JAVELIN Merkel 200 trial  JAVELIN Merkel 200-studie deel B  JAVELIN ovarian cancer cohort  JAVELIN Renal 100-studie  JAVELIN Renal 101  JAVELIN Renal 101 study  JAVELIN Renal 101 trial  JAVELIN Renal 101 trial second interim analysis  JAVELIN Solid Tumor studie  JAVELIN Solid Tumor study mUC cohort two-year follow-up  JAVELIN Solid Tumor Study NSCLC cohort  JAVELIN Solid Tumor trial  JAVELIN Solid Tumor trial mesothelioma cohort  JCOG0203 trial  JCOG0504-studie  JCOG0910-studie  JCOG0912 study  JCOG1001-studie  JCOG1007 study  JCOG1109 NExT trial  JCOG1202 trial  JCOG1211  JFMC37-0801 study  JGO  JIPANG study  JLSSG0901 trial  JME-001 trial  job-exposure matrices  jodium-131  joint replacement. B-cell neoplasms  JPHC nested case-control study  JULIET long-term follow-up  JULIET trial  JULIET-studie  JUPITER-02  JVDL study  Kailuan study  KAMILLA exploratory analysis  kanker  kanker bij kinderen  kanker-immunotherapie  kankerchirurgie  kankerincidentie  kankermortaliteit  kankermortaliteit 2015  kankerpijn  kankerrisico  kankerrrisico  kankersterfte  kankersubtypes  KARISMA study  KARISMA trial  KARMA study  KATE2 study  KATHERINE phase 3 study  KATHERINE study  KATHERINE trial  katheter  KC  KCSG-HB19-14  KDD  KdD versus Kd  keratinocytcarcinoom  keratinocyte carcinoma  Keratinocyte Carcinoma Chemoprevention Trial  keratinocyte carcinomas  kerncentrales  ketotifen  KEYNOTE-001  KEYNOTE-001 (secundaire analyse)  KEYNOTE-001 study  KEYNOTE-006  KEYNOTE-006 study  KEYNOTE-010  KEYNOTE-010 study  KEYNOTE-012  KEYNOTE-013 and -170  KEYNOTE-017 study  KEYNOTE-020  KEYNOTE-021  KEYNOTE-021 cohort G  KEYNOTE-021 study  KEYNOTE-022 study  KEYNOTE-024  KEYNOTE-024 five-year outcomes  KEYNOTE-028  KEYNOTE-028 and -158  KEYNOTE-028 and -158 pooled analysis  KEYNOTE-028 and -158 studies  KEYNOTE-028 studie  KEYNOTE-028 study  KEYNOTE-029  KEYNOTE-029 cohort C  KEYNOTE-029 Part 1B long-term follow-up  KEYNOTE-029 studie  KEYNOTE-040 study  KEYNOTE-040 study HRQOL analysis  KEYNOTE-042 five-year outcomes  KEYNOTE-042 study  KEYNOTE-045  KEYNOTE-045 and KEYNOTE-052 long-term follow-up  KEYNOTE-048 secondary analysis  KEYNOTE-048 study  KEYNOTE-048 subgroup analyses  KEYNOTE-048 trial  KEYNOTE-052 long-term oucomes  KEYNOTE-052 studie  KEYNOTE-055  KEYNOTE-057  KEYNOTE-057 cohort B  KEYNOTE-059 studie  KEYNOTE-061 exploratory analysis  KEYNOTE-061 studie  KEYNOTE-062 analysis  KEYNOTE-062 phase 3 study  KEYNOTE-086 cohort A  KEYNOTE-086 cohort B  KEYNOTE-087  KEYNOTE-100 study  KEYNOTE-119 trial  KEYNOTE-146 study  KEYNOTE-158  KEYNOTE-158 study  KEYNOTE-158 trial  KEYNOTE-164  KEYNOTE-164 studie cohort B  KEYNOTE-177 health-related quality of life analysis  KEYNOTE-177 study  KEYNOTE-177 trial final analysis  KEYNOTE-180 study  KEYNOTE-181  KEYNOTE-181 study  KEYNOTE-189 studie  KEYNOTE-189 study  KEYNOTE-189 study 5-year outcomes  KEYNOTE-189 trial final analysis  KEYNOTE-199 study  KEYNOTE-204 trial  KEYNOTE-224 trial cohort 2  KEYNOTE-240 study  KEYNOTE-355  KEYNOTE-355 PRO analysis  KEYNOTE-355 trial  KEYNOTE-361  KEYNOTE-394  KEYNOTE-407  KEYNOTE-407 final analysis  KEYNOTE-407 study  KEYNOTE-412  KEYNOTE-426 extended follow-up  KEYNOTE-426 study  KEYNOTE-427 cohort B  KEYNOTE-427 study cohort A  KEYNOTE-427 study cohort B  KEYNOTE-495 KeyImPaCT  KEYNOTE-522 study  KEYNOTE-522 trial  KEYNOTE-564  KEYNOTE-564 30-month follow-up  KEYNOTE-564 trial  KEYNOTE-567  KEYNOTE-585  KEYNOTE-590 study  KEYNOTE-598  KEYNOTE-604  KEYNOTE-629 study  KEYNOTE-671  KEYNOTE-689  KEYNOTE-716  KEYNOTE-716 DMFS results  KEYNOTE-716 trial  KEYNOTE-756  KEYNOTE-775 final analysis  KEYNOTE-775 trial  KEYNOTE-782  KEYNOTE-799 trial  KEYNOTE-811 trial  KEYNOTE-826  KEYNOTE-826 HRQOL analysis  KEYNOTE-826 study  KEYNOTE-942  KEYNOTE-966 trial  KEYNOTE-A18  KEYNOTE-B10  KEYNOTE-B21  KEYNOTE-B61  Khorana-score  Ki-67  Ki-67 labeling index  Ki67  kidney cancer  kidney disease in long-term survivors  kidney function and cancer risk  kidney stones and risk of RCC and UTUC  kidney transplant recipients  kidney transplantation  kiemceltumor  kiemceltumoren  kinaseremmers  kinderkanker  KIT  klachten aromataseremmers  KLASS-01 studie  KLASS-02-RCT  klassiek Hodgkin lymfoom  klein lymfocytair lymfoom  kleincellig longcarcinoom  kleincellig prostaatcarcinoom  kleincellige longkanker  kliernegatief mammacarcinoom  klierpositief mammacarcinoom  Klinische uitkomsten en gebruik van gezondheidszorg onder patiënten met Burkitt lymfoom  KMT2A-rearranged ALL in infants  KMT2A-rearranged or NPM1-mutant leukemia  KMT2A-rearranged relapsed or refractory acute leukemia  KN046 plus KN026  Know Your Tumor registry trial  KO-TIP-001 trial  koffie  koffieconsumptie  KOMET-001 trial  Koos grade IV VS in young patients  kosten behandeling HER2-positief MBC  kosten van gezondheidszorg  kosteneffectiviteit hematologische middelen  kosteneffectiviteit screening  KP-BSI  KRAS  KRAS allelic variants  KRAS and BRAF mutations in stage II III colon cancer  KRAS G12C mutated NSCLC  KRAS G12C mutation  KRAS G12C-mutated aNSCLC  KRAS G12C-mutated NSCLC  KRAS G12C-positive CRC  KRAS G12D NSCLC  KRAS mutation  KRAS mutation positive rNSCLC  KRAS NRAS BRAF WT metastatic colorectal cancer  KRAS p.G12C-mutated advanced pancreatic cancer  KRAS variant status  KRAS variant subypes  KRAS wild-type mCRC  KRAS-BPI  KRAS-G12C mutant NSCLC  KRAS-G12C mutated NSCLC  KRAS-G12C mutated NSCLC with untreated CNS metastases  KRAS-mutant metastatic colorectal cancer  KRAS-mutatie  KRAS-mutaties  KRASG12C mutated NSCLC  KRd versus R maintenance  KRd versus VRd for newly diagnosed multiple myeloma  KRISTINE study  KRISTINE-studie  KROG 15-03 study  KRYSTAL -1 study  KRYSTAL-1 study  KRYSTAL-1 trial  KS  KS with or without HIV infection  KSHV-transmissie  KT  KTE-X19 CAR T-cell therapy  KUNPENG study cohort 1  kwaliteit van leven  L-COSY  L-MIND study  LA BCC  LA CC  LA ccRCC  LA dMMR colon cancer  LA ESCC  LA G GEJ adenocarcinoma  LA HCC  LA HNSCC  LA M CSCC  LA M PDAC  LA M solid tumors  la mUC in cisplatin-ineligible patients  LA NPC  LA NSCLC  LA OSCC  LA VSCC  LA-CSCC  LA-ESCC  LA-HNSCC  LA-NPC  LA-NSCLC  laag-moleculairgewicht heparine  laag-vet voeding  laaggradig glioom  laaggradig niet-spierinvasief urotheelcarcinoom  laaggradig sereus ovarium- of peritoneaal carcinoom  laat recidief coloncarcinoom  LABC  labeled sodium fluoride PET CT  laboratory prognostic scores  LACC  LACC trial final analysis  LACE-Bio studies  LACE-Bio-II study  LACE-studie  LACOG0415 trial  LAcSCC  LADG  LADG versus ODG  LADG versus ODG for advanced gastric cancer  LAEGSC  LAFA-studie  LAGC  LAGC in elderly patients  LAHNC  LAM  LAM-SA 2007 study  LAMIS  LAN  Lancet Haematology  Lange-termijn analyse van SBG 2004-1 studie  lange-termijn follow-up van KEYNOTE-001  lange-termijn uitkomsten GeparQuinto  langerhanscel histiocytose  LAP07  LAPA and BRPA  LAPACT study  laparascopic versus open hemihepatectomy  laparoscopic surgery for CRC  laparoscopic versus open distal gastrectomy  laparoscopic versus open gastrectomy  laparoscopic versus open pancreatoduodenectomy  laparoscopic versus open resection  laparoscopic versus open surgery  laparoscopic versus open total gastrectomy  laparoscopie  laparoscopische chirurgie  laparoscopische hysterectomie  laparoscopische ingreep  laparoscopische resectie  lapatinib  LAPC  LAPC mPC with associated pain  LAPC-1 trial  LARC  LARC in older patients  large B cell lymphoma  large B-cell lymphoma  large brain metastases  large brain metastases from NSCLC  large skull base meningiomas  larotrectinib  laryngectomy  laryngectomy outcomes  larynxcarcinoom  larynxkanker  larynxpreservatie  Lasker Award  LASRE randomized trial  late adverse events  late alopecia  late bone marrow relapse of B-cell ALL in children  late cardiac adverse events  late cardiac effects  late distant recurrence  late health outcomes  late lower cranial neuropathy  late mortaliteit  late mortality in the North American CCSS versus the UK BCCSS  late outcomes  late radiation toxicity  late recurrence  late recurrence after liver resection  late recurrence and second primary cancers  late toxicity of moderately hypofractionated PBT versus IMRT  late-onset anorectal disease  late-onset cognitive impairment  late-onset irAEs  later-line atezolizumab  later-line irinotecan and TAS-102 plus bevacizumab  later-line nanvuranlat  Lateral Node Study  LATITUDE study  LATITUDE-studie  LATP versus TRUS  LAUNCH trial  LAURA trial  LAVC  lazertinib  lazertinib for CNS metastases  LBCL  LBCL in autoSCT ineligible patients  LC  LCH  LCL161  LCMC3 study  LCNEC  LCS-6 KRAS  LDCT lung cancer screening  LDH response as prognostic biomarker  LE  LEA-studie  lead time to recurrence  leaflet versus film impact on understanding of GEP  LEANer study  LEAP-002 trial  LEAP-004 study  LEAP-005 study TNBC cohort  LEAP-006 study  LEAP-007 trial  LEBS  leefstijl  leefstijl-geassocieerde maligniteit  leefstijlfactoren  leefstijlinterventies  leeftijd  left anterior descending coronary artery radiation dose  left lung cancer  left ventricular global longitudinal strain  left-sided RPC  LEGEND-2 trial  leighl  leiomyomatose  leiomyosarcoma  leiomyosarcoom  leisure-time physical activity  lenalidomide  lenalidomide and dexamethasone  lenalidomide dose  lenalidomide for hematological cancers  lenalidomide maintenance  lenalidomide maintenance after autologous hematopoietic stem cell transplantation  lenalidomide maintenance versus observation  lenalidomide plus eltrombopag  lenalidomide plus obinutuzumab  lenalidomide plus rituximab  lenalidomide with or without EPO alfa  lenalidomide-refractory MM  LENPEM  lentiviral anti-CD20 anti-CD19 CAR T cells  lenvatinib  lenvatinib after atezolizumab plus bevacizumab  lenvatinib after atezolizumab-bevacizumab  lenvatinib after immunotherapy  lenvatinib plus PD-1 blockade  lenvatinib plus PD-1 inhibitor  lenvatinib plus pembrolizumab  lenvatinib plus pembrolizumab or everolimus versus sunitinib  lenvatinib plus pembrolizumab salvage therapy  lenvatinib plus toripalimab and chemotherapy  lenvatinib with etoposide plus ifosfamide  lenvatinib with or without pembrolizumab  lenvatinib-pembrolizumab  leptomeningeal disease  leptomeningeal disease in metastatic melanoma patients  leptomeningeal disease recurrence  leptomeningeal metastases  leptomeningeal metastases from EGFR-mutant NSCLC  leptomeningeal metastases from NSCLC  leptomeningeale ziekte  letrozol  letrozole  letrozole compared to exemestane  letrozole for early breast cancer  letrozole maintenance therapy  letrozole plus abemaciclib  letrozole with or without bevacizumab  letrozole with or without ribociclib  leucine-rich repeating G-protein-coupled receptor 5  leukapheresis  leukemia  leukemia cutis  leukemie  leukemie in kinderen  leukocyt-telomeerlengte  leukocytenattractie  leukocytosis  leumie  levensverwachting  levercarcinoom  levercelcarcinoom  levercelkanker  leverfunctie  leverkanker  levermetastasen  levofloxacin prophylaxis of infection  Leydig cell function  LFS  LGB AYACS  LGG  LGG before one year of age  LGIN  LGSC  LGSOC  Li-Fraumeni syndrome  Li-Fraumeni syndroom  LIBELULE trial  liberal versus restrictive thresholds  LibraT1 study  LIBRETTO-001  LIBRETTO-001 long-term follow-up  LIBRETTO-001 study  LIBRETTO-001 updated results  LIBRETTO-431  LIBRETTO-531  lichaamsgewicht  lichaamslengte  lichaamsomvang  lichaamsvet  lichaamsvetgehalte  lichte keten-geassocieerd Fanconi syndroom  lidocaïne  lieu  lifastuzumab vedotin  life expectancy  life expectancy free from major chronic diseases  life expectancy of adult survivors of childhood cancer diagnosed between 1970 and 1999  lifestyle  lifestyle and breast cancer risk  lifestyle factors  lifestyle factors and risk of MPN  lifestyle intervention  lifileucel  lifirafenib  ligating veins first versus arteries first  light-chain amyloidosis  limited e-Health literacy  limited stage small-cell lung cancer  limited-stage diffuse large B-cell lymphoma  limited-stage plasmablastic lymphoma  limited-stage small cell lung cancer  LINC00472  lincRNA  linked color imaging  linperlisib  linsitinib  linvoseltamab  Linxian NIT cohort  LIP  lip-SCC  LIPI  lipophilic statin use  lipophilic statins  liposarcoom  liposomal irinotecan  liposomal irinotecan versus topotecan  lipoxygenases  liquid biopsies for detecting MRD  liquid biopsy  liquid biopsy detected MSI-H  liquid biopsy versus tissue biopsy  liquid biopt tracking in surveillance  liquide biopten  liso-cel  Listeria expressing mesothelin  LITE risk model  LITESPARK-003 study cohort 1  LITESPARK-004  LITESPARK-005  LITESPARK-005 trial  LITESPARK-013 study  lithium in drinking groundwater  LITT  liver cancer  liver cancer mortality  Liver Cancer Pooling Project  liver cancer risk  liver malignancies  liver metastasis  liver metastatic breast cancer  liver or lung oligometastatic CRC  liver resection for a cancer-related indication  liver resection for malignancy  liver resection versus nonsurgical treatments  liver surgery for primary liver cancer  liver transplant  liver transplant for HCC  liver transplantation  liver transplantation after tumor downstaging  liver-directed local therapy  liver-only mCRC  living alone and cancer mortality  living donors  living-donor liver transplant  LL-mCRC  LLPCa  LLR versus RFA  LM  LM from HER2-positive BC  LMB-2  LMD  LMIS study  LMM  LMR  LMS-04 trial  LN regression after NACT  LNC-PATH score  lncRNA expression  lncRNAs  LOAd703 plus chemotherapy  lobaplatin versus cisplatin non-inferiority trial  lobar versus sublobar resection  lobectomie  lobectomy  lobectomy versus sublobar resection  lobulair carcinoom in situ  lobulair mammacarcinoom  lobular breast cancer  local and systemic therapy  local consolidative therapy  local control  local failure  local recurrence  local recurrence after complete resection  local recurrence after transanal TME  local therapy  local treatment-related adverse effects  localized anal cancer  localized bone or soft tissue sarcoma  localized breast cancer  localized GIST  localized high-grade STS  localized high-risk prostate cancer  localized low- or intermediate-risk prostate cancer  localized MIBC  localized myxofibrosarcoma  localized OPSCC  localized pancreatic adenocarcinoma  localized pancreatic cancer  localized pancreatic ductal adenocarcinoma  localized PCa  localized PDAC  localized prostate cancer  localized recurrent prostate cancer  localized renal cell carcinoma  localized small bowel adenocarcinoma  localized TNBC  localized versus advanced stage  localizing recurrent prostate cancer  locally advaced cervical carcinoma  locally advanced adenocarcinoma of stomach or gastroesophageal junction  locally advanced BCC  locally advanced BCC after HHI  locally advanced bladder cancer  locally advanced breast cancer  locally advanced cancer  locally advanced cervical cancer  locally advanced colon cancer  locally advanced dMMR MSI-H solid tumors  locally advanced ESCC  locally advanced esophageal cancer  locally advanced esophageal squamous cell carcinoma  locally advanced esophagogastric adenocarcinoma  locally advanced G GEJ adenocarcinoma  locally advanced gastric adenocarcinoma  locally advanced gastric cancer  locally advanced gastric or gastroesophageal cancer  locally advanced HCC  locally advanced head and neck squamous cell cancer  locally advanced head and neck squamous cell carcinoma  locally advanced HER2-negative breast cancer  locally advanced HER2-positive BC  locally advanced intrahepatic cholangiocarcinoma  locally advanced large cell neuroendocrine carcinoma of the lung  locally advanced laryngeal and hypopharyngeal cancer  locally advanced laryngeal cancer  locally advanced lung cancer  locally advanced metastatic ALK-rearranged NSLC  locally advanced non-small cell lung cancer  locally advanced NSCLC  locally advanced NSCLC not progressing after CRT  locally advanced operable colon cancer  locally advanced or early breast cancer  locally advanced or metastatic ALK-positive NSCLC  locally advanced or metastatic EGFR mutation-positive NSCLC  locally advanced or metastatic ESCC  locally advanced or metastatic melanoma  locally advanced or metastatic non-squamous NSCLC  locally advanced or metastatic nonsquamous NSClC  locally advanced or metastatic NSCLC  locally advanced or metastatic sarcoma  locally advanced or metastatic UC  locally advanced or recurrent metastatic cSCC  locally advanced pancreatic adenocarcinoma  locally advanced pancreatic cancer  locally advanced pancreatic cander  locally advanced pancreatic neuroendocrine tumors  locally advanced prostate cancer  locally advanced rectal cancer  locally advanced rectal cancer in patients aged 70 years or older  locally advanced rectal cancer not responding to preoperative CRT  locally advanced resectable GC GEJC  locally advanced squamous cell carcinoma of the head and neck  locally advanced squamous cell lung cancer  locally advanced unresectable hepatocellular carcinoma  locally recurrent brain metastases  locally recurrent breast cancer  locally recurrent endometrial cancer  locally recurrent NPC  locally recurrent or metastatic HER2-positive breast cancer  locally recurrent pancreatic cancer  locally recurrent pancreatic cancer after resection  locally recurrent PCa  locally recurrent STS  locally-advanced or metastatic HER2-positive cancers  locally-advanced rectal cancer  locatie  locatie van overlijden  LocoMMotion study  locoregionaal recidief  locoregional progression during neoadjuvant systemic therapy  locoregional recurrence  locoregional recurrence of breast cancer  Locoregional recurrent rhabdomyosarcome  locoregional treatment of primary tumor  locoregionale behandeling  locoregionally advanced HNSCC  locoregionally advanced nasopharyngeal carcinoma  locoregionally advanced NPC  locoregionally advanced resectable CSCC-HN  LOGICA trial  LOH  lokaaal-gevorderd rectumcarcinoom  lokaal gevorderd prostaatcarcinoom  lokaal gevorderd rectumcarcinoom  lokaal recidiverend mammacarcinoom  lokaal-gevorderd hoofd-halscarcinoom  lokaal-gevorderd metastatisch mammacarcinoom  lokaal-gevorderd rectumcarcinoom  LOKON001 study  LOLE  lomustine  lomustine plus temozolomide  loncastuximab tesirine  loncastuximab tesirine plus rituximab  Long Island Breast Cancer Study Project  long term VTE risk  long-term adverse effects and complications  long-term antiandrogen therapy  long-term bone-modifying agents for bone metastases  long-term cancer risk  long-term cause-specific mortality  long-term cerebrovascular changes  long-term clinical outcomes  long-term consequences  long-term CRC risk  long-term CRC risk after screen detected adenoma  long-term CVD risk and all-cause mortality  long-term disease control after discontinuation of ICIs  long-term disease-free breast cancer survivors  long-term effects  long-term efficacy and toxicity  long-term follow-up  long-term follow-up BIG 1-98 trial  long-term follow-up KEYNOTE-012  long-term follow-up of CASSIOPEIA  long-term follow-up of CD19-CAR T-cell therapy  long-term follow-up of combination CAR T cell therapy  long-term follow-up of FS  long-term health outcomes  long-term health outcomes of BSO  long-term heart function  long-term HRQOL  long-term hypertension and cardiovascular toxicity  long-term IHD risk  long-term impact  long-term local recurrence  long-term mental health service utilization  long-term morbidity  long-term morbidity and mortality  long-term mortality  long-term neurocognitive and psychosocial outcomes  long-term OPC survivors  long-term oropharyngeal cancer survivors  long-term outcomes  long-term outcomes after first-line NIVO+IPI versus SUN  long-term outcomes in Poland  long-term outcomes of survivors  long-term PROs following primary surgery versus radiotherapy  long-term QOL  long-term quality of life  long-term responders  long-term results  long-term results OlympiAD study  long-term risk of cardiovascular disease mortality  long-term risk of CAS  long-term risk of endocrine and metabolic diseases  long-term risk of hospitalization  long-term risk of infections  long-term risk of infections associated with hospitalization  long-term somatic disease risk  long-term survival  long-term survival with RT  long-term survivors  long-term survivors NHL  long-term survivors of advanced melanoma treated with checkpoint inhibitor  long-term survivors of childhood cancer  long-term survivors of cisplatin for testicular cancer  long-term survivors of IDH-wildtype glioblastoma  long-term survivos of childhood cancer  long-term thyroid cancer risk  longadenocarcinoom  longcarcinoom  longer interval between first colonoscopy with negative findings for CRC and repeat colonoscopy  longer intervals after negative low-dose CT result  longfunctie  longitudinal analysis of fatigue and anxiety and quality of life  longitudinal analysis of HRQOL  longitudinal ctDNA analyses  longitudinal impact of surgery on HRQOL  longitudinal monitoring of ctDNA  longkanker  longkanker-screening  longkankerchirurgie  longkankerscreening  longmetastasen  LORELEI study  lorlatinib  lorlatinib after second-generation ALK TKI  lorlatinib serum concentrations  lorlatinib versus crizotinib  loss of CEACAM1-expression  loss of HER2-positivity after neoadjuvant therapy  loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer  loss of heterozygosity 1p and 16q  loss of life expectancy  LOTIS-2 study  LOTUS trial  LOTUS-studie  low cT3 4 rectal cancer  low dose radioiodine ablation  low grade and anaplastic glioma  low grade glioma  low rectal cancer  low skeletal muscle mass  low- and high-fat dairy intake  low- or intermediate MDS  low- or intermediate risk prostate cancer  low- versus high-dose 5-fluorouracil  low-carbohydrate diets  low-dose aspirin  low-dose aspirin use  low-dose bisphosponates or denosumab  low-dose dasatinib  low-dose erlotinib  low-dose immunotherapy  low-dose lenvatinb plus anti-PD-1 therapy  low-dose metronomic versus conventional chemotherapy  low-dose tamoxifen  low-dose tamoxifen for mammographic density reduction  low-dose versus standard-dose olanzapine  low-grade and anaplastic gliomas  low-grade glioma  low-grade glioma in children  low-grade serous OC  low-grade toxicities  low-grade upper tract urothelial carcinoma  low-intensity chemotherapy  low-intensity regimens  low-intensity vibration  Low-PV study  low-risk BD-IPMNs  low-risk breast cancer  low-risk cervical cancer  low-risk CRC symptoms  low-risk ductal carcinoma in situ  low-risk early-stage breast cancer  low-risk HPVOPC  low-risk meningioma  low-risk NPC  Low-risk PrCa  low-risk prostate cancer  low-risk PTC  low-risk thyroid cancer  low-stage low-grade EEC  low-tumor burden FL  low-volume mHSPC  lower extremity lymphedema  lower-risk MDS  lower-risk myelodysplastic syndromes  lowering recommended CRC screening age in Canada  LP  LPHL  LPL  LPPG  LPS  LR-ESHAP  LR-HL  LR-MDS  LR-MDS with thrombocytopenia  LRA NPC  lraNPC  LRBC  LRC  LRPC  LRR  LRR after breast cancer treatment  LRRs detected at routine and interval visits  LS  LS SCLC  LS SCLC in elderly patients  LS-SCLC  LSCC  LSNNS versus LSG  LT  LTL  LTL-3MS  LTLD  LTSC trial  Lu-177 for metastatic castration-resistant prostate cancer  Lu-177-octreotate peptide radionuclide therapy for NETs  Lu-PSMA-617 versus cabazitaxel  LUAD  LUAD with EGFR ex20ins  LUAD with LM  LUAD-LM  LUME-Meso studie  LUMINA trial  luminal A breast cancer  luminal B  luminal B breast cancer  luminal B HER2 negative breast cancers  LUMINOSITY trial  lumpectomy for early breast cancer  lumpectomy without RT in elderly women  LUN 14-179 study  LUNA-studie  lung adenocarcinoma  lung adenocarcinoma brain metastases  lung adenocarcinoma with CNS metastases  lung and colorectal cancer  lung and gastrointestinal cancers  lung ASC  lung cancer  lung cancer brain metastases  lung cancer breath biomarkers  lung cancer diagnosis  lung cancer incidence  lung cancer incidence in young women versus young men in 40 coutnries  lung cancer mortality  lung cancer mortality among never smokers  lung cancer patients in France  lung cancer patients of Institut Curie  lung cancer resection  lung cancer risk  lung cancer screening  lung cancer screening efficacy  lung cancer stage at diagnosis  lung cancer surgery  lung cancer survival  lung cancer survivors  lung cancer-associated T cell repertoire as biomarker for early detection of stage I lung cancer  lung nodule progression to cancer  lung oligometastases  lung squamous cell carcinoma  Lung-MAP S1800A  Lung-MAP SWOG S1400  LUNGCA-1 study  LungMate 002 trial  LUNGSTAR  LUPER study  LuPSMA  LuPSMA-studie  lurbinectedin  lurbinectedin plus pembrolizumab  lurbinectedine  LUSC  luspatercept  luspatercept versus epoetin alfa  LUSTRE trial  lutathera  lutetium-177 PSMA-617 versus cabazitaxel  lutetium-177-PSMA-616  lutetium-177-PSMA-617  LUX-Lung 8 trial  LUX-Lung3; LUX-Lung6  LUZERN trial  LV-V5  LVI  LY3039478  LY3127804 with or without ramucirumab  lycopeen  LYM-3002  LYM-3002 study  LYMA trial  LyMa-101 study  lymfadenectomie  lymfekliermetastasen  lymfeklierpositiviteit  lymfoblastisch non-Hodgkin lymfoom  lymfocyten  lymfocyteninfiltratie  lymfoedeem  lymfoïde neoplasie  lymfoom  lymph node burden  lymph node irradiation in breast cancer  lymph node ITCs in endometrial cancer patients  lymph node macrometastases  lymph node metastasis  lymph node ratio  lymphadenectomy  lymphatic versus hematogneous dissemination  lymphaticovenous anastomosis  lymphedema  lymphocyte doubling time in CLL  lymphoid blast phase of CML  lymphoid cancers  lymphoma  lymphoma patients aged ≥85 years  Lymphome Malin de Burkitt chemotherapy  lymphopenia  lymphoplasmatcytic lymphoma Waldenström macroglobulinemia  lymphoscintigraphy  Lynch syndrome  Lynch syndrome associated cancers  lynch syndroom  Lynch syndrooom  LYRA study  M-trap  MA.17R  MA.17R-studie  MA.27  MA.32 randomized clinical trial  maag maag-slokdarmovergangkanker  maag-slokdarmadenocarcinoom  maagadenocarcinoom  maagcarcinoom  maagkanker  MaBC  MaBC risk  MaBC with positive sentinel nodes  MabEase-studie  MABLE-studie  MACBETH-studie  MACE  machine learning model to predict undectable minimal residual disease and survival  machine-learning risk prediction model for mesothelioma  machine-learning-directed clinical evaluation of RT and CRT patients  MACRO2 TTD study  MAESTRO study  Magee Equation 3  MAGIC-studie  magnesium  magnesiuminname  MagnetisMM-1 trial  MagnetisMM-3 trial  MAGNITUDE trial  MAGNITUDE trial second interim analysis  Magnolia trial  magrolimab plus azacitidine  MAIA frailty subgroup analysis  MAIA study  MAIA trial  main-duct intraductal papillary mucinous neoplasms  maintenance  maintenance pembrolizumab after first-line chemotherapy  maintenance rituximab  maintenance therapy  maintenance treatment  maintenance with or without pembrolizumab  maitenance chemotherapy  MAJA study  MAJA-studie  MajesTEC-1 trial  MAJIC-PV trial  major abdominal surgery for cancer  major adverse cardiovascular events  major head and neck surgery  MALDI-MS  male BRCA mutation carriers  male breast cancer  male breast cancer after Hodgkin lymphoma  male breast cancer survivors  male excess risk of advanced colorectal neoplasms  male germ cell cancer treatment  male patients  male pattern baldness  male sex disease-specific mortality  MALE study  male-pattern baldness  malignant glioma  malignant gliomas  malignant lymphoma  malignant melanoma  malignant mesothelioma  malignant pheochromocytoma and paraganglioma  malignant pleural disease  malignant pleural effusion  malignant pleural mesothelioma  maligne ascites  maligne glioom  maligne pleura mesothelioom  maligne pleuraal mesothelioom  Malmö Breast Tomosynthesis Screening Trial  Malmö Diet and Cancer Study  malnutrition in older adults with gastrointestinal malignancies  MALT lymfoom  MALT-IPI  MALT-lymfoom  mamacarcinoom  mammacarcinoom  mammacarcinoom in mannen  mammacarcinoom mannen  mammacarcinoom; SABCS 2015  mammacarcinoom. lichaamsgewicht  mammacarcinoomscreening  mammacarcinooom  mammacarcionoom  mammacarcioon  MammaPrint  MammaPrint-assay  Mammo-50  mammografie  mammografiescreening  mammographic density  mammographic microcalcifications and breast cancer risk  mammographic surveillance in young women  mammography  mammography breast cancer screening in high-risk males  mammography screening  mammograpic screening  MAN  management and outcomes  managing oral complications of oral cavity and oropharyngeal cancer  mandibular preservation  MANHATTAN trial  MANIFEST trial  MANIFEST-2  mannen  Mannuci  mantelcellymfoom  mantle cell lymphoma  mantle cell lymphoma in younger patients  manual therapy  MAPPYACTS  MAPS IFCT-GFPC-0701 study  MAPS2-studie  MARBLE trial  MARCH  margetuximab  margetuximab plus pembrolizumab  margin status and survival outcomes  marginaal zone lymfoom  marginal zone lymphoma  MARIANNE study final results  MARIE study  MARIE-cohort  marihuana  marijuana use  MARIPOSA trial  marital status  marizomib  marker borstkanker  MARQUEE study  MARS mutation-adjusted risk score  MARTA trial  MASAI trial  masitinib  MasSpec Pen  MAST study  mastectomie  mastectomy for breast cancer in males versus females  mastectomy for clinical N0 SLN-positive breast cancer  mastectomy versus lumpectomy plus RT  mastectomy with IBR  mastectomy with immediate breast reconstruction after NACT in young women with breast cancer  MASTER trial  matched sibling donor transplantation  matched sibling transplantation  matched therapy  MATCHPOINT trial  MATE-1 inhibiting TKIs  maternal and fetal outcomes  maternal breast cancer risk  maternal cancer diagnosis during pregnancy  maternal cancer during pregnancy  maternal infection during pregnancy  maternal obesity during pregnancy  MATISSE-studie  MATRix induction  matrix metalloproteïnase-8  MATRix regimen followed by ASCT or WBRT  mature B-cell malignancies  MAVORIC study  MAVORIC-studie  MaxRP  MaxRT  MAYA trial  MBC  mBC after endocrine therapy  mBC in elderly women  mBC in older patients and patients with comorbidities  MBC in real-world patients  MBC in Swedish patients  MBC with high TMB  mBC with variable HER2 expression  mBCC  MBI  MBL  MBM  MBMs  MBO in advanced cancer patients  mBTC  MC1631 trial  MCARH109  MCC  MCC-Spain follow-up study  mccRCC  mCDC  MCL  MCL in older patients  MCL in young patients  MCL in younger patients  MCL Younger trial long-term follow-up  mCRC  mCRC after failure of FOLFOX-bevacizumab  mCRC extremes of survivorship  mCRC with KRAS G12C mutation  mCRC with response or stable disease with 16 weeks first line treatment  mCRPC  mCRPC and DRDs  mCRPC in DDRmut patients  mCRPC in older patients  mCRPC taxane after radium-223  mCRPC with or without PTEN-loss  mCSCC  mCSPC  MD  MDNA55-05 study  MDS  MDS and CMML  MDS and sAML  MDS or AML  MDS-EB-1 or EB-2  MDS-RAEB or secondary AML  MDT  MDTB  meat consumption  meat intake  mebendazol  MEC  MECCA trial  mechanisms of resistance to BRAF-targeted therapy  MED10562  MEDALIST study  MedCan1-CBD study  median 15.7 years follow-up  mediating factors  mediation analysis of racial disparities  medical decision-making capacity  medically diagnosed postnatal infection  medication interactions  medication-associated phthalate exposure and childhood cancer incidence  medication-related osteonecrosis of the jaw  MEDIOLA study  medische marihuana  mediterrane voeding  MEDITREME trial  medium-sized brain metastases  medium-throughput drug screening  MEDOCC  medullair schildkliercarcinoom  medullair thyroïdcarcinoom  medulloblastoma  medulloblastoma subgroups  medulloblastoom  meeroken  mEGA  MEI  MEK- plus AKT-remming  MEK-remmers  MEK-remming  Mel-Ipi-Rx study  melanoma  melanoma after SLNB  melanoma brain metastases  melanoma brain metastasis  melanoma CNS metastases  melanoma detection  melanoma in adolescents and young adults  melanoma in children and adolescents  melanoma in situ  melanoma in-transit metastases  melanoma incidence  Melanoma Institute Australia nomogram  melanoma metastatic to the adrenal gland  melanoma of unknown primary  melanoma risk  melanoma survival  melanoma trends in Sweden  melanoma with CNS metastases  melanoma with LMD  melanoma with rare BRAF mutations  melanoom  melanoom-geassocieerde leucoderma  melanoom-mortaliteit  melanoomrisico  melatonin after lung cancer resection  melatonine  MelBase French cohort  melfalan  melflufen plus dexamethasone  melkconsumptie  MEMMAT  MEMOIR study  Memorial Sloan Kettering Cancer Center nomogram  men with germline BRCA1 and BRCA2 pathogenic variants  MEN1  Mendelian randomisation analysis  Mendelian randomization study  menigioma risk following treatment for childhood cancer  meningioma  meningioma in patients exposed to progestin drugs  meningioma risk factors  meningiomas of the confluence of falx and tentorium  meningioom  menopausal hormone therapy  menopausal hormone therapy options  menopauzale hormoontherapie  mental disorders  mental health  mental health care utilization  mental health disorders  mental health disorders and survival  mental health of mothers and siblings  mental health resource use  mental health service users  mental health symptoms and chemotherapy toxicity  mental health trajectories  mentale stoornis  mepitel film  Merkel celcarcinoom  Merkel cell carcinoma  Merkel cell carcinoma of unknown primary cutaneous lesion  Merkelcelcarcinoom  MESCC  mesenchymal stem cells for cGVHD prophylaxis  mesenchymal stromal cells  mesothelin-targeted CAR T cells  mesothelioma  mesothelioom  mestcel-neoplasmata  MET exon 14 altered lung cancer  MET exon 14 skipping in NSCLC  MET exon 14-altered NSCLC  MET exon 14-mutated or MET-amplified NCSLC  MET-amplificatie  MET-driven metastatic papillary RCC  MET-dysregulated NSCLC  MET-mutated aNSCLC  meta-analysis  meta-analysis of outcomes  meta-analysis of studies of immunotherapy for NSCLC  metabole gezondheid  metabolic and cardiac and bone health testing  metabolic dysregulation  metabolic health  metabolic syndrome  metabolic syndrome biomarkers  metabolomic biomarkers of cancer  metabool syndroom  metachronous CLMs after chemotherapy for stage III CRC  metachronous contralateral testicular cancer  MetaPHER study  metastase  metastasectomie  metastasering  metastasevrije overleving  metastasis sites  metastasis-directed therapy  metastasis-free interval  metastatic biliary tract cancer  metastatic brain tumors  metastatic breast cancer  metastatic breast cancer in BRCA-mutated patients  metastatic breast cancer in geriatric patients  metastatic cancer  metastatic cancers  metastatic cardiophrenic lymph nodes  metastatic castration resistant prostate cancer  metastatic castration-naïve prostate cancer  metastatic castration-resistant prostate cancer  metastatic castration-resistant prostate cancer with DNA repair defects  metastatic castration-sensitive prostate cancer  metastatic clear cell RCC  metastatic colorectal cancer  metastatic colorectal cancer cetuximab plus FOLFOX-4  metastatic colorectal cancer in older vulnerable patients  metastatic CRC and other cancers  metastatic CRC and other solid tumors with KRAS G12C mutation  metastatic desmoplastic melanoma  metastatic disease at diagnosis  metastatic EGFR-mutated NSCLC after TKI failure  metastatic endometrial cancer  metastatic esophagastric cancer  metastatic esophageal cancer  metastatic esophagogastric adenocarcinoma  metastatic esophagogastric cancer  metastatic gastric and gastroesophageal junction adenocarcinoma  metastatic gastric cancer  metastatic gastric or gastroesophageal junction cancer  metastatic gastric or junctional adenocarcinoma  metastatic gastrointestinal stromal tumors  metastatic gastrointestinal tract cancer  metastatic HER2-positive breast cancer  metastatic hormone sensitive prostate cancer  metastatic hormone-sensitive prostate cancer  metastatic intracranial lesions  metastatic intrahepatic cholangiocarcinoma  metastatic lung NEC  metastatic lung tumors  metastatic melanoma  metastatic melanoma after failure anti-PD-1 therapy  metastatic melanoma after ICIs and targeted agents  metastatic melanoma and NSCLC  metastatic melanoma of the heart  metastatic Merkel cell carcinoma  metastatic MSI-H dMMR CRC  metastatic mucosal melanoma  metastatic nasopharyngeal carcinoma  metastatic non-small cell lung cancer  metastatic non-squamous NSCLC  metastatic nonseminomatous germ cell tumors  metastatic nonsquamous non-small cell lung cancer  metastatic nonsquamous NSCLC  metastatic or inoperable locally advanced DDLPS  metastatic or persistent or recurrent cervical cancer  metastatic osteosarcoma  metastatic pancreatic adenocarcinoma  metastatic pancreatic cancer  metastatic pancreatic ductal adenocarcinoma  metastatic papillary renal cell carcinoma  metastatic papillary thyroid cancer  metastatic prostate cancer  metastatic prostate cancer incidence  metastatic prostate cancer patients  metastatic renal cell carcinoma  metastatic seminoma  metastatic soft tissue sarcoma in patients aged 60 years or older  metastatic soft-tissue sarcoma  metastatic solid tumors  metastatic spinal canal compression  metastatic squamous cell carcinoma of head and neck  metastatic squamous cell carcinoma of the anal canal  metastatic squamous non-small cell lung cancer  metastatic squamous NSCLC  metastatic thyroid cancer  metastatic triple-negative breast cancer  metastatic unresectable STS  metastatic urothelial carcinoma  metastatic urothelial carcinoma in cisplatin-unfit patients  metastatic uterine leiomyosarcoma  metastatic uveal melanoma  metastatisch castratieresistent prostaatcarcinoom  metastatisch cervixcarcinoom  metastatisch colorectaalcarcinoom  metastatisch colorectaalkanker  metastatisch colorrectaalcarcinoom  metastatisch heldercellig niercelcarcinoom  metastatisch maagcarcinoom  metastatisch mammacarcinoom  metastatisch melanoom  metastatisch niercelcarcinoom  metastatisch niet-castratieresistent prostaatcarcinoom  metastatisch pancreas ductaal adenocarcinoom  metastatisch pancreascarcinoom  metastatisch PDAC  metastatisch potentieel  metastatisch prostaatcarcinoom  metastatisch squameus celcarcinoom van hoofd en hals  metastatische borstkanker  metastatische botziekte  metastatische castratieresistente prostaatkanker  metastatische colorectaalkanker  metastatische niet-kleincellige longkanker  metastatische prostaatkanker  metastatische triple-negative borstkanker  metastic castration-sensitive prostate cancer  metastic melanoma progressing on anti-PD-1  METEOR  METEOR trial analysis  METEOR-studie  METEORA-II trial  METex14 aNSCLC  METex14-positive NSCLC  METex14-positive pulmonary sarcomatoid carcinomas and other NSCLC-subtypes  metformin  metformin plus CRT  metformin plus irinotecan  metformin use  metformine  methionine  methotrexate  methotrexate neurotoxicity  metronome chemotherapie  metronomic chemotherapy  metronomic chemotherapy plus toripalimab  metronomic cyclophosphamide-methotrexate with or without bevacizumab  metronomic eribulin  metronomic methotrexate-celecoxib-erlotinib  metronomic oral vinorelbine plus trastuzumab  MetroPancreas model to predict futility of upfront resection for PDAC  METROS study  MetS  MetS scores trajectory patterns  mezigdomide plus dexamethasone  MF  mFOLFOX6  MFS  mGC  mGCT  mGEA after progression on ICI  MGMT promoter methylation  MGMT-NET trial  mGPS  MGPT  MGUS  MGUS progression to myeloma  MHD  MHL  mHNSCC  mHSPC  MHSs  MHT  MHT and ovarian and endometrial cancer risk  MIA calculator for predicting RFS and OS  MIBC  MIC-1  microductectomy  microRNA-203  microRNA-371a-3p test  microRNA-classifier  microRNAs  microRNAs as biomarkers and radiosensitivity modifiers  microsatelliet-instabiele kanker  microsatellite instability  microsatellite instability-high advanced endometrial cancer  microsatellite instability-high gastric or gastroesphageal junction cancer  microsatellite instability-high mCRC  microsatellite instability-high mismatch repair deficient tumors  microsatellite instability-high mismatch repair-deficient mCRC  microsatellite instability-high solid tumors  microsatellite-instability-high advanced CRC  microsatellite-stable mismatch repair-proficient mCRC  microvascular invasion  microwave ablation  mIDC  middel-heupomtrekverhouding  middelomtrek  middelomvang  middle low rectum versus left-sided colon  middle-aged and older adults  midgut NETs  midline low-grade gliomas of early childhood  migraine  migratie naar hersenparenchym  mILC  MILD trial  MILES-3  MILES-4  Miller-Payne score  million women study  MILO ENGOT-ov11 study  MILS  MIMOSA-1 study  MINDACT  MINDACT trial  MINDACT trial post-hoc analysis  mindfulness  mindfulness-based cognitive therapy  mini-mental state examination  minimal access breast surgery versus conventional breast surgery  minimal invasive secondary cytoreduction  minimal invasive versus open liver resection  minimal residual disease  minimal residual disease status  minimally invasive robotic surgery  minimally invasive surgery  minimally invasive versus open radical hysterectomy  minimally invasive versus open surgery  Minnesota Colon Cancer Control Study  minoxidil  MIPS versus OPS  mipsagargin  MIPSS70  miR-126  miR-190b  miR-34  miR-345  miR-506  MIRACLE trial  MIRAGE trial  MIRASOL trial  mirdametinib  mirdametinib (PD-0325901)  miRNA  miRNA as independent prognostic marker  miRNA signature  miRNA-based signature for early detection of gastric cancer  miRNAs  MIRO trial  MIRO-studie  MIRV  mirvetuximab soravtansine  mismatch repair deficient small bowel adenocarcinoma  mismatch repair genes pathogenic variants  mismatch repair status  mismatch repair-deficient LARC  MiST2 trial  mitazalimab plus mFOLFIRINOX  Mitchell  MITCI study  MITCI-studie  MITNEC-A1 trial  MITO END-3  MITO-8 studie  MITO-9 study  mitochondrially targeted tamoxifen  mitomycin C  mitosesnelheid  mitotische activiteitsindex  mitoxantrone  MIUC  mivebresib with or without venetoclax  MK-2206  MK-3475  MK-4166 with or without pembrolizumab  MK-6482  MK-6482-004 trial  ML  MLBO  MM  MM and AL amyloidosis  MM before age 41 years  MM in octogenarians  MM-302  mMCC  mMGMT  MMR  MMR-D noncolorectal cancers  MMR-deficiency  MMR-deficient or hypermutated gynecological cancer  MMR-deficiëntie  MMRd  MMRd cancers  MMRD in pediatric gliomas  MMRP EC  MMS vs WLE  MMSE  MN-HLH CS  mNPC  mNSCLC  mNSCLC after ICI and chemotherapy  mNSCLC in patients aged 80 years and over  mNSCLC with atypical EGFR mutations  mNSCLC with high expression PD-L1+  mNSCLC with PD-L1 TPS≥50%  mNSCLC with PD-L1 tumor proportion score ≥1%  mNSCLC with uncommon EGFR mutations  mNSCLCwith PD-L1 tumor proportion score ≥ 50%  mnsqNSCLC with high TMB  MNTX  mobility program for hospitalized patients with cancer  mobocertinib  modakafusp alfa  mode of detection  mode of progression  model for predicting acute complications after surgery for breast cancer  model for predicting individualized outcomes  modelling study of cost-effectiveness of various mammography screening strategies  moderately hypofractionated helical IMRT  moderately hypofractionated IMRT  modern chemotherapy  modern treatments for newly diagnosed lymphoma  Moderna vaccine in patients receiving systemic therapy for solid tumors  modifiable risk factors for early ET discontinuation  mogamulizumab  mogamulizumab plus nivolumab  Mohs micrographic surgery for T1a-T2a invasive melanoma  Mohs surgery versus wide margin excision  Mohs surgery versus WLE  moleculaire subtypen  moleculaire tumormarkers  molecular analysis  molecular classification  molecular classification and recurrence risk  molecular expression assays  molecular features and outcomes  Molecular International Prognostic Scoring System for Myelodysplastic Syndromes  molecular markers of prognosis  molecular markers of recurrence  molecular pahtological subtypes and pathways  molecular predictors of response to neoadjuvant therapy  molecular profiling  molecular profiling for assessment of distant metastasis risk  molecular recurrence  molecular relapse detection  molecular residual disease  molecular risk stratification  molecular subtype  molecular subtypes  molecular subtypes of breast cancer  molecularly-defined diffuse glioma types  Molina  MOLTO trial  momelotinib  MOMENTUM trial  MONALEESA studies exploratory analysis  MONALEESA-2  MONALEESA-2 OS analysis  MONALEESA-2 studie  MONALEESA-3 OS analysis  MONALEESA-3 overall survival analysis  MONALEESA-7 studie  MONALEESA-7 trial  MONALEESA-7 update  monalizumab plus durvalumab  MONARCH 1  MONARCH 1-studie  MONARCH 2 study  MONARCH 2 trial premenopausal subgroup analysis  MONARCH 2-studie  MONARCH 3 trial  MONARCH 3-studie  monarchE study  monarchE trial  monarchE trial analysis  monarcHER trial  mondholte squameus celcarcinoom  mondholtecarcinoom  mondhygiëne  mondkanker  monitoring of ctDNA in CSF  monoclonal antibody combined with induction chemotherapy  monoklonale B-cel lymfocytose  montelukast and rupatadine premedication  Moore-criteria  MOR202  morbidity and mortality  morbidity in midlife  morcellatie  MORPHEUS-Liver trial  morphomics and survival  mortaliteit  mortaliteit colorectaalcarcinoom  mortaliteit na kankerdiagnose  mortality  mortality after breast cancer  mortality after late recurrence  mortality after PCa diagnosis  mortality and chronic health conditions  mortality and overall survival trends  mortality as function of age  mortality due to cancer treatment delay  mortality from unrelated causes  mortality prediction by Oncotype DX  mortality rates  mortality risk  mortality trends  mortality trends in multiple myeloma after introduction of novel therapies in the USA  mortalteit  MOSAIC  MOSAIC trial post hoc analysis  mosunetuzumab  MOTION trial  moxetumomab pasudotox  mPaC  mPanNET  mPC  mPCa  mPDAC  MplBC  MPM  mpMRI  MPN  MPNs  MPNs treated during pregnancy  MPPGs  MPR  mPRC  mPTC  MR analysis  mRCC  mRCC histologic varants  MRCLS  MRD  MRD and clinical outcomes  MRD at EOC  MRD detection  MRD dynamics  MRD response and prognosis  MRD response-adapted Dara-KRd therapy  MRD status  MRD-based endpoint  MRD-guided stop and start of venetoclax plus ibrutinib  MRD-negative ALL in adult patients  MRD-status  MRD-stratified treatment  MRE11 expression and mortality  mRECIST objecte response  MRg-A-SBRT  MRI  MRI background parenchymal enhancement  MRI of ultrasonography for prostate concer screening  MRI plus targeted biopsy versus systematic biopsy alone  MRI staging of breast camcer  MRI surveillance and breast cancer mortality  MRI versus conventional endoscopy  MRI versus TURBT  MRI- versus CT-guided SBRT  MRI-based versus PSA-based PCa screening  MRI-detected additional lesions  MRI-FIRST study  MRI-guided adaptive brachytherapy  MRI-guided biopsy to verify pCR  MRI-guided focused ultrasound focal therapy  MRI-guided or standard biopsy  MRI-guided salvage focal cryoablation  MRI-screening  MRI-screening mammacarcinoom  MRI-targeted versus systematic versus combined biopsy  MRLN region sparing RT  mRNA-4157 vaccine plus pembrolizumab  MRONJ  MS2010 study  MSC  MSCC  mSCLC  MSE  MSG-carcinomen  MSI  MSI dMMR mCRC  MSI mCRC  MSI-CRC  MSI-H dMMR CRC  MSI-H dMMR gastrointestinal tumors  MSI-H dMMR mCRC  MSI-H mCRPC  MSLCs  MSLT-II studie  msRCC  MSS and MGMT-silenced mCRC  MSS colorectal cancer and pancreatic ductal adenocarcinoma  mss CRC  MSS CRC after chemotherapy  MSS LARC  MSS mCRC  MSS metastatic colorectal cancer  MT-GCT  MTC  mtDNA  mtDNAfb  mtFIT versus FIT  MTH1-remmers  MTL-CEBPA  mTNBC  mTOR-remmer  mTOR-remmers  mUC  mUC after platinum-based chemotherapy  mUC and other genitourinary tumors  mUC in patients with renal insufficiency or mixed variant histology  mUC progressing after chemotherapy and ICIs  MUC16 mutations  mucosa-associated lymphoid tissue lymphoma  mucosaal melanoom  mucosal melanoma  mucosalaesies  mucositis  mucositispijn  MUIC  mulitpel myeloom  Müllerian carcinoom  multi-antigen targeted T cells  multi-cancer detection and localization  multi-cancer early detection test  multi-gen panel testing HBOC  multi-organ irAEs  multicenter phase 3 RESOLVE trial  multicenter randomized phase 2 NeoTrio trial  multidisciplinary salvage treatment  multidrugresistentie  Multiethnic Cohort  Multiethnic Cohort Study  multifocal iCCA  multigene testing for all patients  multikinase inhibitors  multimodal therapy  multimodal treatment  multimodality management  multimodality therapy  multimorbidity  multinational phase 3 SEQUOIA trial  multinational phase 3 TALAPRO-2 trial  multinational post registration study of nivolumab  multipel myeloom  multipel myeloom. KTd  multipele endocriene neoplasie  multiple brain metastases  multiple foci of microinvasion  multiple myeloma  multiple myeloma refractory to CD38 MoABs  multiple myeloma survival  multiple primary melanoma  multiple primary melanoma incidence  multiple sclerosis  multitarget stool RNA test for screening  MULTOMAB study  mUM  MUP  MURANO study  MURANO study 4-year results  MURANO-studie  muscle mass  muscle radiodensity  muscle-invasive bladder cancer  musculoskeletal burden  mutatiescreening  mutatievolgorde  mutation burden  mutation clearance  mutation profiling  mutation status and prognosis  mutation-enhanced prognostic system  mutational profile  mutational signature changes  mutational signature in colorectal cancer  mutations associated with high-grade irAEs  mutations in cancer-associated genes  mutations in cancer-related genes  mutations in homologous recombination-related genes  mutp53 proteins  muziektherapie  MVAC  MVD and MCD  MVI  MVPA  MWA versus LR  MYC  MYC deregulated cancers  MYC rearrangement and translocation partner  Myc-remming  MyCARe model  MYCN  mycobacterial infections  mycosis fungoides  mycosis fungoides and Sézary syndrome  mycosis fungoides cutaneous T-cell lymphoma  myelodysplasie  myelodysplastic syndrome  myelodysplastic syndromes  myelodysplastic syndromes and chronic myelomonocytic leukemia  myelodysplastic syndromes refractory to hypomethylating agents  myelodysplastisch syndroom  myelodysplastisch syndroom myeloproliferatieve neoplasmen  myelodysplastische syndromen  myelofibrose  myelofibrosis  myelofibrosis patients with anemia  myeloid cancers  myeloid malignancies  myeloid neoplasms after allogeneic versus autologous HCT  myeloïde neoplasie  myeloma  Myeloma X trial  Myeloma XI study  Myeloma XI trial  myeloom  myelopreservation with trilaciclib  myeloproliferatieve neoplasmen  myelosuppression with chemotherapy for extensive-stage SCLC  MYL-14010  myocarditis  myomectomie  MyPathway  MyPathway study  MyPathway-studie  MYSTIC study  myxofibrosarcoma  myxoid liposarcoma  MZL  MZL-IPI  n-3 fatty acids  n-3 PUFAs  N-cadherine  N-terminal-pro-B-type natriuretic peptide  N107C CEC.3 trial  N1087-studie  N2-3 breast cancer  N2-3 NPC  N3 stage IIIB NSCLC in elderly patients  N3C  NA-PHER2 studie  Naakte molrat  nab-paclitaxel  nab-paclitaxel after taxanes  nab-paclitaxel plus gemcitabine  nab-paclitaxel plus gemcitabine dose-reduction strategy  nab-paclitaxel plus gemcitabine plus cisplatin  nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine  nab-paclitaxel versus paclitaxel  nab-sirolimus  nabiximols oromucosal spray  NABON Breast Cancer Audit  NABPLAGEM  NAC  NAC for BC  NAC for breast cancer  NACATRINE trial  nachtarbeid  NACI study  NACRT versus NACT  NACT  NACT and IDS with or without HIPEC  NACT versus PCS  NACT-induced immune microenvironment changes  NADIM II trial  NADIM study  NADIM trial  nadofaragene firadenovec  nadunolimab plus chemotherapy  naevi  NAG  naI-IRI plus FU and LV  naive T-cell depletion  Nal-IRI plus 5-FU and LV  NALA study  NALA study health-related quality of life analysis  NALA trial  naldemedine  NALIRIFOX  naming of cancers needs to change  nanoparticle-assisted axillary staging after NAC for pretreatment node-positive breast cancer  nanoparticles  nanotechnologie  nanvuranlat  NAPOLI 3 trial  NAPOLI-1 study  naporafenib plus trametinib  narsoplimab  NAS  nasofarynxcarcinoom  nasopharyngeal cancer  nasopharyngeal carcinoma  nasopharyngeal carcinoma early detection  NAST in geriatric breast cancer patients  NAT for breast cancer  NATALEE trial  Natalie Trial  NATION-1907 trial  National Breast and Cervical Cancer Early Detection Program  National Cancer Data Base  National Cancer Database analysis  national health expenditure  National Institute for Health and Care Excellence  National Lung Cancer Screening Trial secondary analysis  natriumthiosulfaat  natural history and prognostic factors  natural killer  natural killer T-cel lymfoom  natural killer T-cell lymphoma  navicixizumab plus paclitaxel  NAVIGATOR trial  NBTXR3  NC  NC-6004  NCCN-richtlijnen  nccRCC  NCDB analysis  NCDB analysis of immunotherapy in resected stage III melanoma  NCDB analysis of treatment utilization and outcomes  NCDB analysis of use of mastectomy for DCIS in young women  NCGA  NCGC  NCI 8628  NCI Protocol 10250  NCI trial 9984  NCI-CONNECT  NCI-Maryland Case Control Study  NCI-MATCH ECOG-ACRIN trial subprotocol E  NCI-MATCH study  NCI-MATCH subprotocol EAY131-Y  NCI-MATCH Subprotocol J  NCI-MATCH subprotocol Z1F  NCI-MATCH trial  NCI-Match Trial E131-Y  NCI-MATCH trial subprotocol H  NCI9673  NCIC CTG MA.27-studie  nCIT versus nCT  NCM  NCRI AML18 trial  nCRT  NCSLC  NCT03931291 trial  NCTN study S1001  ND AML in patients aged 16-60 years  ND Ph- B-ALL in older patients  ND- or R R-AML  NDMM  NDMM in transplant-ineligible patients  near real-time intraoperative brain tumor diagnosis  NEC study  NECC  necitumumab  NECs  NECTAR trial  nectin-4-positive solid tumors  NECTORS versus CCRT  nedaplatin- versus cisplatin-based CCRT  negative colonoscopy  negative for intraepithelial lesions or maligancy  negative thyroid biopsy  neighborhood deprivation and breast cancer mortality among Black and White women  neighborhood opportunity  neighborhood-level household income  NEJ009 study  NEJ047  nelarabine  nelfinavir plus chemoradiotherapy  nelfinavir with concurrent chemoradiotherapy  NELM  NELSON study  NELSON-studie  NEMO  NENs  NENs of the breast  NEO trial  neo-adjuvant-adjuvant versus neoadjuvant-only PD-(L)1 inhibition  Neo-CRAG trial  NEO-GAP trial  Neo-PATH phase 2 trial  Neo-Pre-IC trial  Neo-Real trial  neoadjuvant adebrelimab  neoadjuvant and adjuvant chemotherapy  neoadjuvant and adjuvant nivolumab plus lirilumab  neoadjuvant and adjuvant pembrolizumab  neoadjuvant and adjuvant toripalimab  neoadjuvant anlotinib plus chemotherapy  neoadjuvant anti-HER2 therapy for HER2-positive breast cancer  neoadjuvant apatinib plus chemotherapy  neoadjuvant aspirine  neoadjuvant atezolizumab  neoadjuvant atezolizumab plus chemotherapy  neoadjuvant atezolizumab plus gemcitabine and cisplatin  neoadjuvant atzolizumab plus chemotherapy  neoadjuvant bevacizumab  neoadjuvant breast cancer treatment  neoadjuvant cabozantinib  neoadjuvant cabozantinib plus nivolumab  neoadjuvant camrelizumab plus apatinib  neoadjuvant camrelizumab plus chemotherapy  neoadjuvant camrelizumab plus chemotherapy and apatinib  neoadjuvant camrelizumab plus CT  neoadjuvant CAPOX plus radiotherapy  neoadjuvant carboplatin  neoadjuvant carboplatin plus docetaxel  neoadjuvant carboplatin with or without anthracycline  neoadjuvant cemiplimab  neoadjuvant cemiplimab and surgery  neoadjuvant chemo-immunotherapy  neoadjuvant chemoimmunotherapy  neoadjuvant chemoradiation  neoadjuvant chemoradiation with or without PD-1 blockade  neoadjuvant chemoradiotherapy  neoadjuvant chemotherapie  neoadjuvant chemotherapy  neoadjuvant chemotherapy followed by excision and observation  neoadjuvant chemotherapy for breast cancer  neoadjuvant chemotherapy for early breast cancer  neoadjuvant chemotherapy for ovarian cancer  neoadjuvant chemotherapy for TNBC  neoadjuvant chemotherapy or chemoradiation  neoadjuvant chemotherapy plus durvalumab  neoadjuvant chemotherapy plus nivolumab  neoadjuvant chemotherapy versus upfront surgery  neoadjuvant chemotherapy with or without PD-1 inhibitor  neoadjuvant CRT  neoadjuvant CRT for rectal cancer  neoadjuvant CRT plus atezolizumab  neoadjuvant CRT versus CT  neoadjuvant CRT versus upfront surgery  neoadjuvant CRT with UGT1A1 status guided irinotecan dose  neoadjuvant dabrafenib plus trametinib  neoadjuvant docetaxel plus cisplatin  neoadjuvant dual checkpoint blockade  neoadjuvant durvalumab  neoadjuvant durvalumab plus chemotherapy  neoadjuvant EBC RCTs  neoadjuvant endocrine therapy  neoadjuvant endocrine versus chemotherapy  neoadjuvant enoblituzumab  neoadjuvant erlotinib  neoadjuvant exercise therapy  neoadjuvant FOLFIRINOX  neoadjuvant FOLFIRINOX followed by CRT  neoadjuvant FOLFIRINOX or gemcitabine plus nab-paclitaxel  neoadjuvant FOLFOX versus CRT  neoadjuvant FOLFOX versus FOLFIRINOX  neoadjuvant gemcitabine plus cisplatin  neoadjuvant gemcitabine plus S-1  neoadjuvant gemcitabine-cisplatin plus tislelizumab  neoadjuvant gemcitabine-cisplatin-nab-paclitaxel  neoadjuvant gemcitabine-cisplatin-pembrolizumab before radical cystectomy  neoadjuvant HCRT  neoadjuvant ICI  neoadjuvant ICI for stage III melanoma  neoadjuvant ICIs  neoadjuvant ICIs for solid tumors  neoadjuvant ICIs plus chemotherapy  neoadjuvant immune checkpoint blockade  neoadjuvant immunoradiotherapy  neoadjuvant immunotherapy  neoadjuvant immunotherapy and chemotherapy  neoadjuvant immunotherapy plus chemotherapy  neoadjuvant immunotherapy plus chemotherapy for NSCLC  neoadjuvant intensity-modulated radiotherapy  neoadjuvant ipilimumab plus nivolumab  neoadjuvant K522 chemoimmunotherapy for TNBC  neoadjuvant lapatinib plus trastuzumab without chemotherapy  neoadjuvant larotrectinib  neoadjuvant mFOLFIRINOX and postoperative gemcitabine  neoadjuvant mFOLFIRINOX with or without HFRT  neoadjuvant nab-paclitaxel  neoadjuvant niraparib  neoadjuvant nivolumab  neoadjuvant nivolumab for NSCLC  neoadjuvant nivolumab plus chemotherapy  neoadjuvant nivolumab plus ipilimumab  neoadjuvant nivolumab plus relatlimab  neoadjuvant nivolumab with or without ipilimumab  neoadjuvant nivolumab with or without relatlimab  neoadjuvant nivolumab with or without tadalafil  neoadjuvant osimertinib  neoadjuvant paclitaxel plus platinum  neoadjuvant PD-(L)1 inhibitors  neoadjuvant pegylated liposomal doxorubicin  neoadjuvant pembrolizumab  neoadjuvant pembrolizumab plus HDI  neoadjuvant pembrolizumab plus ramucirumab  neoadjuvant pembrolizumab-carboplatin-docetaxel  neoadjuvant pertuzumab  neoadjuvant plus adjuvant durvalumab-based treatment  neoadjuvant plus adjuvant erlotinib  neoadjuvant radiotherapy  neoadjuvant relatlimab plus nivolumab  neoadjuvant ribociclib-letrozole versus chemotherapy  neoadjuvant SABRT  neoadjuvant SBRT after CT  neoadjuvant SBRT plus single-dose durvalumab  neoadjuvant SG  neoadjuvant SHR-A1811  neoadjuvant single or dual HER2 blockade  neoadjuvant sintilimab  neoadjuvant sintilimab for NSCLC  neoadjuvant sintilimab plus chemotherapy  neoadjuvant stereotactic radiotherapy for brain metastases  neoadjuvant systemic therapy  neoadjuvant systemic therapy for breast cancer  neoadjuvant T-DM1  neoadjuvant T-DM1 plus lapatinib plus paclitaxel  neoadjuvant talazoparib  neoadjuvant talimogene laherparepvec  neoadjuvant targeted therapy  neoadjuvant TCHP  neoadjuvant therapy  neoadjuvant therapy before metastasectomy  neoadjuvant therapy for breast cancer  neoadjuvant therapy for NSCLC  neoadjuvant toripalimab  neoadjuvant toripalimab plus axitinib  neoadjuvant toripalimab plus chemotherapy  neoadjuvant trastuzumab emtansine plus pertuzumab  neoadjuvant trastuzumab plus pertuzumab  neoadjuvant trastuzumab plus pyrotinib  neoadjuvant treatment  neoadjuvant tucidinostat plus exemestane  neoadjuvant zoledronic acid  neoadjuvant-treated breast cancer  neoadjuvante chemotherapie  neoadjuvante CRT  neoadjvuant systemic therapy  neoALTAL trial  NeoALTTO  neoantigen T-cell receptor gene therapy  NeoBCC trial  NEOCAP study  NeoCF  NeoCF+D  NeoCF+RT  NeoCombi study  NeoCombi trial  NEOCRTEC-1601  NEOCRTEC1901 trial  neodjuvant studies of early stage breast cancer  neonatal inflammatory markers  neonatal phototherapy  NEONIPIGA phase 2 study  NeoPACT phase 2 clinical trial  NeoPAL study  NeoPalAna  NEOPAN trial  neoplasm detection in upper gastrintestinal tract  neoplasm risk  NEOpredict-Lung trial  neopterine  NeoRTPC02  NEOS trial  NEOSTAR trial  NeoSTOP study  NEOSUMMIT-01 trial  NeoTENNIS trial  Neotorch randomized trial  NEOZOTAC trial  nephrectomy  nephrotoxicity  NEPTUN study  neratinib  neratinib for HER2-positive breast cancer  neratinib plus trastuzumab emtansine  nercelcarcinoom  NET  NET liver metastases  NET versus NACT  NETs  NETTER-1 study  network meta-analysis  network meta-analysis of first-line treatments  network meta-analysis of long-term efficacy of interventions  network meta-analysis of regimens  network meta-analysis of treatments  neurale invasie  neuro-endocrien carcinoom  neuro-endocriene neoplasmen  neuro-endocriene tumoren  neuroblastoma  neuroblastoom  NeuroCARE  neurocognitie  neurocognition  neurocognitive function  neurocognitive problems  neurodegenerative outcomes  neuroendocrine carcinoma  neuroendocrine prostate cancer  neuroendocrine tumors  neuroeondocriene tumoren  neurofibromatose  neurofibromatose 1  neurofibromatosis type 1  neurofibromatosis type 1-related plexiform neurofibromas  neurologic adverse events  neurologic disorders  neurologic symptoms  neuropathie  neuropsychiatric functioning  neuropsychological outcomes  neurosurgical resection  neutrofiel lymfocyt-ratio  neutrofiel-lymfocyt ratio  neutropenie  neutrophil to lymphocyte ratio  neutrophilia  never-smoker lung adenocarcinoma patients  new cancer diagnoses before and during the COVID-19 pandemic  new cancer diagnosis over a ten-year period  New EPOC trial  new long-term opioid use after lung cancer surgery  new treatment options  new-generation BCR-ABL TKIs versus imatinib for CML  new-onset NAFLD age  newly diagnosed acute myeloid leukemia  newly diagnosed AML  newly diagnosed AML in elderly patients  newly diagnosed AML in older patients  newly diagnosed AML or high-risk MDS  newly diagnosed AML with IDH1 mutation  newly diagnosed AML with IDH1-mutation in elderly patients  newly diagnosed and relapsed or refractory FLT3-mutated AML  newly diagnosed APL  newly diagnosed average-risk medulloblastoma in children  newly diagnosed cancer patients  newly diagnosed CD22+ Ph- B-cell precursor acute lymphoblastic leukemia  newly diagnosed cHL in children and AYAs  newly diagnosed CML  newly diagnosed CP CML  newly diagnosed DLBCL  newly diagnosed early NK T cell lymphoma  newly diagnosed endometrial cancer  newly diagnosed glioblastoma  newly diagnosed high-risk neuroblastoma in children  newly diagnosed low-burden metastatic prostate cancer  newly diagnosed metastatic colorectal cancer  newly diagnosed metastatic nasopharyngeal cancer  newly diagnosed multipel myeloma  newly diagnosed multiple myeloma  newly diagnosed multiple myeloma in frail patients  newly diagnosed multiple myeloma in transplant-ineligible patients  newly diagnosed mutant IDH2 AML  newly diagnosed OPC  newly diagnosed or relapsed multiple myeloma  newly diagnosed Ph-negative B-cell ALL  newly diagnosed Ph+ALL  newly diagnosed stage II-IVa esophageal squamous cell carcinoma  newly diagnosed stage III IV ovarian cancer in vulnerable patients  newly diagnosed stage IV squamous cell lung cancer  newly diagnosed T-ALL  newly diagnosed transplant-ineligible multiple myeloma  newly-diagnosed glioblastoma  newly-diagnosed multiple myeloma  newly-diagnosed transplant-eligible multiple myeloma  newly-diagnosed triple-negative breast cancer  Next Generation Trial  NeXT Personal  NEXT trial  next-generation BRAF inhibitor PLX8394  next-generation flow cytometry for assessing measurable residual disease  next-generation sequencing  next-generation sequencing detected MET amplification  next-generation sequencing of ctDNA  NEXUS-1 trial  NF1  NF1 mutations  NF1-PNs  NF1-related PNs  NF106 trial  NF2  NF2-SWN  NFD related donor  Nfl levels  NFSI after new cancer diagnosis  NFκB  nGBM  NGS  NHANES III analysis  NHB versus NHW CCSs  nHL  NHL in AYAs  NHL risk  NHL subtypes  NHL subtypes in Sweden 2000-2016  NHL-001 study  NHS  NIBIT-MESO-1 studie  nice-or-naughty theorie  NICHE study  NICHE-2 study  NICHE-2 trial  NICHE-3 study  nicotine  nICRT versus nCRT  NICT  niercarcinoom  niercelcarcinoom  niercelkanker  nierfunctie  niet-cervicale anogenitale maligniteit  niet-chirurgische behandeling  niet-invasief prenataal testen  niet-kelincellig longcarcinoom  niet-kleincellg longcarcinoom  niet-kleincellig longcarcinoom  niet-kleincellige longkanker  niet-melanoom huidkanker  niet-seminomateus testiscarcinoom  niet-squameus niet-kleincellig longcarcinoom  nieuw logo  Nieuw-Zeeland  NIFTP  NIFTY trial  night shift work  NIH-AARP  NIH-AARP cohort  NIH-AARP Diet and Health study  NIH-AARP Diet and Health Study prospective cohort  NIH-AARP Diet and Health Study; alcohol consumption  Nijmegen breakage syndrome  NILM  NiloPeg  nilotinib  nimotuzumab  nimotuzumab plus concurrent CRT  nine weeks versus one year trastuzumab  nintedanib  nipple-sparing mastectomy  NIPPON DATA 80  niraparib  niraparib after response to chemotherapy  niraparib and abiraterone acetate  niraparib maintenance  niraparib maintenance therapy  niraparib plus anlotinib  niraparib plus pembrolizumab  nirogacestat  nitraat  nitriet  NIVAHL trial  NIVO  nivo + ipi  NIVO or IPI  nivo+ipi vs sun  nivolumab  nivolumab adjuvant to CRT  nivolumab and AVD  nivolumab combination therapy  nivolumab for advanced cancer  nivolumab for mccRCC  nivolumab for metastatic renal cell carcinoma  nivolumab for NSCLC  nivolumab for recurrent or metastatic head and neck squamous cell carcinoma  nivolumab maintenance after ir AEs on nivolumab plus ipilimumab  nivolumab plus AVD  nivolumab plus cabozantinib  nivolumab plus cabozantinib versus sunitib  nivolumab plus chemotherapy  nivolumab plus gemcitabine and cisplatin  nivolumab plus ipilimumab  nivolumab plus ipilimumab and radiotherapy  nivolumab plus ipilimumab for NSCLC with brain metastases  nivolumab plus ipilimumab versus sunitinib  nivolumab plus ipilimumab with or without local therapy  nivolumab plus relatlimab  nivolumab plus rucaparib  nivolumab plus SBRT  nivolumab plus SRS  nivolumab plus sunitinib  nivolumab plus temozolomide  nivolumab versus bevacizumab  nivolumab versus docetaxel  nivolumab versus nivolumab plus ipilimumab  nivolumab versus sorafenib  nivolumab with chemotherapy with or without relatlimab  nivolumab with or without docetaxel  nivolumab with or without ipilimumab  nivolumab with or without relatlimab  nivolumab-ipilimumab vs nivolumab for advanced cancers other than melanoma  nivolumab-ipilimumab with or without stereotactic body radiation therapy  NIVOREN study  NIVOREN trial  NJLCG trial 1901  NK  NKTCL  NLCS  NLPHL  NLR  NLR after SBRT for early-stage NSCLC  NLR and survival outcomes  NLR as prognostic factor  NMA of treatment options  NMBC in women aged ≥ 70 years  nmCPRC  nmCRC  nmCRPC  NMIBC  nmMIBC  nmPaC  nmPrC  nmPrCa  NMR  nmRCC  NMSC  NMSC-ASE  NMSIs  NNAL  no AST versus ET  no evidence of increased breast cancer risk  NO LIMIT trial  NO16968  NO2  NOA-07 studie  NOA-08 study  NOCCA study  nociplastic pain  nodal PTCL  nodal-positve breast cancer  node-negative GC  node-negative TNBC in older women  node-positive breast cancer  node-positive HER2-positive breast cancer  node-positive HR-positive HER2-negative breast cancer  node-positive melanoma  node-positive vulvar cancer  node-postive HR+ HER2-breast cancer with RS≤25  nodulair lymfocyt-predominant Hodgkin lymfoom  nodular BCC  nodular desmoplastic medulloblastoma in young children  NOM  nomogram for individualized prediction of survival  nomogram for predicting mortality  nomogram for predicting pathological respons to neoadjuvant treatment  nomogram to estimate individualized overall survival  nomogram to predict postoperative outcome  nomograms for overall and cancer-specific survival  nomograms to predict outcomes  Non Core Binding Factor AML  non-adherence to aromatase inhibitors  non-adipocytic soft tissue sarcoma  non-alcoholic fatty liver disease  non-alcoholic fatty liver disease-related HCC  non-engineered multi-antigen specific T cells  non-erosive GERD  non-germinal center B-cell DLBCL  non-germinal center B-cell like diffuus grootcellig B-cel lymfoom  non-HAS  non-Hispanic black versus non-Hispanic white AYAs  non-Hodgkin lymfoom  non-Hodgkin lymphoma  non-inferioriteits fase 3-studie AXEPT  non-initiation and non-persistence of adjuvant ET  non-melanoma skin cancer  non-metastatic castration-resistant prostate cancer  non-metastatic castration-resistant prostate cancer in older men  non-metastatic central nervous system germinoma  non-metastatic esophageal cancer  non-metastatic esophagogastric cancer  non-metastatic SCCA  non-muscle invasive bladder cancer  non-muscle-invasive bladder cancer  non-muscle-invasive bladder cancer unresponsive to BCG  non-relapse mortaliteit  non-remission AML  non-rhabdomyosarcoma STS  non-RMS soft tissue sarcoma in patients younger than 30 years  non-seminoom testikelkanker  non-small cell lung cancer  non-small cell lung cancer brain metastases  non-small cell lung cancer surgery  non-small cell lung cancer with MET exon 14 skipping mutations  non-specific symptoms and signs of cancer  non-squamous metastatic non-small cell lung cancer  non-squamous non-small cell lung cancer  non-squamous NSCLC  non-squamous NSCLC with BMs  non-squamous NSCLC with high PD-L1 expression  non-V600 BRAF mutations  nonadherence  nonadherence to cancer screening  nonalcoholic fatty liver disease  nonaspirin NSAIDs  noncancer mortality  noncolorectal dMMR MSI-H cancers  noncutaneous and cutaneous cancer risk  nonelderly adult cancer survivors  nonepithelioid pleural mesothelioma  nonfatal self-injury after a cancer diagnosis  nonfunctional adrenal tumors  nonfunctioning pituitary adenomas in elderly patients  nongerminomatous malignant germ cell tumors  nonhereditary breast cancer  noninferiority phase 3 study HYPO-RT-PC  noninvasive prediction of occult peritoneal metastasis  nonkeratinocyte skin cancer  nonkeratinocyte skin cancer risk  nonmelanoma skin cancer  nonmetastatic breast cancer  nonmetastatic castration-resistant prostate cancer  nonmetastatic head and neck cancer  nonmetastatic NPC  nonmetastatic prostate cancer  nonmetastatic retroperitoneal sarcoma  nonmetastatic unfavorable-risk prostate cancer  nonmetastic castration-resistant prostate cancer  nonoperative management in older women  nonoropharyngeal squamous cell carcinoma  nonpancreatic neuroendocrine tumors  nonrelapse mortality  nonsquamous non-small cell lung cancer with high PD-L1 expression  nonsquamous NSCLC  nonsteroidal aromatase inhibitor with or without abemaciclib  nonverbale communicatie  Noorwegen  NOP10  NOPHO ALL2008 protocol  NOPHO ALL2008 study  NORA overall survival results  NORA trial  NORCCAP-studie  Nordic BRCA2 mutation carriers  Nordic Lymphoma Group  NORDIC9 study  NORPACT-1 trial  not previously treated mNSCLC  not transplant-eligilbe MM  NOTABLE study  notifying GPs regarding nonadherence to FIT screening  novel prognostic staging system  novel regrouping  novel treatment sequences for transplant-ineligible MM patients  NOx  NPC  NPC mortality  NPC risk  NPM1-gemuteerde AML  NPM1-mutated AML  NPNSCC  NPY methylated ctDNA  NRAS-mutant melanoma  NRAS-mutated NSCLC  NRAS-mutatie  NRAS-mutaties  NRF2 expression  NRG Oncology CC001 trial  NRG Oncology NSABP R-04 study  NRG Oncology RTOG 0617 study  NRG Oncology RTOG 0926  NRG Oncology RTOG 1203  NRG Oncology RTOG studie 0621  NRG-BN002  NRG-GU003 trial  NRG-GY003  NRG1 fusion-positive cancer  NRT versus upfront surgery  NS7CAR T cells  NSABP B-28 studie  NSABP B-31 study  NSABP B-40  NSABP B-41 neoadjuvant trial  NSABP B-42  NSABP B-42 study  NSABP FB-10 trial  NSAID  NSAID use  NSAID-gebruik  NSAIDs  NSCLC  NSCLC after EGFR TKI  NSCLC after PD-1 PD-L1 blockade  NSCLC BMs  NSCLC brain metastases  NSCLC brain metastasis  NSCLC harboring uncommon EGFR mutations  NSCLC in older adults  NSCLC in older patients  NSCLC in patients with interstitial lung disease  NSCLC in performance status 2 patients  NSCLC in postmenopausal women  NSCLC patients aged ≥ 65 years  NSCLC patients receiving immunotherapy  NSCLC progressing on various EGFR TKIs  NSCLC refractory to second-generation ALK inhibitor  NSCLC survivors  NSCLC with ALK or ROS1-rearrangement  NSCLC with BMs  NSCLC with bone metastases  NSCLC with brain metastases  NSCLC with common or uncommon EGFR mutation  NSCLC with EGFR variant  NSCLC with G12C mutation  NSCLC with HER2 exon 20 mutations  NSCLC with HER2ex20ins  NSCLC with high PD-L1 expression  NSCLC with MET exon 14 skipping mutations  NSCLC with RET fusion  NSCLC with RET fusions  NSCLC with TPS ≥ 1%  NSCLC with uncommon EGFR mutations  NSCLC; linifanib  NSGCT  NSM  nsq NSCLC  nsq-NSCLC  NSQIP  nsqNSCLC  NST for HER2-positive IBC  NTD-Haplo versus SUCBT  NTP  nucleaire installaties  nuclear ZEB2 expression  number of doses  number of lines of NAC  NURE-Combo trial  Nurses' Health Study  Nurses’ Health Studies  Nurses’ Health Study  Nurses’ Health Study I and II  Nurses’ Health Study II  nursing home residents  nut consumption  nutrient intake  NutriNet-Santé cohort  NutriNet-Santé prospective cohort  NutriNet-Santé studie  NutriNet-Santé study  nutrition interventions for improved cancer outcomes  nutritional status  NVALT19 trial  NWAS  NWTS 3-5  NWTS-5  O E incidence ratios of second malignant neoplasms  OA-MCL  OAC  OAC for AF  OACs  OAK  OAK and POPLAR trials  OAK-studie  obe-cel  obesitas  obesitasparadox  obesity  obesity paradox  obesity-related cancer survival  obesity-related cancer trends  obinutuzumab  obinutuzumab plus DHAP  obinutuzumab plus lenalidomide  obinutuzumab versus rituximab  observation versus SABR  Observationele studie van discontinueren van TKIs voor CML in de Italiaanse klinische praktijk  obstetric and maternal outcomes  obstetric outcomes  obstetrical and perinatal outcomes  OC  OCC  OCCC  occult breast cancer  occulte kanker  occupational environment  occupational variation  OCEAN study  OCOG-ALMERA trial  OCSCC  OCT versus punch biopsy  octagenarians compared to younger patients  OCTOVA trial  ocular toxicity  ocular toxicity of bortezomib  OCUM study  ODG  ODM-201  ODM-208  odontoom  odronextamab  ODXRS  oedeem  oesofagaal squameus celcarcinoom  oesofagastrische tumoren  oesofagectomie  oesofagogastrisch adenocarcinoom  oesofagus squameus celcarcinoom  oesofagusadenocarcinoom  oesofaguscarcinoom  oesofaguskanker  oesophageal cancer  oesophageal squmous cell carcinoma  oestradiol  oestrogeengebruik  oestrogeenreceptor  oestrogeensuppressie  OFA versus OBA  ofatumumab  offspring donors versus HLA-matched siblings  offspring of survivors of childhood or adolescent CNS tumors  ofranergene obadenovec  OGC  OHERA study  OIPN  Okayama Lung Cancer Study Group Trial 1404  olanzapine  olaparib  olaparib and temozolomide  olaparib maintenance  olaparib monotherapy  olaparib plus abiraterone  olaparib plus bevacizumab first-line maintenance  olaparib plus bevacizumab maintenance  olaparib plus cetuximab and IMRT  olaparib plus durvalumab  olaparib plus temozolomide combination  olaparib with or without cediranib  olaparib without ADT  olaratumab  older adults receiving cancer chemotherapy  older adults undergoing cancer surgery  older adults with blood cancer  older adults with cancer  older adults with GI cancers  older breast cancer patients with high recurrence scores  older breast cancer survivors  older breast cancer survivors with and without prior chemotherapy  older cancer patients  older cancer survivors  older MSDs versus younger MUDs  olfactorisch neuroblastoom  oligo-organ mNSCLC  oligo-residual EGFR-mutant NSCLC  oligometastase  oligometastatic breast cancer  oligometastatic cancer  oligometastatic cancers  oligometastatic CRPC  oligometastatic EGFR-mutated NSCLC  oligometastatic non-small cell lung cancer  oligometastatic NSCLC  oligometastatic oesophageal squamous cell carcinoma  oligometastatic oligoprogressive NSCLC  oligometastatic prostate cancer  oligometastatic RCC  oligometastatic squamous cell carcinoma of head and neck  oligoprogressive HCC  OLIVIA  olmutinib  olutasidenib  olverembatinib  Olvi-Vec  OlympiA study  OlympiA trial  OlympiaD subgroup analyses  OlympiAD-studie  OLYMPUS study  OM  OM-CRC  omacetaxine mepesuccinate  omalizumab  omega 3-vetzuren  OMEGA offspring cohort  omission of adjuvant RT in breast cancer  omission of dexamethasone  omission of radioiodine after thyroidectomy  omitting axillary dissection  omitting RT after BCS  Ommaya reservoir  on-target adverse events  on-target ALK resistance mutations  ONC201  once weekly selinexor-bortezomib-dexamethasone  once-weekly XVd  OncoCast-MPM  oncogenic drivers of NSCLC  oncologic and reproductive outcomes  oncolytic adenoviral therapy  oncolytic coxsackievirus A21  oncolytic DNX-2401 virotherapy plus pembrolizumab  oncolytic DNX-2401 virus for pediatric DIPG  oncolytic HSV-1 G207 immunovirotherapy  oncolytic T-VEC therapy plus neoadjuvant chemotherapy  oncolytic virotherapy  oncolytisch adenovirus  oncolytische virustherapie  oncoplastische mammoplastie  ONCOS-102  ONCOS-102 plus pembrolizumab  Oncoscience  Oncotype  Oncotype DX  Oncotype DX DCIS-score  OnCovid study  ondergewicht  onderhoudstherapie  ondervoeding  onderzoeksfraude  one versus two doses of Pfizer-BioNTech vaccine for patients with cancer  one week off  one-off low-dose CT  ONJ  ONKOTEV risk prediction model for VTE  online predictor of short-term postoperative outcomes  online preview AACR Annual Meeting  online videos about prostate cancer  ONO-4538-52 TASUKI-52  ONT-380  Ontario Lung Cancer Screening Pilot  ontstaan colorectaalkanker  ontwikkeling resistentie  onvansertib  oogmelanoom  oophorectomy  Oost-Afrika  OP-TIL  OpACIN and OpACIN-neo trials  OPAL research platform  OPAS-1 study  OPC  open resectie  open versus laparoscopic surgery  open versus minimally invasive surgery  open versus robot-assisted radical cystectomy  operability and post-treatment mortality  operable bladder cancer  operable oral and oropharyngeal cT1-T2N0 cancer  operable stage I-IIIA NSCLC  operable TNBC  opioid use  opioid use among older cancer survivors  opioid use and toxicity among cancer survivors  opioid-associated mortality in cancer survivors versus general population  opioid-induced constipation  opleidingsniveau  OPN  opportuniby costs of receiving palliative chemotherapy  opportunistic salpingectomy for ovarian cancer prevention  opportunities to achieve 50% reduction of mortality by 2047  OPRA trial long-term results  OPSCC  opsoclonus-myoclonus ataxie syndroom  OPTICAL trial  OPTIMA II trial  OPTIMA Prelim  optimal adjuvant trearment time  Optimal Breast Cancer Chemotherapy Dosing Study  optimal duration of adjuvant AI therapy  optimal duration of adjuvant endocrine therapy  optimal imaging surveillance interval  optimal neoadjuvant sequence of anthracyclines and taxanes  optimal RT regime  optimal RT strategy after breast-conserving surgery  optimal sequence of enzalutamide and abiraterone acetate plus prednisone  optimal time interval between breast cancer diagnosis and surgery  optimal timing of chemoradiotherap  optimal treatment duration of adjuvant bevacizumab  OPTIMISMM study  OPTIMIZE-1 trial  optimizing chemotherapy  optimizing patient selection for cytoreductive nephrectomy  OPTIMUM randomized clinical trial  OPTION-studie  OptiTROP-Breast01 trial  Opto-RTKs  oraal carcinoom  oraal oncogeen HPV  ORACLE study  oral agents  oral androgen signaling inhiibitos  oral antibiotic use  oral arsenic trioxide  oral azacitidine  oral azacitidine maintenance  oral cancer  oral cavity cancer outcomes  oral cavity or oropharyngeal squamous cell carcinoma  oral cavity squamous cell carcinoma  oral contraceptive use  oral decitabine plus cedazuridine and venetoclax  oral endocrine therapy  oral health  oral hydration after cisplatin  oral microbiome and subsequent HNSCC risk  oral mucositis  oral mucositis after chemoradiotherapy for OCC OPCC  oral mucositis after hematopoietic stem cell transplantation  oral mucositis with high-dose chemotherapy and transplanation  oral paclitaxel plus encequidar versus intravenous paclitaxel  oral S-1  oral selinexor  oral squamous cell carcinoma  ORAL Surveillance trial  orale anticonceptiva  orale contraceptiva  ORALEV study  ORANGE II PLUS trial  ORATOR study  ORATOR2 trial  orbital indolent BCL  orbital metastases  ORCA-010  ORCHARRD  orelabrutinib  orgaantransplantatie  organ preservation  organ preservation trends  Organ transplant recipients  organ-sparing chemo-immunotherapy  organ-sparing transanal endoscopic microsurgery  organic food consumption  organische oplosmiddelen  organoids from colorectal peritoneal metastases  orgnnoïdencultures  ORIENT-1 study  ORIENT-11  ORIENT-11 study  ORIENT-11 trial  ORIENT-12 study  ORIENT-15  ORIENT-15 trial  ORIENT-16 trial  ORIENT-31 second interim analysis  ORIENT-31 study  ORIENT-31 trial  ORIENT-32 study  ORIOLE trial  orofaryngeaal squameus celcarcinoom  orofarynx squameus celcarcinoom  orofarynxcarcinoom  oropharyngeal cancer  oropharyngeal carcinoma in older patients  oropharyngeal HPV infections  oropharyngeal squamous cell carcinoma  ORR and six months PFS as surrogate endpoints for OS  orthopedische oncologie  OS  OS impact of pembrolizumab treatment duration  OS impact of surgical margins larger than 1 cm  OS with CDK4 6-inhibitors  OS with ivosidenib  OS2006 Sarcome-09 study  OSCC  OSCC survivors  OSI-FACT-EP  osimertinib  osimertinib 160 mg  osimertinib after CRT  osimertinib combination therapy  osimertinib for advanced T790M-positive and -negative NSCLC  osimertinib for NSCLC  osimertinib plus chemotherapy  osimertinib plus local treatment versus osimertinib alone  osimertinib plus navitoclax  osimertinib plus savolitinib  osimertinib plus selpercatinib  OSJ  Oslo 1-studie  OSLO-COMET study  osteonecrose van de kaak  osteopenie  osteopontin  osteoporosis  osteosarcoma  osteosarcoma with cell-cycle and fibroblast growth factor mutations  osteosarcoom  ototoxiciteit van chemotherapie  ototoxicity  OTX015  outcome of patients with ultralow-risk 70-gene signature  outcomes  outcomes after allogeneic hematopoietic cell transplantation  outcomes after CD19-CAR  outcomes after complete response to immunotherapy  outcomes after contemporary first-line treatment  outcomes after nonrespons and relapse post-tisagenlecleucel  outcomes after suboptimal pretransplant respons  outcomes after surgery  outcomes after various types of radiotherapy  outcomes by primary tumor location  outcomes by prior treatment at first relapse  outcomes in AYAs compared with children  outcomes in cancer patients  outcomes in pregnant individuals and newborns  outcomes of AML  outcomes of CRT  outcomes of different breast cancer screening strategies  outcomes of first therapy after CD19-CAR-T treatment failure  outcomes of melanoma in smokers  outcomes of patients treated with CAR T-cell therapy admitted to intensive care  outcomes of primary endocrine therapy  outcomes of rechallenge after high-grade heaptitis  outcomes of risk-reducing total gastrectomy  outcomes of surgery  outcomes of transgender cancer patients in the USA  outcomes of various RIC-NMAC conditioning regimes  outcomes outside clinical studies  outcomes with care in high- versus low-volume centers  outcomes with chemotherapy  outcomes with delayed surgery  outcomes with ICIs  outcomes without locoregional treatment  outpatient medication errors among children with leukemia and lymphoma  outpatient versus inpatient neutropenia management  outpatients with cancer  OV21 PETROC  ovarian cancer  ovarian cancer and borderline tumors  ovarian cancer in women aged 65 years and older  ovarian cancer risk  ovarian cancer survival  ovarian cancer survivors  ovarian carcinoma with BRCA-like genomic aberrations  ovarian clear cell carcinoma  ovarian function  ovarian function suppression  ovarian or endometrial cancer  ovarian removal at or after benign hysterectomy  ovarian stimulation  ovarian suppression  ovarian tumors  ovariëctomie  ovariumcacrinoom  ovariumcarcinoom  ovariumfunctie  ovariumfunctie-suppressie  ovariumfunctiesuppressie  ovariumkanker  ovariumtumoren  ovariumvolume  OVC  overall and specific cancer risks  overall mortality in men versus women  overall survival  overall survival after treatment failure for rectal cancer  overall survival trend from 2000 to 2019  overall survival-analyse van fase 3-studie ARCHER 1050  overdiagnose  overdiagnosis  overgewicht  overhospitalisatie overlevers  overlevers jeugdkanker  overlevers kinderkanker  overleving  overleving borstkanker  overleving CRC  overleving in Europa  overleving melanoom  overleving oudere patiënten  overtreatment among men with limited longevity  overweight  OVHIPEC-1 final analysis  oviductcarcinoom  oxaliplatin  oxaliplatin hepatic artery infusion  oxaliplatin versus ALKY  oxaliplatin-based adjuvant chemotherapy  oxaliplatine  oxybutynin  P LP germline TP53 variants  P LP variants  P R M CC  p16 Ki-67 dual stain and HPV16 18 genotyping  p16+ locally advanced OPC  p16ink4A-deficient mesothelioma  p53  PABC  PABC versus non-PABC  PaC  PACE study  PACE-B study  PACE-B trial  PACE-MDS study  PACE-studie  pachymeningeal seeding  PACIFIC study  PACIFIC study post-hoc analysis  PACIFIC trial  PACIFIC trial update  PACIFIC-studie  paclitaxel  paclitaxel for breast cancer  paclitaxel- and oxaliplatin-induced peripheral neuropathy  PACMEL trial  pacmilimab for advanced or recurrent solid tumors  PACT trial  PACT-15 studie  PACT-19 study  PADA-1 trial  PADT  pain and pain interference  pain control for SNL radiotracer injections in breast cancer patients  pain in advanced cancer  pain in older survivors  pain monitoring app  pain prevalence in cancer patients and survivors  painful bone metastases  painful hepatic cancer  painful spinal metastases  Painyanitikul  PAKT trial  PALB2 germline mutations  PALB2-mutatie  PALB2-mutaties  palbociclib  palbociclib and fulvestrant  palbociclib combination therapy for advanced or metastatic breast cancer  palbociclib for advanced breast cancer  palbociclib monotherapy  palbociclib plus endocrine therapy  palbociclib plus fulvestrant  palbociclib rechallenge  PALLAS trial final analysis  palliatie  palliatieve radiotherapie  palliative care referral  Palliative Prognostic Index  palliative radiotherapy  PALMARES-2 study  PALOMA-1 TRIO-18  PALOMA-2 analyse  PALOMA-2 and PALOMA-3 pooled analysis  PALOMA-3  PALOMA-3 analysis  PALOMA-3 study  palonosetron  PAM50 signature  PAMELA  PAMELA-studie  pamiparib  pamiparib plus tislelizumab  pAML  pan-cancer analysis of postdiagnosis exercise and mortality  pan-cancer incidence  pan-cancer noninvasive detection of MSI and high TMB  pan-RAF remmers  pan-tumor retrospective analysis  PANACEA study  PANACHE01-PRODIGE48  PANAMA trial  PanCarSurFup study  pancreas  pancreas cancer  pancreas ductaal adenocarcinoom  pancreas-adenocarcinoom  pancreas-ductaaladenocarcinoom  pancreas-MCNs  pancreasadenocarcinoom  pancreascarcinoom  pancreaskanker  pancreatectomie  pancreatectomy for cancer  pancreatic adenocarcinoma  pancreatic adenocarcinoma in patients older than 79 years  pancreatic cancer  pancreatic cancer incidence and mortality  pancreatic cancer risk  pancreatic cancer with vascular involvement  pancreatic cystic neoplasms  pancreatic ductal adenocarcinoma  pancreatic fistula  pancreatic head adenocarcinoma  pancreatic NETs  pancreatic neuroendocrine tumors  pancreatic or periampullary tumors  pancreatic-colorectal-stomach cancer  pancreaticobiliary malignancies ctDNA from plasma or bile  pancreaticoduodenectomie  pancreaticoduodenectomy  pancreaticoduodenectomy for pancreatic cancer  pancreatoduodenectomy for pancreatic and periampullary cancers  PANDA trial  PANFIRE  PANFIRE-2 study  PANIB trial  PanIN lesions in healthy individuals  panitumumab  panitumumab maintenance  panitumumab rechallenge  panitumumab versus bevacizumab  panitumumab versus cetuximab after bevacizumab  panNEC  panobinostat  PANOPTIMOX-PRODIGE 35 trial  PANORAMA 3 study  PANTHER trial  PANTHER trial end-of-study results  Panther trial long-term HRQOL  PANVAC  PAOLA-1 ENGOT-ov25  PAOLA-1 ENGOT-ov25 trial  PAOLA-1 secondary analysis  PAOLA-1 study  PAOLA-1 trial  PAPAGEMO trial  papillair craniofaryngioom  papillair metastatisch niercelcarcinoom  papillair schildkliercarcinoom  papillary craniopharyngioma  papillary neoplasms of the breast  papillary thyroid cancer risk  papillary thyroid carcinoma aggressive variants  PAPILLON trial  paraganglioma  paraneoplastisch neurologisch syndroom  parasagittal meningioma  PARCER trial  parental cancer history  parenthood rates and use of assisted reproductive techniques  parents of children with cancer  parity  Parkinson  PARP inhibitor maintenance  PARP inhibitor maintenance therapy  PARP inhibitor treatment  PARP inhitibors  PARP-remmer  PARP1-expressie  parsaclisib  partial hepatectomy versus TACE  partial nephrectomy for RCC  partial prostate treatment  partial versus whole breast irradiation  particle radiation therapy  particpating in randomized breast cancer study  PARTNER trial  ParvOryx  PAs  passief roken  PASSION trial  PASSOS Heart studie  PATCH trial program  paternity after treatment for testicular germ cell cancer  PATHFINDER study  PATHFINDER study interim analysis  pathogenic germline variants  pathogenic variants in less familiar cancer susceptibily genes  pathogenic variants in RAD51C and RAD51D  pathologic fractures  pathologic response  pathologic response and survival  pathologic stage II nonseminomatous ger cel tumors  pathological complete response  pathological nipple discharge  pathological response to neoadjuvant chemotherapy  pathological stage I-IIIA NSCLC  pathologically node-negative neck  Pathways Heart Study  Pathways Study  patient age and progression  patient and diagnostic intervals of sarcoma survivors  patient enrollment to industry-sponsored versus federally sponsored cancer trials  patient factors and ratio of basal cell to cutaneous squamous cell carcinoma  patient factors associated with prognosis  patient mortality after surgery on surgeon’s birthday  patient navigation  patient portal messaging before mailing FIT kit  patient reported outcome  patient reported outcomes  patient reported symptoms  patient volume of oncologist  patient with cancer and cryptogenic stroke  patient withdrawal of consent  patient- and clinican-reported  patient- and clinician-reported symptoms during standard RT or IMRT  patient- and hospital-level risk factors  patient-collected versus clinician-collected samples  patient-derived xenograft engraftment  patiënt-gerapporteerde uitkomsten  patient-reported functional impairment  patient-reported outcome measures  patient-reported outcomes  patient-reported outcomes with first-line EV w wo P  patient-reported symptom burden  patient-specific measurable residual disease markers  patiëntnavigatie  patients aged 40 years or younger  patients on active anticancer treatment  patients receiving CAR T-cell therapy in the USA  patients with 4-15 brain metastases  patients with advanced cancer and their family caregivers  patients with BRCA1 2-wt and mutations in other HR pathway genes  patients with breast cancer harboring TP53 germline variants  patients with cancer and acute deep venous thrombosis  patients with cancer and DPYD variant alleles  patients with COVID-19 and solid tumors  patients with hematologic malignancy and other independent cancer  patients with melanoma considering adjuvant immunotherapy  patients with myelofibrosis and anemia  patients with non specific symptoms  patients younger than 50 years  patterns and survival  patterns in incidence 2010 to 2019  patterns of invasive recurrence  patterns of locoregional recurrence  patterns of practice  patterns of recurrence  patterns of relapse  patterns of relapse after neoadjuvant chemotherapy in clinical practice  patterns of treatment and outcome in The Netherlands  PAVO study  pazopanib  pazopanib plus cetuximab  pazopanib versus doxorubicin  pazopanib with or without gemcitabine  PBC  PBDEs  PBI or IORT versus WBI  PBI versus WBI  PBL  PBRT  PBS  PBSO  PBT  PBT versus IMRT  PBT versus TACE  PBTs  PC  PC epidemiology  PCa  PCa diagnosis  pCBCL  PCCRC risk  PCD  PCF after laryngectomy  PCI  PCI versus HA-PCI  PCLO  PCM  PCNSL  PCNSL in fit older patients  PCNSL in patients aged 60 years or younger  PCNSL SCNSL  PCOS  pCR  pCR after NAC for gastric cancer  pCR after NACT  pCR and iDFS as surrogate endpoints for OS  pCR and outcomes by intrinsic subtypes of breast cancer  pCR of DCIS component  pCR to NACT  pCR to neoadjuvant chemoimmunotherapy  pCR to pertuzumab and trastuzumab  PCS with or without HIPEC  PCSM  PCSM with AS  PCSNL  PCT for aPSCC  PCYC-1123-CA study  PD  PD patterns and PPOS  PD-(L)1 blockade for NSCLC  PD-(L)1 blockers for advanced NSCLC  PD-(L)1 immune checkpoint inhibitors  PD-(L)1 inhibitors  PD-(L)1 inhibitors plus chemotherapy for aNSCLC  PD-(L)1 targeting therapy  PD-(L)1-based combination therapies  PD-(L)1-blockade  PD-1  PD-1 Ab  PD-1 and PD-L1 checkpoint inhibitors  PD-1 and PD-L1 expression in breast cancer  PD-1 and PD-L1 inhibitos  PD-1 blockade  PD-1 blockade for melanoma  PD-1 inhibition  PD-1 inhibition plus antiangiogenic therapy  PD-1 inhibitor  PD-1 inhibitors for metastatic melanoma  PD-1 inhibitors for mNSCLC  PD-1 or PD-L1 blockade refractory metastatic melanoma  PD-1 PD-L1 inhibitors  PD-1 PD-L1 targeting  PD-1 pretreated mNSCLC and metastatic melanoma  PD-1 VEGF bispecific antibody  PD-1-inhibitor therapy  PD-L1  PD-L1 blockade plus carboplatin  PD-L1 combined positive score  PD-L1 expression  PD-L1 expression as predictive biomarker  PD-L1 expression as predictive biomarker for EGFR TKIs  PD-L1 expression on immune cells  PD-L1 inhibitor-based combination therapy  PD-L1 negative NSCLC  PD-L1 positive mUC in cisplatin ineligible patients  PD-L1 positive NSCLC  PD-L1-inhibitor LY3300054  PD-L1-negative mNSCLC  PD-L1-positive advanced NSCLC  PD-L1-positive mTNBC  PD-L1-positive recurrent or metastatic cervical cancer  PD1 inhitiors for NSCLC  PD1-based immunotherapy for melanoma  PDAC  PDAC in the real world  PDAC patients undergoing PD with vascular resection  PDAC PMs  PDAC surveillance and survival of high-risk individuals  PDAC survival  PDGFRA D842V-mutated GIST  PDR and postcolonoscopy colorectal cancer risk  PDS  PDT  PDX engraftment  PE-related mortality in cancer patients  PEA versus PEAT for ES-SCLC  PEACE randomized trial  PEACE V-STORM trial  PEACE-1 study  PEACOCC trial  PEAK study  PEARLS KEYNOTE-091 trial  PEComa  pediatric acute leukemia  pediatric ALK-positive malignancies  pediatric ALL  pediatric AML  pediatric and adolescent HL patients  pediatric and adolescent melanocytic lesions  pediatric and youg adult cancer surivors  pediatric and young adult DS-ALL  pediatric and young adult EWS  pediatric and young adult R R B-ALL  pediatric APL  pediatric B-NHL  pediatric BRAF V600E-mutated glioma  pediatric BRAFV600-mutant LGG  pediatric brain tumor survivors  pediatric brain tumors  pediatric cancer  pediatric cancer patients  pediatric cancer patients with febrile neutropenia  pediatric cerebral microbleeds  pediatric CNS and head-and-neck cancer  pediatric cranial SRS  pediatric craniopharygioma  pediatric CT-related radiation exposure  pediatric ependymoma  pediatric germ cell tumors  pediatric hepatoblastoma  pediatric high-grade gliomas  pediatric high-grade malignancies  pediatric high-risk HL  pediatric high-risk medulloblastoma  pediatric inflammatory bowel disease  pediatric locally advanced TRK fusion sarcomas  pediatric low-grade glioma  pediatric medulloblastoma  pediatric neuro-oncology  pediatric neuroblastoma  pediatric NPC  pediatric or adolescent NHL  pediatric patients treated for optic pathway gliomas  pediatric Ph+ ALL  pediatric Ph+ CML-CP  pediatric posterior fossa tumors  pediatric R R ALL  pediatric recurrent ependymoma  pediatric recurrent or refractory CNS tumors  pediatric relapsed HRNB  pediatric relapsing high-risk ALL  pediatric sarcoma  pediatric spinal cord low-grade glioma  pediatric thyroid cancer  pediatric thyroid cancer incidence and mortality trends  pediatric-style chemotherapy versus alloHCT  pediatrisch ALL  pediatrisch AML  pediatrisch ependymoom  pediatrisch sarcoom  pediatrische AML  pediatrische CNS-tumoren  pediatrische hersentumoren  pediatrische leukemie  pediatrische NETs  pediatrische patiënt-gerapporteerde uitkomsten  pediatrische stamceltransplantatie  PEF  PEG  PEG-IFN  pegaspargase versus calaspargase  PEGASUS  PEGASUS-D trial  pegfilgastrim  pegfilgrastim-profylaxe  pegilodecakin  peginterferon alpha-2b  pegteograstim  PEH with cancer  pelabresib plus ruxolitinib  pelabresib plus ruxolutinib  pelareorep  pelvic exenteration  pelvic fractures and changes in bone mineral density  pelvic radiotherapy  pelvic RT versus IMRT  pembolizumab  pembolizumab plus ipilimumab  pembolizumab with bevacizumab and oral metronomic cyclophosphamide  PEMBRO-RT study  pembrolizmab  pembrolizumab  pembrolizumab activity  pembrolizumab after concurrent CRT  pembrolizumab after locally ablative therapy  pembrolizumab and chemotherapy  pembrolizumab and concurrent CRT  pembrolizumab for advanced melanoma  pembrolizumab for advanced NSCLC  pembrolizumab for advanced prostate adenocarcinoma  pembrolizumab for mUC  pembrolizumab for non-small cell lung cancer  pembrolizumab for NSCLC  pembrolizumab for previously treated mTNBC  pembrolizumab for previously treated PD-L1 positive advanced NSCLC  pembrolizumab for previously untreated  pembrolizumab for solid tumors  pembrolizumab monotherapy  pembrolizumab monotherapy for aNSCLC  pembrolizumab plus axitinib  pembrolizumab plus axitinib versus sunitinib  pembrolizumab plus bevacizumab  pembrolizumab plus bevacizumab and oral cyclophosphamide  pembrolizumab plus cabozantinib  pembrolizumab plus cetuximab  pembrolizumab plus chemotherapy  pembrolizumab plus concurrent chemoradiation  pembrolizumab plus CRT  pembrolizumab plus doxorubicin  pembrolizumab plus enzalutamide  pembrolizumab plus GX-188E DNA vaccine  pembrolizumab plus ipilimumab  pembrolizumab plus lenvatinib  pembrolizumab plus nab-paclitaxel salvage  pembrolizumab plus NACT  pembrolizumab plus olaratumab  pembrolizumab plus RT after induction chemotherapy  pembrolizumab plus single-fraction RT  pembrolizumab plus T-DM1  pembrolizumab plus trastuzumab  pembrolizumab versus best supportive care for advanced HCC  pembrolizumab versus brentuximab vedotin  pembrolizumab versus chemotherapy  pembrolizumab versus ipilimumab  pembrolizumab with or without bevacizumab  pembrolizumab with or without chemotherapy  pembrolizumab with or without LAT  pembrolizumab with or without mRNA-4157  pembrolizumab with or without RT  pembrolizumab-chemotherapy  pembrolizumab-etoposide-platinum  PEMBROSARC trial  pemetrexed and platinum  pemetrexed for lung cancer  pemetrexed plus carboplatin  pemetrexed plus cisplatine  pemigatinib  PEMMELA trial  penpulimab  penta-refractory MM  PEPI  pepinemab plus avelumab  peptide receptor radionuclide therapy  percent ctDNA  percentage dense area  perception of cancer risk  perceptions and practice regarding patient request to record clinical visits  perceptions of telehealth in real-world oncological care  percutaneous ablation  percutaneous cryoablation  percutaneous image-guided ablation  percutaneous IRE  PerELISA neoadjuvant study  PERFECT trial  perfluarinated alkylated substances in serum  performance of liquid biopsy for diagnosis and surveillance  performance status  performance status ratings in pediatric cancer  Peri-Appendicitis Acuta Tumor study  pericardial disease  perifeer T-cel lymfoom  perifere neuropathie  perinatal and postnatal exposures  perinatal exposures  perinatal outcomes  periodontale ziekte  perioperative adebrelimab plus chemotherapy  perioperative anti-HER2 therapy  perioperative beta-blocker supply  perioperative camrelizumab plus apatinib  perioperative cell-free DNA dynamics  perioperative chemotherapy  perioperative chemotherapy plus ICB  perioperative chemotherapy plus nivolumab  perioperative chemotherapy with without ramucirumab  perioperative COX2 and β-adrenergic blockade  perioperative ctDNA as prognostic marker  perioperative ctDNA-based molecular residual disease detection  perioperative dexamethasone  perioperative dexamethasone dosing  perioperative durvalumab  perioperative durvalumab and tremelimumab  perioperative dynamic changes in ctDNA  perioperative FLOT versus ECF ECX  perioperative FLOT versus preoperative CRT  perioperative ghrelin administration  perioperative immunotherapy plus chemotherapy  perioperative LP002 plus chemotherapy  perioperative mFOLFIRINOX  perioperative nivolumab  perioperative nivolumab and chemotherapy  perioperative pembrolizumab  perioperative pembrolizumab plus chemotherapy  perioperative radiotherapy  perioperative sintilimab  perioperative SOX versus FOLFOX  perioperative toripalimab plus chemotherapy  perioperative trastuzumab plus FLOT  perioperative versus adjuvant SOX  peripheral blood derived neutrophil-to-lymphocyte ratio  peripheral neuropathy  peripheral stage IA NSCLC  peripheral T-cell lymphoma  peripheral T-cell lymphoma in elderly patients  perirectal hydrogel spacer  periSCOPE trial  peritoneal mesothelioma  peritoneal metastases from gastric cancer  peritoneal sarcomatosis  peritoneale carcinomatose index  peritoneale metastasen  PERLS  PERMEATE trial  PERSEPHONE trial  PERSEUS trial  PeRSIA study  PERSIST-1  PERSIST-2 studie  PERSIST-5 trial  persistence of ctDNA  persistence of F. nucleatum  persistent acromegaly  persistent febrile neutropenia  persistent or recurrent or metastatic cervical cancer  persistent peripheral neuropathy  persistent postchemotherapy alopecia  persistent PSA after radical prostatectomy  persistent radiation-induced alopecia in cancer patients  persistente pijn  personalised versus standard dosimetry  personalized ctDNA as predictive biomarker  personalized ctDNA profiling  personalized mRNA neoantigen vaccine  personalized neoantigen vaccine monotherapy  personalized radioimmunotherapy  personalized selection of experimental treatment  PERTAIN study  pertuzumab  pertuzumab plus trastuzumab  pertuzumab plus trastuzumab and chemotherapy  pertuzumab plus trastuzumab with or without chemotherapy  pertuzumab retreatment  peru  PERUSE study  pesticide exposure  PET  PET CT  PET CT for predicting PD-L1 expression  PET-adapted regimen for advanced HL  PET-adapted therapy  PET-CT  PET-CT staged localized follicular lymphoma  PET-CT versus conventional staging  PET-guided BrECADD versus eBEACOPP  PET-guided neoadjuvant chemotherapy de-escalation  PET-guided omission of radiotherapy  PET-guided risk adapted treatment  PET-guided therapy  PET-guided treatment  PETAL study  PETAL-studie  PETHEMA GEM2012 study  PETra trial  peulvruchten  pevonedistat  pexidartinib  PF-05280014  PFAS in residential settled dust  PFAS in serum  PFS  PFS on ET before or after CT  PFT  PGA  PGC-1α  PGF  PGHD  PGINKTL  PGT  PGV frequency  PH  Ph- ALL  Ph-ALL  Ph-like ALL  Ph-negative ALL in adults  Ph-negative ALL in AYAs in first CR  Ph-negative ALL in older patients  Ph-negative B-ALL  Ph-negative CD20-positive B-cell ALL  Ph-positive ALL  Ph-positive ALL in adults  Ph-positive CML  Ph+ ALL  Ph+ ALL in adult patients  Ph+ALL in first CMR  PhALLCON trial  pharmacological ovarian suppression  phase 1 oncology trials  phase 1-2 MajesTEC-1 trial  phase 1b COSMIC-021 trial expansion cohorts  phase 2 ACCRU study  phase 2 adaptively randomized I-SPY2 trial  phase 2 AMPECT trial  phase 2 BENEFIT trial  phase 2 COAST study  phase 2 CONTROL trial  Phase 2 DEPEND trial  phase 2 DESTINY-Gastric02 study  phase 2 FAKTION trial  phase 2 GALAHAD study  phase 2 GEMCAD 1402 study  phase 2 GEOMETRY mono-1 trial  phase 2 HORIZON trial  phase 2 IMPemBra trial  phase 2 METALLICA trial  phase 2 MOUNTAINEER trial  phase 2 NeoATP study  phase 2 PEANUT study interim results  phase 2 PETREMAC study  phase 2 RIGHT Choice trial  phase 2 STOMP trial  phase 2 study JULIET  phase 2 TRAIN-3 study  phase 2 TUXEDO-1 trial  phase 2 VIRO-15 trial  phase 2-3 DANTE trial  phase 2b NIFTY study  phase 3 ADAURA trial  phase 3 AEGEAN trial  phase 3 ANCHOR study  phase 3 APHINITY trial  phase 3 CAIRO5 trial  phase 3 CASTOR study  phase 3 COSMIC-311 trial  phase 3 EA1131 study  phase 3 ESCORT-NEO NCCES01 trial  phase 3 FIRE-3 study  phase 3 FOWARC trial  phase 3 GLOW study  phase 3 IMpassion050 trial  phase 3 IPSOS study  phase 3 JAVELIN Gastric 100 study  phase 3 KCSG CO09-07 trial  phase 3 KEYNOTE-062 study  phase 3 KEYNOTE-522 trial  phase 3 LUNAR trial  phase 3 MAIA study  phase 3 MOMENTUM trial update  phase 3 monarchE study  phase 3 monarchE trial 5-year follow-up  phase 3 NEJ026 study  phase 3 NIAGARA trial  phase 3 NRG RTOG 9804 study long-term outcomes  phase 3 OlympiA trial  phase 3 PRODIGY study  phase 3 PUFFIN trial  phase 3 RESOLVE trial  phase 3 RESORT study  phase 3 STELLAR trial  phase 3 studies supporting FDA approval of cancer drugs  phase 3 study AML08  phase 3 study COMBI-AD  phase 3 study TRAIN-2  phase 3 study TRIBE 2  phase 3 trial RADAR  phase 3 VESPER trial  phase 3b-4 CheckMate 920 trial  phase 4 BYOND trial  phase I trials in hematologic malignancy  phase III APROMISS study  phase III IMpower131 study  phase III iNNOVATE study  phase III POLO trial  phase III SUCCESS-A trial  Phc  pheochrmocytoma  pheochromocytoma  pheochromocytoma and paraganglioma  PHEREXA-studie  PHERGain trial  Philadelphia chromosome-negative ALL  Philadelphia-negative B-cell ALL  PHILEMON-studie  PHL86 NCI#9322 study  phlebotomy with or without ropeginterferon α-2b  PHOEBE trial  PHOENIX study  photobiomodulation  photodynamic therapy  PHP-Mel  physical activity  physical activity and mortality  physical activity and survival  physical activity during adolescence  physical activity during adolescence and early adulthood  physical health and neurocognitive outcomes  physical health decline after CT or ET  physican workforce requirements  physician adenoma detection rate  physicians’ perspectives  physiotherapy regimens in esophagectomy and gastrectomy  PI-RADS 3 lesions  PI3K inhibitors  PI3K mTOR-remming  PI3K-signalering  PI3Kδ  PIB  PICCOLO trial  PICN  pictilisib  PICTURE trial  PID  pigmented skin lesion classification  pIIIA-N2 NSCLC  pijnlijke botmetastasen  PIK3CA  PIK3CA mutation  PIK3CA mutation and survival outcomes  PIK3CA mutation status  PIK3CA mutations  PIK3CA-activated stage III colon cancer  PIK3CA-altered HNSCC  PIK3CA-mutated aBC  PIK3CA-mutated HR-positive advanced breast cancer  PIK3CA-mutated HR+ ABC  PIK3CA-mutated HR+ HER2- advanced breast cancer  PIK3CA-mutaties  pilaralisib  pilocarpine  pilocytic astrocytoma and optic pathway glioma  PILOT trial  pimasertib versus dacarbazine  pimecrolimus  PimTo-MF trial  pink SWAN study  pioglitazon  PIONEER trial  pirtobrutinib  pirtobrutinib after a covalent BTK inhibitor  pituitary and cavernous sinus metastases  pituitary macroadenomas  pituitary metastasis  PIV  pivekimab sunirine  PIVOT-02 study  PIVOT-studie  pixatimod plus nivolumab  PK-guided pembrolizumab administration  PL  placebo adverse events in cancer trials  PLACOL-studie  plant-based diet and survival  plant-based diets  plant-based diets and disease progression  plaque radiotherapy for uveal melanoma  plasma and saliva HPV DNA testing  plasma arginine  plasma circulating tumor DNA fraction  plasma EBV DNA  plasma Epstein-Barr virus DNA  plasma exosomal miRNAs  plasma metabolomic signatures  plasma prolactin and postmenopausal breast cancer risk  PLASMA study  plasma tumor gene conversions after one cycle of abiraterone acetate  plasma-based genotyping  plasma-biomarkers  plasmacarotenoïden  plasmaMATCH trial  platinum exposure  platinum ineligibilty and survival  platinum versus capecitabine  platinum-based chemotherapy  platinum-pemetrexed  platinum-refractory aUC  platinum-refractory early failure oral cancer  platinum-refractory mUC  platinum-resistant grade 2-3 ovarian cancer  platinum-resistant high-grade serous ovarian cancer  platinum-resistant or platinum-refractory ovarian cancer  platinum-resistant ovarian cancer  platinum-resistant recurrent ovarian cancer  platinum-resistente ovariumkanker  platinum-sensitive advanced pancreatic cancer  platinum-sensitive recurrent ovarian cancer  platinum-sensitive recurrent ovarian carcinoma  platinum-sensitive relapsed ovarian cancer  platinum-sensitive relapsed ovarian cancer in gBRCA1 2 mutated patients  PLATO study  PLATO-ACT4 trial  plaveiselcelcarcinoom  PLCO cancer screening trial  PLCO RCT secondary analysis  PLCO trial  PLD  PLD with or without apatinib  pleiomorf lobulair mammacarcinoom  pleister  pleural mesothelioma  pleurectomie  pleurectomy decortication  PLGA  PLGG  plinabulin plus docetaxel versus docetaxel  plinabulin versus pegfilgrastim for CIN prevention  plinabulin vs pegfilgrastim  ploegendienst  PLP  PLR  PLRG Observational Study  PM  PM from CRC  PMBCL  PMBT caregivers  PMF  pMGMT and dMGMT  PMRT  PMs from GC  PN  pN1 prostate cancer  pnacreascarcinoom  pNEN  pNET  PNET HR+5 trial  PNETs  pneumonitis  pneumonitis after CRT for LA SNSCLC  PNS  PO-IMRT versus PPLN-IMRT  POAF in cancer patients  POD24  POEMS final analysis  POHIM-CCRT trial  Pola-G-Len  Poland  POLAR  POLAR signature  POLAR trial  POLARIS trial  POLARIS-02 trial  POLARIS-03 study  POLARIX study  polatuzumab vedotin  POLE-mutaties  POLLUX and CASTOR studies  POLLUX trial  POLLUX-studie  POLO study  POLO trial OS results  polo-like kinaseremmer  poly-G repeats  polycyclische aromatische koolwaterstoffen  polycystic ovary syndrome and breast cancer risk  polycystische nierziekte  polycythemia vera  polyfarmacie  polygenic breast cancer risk scores  polymerase theta  polymicrobial bloodstream infections in oncohematological patients  polymorfismen  polyp subtype  polypectomie  polypharmacy  polypose  pom-dex  pomalidomide  pomalidomide-dexamethasone-daratumumab  ponatinib  ponatinib plus blinatumomab  ponatinib versus imatinib  Ponatinib-FLAG-IDA  ponsegromab  pooled analysis  poor dental health and risk of pancreatic cancer  poor KPS  poor prognosis breast cancer  POP-RT study  population diversity  population-based study of immunotherapy-related toxicities  population-based treatment patterns and survival  population-level cure patterns of cancer patients  population-level survival  PORT  PORT after mandibulectomy  PORT for residual TNBC after neoadjuvant chemotherapy  PORT-C trial  PORTEC trials cohort  PORTEC-3  PORTEC-3 analysis  PORTOS  POSEIDON trial  POSH-studie  positive initial margins  positive margins  POSITIVE trial  posoleucel  possible synergy of enzalutamide and Lu-PSMA 617 radioligand therapy  post hoc analyse ASPIRE-studie  post hoc analyse FIRST-studie  post hoc analyse KEYNOTE-001 studie  Post hoc analysis PACIFIC study  post hoc exploratieve analyse RAISE-studie  post-CDK 4 6 inhibitor survival  post-diagnosis dietary and lifestyle factors  post-diagnostic beta blocker use and breast cancer-specific mortality  post-diagnostic statin use  post-hoc analyse PETACC-8 studie  post-hoc analyse REACH-studie  post-hoc analysis of CheckMate 227  post-induction ctDNA analysis  post-mastectomie radiotherapie  post-nephrectomy adjuvant pembrolizumab  post-progression outcomes  post-RP SBRT  post-SRS recurrent brain metastases  post-transplant cyclophosphamide  post-transplantation cyclophosphamide  post-transplantation cyclophosphamide-based GVHD prophylaxis  post-transplantation ICIs  post-transplantie lymfoproliferatieve ziekte  post-treatment inflammation biomarkers and survival  postcolonoscopy colorectal cancer  postdiagnosis BMI and weight change  postdiagnosis smoking cessation  postdiagnostic calcium intake  postdiagnostic coffee and tea consumption  postdiagnostic metformin use  postdiagnostic multivitamin supplement use  postembolization syndrome  postmastectomy implant reconstruction  postmastectomy proton radiotherapy  postmastectomy radiotherapy  postmenopausal advanced HR-positive breast cancer  postmenopausal bleeding  postmenopausal breast cancer  postmenopausal breast cancer risk  postmenopausal breast cancer. oncogenic drivers of late distant recurrence  postmenopausal cancer  postmenopausal CRC risk  postmenopausal early-stage breast cancer  postmenopausal EBC  postmenopausal endometrial cancer screening  postmenopausal ER-positive DCIS  postmenopausal HER2-positive HR-positive MBC  postmenopausal HR+ HER2- metastatic breast cancer  postmenopausal women  postmenopauzaal mammacarcinoom  postmenopauzaal mammarcinoom  postmenopauzal HR+ HER2- breast cancer  postmenopauzale borstkanker  postmenopauzale hormoontherapie  postmenopauzale vrouwen  postMONARCH trial  postoperatieve mortaliteit  postoperative [11C]-methionine accumulation  postoperative complications  postoperative cough  postoperative follow-up  postoperative hypofractionated IMRT plus chemotherapy  postoperative mortality  postoperative outcomes  postoperative outcomes of CRC  postoperative pathology  postoperative radiation field  postoperative radiation therapy  postoperative radiotherapy  postoperative seizures  postoperative SRS  postoperative SRS with or without immunotherapy  postoperative surveillance  postpartum breast cancer and survival  postprostatectomy HYPORT versus COPORT  postprostatectomy salvage radiotherapy  postradiation versus sporadic OCSCC  posttransplantation maintenance with IRd versus Rd  posttraumatische stressstoornis  POTENT trial  potential cost implications  potential of genetics in identifying women at lower risk of breast cancer  potential years of life lost due to cancer  potentially modifiable risk factors  potentially preventable emergency department visits among cancer patients  potentially resectable stage III NSCLC  potentially resectable stage IIIA B NSCLC  potentially resectable stage IIIB NSCLC  POUT trial  power morcellation  poziotinib  PPAR-gamma  PPBC  pPCL  PPGL during pregnancy  PPI use  PPIs  PPM  PPTIDs  PR status  PR-status  PR1  PRACTICAL-studie  pralsetinib  pralsetinib for RET fusion-positive NSCLC  praluzatamab ravtansine  PrC in the UK  PrCa  PRCC  pre- and post-diagnosis leisure time physical activty  pre- and post-diagnosis obesity  pre- and post-diagnosis smoking  pre-BCS MRI  pre-diagnosis dietary patterns and survival  pre-diagnosis tea and coffee consumption  pre-existing autoimmune disease  pre-existing cardiometabolic disease  pre-existing mental illness  pre-existing thyroid autoimmunity  pre-GKRS leucocyt ratios  pre-leukemisch  pre-operative MRI imaging  pre-transplant cytoreductive therapy  PrE0505 study  precancerous lesions that progress to cancer  PRECIOUS study  PRECIS study  PRECISE trial  precisie-oncologie  precisietherapie  precision medicine  PRECISION-studie  preclinical and clinical obesity  PRecur model  precursor stages of multiple myeloma  PREDATOR trial  prediabetes  prediagnositc frailty  prediagnostic alterations in circulating bile acid profiles  prediagnostic bile acid levels  prediagnostic immune cell profiles and breast cancer risk  prediagnostic PSA level  prediagnostic signs and symptoms  prediagnostic telomere length  PREDICT  predicted versus observed metastasis-free survival  predicting 90-day mortality after concurrent chemoradiotherapy  predicting cardiac events  predicting chemotherapy benefit  predicting outcomes of various interventions for DCIS  predicting pCR  predicting response on ICIs  predicting RFS and DSS  predicting severe toxicity from chemotherapy for early-stage breast cancer in older patients  prediction for 2020  prediction model  prediction model for risk stratification  prediction of AML risk in healthy individuals  prediction of early progression  prediction of invasive cervical cancer  prediction of MSI  prediction of Oncotype DX risk category  prediction of outcome  prediction of outcomes  prediction of outcomes of ibrutinib for CLL  prediction of progression  prediction of recurrence in early-stage LUAD  prediction of recurrence risk in endometrial cancer  prediction of response to anti-PD-1 therapy  prediction of response to neoadjuvant chemotherapy plus bevacizumab  prediction of risk for myeloid malignancy  prediction of severe fatigue after breast cancer diagnosis  prediction of toxicity of systemic therapy for mCRPC in older men  predictions for 2019  predictive and prognostic role of HO-1 expression  predictive factors  predictive role of frameshift mutations  predictive role of tumor infiltrate  predictive score for VCF  predictive value of combined biomarkers  predictive value of ctDNA  predictive value of ECOG performance status ≥ 2  predictive value of pretreatment circulating tumor DNA  predictive value of SNP-signature for recurrence  predictive value of TMB for pembrolizumab efficacy  predictor of outcomes with first-line endocrine therapy  predictors of dacomitinib response  predictors of early relapse  predictors of efficacy of neoadjuvant therapy  predictors of outcome and irAEs  predictors of outcome of HCT  predictors of recurrence  predictors of recurrence after laparoscopic radical hysterectomy  predictors of reponse to immune checkpoint inhibitors  predictors of response and survival  predictors of response to anti-PD-1 PD-L1 therapy  predictors of single-agent resistance  predictors of survival  predictors of unplanned hospitalization  predictors of uptake of CPM  PREDIX HER2 trial  preëclampsie  preemptive local ablative therapy to residual oligometastases  preexisting antibodies  preexisting pain  PREF ALL  PREFERABLE-EFFECT trial  pregabalin  pregnancy  pregnancy after breast cancer  pregnancy after cancer diagnosis  pregnancy duration  pregnancy outcomes  pregnancy-associated breast cancer  pregnancy-associated cancer  pregnancy-associated hematological malignancies  pregnancy-related risk factors  prehabilitatie  prehabilitation  preïmplantatie-genetische diagnose  premalignant gastric cardia lesions  premature aging  premature ET discontinuation  premature menopauze  premenopausal aggressive HR+ HER2- ABC  premenopausal avanced breast cancer  premenopausal breast cancer  premenopausal breast cancer patients  premenopausal breast cancer risk  premenopausal early breast cancer  premenopausal ER-positive EBC  premenopausal HR-positive HER2-negative advanced breast cancer  premenopausal HR-positive HER2-negative metastatic breast cancer  PREMER multicenter phase 3 trial  prenatale blootstelling  prenatale carcinogenenblootstelling  PREOPANC study  PREOPANC trial long-term results  preoperatieve chemotherapie  preoperatieve MRI  preoperatieve radiotherapie  preoperatieve radiotherapie voor rectumkanker  preoperative adverse event risk index for head and neck cancer surgery  preoperative anemia  preoperative CA 19-9  preoperative CA19-9 and CEA  preoperative chemotherapy  preoperative chemotherapy or radiotherapy  preoperative CONUT score  preoperative CRT  preoperative CRT plus nivolumab  preoperative CRT with or without pazopanib  preoperative detection of KRAS G12D mutation in ctDNA  preoperative dietary fiber intake  preoperative elevated tumor markers  preoperative embolization  preoperative features and clinical beneficial pathology  preoperative identification of pathologic tumor invasion  preoperative letrozole  preoperative mFOLFOX6 plus cetuximab  preoperative MRI  preoperative nomogram predictive for early recurrence after pancreatectomy  preoperative oral antibiotics  preoperative patient-related prognostic factors  preoperative PBI  preoperative PET CT  preoperative radiotherapy for retroperitoneal primary sarcoma  preoperative risk evaluation  preoperative therapy  Preoperative-Palbociclib studie  presalvage radiotherapy PSA level  prescription opioid use  presentation and characteristics  presentation and outcomes  PRESSING panel mutations  PRESTO trial  presurgical peritumoral lidocaine infiltration  presymptomatic awareness of BRCA1 2 status  preterm birth  preterm birth and risk of childhood cancer  pretest VE versus GC  pretransplant DNA sequencing to detect residual disease  pretreated advanced biliary tumors  pretreated advanced endometrial cancer  pretreated ALK-rearranged mNSCLC  pretreated ALL  pretreated aSCLC  pretreated grade 3 or 4 glioma  pretreated HER2+ metastatic breast cancer  pretreated LA M NSCLC with EGFR exon 20 insertion  pretreated multiple myeloma  pretreated NSCLC  pretreated RAS wild-type metastatic colorectal cancer  pretreated STS  pretreatment metastatic growth rate  pretreatment NLR  pretreatment vitamin D deficiency  pretretreated EGFR-mutant NSCLC  PREVAIL-studie  prevalence and drivers in Ontario  prevalence and prognostic implications of accelerated aging  prevalence and risk factors  prevalence and risk factors for multifocality  prevalence of altered body image  prevalence of clinical diagnosis of ADHD  prevalence of functional disability among US cancer survivors  prevalence of HBV  prevalence of targetable genomic alterations  prevalence of thromboembolic events  prevalence of US cancer survivors  preventable harm  preventie  preventie cervixkanker  preventie mammacarcinoom  prevention of cGVHD  prevention of early menopause  prevention of pancreatic cancer  prevention with polaprezinc  preventive drugs in the last year of life  previously diagnosed primary malignancies in Swedish breast cancer patients  previously treated advanced cervical cancer  previously treated advanced gastric cancer  previously treated advanced hepatocellular carcinoma  previously treated advanced KRAS-mutated NSCLC  previously treated advanced melanoma  previously treated advanced non-squamous NSCLC  previously treated advanced NSCLC  previously treated advanced urothelial carcinoma  previously treated aGBC  previously treated ALK-positive advanced NSCLC  previously treated aNSCLC  previously treated cholangiocarcinoma  previously treated CLL  previously treated CML  previously treated EGFR-mutated NSCLC  previously treated FL and MCL  previously treated HR+ HER2+ breast cancer  previously treated HR+ HER2+ metastatic breast cancer  previously treated mEGA  previously treated MM  previously treated mUC  previously treated NSCLC  previously treated NSCLC harboring KRAS G12C mutation  previously treated NSCLC with KRAS G12C mutation  previously treated NSCLC with KRAS p.G12C mutation  previously treated PD-L1 expressing advanced NSCLC  previously treated Ph-positive CML  previously treated recurrent or metastatic cervical cancer  previously treated SCLC  previously treated small-cell lung cancer  previously treated solid tumors in children and young adults  previously treated sqNSCLC  previously treated WM  previously untreated advanced CRC  previously untreated advanced solid tumors  previously untreated AML  previously untreated BRAF V600E mCRC  previously untreated CLL  previously untreated high-risk AML  previously untreated locally recurrent or metastatic TNBC  previously untreated MPM  prijzen medicatie  PRIMA study  primair CNS-lymfoom  primair melanoom  primair urethracarcinoom  primaire borstkanker  primaire plasmacelleukemie  primary and secondary CNS lymphoma  primary brain tumor patients  primary breast cancer treatment  primary care clinic appointment time  primary care intervention  primary care presentation with fatigue  primary care use  primary care use and 90-day mortality  primary central nervous system DLBCL  primary central nervous system lymphoma  primary central nervous system lymphoma in elderly patients  primary CNS embryonal rhabdomyosarcoma with PAX3-NCOA2 fusion  primary CNS lymphoma  primary cutaneous melanoma  primary debulking surgery  primary definitve CRT versus upfront surgery  primary dural lymphoma  primary gastric cancer risk after H. pylori eradication  primary HPV testing with cytology versus cytology alone  primary liver cancer  primary liver resection for HCC  primary mediastinal large B-cell lymphoma  primary or interval CRS  primary surgery  primary surgery for OCSCC  primary surgery versus CRT  primary tumor location  primary tumor resection  primary tumor sidedness  primary versus acquired T790M mutatiion  PRIME study  PRINCIPAL study  prior ICI treatment  prior or concurrent antibiotic use  PRISM trial  PRO-CTCAE  PRO-IMPACT studie  PROACCT score  probability of live births among female survivors of childhood cancer  ProBio trial  PROC  PROC with high FRα expression  ProCAID study  procarbazine-CCNU-vincristine  procarbazine-lomustine-vincristine  PROCAS Study  PROCLAIM-CX-072 study  PRODIGE 20-studie  PRODIGE 24 trial  PRODIGE 41-BEVANEC trial  PRODIGE 9 trial analysis  PRODIGE-24 CCTG PA6 trial  PRODIGY trial  PRODRIGE18 study  PROFILE 1001 study  ProfiLER-studie  PROFILES registry  PROFIT trial  PROfoud Trial OS analysis  PROfound study  PROfound trial  PROfound trial post-hoc analysis  profylactic salpingo-oophorectomy  profylactische mastectomie  prognose  prognose luminal A  prognosis  prognosis after treatment for testicular cancer  prognosis in women with endometriosis or adenomyosis  prognosis of screen-detected versus interval breast cancers  prognostic and predictive relevance of CMSs  prognostic and predictive value  prognostic and predictive value of HER2 expression in DCIS  prognostic and predictive value of Immunoscore  prognostic biomarkers for salvage chemotherapy following nivolumab  prognostic case volume thresholds  prognostic effect of nodal status  prognostic effects of aspirin  prognostic factors  prognostic factors and outcomes after progression  prognostic factors for relapse  prognostic impact of ETS and DoR  prognostic impact of HR subtypes  prognostic impact of inflammation  prognostic impact of mismatch repair status  prognostic impact of myosteatosis  prognostic impact of number of induction courses to attain CR  prognostic impact of obesity  prognostic impact of TP53 mutations  prognostic implication of body composition change during primary treatment  prognostic implications  prognostic index  prognostic model  prognostic nomogram  prognostic parameters in lobular versus nonlobular disease  prognostic protein-based signature  prognostic relevance  prognostic relevance of 21-gene recurrence score  prognostic risk score  prognostic role in lung cancer  prognostic role of circulating cell-free DNA  prognostic role of hypoxia and angiogenesis  prognostic role of PD-L1 expression on circulating tumor cells  prognostic role of pre-diagnosis health-related quality of life  prognostic role of TILs  prognostic score  prognostic score after neoadjuvant therapy and resection  prognostic signature based on DNA repair genes  prognostic significance  prognostic significance of early detection of KRAS-mutation in cfDNA  prognostic significance of metastatic pattern  prognostic significance of microsatellites  prognostic significance of NLR  prognostic significance of survivin expression  prognostic significance of TILs  prognostic value  prognostic value of chemotherapy-induced neutropenia  prognostic value of circulating tumor DNA  prognostic value of CTCs  prognostic value of ctDNA after resection for mCRC  prognostic value of depth of response  prognostic value of EndoPredict  prognostic value of HER2-status of CTCs  prognostic value of histopathological subtyping  prognostic value of KRAS sequence variation  prognostic value of MPS  prognostic value of MVI  prognostic value of PSA at 6 months after RT  prognostic value of teratoma in primary tumor and postchemotherapy lymph nodes  prognostic value of TILs  prognostic value of VA-FI  prognostic variables in patients achieving CR on initial therapy  prognostication  prognosticators  prognostische biomarker  prognostische discordantie  prognostische test  prognostische tools mammacarcinoom  progress in cancer survival and incidence  progressievrije overleving  progressievrije overleving na 24 maanden  progressing DD-LPS  progression –free survival 2  progression and mortality  progression following durvalumab consolidation  progression of frailty  progression risk in black and white men  progression risk stratification  progression within 24 months of frontline chemoimmunotherapy  progressive and symptomatic medullary thyroid cancer  progressive glioblastoma  progressive mACC  progressive metastatic breast cancer  progressive MPM  proguanil atovaquone  projected lifetime cancer risk  projections until 2030  projections until 2039  prolaris  prolonged infusion of low dose gemcitabine  prolonged-duration chemoprophylaxis of venous thromboembolism  PROLUNG study  PROMIS-studie  PROMISE-GIM6 trial  PROMISE-studie  promotie  promoting physical activity after lung cancer surgery  prone versus supine breast radiotherapy  PRONOPALL-studie  propanolol plus pembrolizumab  PROpel phase 3 trial  PROpel trial  PROPHECY study  prophylactic antibiotics  prophylactic chestwall irradiation  prophylactic contralateral breast irradiation  prophylactic cranial irradiation  prophylactic heparin in ambulatory patients with solid tumors  prophylactic hyperthermic intraperitoneal chemotherapy  prophylactic intravitreal bevacizumab  prophylactic RT versus standard of care  prophylactic use of compression sleeves  proportion of patients receiving ultimately approved treatments  proposed diagnostic criteria  PROREPAIR-B study  PROs  PROs after BCT versus mastectomy with reconstruction  PROs with olaparib or placebo plus abiraterone  PROSELICA-studie  Prosigna  Prosigna risk of recurrence score  Prosigna test in breast cancer  PROSINT trial  PROSPECT trial  prospective analysis  prospective genotyping  prospective IDEA trial  prospective precision oncology  prospective study of association of lever function and CRC risk  prospective study of mid-term neurotoxicity  prospective validation Gail Model  PROSPER study  PROSPER study final OS analysis  prostaatcarcinoom  prostaatcarcinoom. androgeendeprivatietherapie  prostaatkanke  prostaatkanker  prostaatkankermortaliteit  Prostaid  prostate cancer  prostate cancer aggressiveness  prostate cancer among Black men in Canada  prostate cancer diagnosis  prostate cancer in Black and White men  prostate cancer in transgender women  prostate cancer incidence and mortality  prostate cancer incidence in men with PSA below 3 ng ml  prostate cancer long-course versus short-course ADT with PORT  prostate cancer mortality  prostate cancer outcomes  prostate cancer outcomes following solid-organ transplantation  prostate cancer probability in Black and non-Hispanic White men  prostate cancer prognosis  prostate cancer progression  prostate cancer review  prostate cancer risk  prostate cancer risk and mortality  prostate cancer screening  prostate cancer treatment  prostate cancer treatments  prostate cancer; long-term follow up NRG RTOG 9413 study  prostate MRI  prostate radiotherapy  prostate radiotherapy with adjuvant versus neoadjuvant androgen deprivation  prostate tumors from African American and European American men  prostate-only versus whole-pelvic RT  prostatectomie  proteasome inhibitor  proteasoomremmer  ProtecT  ProtecT study  PROTECT-1 en -2 studies  PROTECT-studie  PROTECTIVE-1 study  Proteus Donna study  protocol waivers  proton beam radiation therapy  proton beam radiotherapy  proton beam therapy  proton craniospinal irradiation  proton pump inhibitor use  proton radiotherapy  proton therapy  proton therapy and photon therapy  proton therapy reirradiation  proton versus photon radiation  proton versus photon radiotherapy  protonradiotherapie  protontherapie  PROUD-PV and CONTINUATION-PV studies  proximal colon serrated neoplasia  proximal versus distal detection  PRROC  PRRT  PRRT versus chemotherapy or targeted therapy  PRS  PRT  PRT and CIRT  pruritus related to ICIs and anti-HER2 therapies  PS  PSA  PSA bounce  PSA levels in men aged 55-60  PSA screening  PSA screening and 15-year prostate cancer mortality  PSA screening and PCSM in NHB and NHW veterans  PSA screening in older males  PSA-based EFS as surrogate for OS  PSA-recidief  PSA-screening  PSAD  PSAV  PSCCB  pSCI versus IFRT  PSMA PET-CT versus conventional imaging  PSMA-PET imaging  PSMA-positive solid tumors  pSmad2  PSMAfore trial  PSN  PSO after resection of breast cancer in BRCA1 2 variant carriers  psoriasis  psoriasis and psoriatic arthritis  psoriasis risk  PSPDR  PSROC  psychiatric disorders in cancer patients  psychiatric utilisation prior to cancer diagnosis  psycho-oncology  psychologic distress  psychological distress  psychological outcomes  psychosocial health and lifestyle  pT1 node-negative TNBC  pT1-2N0M0 OTSCC  PTBP1  PTC  PTCL  pten  PTEN loss predicts poor prognosis  PTEN promoter methylation and prognosis  PTEN-verlies  PTGS2  PTH  PTK7-expressing recurrent NSCLC  PTR  PTSD  pubertal timing and breast cancer risk  pulmonaire metastasen  pulmonary adenocarcinoma  pulmonary embolism  pulmonary fibrosis  pulmonary large cell neuroendocrine carcinoma  pulmonary oligometastases  pulmonary oligorecurrence after radical resection of NSCLC  purchase of antidepressants  PURE study  PURE-01  PURE-01 study  PUVA therapy  PV  PVI  PVRL  PVs in hereditary cancer genes  PWH  PWH with cancer  pyrotinib  pyrotinib plus capecitabine  pyrotinib plus metronomic etoposide  pyrotinib-trastuzumab-chemotherapy  Q-122  Q-koorts  QNBC  QoL  QOL analysis  QOL and physical functoning  QOL and psychosocial well-being in young survivors  QOL in CALGB 30610  QOL in CARD study  QOL in older adults after major cancer surgery  QOLIXANE trial  QSkin Study  QSkin-studie  QUADRA study  quadrivalent HPV vacinnation  quality of breast cancer care in The Netherlands and Norway  quality of life  quality of life after lung resection  quality of life after surgery  quality of life and mortality  quality of life in survivors of adolescent and young adult cancer  quality of surgery  quality-adjusted time without symptoms of progression or toxicity  quantification of contribution of risk factors  QuANTUM-First trial  QuANTUM-R study  QUAZAR AML-001 Maintenance Trial  QUAZAR AML-001 trial  QUINTETT trial secondary analysis  QuiRedex  quitting smoking after NSCLC diagnosis  quitting smoking at or around diagnose lung cancer  quizartinib  R M ACC  R M CC  R M cervical cancer  R M cervical carcinoma  R M cervical SCC  R M head and neck cancer  R M HNC  R M HNSCC  R M MCC  R M NPC  R M SDC  R M SNSCC  R M TNBC  R R ALCL  R R ALL  R R ALL in CAR-naive and CAR-exposed children and young adults  R R AML  R R AML in children  R R AML in patients not eligible for intensive therapy  R R AML MDS  R R B-ALL  R R B-ALL in adults  R R B-ALL in children and adolescents  R R B-ALL in young children  R R B-ALLafter allogeneic HSCT  R R B-cel lymphoma  R R B-cell lymphoma  R R B-cell malignancies  R R B-cell non-Hodgkin lymphoma  R R B-NHL  R R BCP-ALL  R R BRAF V600-mutant pHGG  R R cHL  R R CLL  R R CLL or SLL  R R CLL SLL  R R CNSL  R R CTCL  R R diffuse large B-cell lymphoma ibrutinib-lenalidomide-rituximab  R R DLBCL  R R extranodal natural killer T-cell lymphoma  R R FL  R R FLT3-mutated AML  R R folliculair B-cell lymphoma  R R FTL3-mutated AML  R R glioblastoma  R R high-risk CLL  R R high-risk neuroblastoma  R R HL  R R indolent NHL  R R large B-cell lymphoma  R R LBCL  R R lymphoma  R R lymphoma after previous failure  R R mature lymphoid neoplasms  R R MCL  R R MDS  R R MF or SS  R R MF SS  R R MM  R R MSS mCRC  R R multiple myeloma  R R myelofibrosis  R R MZL  R R neuroblastoma  R R NHL  R R OC  R R osteosarcoma  R R PCNSL  R R PCNSL or SCNSL  R R peripheral T-cell lymphoma  R R PMBCL  R R PTCL  R R PTCL or CTCL  R R sarcoma in children  R R T-ALL  R R TCL  R R WM  r r-AML  R R-B-ALL in adults  R-cadherine  R-CHOP  R-CHOP 14 versus 21 studie  R-CHOP-14  R-HAD with or without bortezomib  R-M HNSCC  R2-CHOP  RAAS  race and ethnicity-adjusted age recommendation  race and outcomes  race and PN risk  race and risk of subsequent aggressive breast cancer  race and survival  race ethnicity-associated differences in stage at diagnosis and survival among leading cancer types  race-based differences in survival  race-dependent differences in risk of MGUS progression  race-specific differences  race-specific outcomes in equal access health care setting  racial and ethnic differences  racial and ethnic differences in germline pathogenic variants  racial and ethnic disparities  racial differences  racial disparities  racial disparities in frailty and function limitations  racial disparities in stage at diagnosis and survival  racial disparity in biomarker-directed therapy  racial disparity in distant recurrence-free survival  racial disparity in survival  racial ethnic disparities  racial ethnic disparities in outcomes  RAD51 test  radcial cystectomy  RADIANT-2  RADIANT-4  radiation and androgen deprivation for Pca  radiation and chemotherapy  radiation and chemotherapy for CNS and pediatric head-and-neck tumors  radiation dermatitis in breast cancer  radiation dose  radiation doses to organs at risk  radiation exposure from CT examinations  radiation facility volume  radiation for localized prostate cancer  radiation pneumonitis  radiation segmentectomy  radiation therapy facility patient volume  radiation therapy for cancer  radiation therapy for head and neck cancer  radiation therapy for medulloblastoma  radiation therapy plus ICI therapy  radiation to hypothalamus and pituitary  radiation-associated intracranial malignancy  radiation-associated ototoxicity  radiation-associated trismus after head and neck cancer  radiation-induced cardiac toxicity  radiation-induced cystitis  radiation-induced meningioma  radiation-induced oral mucositis and dermatitis  radiation-related CV risk  radical cystectomy  radical hemi-thoracic radiotherapy  radical hysterectomy  radical prostatectomy versus watchful waiting  RADICALS-HD trial  RADiChol-studie  radioactief jodium  radioactive iodine-refractory differentiated thyroid cancer  radiodermatitis  radiodermatitis in breast cancer patients  radioembolisatie  radiofrequency localization  radiofrequentie-ablatie  radiogenomics  radioiodine-refractory differentiated thyroid cancer  radiojodium-refractair gedifferentieerd schildkliercarcinoom  radiologic complete response  radiomica  radiomics  radionecrosis  RADIOSA trial  radiosensitivity  radiosurgery  radiotherapeutic efficacy  radiotherapie  radiotherapy  radiotherapy after BCS  radiotherapy for breast cancer  radiotherapy for childhood cancer  radiotherapy for esophageal cancer  radiotherapy for gynecologic cancers  radiotherapy for oropharyngeal cancer  radiotherapy for prostate cancer  radiotherapy for rectal cancer  radiotherapy or autologous SCT  radiotherapy or temozolomide  radiotherapy plus docetaxel  radiotherapy plus ipilimumab  radiotherapy techniques  radiotherapy to regional nodes in early breast cancer  radiotherapy versus surgical resection  radiotherapy versus temozolomide  radiotherapy vs surgery  radiotherapy with or without S-1 chemotherapy  radiotherapy-induced OM  radiotherapy-related heuropathic pain  radium 223  radium-223  radon  radotinib  RAGNAR trial  RAI for differentiated thyroid cancer in children and young adults  RAI for hyperthyroidism  RAI-R DTC  RAINBOW-studie  RAINFALL study  RAIR-DTC  RAL versus LAL  ralimetinib  raloxifeen  RAMES study  RAMOSE trial  ramucirumab  ramucirumab beyond progression plus TAS-102  ramucirumab plus atezolizumab  ramucirumab plus chemotherapy  ramucirumab plus osimertinib  ramucirumab plus paclitaxel  ramucirumab plus pembrolizumab  ramucirumab plus pembrolizumab after failure of immunotherapy  ramucirumab plus somatostatin analog therapy  ramucirumab-irinotecan-cisplatin  randomized phase 2 MAINTAIN trial  randomized phase 2 NEONAX trial  randomized phase 2 SALV-ENZA trial  randomized trials of cancer screening  RANGE study  RANGE-studie  RAP trial  rapid binding off-rate CD19 CAR-T therapy  RAPID trial  rapidly proliferating glioblastoma  RAPIDO trial  RARC with IUD versus ORC  rare cancers  rare CNS tumors  rare sarcomas  rare T cell lymphomas  rare versus common genetic variants  RARECAREnet  RAS alterations  RAS BRAF wild-type metastatic colorectal cancer  RAS BRAF-wt metastatic colorectal cancer  RAS mutant unresectable CLM  RAS mutated MGMT methylated mCRC  RAS wild-type left-sided metastatic colorectal cancer  RAS wild-type metastatic colorectal cancer  RAS wildtype metastatic colorectal cancer  Ras-gebonden associaties tussen obesitas en early-onset mammacarcinoom en specifieke moleculaire subtypen  RAS-mutant pancreas adenocarcinoma  RAS-mutated metastatic colorectal cancer  RAS-mutaties  RASER study  RASTEN-studie  rate of memory change  rate of occult contralateral nodal disease  rate of secondary sarcoma  rates of brain metastase of breast cancer subtypes  rates of cancer and all-cause mortality  RATHL trial  RATIONALE 302 study  RATIONALE 304 study  RATIONALE-301 trial  RATIONALE-302 study  RATIONALE-306  RATIONALE-315  RB1 mutation status  RC48 plus toripalimab  RCB after NACT  RCC  RCC after ICI treatment  RCC at intermediate or high risk of relapse  RCC brain metastases  RCC in VHL  RCC incidence and mortality  RCC risk  RCM  RD  RDC plus blinatumomab  RDD  re-biopsy after first-line treatment  re-excisie  RE-ExPEL trial  re-irradiation plus BV and TMZ  re-RT  re-testing predictive biomarkers in surgical specimens  REACH-2 study  REACH2 trial  REACH3 study  REACH5 study  REACHIN study  ReACT study  readministration of anti-PD-1 or anti-PD-L1 after irAE  readmission  readmission risk scoring system  real world effectiveness of nivolumab after systemic therapy  real world evidence  real world outcomes  real world outcomes of pertuzumab and T-DM1  real-life experience  real-life outcomes  real-life outcomes with pazopanib  real-life results of CAR T-cell therapy  real-world analysis  real-world breast cancer screening with DBT versus 2D mammography  real-world cardiovascular outcomes with degarelix versus leuprolide  real-world clinical outcomes with avelumab  real-world comparison of tisa-cel and axi-cel  real-world data  real-world data model  real-world effectiveness against cervical cancer  real-world effectiveness of second-line ICI versus chemotherapy  real-world effectiveness study  real-world effectivenss for prevemtion of high-grade vulvovaginal lesions  real-world evaluation  real-world experience  real-world experience in the UK  real-world incidence of cardiotoxicity  real-world mutation-tailored treatment selection  real-world OS  real-world outcomes  real-world outcomes after definitive radiation therapy  real-world outcomes of first-line immunotherapy  real-world outcomes of ICIs for cancer  real-world outcomes of neoadjuvant endocrine therapy  real-world outcomes with brigatinib  real-world outcomes with first-line treatments  real-world outcomes with ICIs  real-world outcomes with ICIs in cohorts underrepresented in clinical trials  real-world outcomes with second or later line lurbinectedin  real-world overall survival  real-world pooled analysis  real-world QOL with first-line nab-paclitaxel and gemcitabine for mPaC  real-world survival  real-world survival of early-stage breast cancer patients  real-world treatment and survival  real-world treatment drop-off  real-world treatment patterns and survival in Germany  real-world use  real-world use of EGFR TKIs  REALISE phase 2 study  REALITY trial  REASSURE study  rebiopsy  rEC  recent weight loss  receptor conversion in breast cancer metastases  receptor discordance between primary tumor and brain metastases  receptor expression discordance between primary and recurrent breast cancer  receptor status  receptor status conversion following neoadjuvant chemotherapy  receptorstatusverandering  recidief  recidiefrisico  recidiefrisico ER-positief mammacarcinoom  recidiverend multipel myeloom  recidiverend of refractair ALL  recidiverend of refractair mantelcellymfoom  recidiverend of refractair multipel myeloom  recidiverend refractair mantelcellymfoom  recidiverend refractair multipel myeloom  recidiverend refractair PCNSL  recidiverende beroerte  recidiverende ER-positieve borstkanker  RECIST  recombinant erythropoietin-refractory anemia  recombinant human granulocyte colony-stimulating factor  recombinant poliovirus for recurrent glioblastoma  recombinant zoster vaccine  recommended definition  RECORD-2  recovery of gonadal function  recovery of HRQoL of patients and parents  recovery of ovarian function  rectal adenocarcinoma  rectal cancer  rectal cancer in elderly patients  rectal cancer surgery  rectumcarcinoom  rectumccarcinoom  rectumkanker  recurrence  recurrence after complete response to HAE or DEB-TACE  recurrence after incomplete resection  recurrence after nephrectomy for RCC  recurrence in nipple-areola complex  recurrence of breast cancer  recurrence or oligometastases in gynecologic malignancies  recurrence patterns  recurrence patterns after RT for brain metastases  recurrence predictive model  recurrence risk  recurrent aCRC  recurrent acute myeloid leukemia  recurrent advanced urothelial cancer  recurrent and or metastatic HNSCC  recurrent and or metastatic HNSCC with HRAS mutations  recurrent APTs and PCs  recurrent cervical cancer  recurrent CT scans for early gastric cancer  recurrent endometrial cancer  recurrent EOC  recurrent FRα-positive PSOC  recurrent GBM  recurrent glioblastoma  recurrent glioma  recurrent H3 K27M-mutant diffuse midline glioma  recurrent head and neck squamous cell carcinoma  recurrent hepatocellular carcinoma  recurrent HGG  recurrent high grade glioma  recurrent high-grade serous ovarian cancer  recurrent HNSCC  recurrent intermediate-stage HCC  recurrent LA NPC  recurrent low-grade serous ovarian cancer  recurrent malignancies in children and adolescents  recurrent medulloblastoma  recurrent melanoma after adjuvant immunotherapy  recurrent meningioma  recurrent metastatic breast cancer  recurrent metastatic head and neck cancer  recurrent metastatic head and neck squamous-cell carcinoma  recurrent metastatic HRAS-mutant salivary gland cancer  recurrent nonmuscle invasive bladder cancer  recurrent of refractory soldi tumors in children and adolescents  recurrent or advanced endometrial cancer  recurrent or advanced mismatch repair-deficient EC  recurrent or metastatic ASPS  recurrent or metastatic cervical cancer  recurrent or metastatic CSCC  recurrent or metastatic endometrial cancer  recurrent or metastatic head and neck squamous cell carcinoma  recurrent or metastatic HNSCC  recurrent or metastatic mucosal HNSCC  recurrent or metastatic nasopharyngeal carcinoma  recurrent or metastatic NPC  recurrent or metastatic triple-negative or BRCA1 2-associated breast cancer  recurrent or persistent gynecologic malignancies  recurrent or persistent ovarian cancer  recurrent or second primary HNSCC  recurrent ovarian and endometrial cancer  recurrent ovarian cancer  recurrent platinum-resistant ovarian carcinoma  recurrent platinum-sensitive ovarian cancer  recurrent prostate cancer  recurrent small hepatocellular carcinoma  recurrent uterine serous carcinoma  recurrent women’s cancers  recurring advanced melanoma  recurring endometrial cancer  red blood cell transfusion  red flag signs and symptoms  red or processed meat intake and risk of red recurrence and mortality  ReDOS study  REDUCE trial  reduced intensity alloHCT  reduced LVEF  reduced-dose capecitabine plus cetuximab maintenance  reduced-dose fluoropyrimidine therapy  reduced-dose radiation therapy  reducing early discontinuation adjuvant aromatase inhibitor therapy  refractory B cell malignancies  refractory B-cell lymphoma  refractory cancers  refractory central nervous system leukemia  refractory colorectal cancer  refractory EGFR-mutated NSCLC  refractory EGFR-T790M-positive NSCLC with CNS metastases  refractory esophageal cancer  refractory large B cell lymphoma  refractory large B-cell lymphoma  refractory mCRC  refractory mCRPC  refractory metastatic colorectal cancer  refractory MM  refractory or relapsed hairy-cell leukemia  refractory RAS wt mCRC  refractory relapsed B-cell malignancies  refractory soft tissue sarcomas  refractory solid tumor  refractory solid tumors harboring CCNE1 amplification  refractory solid tumors in children  refractory viral infections after allo-HCT  refusal of conventional cancer therapy  refusal of surgery  REGARDS cohort study  REGARDS study  regional inequalities of tumor size at diagnosis  regional lymph node irradiation  regional nodal irradiation  regional versus general anesthesia  regionale lymfeklierbestraling  REGN5459  REGOBONE study  REGOMA study  REGOMUNE trial  REGONIVO  REGONIVO study  regorafenib  regorafenib plus avelumab  regorafenib plus nivolumab  regorafenib-ipilimumab-nivolumab  REGOSARC  reintroduction of chemotherapy  reintroduction of ICIs  rejection of systemic therapy  relacorilant plus nab-paclitaxel  relapse  relapse after adjuvant BEP  relapse after allogeneic stem-cell transplantation  relapse after alloHCT  relapse after autoSCT  relapse detection by routine CT scan versus symptoms  relapse of ALL in children and young adults  relapse rate  ReLApsE trial  relapsed aggressive B-cell non-Hodgkin lymphoma  relapsed AL amyloidosis  relapsed AML in children  relapsed and or refractory multiple myeloma  relapsed BRCA1 or 2 mutated ovarian cancer  relapsed cHL in patients aged 5 to 30 years  relapsed CLL  relapsed CLL SLL  relapsed diffuse large B-cell lymphoma  relapsed early-stage favorable HL  relapsed EGFRvIII-expressing glioblastoma  relapsed Ewing sarcoma  relapsed follicular lymphoma  relapsed glioblastoma  relapsed indolent non-Hodgkin lymphoma  relapsed metastatic germ cell tumors  relapsed MM  relapsed multiple myeloma  relapsed of refractory solid tumors or lymphoma  relapsed or refractory ALL in children and young adults  relapsed or refractory AML  relapsed or refractory AML in children  relapsed or refractory B-ALL  relapsed or refractory B-cell ALL in children and young adults  relapsed or refractory B-cell malignancies  relapsed or refractory bone tumors  relapsed or refractory cHL  relapsed or refractory chronic lymphocytic leukemia  relapsed or refractory classic Hodgkin lymphoma  relapsed or refractory classical Hodgkin lymphoma  relapsed or refractory diffuse large B cell lymphoma  relapsed or refractory diffuse large B-cell lymphoma  relapsed or refractory DLBCL  relapsed or refractory ENKTL  relapsed or refractory follicular lymphoma  relapsed or refractory Hodgkin lymphoma  relapsed or refractory Hodgkin lymphoma. BV plus bendamustine as first salvage therapy  relapsed or refractory indolent lymphoma  relapsed or refractory large B-cell lymphoma  relapsed or refractory lymphoma  relapsed or refractory MCL  relapsed or refractory multiple myeloma  relapsed or refractory neuroblastoma  relapsed or refractory non-Hodgkin lymphoma  relapsed or refractory primary CNS or introcular lymphoma  relapsed or refractory rhabdomyosarcoma  relapsed or refractory Sézary syndrome  relapsed or refractory solid tumors  relapsed or refractory WM  relapsed or relapsed and refractory multiple myeloma  relapsed or untreated MCL  relapsed ovarian cancer  relapsed PCNSL  relapsed Ph+ ALL after allogeneic hematopoietic cell transplantation  relapsed platinum-sensitive ovarian cancer  relapsed refractory acute lymphoblastic leukemia  relapsed refractory AML  relapsed refractory diffuse large B cell lymphoma  relapsed refractory ENKTL  relapsed refractory Hodgkin lymphoma  relapsed refractory multiple myeloma  relapsed refractory multiple myeloma. subcutaneous daratumumab  relapsed refractory NHL  relapsed refractory Ph+ ALL  relapsed refractory systemic light-chain amyloidosis  relapsed SCLC  relative dose intensity  relative lymphocyte count  relative SMN risk in adult cancer patients  relative survival  RELATIVITY-020 trial  RELATIVITY-047  RELATIVITY-047 and CheckMate 067  RELATIVITY-047 trial  relatlimab  RELAY study  RELAZA2 study  RELEVANCE study  RELEVANCE trial  RELEVENT trial  religieuze overtuigingen  relmacabtagene autoleucel  relugolix for ADT  REMAGUS02 study  remaining life expectancy  REMARC study  remming CD95-route  remming hedgehog-signaalroute  remnant liver ischemia  REMORA study  REMOTUX trial  renal cancer risk  renal cell carcinoma  renal function  renal impairment  ReNeu trial  RENMIN-215 trial  RENO study  RENOBATE trial  reovirus  repeat hepatectomy vs percutaneous radiofrequency ablation  repeat radiosurgery  repeat SRS  repeated CTC enumeration for early treatment monitoring  repeated prostate cancer screening with PSA testing and MRI  repotrectinib  reproduction outcomes after breast cancer  reproductive factors  reproductive factors and endometrial cancer risk in East Asian women  reproductive history and molecular subtype of breast cancer diagnosed before age 51 years  RERISE long-term follow-up  RERISE-studie  resctable esophageal cancer  resctable NSCLC  resectable and borderline resectable pancreatic cancer  resectable CLM  resectable colorectal cancer  resectable colorectal cancer liver metastases  resectable esophageal adenocarcinoma  resectable esophageal cancer  resectable gallbladder cancer  resectable gastric cancer  resectable HCC  resectable head and neck squamous cell carcinoma  resectable HPV-unrelated head and neck cancer  resectable LAHPC  resectable locally advanced HNSCC  resectable locally advanced rectal cancer  resectable lung SCC  resectable malignant pleural mesothelioma  resectable melanoma  resectable MIBC  resectable mucosal melanoma  resectable NSCLC  resectable pancreatic cancer  resectable pancreatic head cancer  resectable PD-L1 negative NSCLC  resectable PDAC  resectable PLELC  resectable regionally advanced melanoma  resectable stage IB-IIIA NSCLC  resectable stage III melanoma  resectable synchronous CLM  resected ampullary carcinoma  resected biliary tract cancer  resected brain metastases  resected colon cancer  resected colorectal liver metastases  resected early-stage EGFR-mutated LUAD  resected early-stage NSCLC  resected esophageal of gastroesophageal junction cancer  resected glioblastoma  resected high-risk melanoma  resected lung adenocarcinoma  resected NSCLC BMs  resected pancreatic cancer  resected PDAC  resected RPS  resected stage 3 and oligometastatic stage 4 melanoma  resected stage IB-IIIA NSCLC  resected stage II-IIIA NSCLC  resected stage III colon cancer  resected stage III IV melanoma  resected stage III melanoma  resected stage IV melanoma  resectie laaggradig glioom  resection  resection before immunotherapy  resection of brain metastases  resection of primary tumor  residual cancer burden  residual cancer burden index  residual HER2-positive breast cancer  residual or recurrent glioblastoma  residual risk of breast cancer after bariatric surgery  residual TNBC after neoadjuvant chemotherapy  RESILIENT  resiquimod  resistance alterations  resistant starch  resistentie  RESONANCE trial  RESONATE study  RESONATE-17  respiratory morbidity  respiratory outcomes  Response Assessment in Neuro-Oncology werkgroep  response of localized prostate cancer to definitive RT  RESPONSE study 5-year follow-up  response to anti-EGFR therapy  response to HER2-targeted therapy  response to ICI  response to ICIs  response to immunotherapy  response to lung cancer immunochemotherapy  response to neoadjuvant treatment  response to nivolumab plus ipilimumab  response to preoperative CRT  response to stereotactic radiosurgery  response to third dose of BNT162b2 vaccine in actively treated cancer patients  RESPONSE-2  RESPONSE-2 trial 5-year follow-up  response-adapted low dose radiotherapy  response-adapted treatment following radiotherapy  response-based radiotherapy  responses to retreatment  RESQ study  REST study  restart of durvalumab after pneumonitis  RESTART trial  restarting durvalumab after stopping without disease progression  RESTORE  Restoring Invisible and Abandoned Trials  results in North America  resumption of immune checkpoint inhibitor therapy  Ret  RET fusion-positive advanced non-small cell lung cancer  RET fusion-positive NSCLC  RET fusion-positive solid tumors  RET TKIs for cancer  RET-activated thyroid cancer  RET-altered thyroid cancers  RET-fusion positive NSCLC  RET-MAP trial  RET-rearranged lung cancer  RETAIN 1 trial  retinoblastoma  retinoblastoma patients  retinoblastoom  retinol  retroperitoneaal sarcoom  retroperitoneal liposarcoma  retroperitoneal lymph node dissection  retroperitoneal sarcoma  retrospectieve analyse PETACC-3 studie  retrospective study of W&S vs TMZ vs RT  reumatoïde artritis  REVERCE study  reverse gene expression profiling  reversions in BRCA and PARP  revised STARS trial  REVIVE Trial  revumenib  rezivertinib  REZOR study  rezvilutamide (SHR3680)  RFA  RFA after TACE plus sorafenib  RFA versus SBRT  RFA with or without toripalimab  RFS  rGBM  rhabdomyosarcoma  rhabdomyosarcoom  rHCC  rHGG  rHNSCC  rHR-NB  ribociclib  ribociclib plus ET vs combination therapy  ribociclib plus fulvestrant  ribociclib plus letrozole  riboflavine  RIC alloHSCT  rich TILs  RICH-ART study  Richter syndrome  Richter transformation  RICMAC-studie  ridaforolimus  RIGHT Choice trial  right-sided colon cancer  rilotumumab  RILT  riluzole plus mFOLFOX6 and bevacizumab  RINDBeRG trial  rindopepimut  ripretinib  ripretinib versus sunitinib for gastrointestinal stromal tumor  risedronaat  risico borstkanker  risicoscore  risicostratificatie  rising ctDNA as early biomarker of progression  risk and outcomes of COVID-19 in cancer patients  risk factor for low RDI  risk factors  risk factors and outcomes  risk factors and prognostic implications  risk factors and racial or ethnic disparities  risk factors associated with second primary lung cancer  risk factors for breast cancer  risk factors for cardiovascular disease  risk factors for clinically significant prostate cancer  risk factors for depression and anxiety  risk factors for development of bullous pemphigoid  risk factors for early mortality  risk factors for first and second primary melanoma  risk factors for immune-related adverse events  risk factors for keratinocyte carcinoma  risk factors for primary bone cancer  risk factors for primary resistance to immunotherapy  risk factors for progression  risk factors for recurrence  risk factors for recurrence and death  risk factors for short-term PSA recurrence  risk factors for small adult height  risk factors for voice and speech symptoms  risk factors of late distant recurrence  risk model  risk of adverse events with RT in patients receiving immunotherapy  risk of aggressive breast cancer subtype  risk of all cancer types  risk of Alzheimers disease in survivors  risk of bladder cancer  risk of breast cancer  risk of breast cancer after breast radiation and anthracycline use  risk of breast cancer by intrinsic subtypes  risk of breast SCC  risk of cancer  risk of cancer in regular and low meat-eaters and vegetarians  risk of cardiac diseasse  risk of cardiac events  risk of cardiovascular disease mortality  risk of cardiovascular hospitalization  risk of cerebrovascular disease  risk of chemotherapy-related amenorrhoea in early stage breast cancer patients  risk of childhood ALL  risk of childhood brain tumors  risk of childhood cancer  risk of childhood cancers  risk of chronic health conditions  risk of CKD and hypertension  risk of colorectal adenoma  risk of congenital malformation  risk of contralateral breast cancer  risk of death from breast cancer  risk of developing ipsilateral BC post-treatment  risk of developing or dying of cancer  risk of digestive tract cancers  risk of early-onset cancer  risk of early-onset colorectal cancer  risk of elevated intraocular pressure  risk of endometrial cancer  risk of esophageal and gastric cancer  risk of future new cancer  risk of gastric and oesophageal cancer  risk of gastrointestinal cancer  risk of genitourinary diseases  risk of glioma  risk of hematologic cancer  risk of hematological malignancies  risk of herpes zoster  risk of IBTR and CBC  risk of in situ and invasive lesions after primary DCIS  risk of incident and fatal breast cancer  risk of infections  risk of infectious complications  risk of internal malignancies  risk of interstitial lung disease  risk of late-onset breast cancer in genetically predisposed women  risk of lethal prostate cancer  risk of lifestyle-related cancers  risk of liver cancer  risk of lung  risk of lung cancer histological subtypes  risk of major psychiatric disorders  risk of malignancy  risk of malignant neoplasms  risk of MDS and AML  risk of mental health problems  risk of MM  risk of obesity-related cancers  risk of ocular adverse events  risk of ovarian and breast camcer  risk of PaC  risk of pancreatic cancer  risk of peritoneal disease  risk of pneumonitis  risk of preterm birth  risk of primary lung cancer after treatment for breast cancer  risk of primary urological and genital cancers after breast cancer  risk of progression  risk of psychiatric disorders  risk of QTc prolongation  risk of RCC  risk of recurrence  risk of recurrence and mortality  risk of recurrence and pregnancy outcomes  risk of second brain tumor  risk of second cancer  risk of second event after DCIS  risk of second malignancies  risk of second non-breast primaries  risk of second primary breast cancer  risk of second primary cancer  risk of second primary lung cancer  risk of secondary cancer  risk of secondary malignancies  risk of simultaneous of subsequent cancers  risk of SMNs after treatment for testicular germ cell cancer  risk of somatic diseases in offspring  risk of SPC after breast cancer  risk of SPCs  risk of SPMs  risk of stroke  risk of subsequent cancers  risk of subsequent primary cancers  risk of subsequent primary neoplasms  risk of suicidal self-directed violence  risk of suicide  risk of suicide after cancer diagnosis  risk of testicular germ cell tumors  risk of thoracic vertebral fracture  risk of uterine cancer in breast cancer survivors  risk of uterine diseases  risk of venous thromboembolism  risk of VTE and ATE  risk of VTE and ATE with KRd or VRd  risk of young-onset breast cancer  risk prediction calculator for sentinel node positivity  risk prediction model  risk stratification  risk stratification of EO-CRC  risk-adapted chemoimmunotherapy  risk-adapted maintenance therapy  risk-adapted omission of nCRT  risk-adapted therapy for pediatric Hodgkin lymphoma  risk-adapted tocilizumab to prevent CRS  risk-based treatment strategy  risk-based treatment stratgy  risk-directed thromboprophylaxis  risk-reducing salpingo-oophorectomy  risks and benefits of anticancer drugs  risks of subsequent primary cancers according to HR status  risks of watch-and-wait approach  RIST-rNB-2011 trial  rituximab  rituximab maintenance  rituximab plus lenalidomide  rituximab SC of IV  rituximab-associated infusion reactions  rivaroxaban  RLI before chemotherapy  RLR versus OLR  RM- NPC  RM-NPC  RMHNSCC  RMM  RMP  RMS  RMS 2005 study  RMS 2005 trial  RN  RNA next-generation sequencing  RNA-disruptie  rNPC  RNU  RNU2-1f  ROAR basket study  ROAR basket trial  ROAR study  robot-assisted partial nephrectomy  robot-assisted trachelectomy  robot-assisted versus laparoscopic versus open radical prostatectomy  robot-assisted versus open or laparoscopic surgery  robot-geassisteerde prostatectomie  robotic versus laparoscopic hepatectomy  robotic versus open pancreaticoduodenectomy  robotic-assisted versus laparoscopic liver surgery  ROC’N’ROLL trial  rociletinib  rogaratinib  roken  rolapitant  ROLARR-studie  role of adrenalectomy  role of diet in colorectal cancer incidence  role of perioperative radiotherapy  role of therapy  ROMANA 3-studie  ROME trial  romidepsin and lenalidomide based regimens  romidepsine  romiplostim  ROMULUS study  romyelocel-L to reduce infection during induction chemotherapy  rookloze tabaksproducten  ropeg  ropeginterferon alfa-2b  ROR1  ROR1-specific CAR-T cells  ROS-1 rearranged NSCLC  ROS1 fusion-positive NSCLC  ROS1-positive aNSCLC  ROS1-positive NSCLC  ROS1-rearranged advanced NSLCL  ROS1-rearranged aNSCLC  ROS1-rearranged NSCLC  ROS1+ NSCLC  ROSE TRIO-012  Ross  rotating night shift work  ROTOR  Rotterdam Study  routine splenectomy specimens  Rova-T  roxadustat  RP vs IMRT plus ADT  RP-LPS  rPAC  RPD vs OPD  rPFS  rPFS and cPFS as surrogates for OS  RPLMS  RPLND  RPS  RR CLL SLL  RR DLBCL  RR MF SS  RR multiple myeloma after lenalidomide  RR PTCL  RR versus MR strategy  RRFL  RRFL after two or more prior lines of therapy  rrHL  RRM  RRM in high-risk patients  RRMM  rrPMBCL  RRSO  RRSO in BRCA1 2 mutation carriers  RRx-001  RS  rs4143094  RSClin risk calculator  RT  RT after BCS  RT after complete response to ABVD  RT and trastuzumab for HER2-positive breast cancer  RT dose escalation  RT for BC  RT for cancer in adolescent and young adults  RT for HNC  RT for oligometastatic prostate cancer  RT for pituitary adenoma or craniopharyngeoma  RT for prostate cancer  RT in CLL  RT omission after BCS  RT plus immunotherapy  RT plus XRT  RT versus IFL  RT versus sequential DDGP and RT  RT versus surgery  RT versus TOS  RT versus transoral robotic surgery  RT with or without cisplatin  RT with or without icotinib  RT with or without trastuzumab after lumpectomy for HER2-positive DCIS  RT-associated secondary cancer  RT-induced mucocutaneous side effects  RT-naïve CNS metastases from EGFR-mutated NSCLC  RT1 trial  RTOG 0126-studie  RTOG 0214 study  RTOG 0415  RTOG 0521 study  RTOG 0539 trial  RTOG 0617  RTOG 0617 trial  RTOG 0813 trial  RTOG 1014 study  RTOG 1016 study  RTOG 1112 trial  RTOG 1203 trial  RTOG 9402  RTOG 9408 secondary analysis  RTOG-0129 risk groups  RTOG1205  RTSG-SIOP  RTW  RUBY trial  rucaparib  rucaparib maintenance  rucaparib versus placebo maintenance followin chemotherapy  rusfertide for control of erythrocytosis  ruxolitinib  ruxolitinib maintenance after alloHCT  ruxolitinib plus azacytidine  ruxolitinib plus etanercept  ruxolitinib versus BAT after HC failure  RVD induction  RVd with or without daratumumab  RVd with or without isatuximab  RxPONDER study  S-1  S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin  S-1 plus oxiplatin  S-1 versus S-1 plus oxaliplatin versus S-1 plus oxaliplatin plus RT  S-1-based CRT  S-CRC  S-PORT  S-TRAC trial  S. aureus colonisation  S1416  S1500 trial  S1512 trial  S1826 trial  S1P-antagonisme  SA  SABCS 2015  SABR  SABR for patients with early non-small cell lung cancer and interstitial lung disease  SABR for up to 5 oligometastases in patients with cancer  SABR to intrapulmonary lesions  SABR versus IRE  SABR-5 trial  SABR-COMET study  SABR-COMET trial long-term results  SABRINA-studie  SABRT  sac-TMT  sacher  sacituzumab govitecan  sacituzumab govitecan versus chemotherapy  sacituzumab govitecan-hziy  sacral chordoma  SACURA trial  SADAL study  SADAL study survival results  Safe PBM study  SAFE trial  SAFE-HEaRt study  safety and patient-reported outcomes  safety and survival impact  safety implications  safety of AA with glucocorticoids  safety of acalabrutinib monotherapy  safety of CRS HIPEC  safety of discontinuing maintenance pulse therapy beyond one year  safety of first-line nivolumab plus ipilimumab  safety of hormone replacement therapy in breast cancer survivors  safety of repeat BCS  safety outcomes  SAFFRON-103  SAFRON II  SAFRON II study  SaGa  SAKK 01 10 trial  SAKK 06 17 phase 2 trial  SAKK 08 16  SAKK 16 14 study  SAKK 17 16 trial  SAKK 35 10 trial  SAKK 75 08 trial exploratory analysis  sALCL  salivary MECs  salpingectomie  SALTO-studie  salvage chemotherapy after immunotherapy  salvage chirurgie  salvage ipilimumab plus nivolumab after prior anti-PD-1 anti-PD-L1 therapy  salvage PARPi  salvage re-irradiation  salvage reirradiation  salvage repeat breast conservation with re-irradiation  salvage resection plus cesium-131 brachytherapy  salvage surgery after first-line alectinib  salvage surgery after TKI treatment  salvage treatment  salvage treatment after BCMA-specific CAR-T  salvage treatments  SALVO trial  SAMBA 101  SAMCO-PRODIGE 54 trial  sAML  sAML versus dnAML  SANET-p study  SANO trial  sapanisertib plus ziv-aflibercept  saracatinib  SARAH-studie  SARC024 study  SARC028 trial  SARC028-studie  sarcoma  sarcoma survivors  sarcoma-associated immune infiltrate  sarcomatoid HCC  sarcoom  sarcopenia  sarcopenia measures before and after cancer diagnosis in older adults  sarcopenic obesity and outcomes of solid cancers  sarcopenic patients  SARS-CoV-2 infection  SARS-CoV-2 infection in cancer patients  SARS-CoV-2 infection in children and adolescents with cancer  SARS-COV-2 pandemic  SARS-COV2 antibody production in cancer patients  sASCT  SAVOIR study  savolitinib  savolitinib plus durvalumab  sAxl  SBA  SBM  SBRT  SBRT for spinal metastases  SBRT plus ipilimumab versus SBRT plus pembrolizumab  SBRT plus nivolumab with or without ipilimumab  SBRT plus pembrolizumab and trametinib  SBRT schedule  SBRT versus cEBRT  SBRT versus CIRT  SBRT versus CRT  SBRT with or without ADT  SC  SC versus SE  SC.23  scalp cooling  scalp cooling for prevention of alopecia  scalpmelanoom  Scandinavian HYPO-RT-PC study  SCANDIUM trial  SCARCE C17-02 PRODIGE 60  SCC  SCCA  SCCAC  SCCHN  SCCOT  SCCS  SCCUP  sCD23  schade kleine hersenvaten  schildkliercarcinoom  schildklierkanker  schildkliertumoren  schildwachtklier  schildwachtklierbiopsie  schildwachtlymfeklierbiopsie  schwannomatosis  SCIENTIFIC-studie  scIL2  SCIMITAR trial  SCLC  SCLC BMs  SCLC with CTFI ≥ 30 days and without CNS metastases  sclerotic cGVHD  SCORAD III-studie  SCORAD randomized trial  SCORAD trial  scoring system to predict prognosis  SCORPION trial  SCOT post hoc analysis  SCOT-studie  screen-detected and interval breast cancers  screen-detected breast cancer  screen-detected vs non-screen-detected  screening  screening cervixcarcinoom  screening colorectaalcarcinoom  screening contralateraal mammacarcinoom  screening CRC tumors for Lynch syndrome  screening digital mammography  screening for dental infections  screening for lung cancer  screening for multiple cancers during one visit  screening for pancreatic cancer  screening history  screening longcarcinoom  screening mammacarcinoom  screening mammography  screening mammography among women aged 70 years and older  screening ordering and completion  screening status  screening with DBT versus DM  ScreenTrustCAD trial  SCRT-TNT  SCSHN  SD with pembrolizumab  SDF1  SDOH  SDOHs and cancer mortality  SDTT  SEAFOOD Polyp Prevention Trial  SEAL  SEAL study  SEARCH cohort  sebaceous carcinoma  SECOMBIT trial  second allo-HCT versus donor lymphocyte infusion  second cancer risk after 3DCRT versus IMRT versus PBRT for primary cancer  second cancers after radical treatment  second CD19-targeted CAR T-cell infusion  second gynecological malignant neoplasms  second ipsilateral breast event; salvage mastectmy versus second BCS plus brachytherapy  second line FOLFIRI plus ramucirumab  second line options  second lumpectomy and reirradiation  second or later line anlotinib plus camrelizumab  second or later line immunotherapy for aNSCLC  second primary cancer  second primary cancers  second primary invasive melanoma  second primary NSCLC after HNC  second recurrences of retroperitoneal sarcoma  second round HPV testing  second solid cancer outcomes  second-generation antiandrogens  second-generation ARIs  second-line afatinib versus erlotinib  second-line avelumab  second-line avelumab plus gemcitabine  second-line balstilimab plus zalifrelimab  second-line bevacizumab plus FOLFIRI  second-line bevacizumab plus irinotecan with or without GKS  second-line binimetinib plus capecitabine  second-line CAM-apatinib-IRT  second-line camrelizumab-apatinib  second-line CAPTEM versus FOLFIRI  second-line carboplatin plus etoposide versus topotecan  second-line docetaxel plus ramucirumab  second-line FOLFIRI w wo bevacizumab  second-line FOLFOX  second-line Gem-Nab or Gem  second-line HX008 plus irinotecan  second-line liposomal irinotecan  second-line lurbinectedin  second-line lurbinectedin for SCLC after chemotherapy-free interval at least 180 days  second-line lurbinectedin versus topotecan  second-line nivolumab plus paclitaxel and ramucirumab  second-line options  second-line osimertinib for EGFR-mutated NSCLC  second-line PD-1 inhibitors versus chemotherapy  second-line pembrolizumab  second-line pembrolizumab-gemcitabine-vinorelbine-liposomal doxorubicin  second-line platinum doublet chemotherapy  second-line ramucirumab-avelumab-paclitaxel  second-line XELIRI versus irinotecan monotherapy  second-look surgery plus HIPEC versus surveillance  secondary analysis CONVERT study  secondary analysis of CheckMate 141  secondary analysis of SWOG-1216  secondary cytoreduction  secondary cytoreductive surgery  secondary hematological dysplasia  secondary MDS AML  secondary rectal cancer  secondary solid tumor malignancies  secondary surgical cytoreduction  secondhand smoking  secretory breast carcinoma  secundaire analyse ATAC-studie  secundaire analyse AZURE-studie  secundaire analyse BIG 1-98 studie  secundaire analyse GOG-0218 studie  secundaire analyse GOG-210 studie  secundaire analyse LUX-Lung 8-studie  Secundaire analyse NSABP B-30  Secundaire analyse REVEL-studie  secundaire analyse van CANTOS-studie  Secundaire analyse van EF-14  secundaire analyse van EORTC 22952-26001  secundaire analyse van FAPEST-studie  secundaire analyse van GeparSixto  secundaire analyse van GOG-0218 studie  secundaire analyse van RTOG 9704-studie  secundaire analyse van STO-3 studie  Secundaire analyse van SWOG S0221  sedentaire tijd  sedentary behavior  SEER analysis  SEER database analysis  SEER database analysis of survival of primary spinal chordoma  SEER registry analysis  SEER-Medicare analysis of treatments and outcomes  segmentectomie  segmentectomy versus lobectomy  segmentectomy with or without preoperative biopsy  SEHIB-studie  SEIPLUS study  seksueel functioneren  seksuele toxiciteit  SELECT trial  SELECT-1 studie  SELECT-D studie  selecteren van moleculair-geleide therapie  selectieve interne radiotherapie  selective elimination of breast surgery  seleen  SELENIB trial  selenium  Selenium and Celecoxib Trial  SELF-CERV trial  self-compression versus standard compression  SELHEM  selinexor  selinexor for R R DLBCL  selinexor maintenance  selinexor plus ibrutinib  selinexor-dexamethasone  selpercatinib  selpercatinib for RET fusion-positive NSCLC  selumetinib  seminoom  SEMS  SEMS trial  senaparib maintenance  SENIOR study  SENOMAC trial  sensitive relapsed SCLC  sensitive-relapsed SCLC  sensitization to subsequent therapy  SenSzi study  SenTa study  sentinel  sentinel lymph node biopsy  sentinel lymph node detection  sentinel node biopsy  sentinel node biopsy and radiotherapy  sentinel-node micrometastases  sepantronium bromide  sEpCAM  sepsis after transhiatal resection  sepsis surveillance  sequelae among adult survivors  sequence of RT and chemotherapie  sequencing of ADT and external-beam radiotherapy  sequencing plasma cell-free DNA  sequential antiresorptive drugs  sequential CD19 and CD22 CAR T-cell therapy  sequential CD7 CAR T-cell therapy and alloHSCT without GVHD prophylaxis  sequential FOLFIRINOX and SBRT  sequential ICI and crizotinib  sequential or concomitant schedule  sequential PD-(L)1 blockade and osimertinib  sequential PD-(L)1 inhibitors and EGFR TKIs  sequential radiotherapy and chemotherapy  sequential versus concomitant nabP and gemcitabine  SEQUOIA trial  SERENA-2  sereus ovariumcarcinoom  serial ctDNA analysis  serial ctDNA detection  serial ctDNA testing after curative resection  serial imaging  serial molecular annotation  serial postoperative ctDNA analysis  SERM  serological markers of response  serous ovarian cancer  serplulimab  Sertoli-Leydig  serum amyloid A levels  serum assessment of non-adherence  serum exosomal PD-L1  serum hormones  serum levels of soluble B and T lymphocyte attenuator  serum metabolomic signature  serum methionine-related metabolites  serum periostin levels  serum protein classifier associated with benefit from ICIs  serum proteomics  serum thiol levels  serum VEGF  serum vitamin E  serum-metaboloomprofiel  serum-microRNAs  serumlipidem  serumlipiden  SES  SES and OS among Danish patients with hematological malignancies  severe COVID-19 in vaccinated patients with hematologic cancers in the VHA  severe hepatopathy  severe neutropenia  severe sepsis during treatment for childhood leukemia  sex  sex and adverse events of adjuvant chemotherapy for colon cancer  sex as a prognostic factor in glioma  sex cord-stromal tumors  sex difference  sex differences in cancer incidence  sex differences in prognosis  sex differences in severe adverse events  sex disparities in incidence of 21 cancer types  sex disparity  sex-based heterogeneity  sex-linked differences  sex-related differences in cancer incidence  sex-specific neurocognitive impairment  sexually transmitted infections  Sézary syndrome  Sézary syndroom  SFA  SG  SG for mTNBC  SG for TNBC  SG plus pembrolizumab  SGC  SGM patients  SGNTUC-019  SGNTUC-019 mBC cohort  shape of breast cancers  shared decision making  sHB  SHCC  SHIELD-RT  SHINE trial  short regimen of rituximab plus lenalidomide  short-course neoadjuvant therapies  Short-HER study  short-term mortality after starting chemotherapy  short-term outcomes of surgery for breast cancer  short-term RT plus CT versus long-term CRT  ShortHER trial  SHR-1210  SHR-A1811  SI-NETs  SIA  side effects after 15 years  side effects of low-dose tamoxifen in healthy women  sidedness  sidedness-depedent prognosis  SIENDO study  SIERRA trial  sigaren  siglec  siglec15 expression  sigmoidoscopy screening  significance of PD-L1 status  significant hearing loss  signifor  SII  SILIUS trial  siltuximab  silver jk  simian virus 40  SIMONAL study  simple hysterectomy  simple versus radical hysterectomy  SIMPLICITY-studie  Simplified Early Relapse in MM score  simplified risk stratification model  SIMPLIFY study  SIMPLIFY-1 and SIMPLIFY-2  SIMPLIFY-1 studie  simulation of chemotherapy effects  simultaneous versus delayed resection of liver metastases  SINDAS trial  siNET  Singapore Chinese Health Study  single center longitudinal experience  single dose HDR brachytherapy  single hormone receptor-positive breast cancer  single versus multiple primary melanomas  single-agent atezolizumab for pediatric tumors  single-agent chemotherapy  single-fraction SBRT vs multifraction conventional RT  single-fraction versus hypofractionated SRS  single-fraction versus multifraction RT  single-fraction versus multifraction SABRT  sinonasaal adenocarcinoom  sinonasaal carcinoom  sinonasaal melanoom  sinonasal mucosal melanoma  sintilimab  sintilimab plus anlotinib  sintilimab plus anlotinib in second or later line  sintilimab plus bevacizumab  sintilimab plus chemotherapy  sintilimab plus HPV vaccine  sintilimab plus IBI305  sintilimab plus platinum and gemcitabine  SintraREV trial  sipuleucel –T with or without radium-223  sirolimus  sirolimus versus prednisone  SIRT for LA-HCC  SIRveNIB-studie  Sister Study  Sisters Study  site-specific therapy versus empiricial chemotherapy  sites and sequence of metastases  sitravatinib plus tislelizumab  six month efficacy and toxicity of BNT162b2 vaccine in solid cancer patients  six R-CHOP cycles versus four CHOP cycles plus six doses rituximab  six versus 12 months adjuvant capecitabine  skelet-gerelateerde gebeurtenissen  skeletal adverse events  skeletal metastases  skeletal muscle loss  skeletal muscle loss after esophagectomy  skin cancer  skin cancer incidence  skin cancer prevention  skin cancer rates by transplanted organ type  skin cancer risk  skin microbiome  skin reaction  skin toxicity  skip N2 metastasis  skipping ALND  skull base chordomas  skull base osteosarcoma  skull-base chondrosarcoma  skull-based meningioma  slaapduur  sleep and cancer recurrence and survival  sleep apnea  sleep characteristics  sleep medication use and risk of fractures  SLFN11  SLL  SLN mapping versus lymphadenectomy  SLN-biopsie  SLN-status  SLNB  SLNB after NACT for selective axillary approach in node-positive breast cancer  SLNB in stage II endometrial cancer  SLNB versus ALND  slokdarm adenocarcinoom  slokdarm squameus celcarcinoom  slokdarmadenocarcinoom  slokdarmcarcinoom  slokdarmkanker  slokdarmkanker; chemoradiotherapie  SM  SMAD4 loss  small bowel adenocarcinoma  small bowel neuroendocrine tumors  small cell carcinoma of the cervix  small cell lung cancer brain metastases  small CLM  small ground-glass-dominant lung cancer  small HR-positive HER2-positive node-negative breast cancer  small ipsilateral breast cancer recurrence after BCS  small lymphocytic lymphoma  small NF-PanNETs  small node-negative HER2-positive breast cancer  small- or medium-sized VS  small-cell lung cancer  small-sized peripheral NSCLC  SMART  Smart Start trial  SMD  smeulend multipel myeloom  SMM  SMN  SMNs  smoking  smoking behaviors and prognosis  smoking cessation  smoking history and overall survival  smoking or alcohol consumption and risk of bladder cancer  smoking status  smoking status and survival  smoldering multiple myeloma  SMT  SN biopsy versus neck lymph node dissection  SNIPP study  snoRNAs  SNP  SNPs  SNPs correlated with sunitinib benefit  SNSCC  SNTI  SNUC  SOAR-studie  SOC-1 trial  socazolimab  sociaal-economische status  Sociaaleconomische status  social and economic challenges  social characterics and endocrine therapy adherence  sociale media  socioeconomic deprivation  socioeconomic inequalities  socioeconomic status  SoFEA and EFECT trials analysis  SOFT 12-year follow-up  SOFT and TEXT combined analysis  soft tissue sarcoma  SOFT- en TEXT-studies  soft-tissue sarcoma  soft-tissue sarcoma expressing NY-ESO-1  sojaconsumptie  SOLAR study  solar UV radiation  SOLAR-1 OS analysis  SOLAR-1 overall survival results  SOLAR-1 study  SOLD randomized trial long-term follow-up  SOLD-studie  SOLE-studie  solid cancer diagnosis  solid cancers  solid organ transplant  solid organ transplant recipients  solid tumor LM  solid tumors  solid tumors and hematologic cancers  solid tumors wit KRAS G12C mutation  solid tumors with activating HER2 mutations  solid-organ transplant  solide maligniteiten  solide tumoren  solitair intrathyroïdaal papillair schildkliercarcinoom  solitary breast cancer brain metastastasis  solitary fibrous tumor  solitary pulmonary nodules  SOLO1 GOG 3004 five-year follow-up  SOLO1 study  SOLO1 trial subgroups  SOLO2 ENGOT-Ov21 final analysis  SOLO2 ENGOT-Ov21 studie  SOLO2 trial post-hoc analysis  SOLO3 final overall survival results  SOLO3 study  SOLSTICE phase 3 study  SOLSTICE study  SOLTI-1402 CORALLEEN study  soluble immune checkpoint-related proteins  somatic and germline genomic alterations  somatic mutations predicting thromboembolic risk in patients with solid tumors  somatische variatie  somatostatin analogues  somatostatine-analogen  SONABRE registry  SONIA trial  SOPHIA trial  SOR-TACE versus TACE  sorafenib  sorafenib combined with conventional treatments  sorafenib for advanced HCC  sorafenib for HCC  sorafenib maintenance  sorafenib maintenance after alloHSCT  sorafenib plus OME  sorafnib maintenance after allo-transplantion  SORAML  SORAML trial long-term follow-up  SORAYA study  SORCE trial  SORMAIN study  SORMAIN Trial  SOS study  SOS-studie  sotatercept  sotigalimab (APX005M)  sotigalimab plus nivolumab  sotorasib  SOTR  SOTRs  South Korean lung cancer screening program  SOX2  soy-based dietary supplements  SPARC  spartalizumab  SPARTAN final survival results  SPARTAN trial secondary analysis  SPARTAN-studie  spatial location of local recurrences after mastectomy  SPC  SPC risk  SPCG-4  SPEARHEAD-1 study  SPEARHEAD-1 trial  special section of Supportive Care in Cancer  specific cardiovascular diseases  specific type of ovarian cancer  SPECT versus PET-CT for detection of skeletal metastases  spectroscopie  SPECTRUM study  sperm count  sperm-associated antigen 5 expression  Spierinvasief blaascarcinoom  spinaal myxopapillair ependymoom  spinal metastases  spinal metastases from GI cancers  spinal metastases from prostate cancer  spinal metastatic disease  spinale epidurale metastase  spinale metastase  spinale SRS  spine metastases from hepatobiliary malignancy  SPIONs  SPIRAL-STEP study  SPIRIT trial  spirituality and religiosity  spirometry at diagnosis  splanchnische veneuze trombose  splenisch DLBCL  splenomegaly  splicing factor  SPM risk  SPM risk after high-dose chemotherapy and autoHSCT for lymphoma  SPM risk among cancer survivors  SPMN  SPMs  SPMs following intensive treatment for adult AML  spontane abortus  sporadic colorectal cancer  sporadic versus familial microsatellite instable metastatic colorectal cancer  SPOTLIGHT retrospective study  SPOTLIGHT trial  spouses of cancer patients  SPPORT trial  spread through air spaces  SPRING trial  SPS  sputum miRNA  sqCLC  sqNSCLC  squameus celcarcinoom  squameus celcarcinoom van de mondholte  squameus celcarcinoom van de orofarynx  squameus celcarcinoom van hoofd en hals  squameus-celcarcinoom  squamous cell carcinoma  squamous cell carcinoma bladder cancer  squamous cell carcinoma of head and neck  squamous cell carcinoma of the base of the tongue  squamous cell carcinoma of the breast  squamous cell carcinoma with HRAS mutations  squamous NSCLC  squamous NSCLC in elderly patients  SQUIRE-studie  SR-cGVHD after alloHSCT  SRA737 plus low-dose gemcitabine  SRCC  SRE  SREs  SRS  SRS for atypical meningioma  SRS for BMs  SRS for intracranial metastases  SRS versus active surveillance  SRS versus WBRT for resected brain metastasis  SRS with immune checkpoint inhibiton or targeted therapy  SRT  SRT versus ART  SS  SS MF  SS or MRCLS  SSA  SSIs  SsK12  SSTR2  St Jude Lifetime Cohort Study  St Jude Total Therapy Study 16  St. Jude Lifertime Cohort  St. Jude Lifetime Cohort  St. Jude Lifetime Cohort Study  stadium IV colorectaalcarcinoom  stadium IV-NSCLC  stage 0 to II breast cancer  stage 1 and 2 melanoma  stage 1 nonseminomatous GCTs  stage 1 NSCLC  stage 1 pT1N0 HER2+ breast cancer  stage 1 RCC  stage 1A or 1B gastric cancer  stage 1A RCC  stage 1A uterine papillary serous cancers  stage 2 colorectal cancer  stage 3 colon cancer  stage 4 high-risk neuroblastoma  stage and grade I endometrioid endometrial cancer  stage at cancer diagnosis  stage at lung cancer diagnosis  stage I breast cancer in women 65 years and over  stage I CRC  stage I ER+ HER2 breast cancer  stage I HCC  stage I II HCC  stage I lung cancer  stage I non-small cell lung cancer with spread through air spaces  stage I NSCLC  stage I NSCLC in patients aged 80 years or older  stage I NSCLC with sensitive EGFR mutations  stage I to III colorectal cancer  stage I to III CRC  stage I triple-negative breast cancer  stage I-II cutaneous melanoma  stage I-IIA cHL  stage I-III breast cancer in elderly women  stage I-III CRC  stage I-III HR-positive breast cancer in men  stage I-III HR-positive HER2-negative BC  stage I-III NSCLC  stage I-IIIA breast cancer  stage IA NSCLC  stage IA part-solid lungadenocarcinoma  stage IA PDAC  stage IB NSCLC  stage IB-IIIA EGFR-mutated NSCLC  stage IB-IIIA NSCLC  stage IE IIE natural killer T-cell lymphoma  stage II and III CRC  stage II and III cutaneous melanoma  stage II and III esophageal cancer  stage II colon cancer  stage II CRC in patients aged ≥ 75 years  stage II endometrial cancer  stage II III CRC  stage II III gastric cancer  stage II III rectal cancer  stage II melanoma  stage II or III gastric cancer  stage II or III gastric cancer in older patients  stage II or III rectal adenocarcinoma  stage II or III resectable gastric cancer  stage II or III TNBC  stage II to IVB NPC  stage II-III colorectal cancer  stage II-III CRC  stage II-III NSCLC  stage II-IIIA (N1-N2) NSCLC  stage II-IIIA EGFR-mutant NSCLC  stage II-IIIA NSCLC  stage II-IV CRC  stage IIA and B seminoma  stage IIA node-negative NSCLC > 5 cm  stage IIa-IIIB NSCLC  stage IIB C melanoma  stage IIB or IIC melanoma  stage III and IV melanoma  stage III and IV Wilms tumor  stage III CC  stage III colon cance  stage III colon cancer  stage III colon cancer in older patients  stage III CRC  stage III EGFR-mutated NSCLC  stage III epithelial ovarian cancer  stage III gastric cancer  stage III inflammatory breast cancer  stage III IV melanoma  stage III MCC  stage III melanoma  stage III NSCLC  stage III or IV HL  stage III ovarian cancer  stage III unresectable NSCLC  stage III-IV melanoma  stage III-IVB nasopharyngeal carcinoma  stage IIIA cutaneous melanoma  stage IIIA EGFR-positive NSCLC  stage IIIA non-small cell lung cancer  stage IIIA NSCLC  stage IIIA or IIIB non-small cell lung cancer  stage IIIA-N2 EGFR mutation-positive NSCLC  stage IIIA(N2) NSCLC  stage IIIB and IIIC melanoma  stage IIIB-C and IV melanoma  stage IIIB-C BRAF-V600 mutated melanoma  stage IV ALK rearranged NSCLC  stage IV BC  stage IV breast cancer  stage IV breast cancer at diagnosis  stage IV EGFR-mutated NSCLC  stage IV lung adenocarcinoma  stage IV lung cancer  stage IV male breast cancer  stage IV melanoma  stage IV NSCLC  stage IV PABC  stage IV TNBC  stage IV uterine cancer  stage of breast cancer diagnosis  stage-specific survival  staged stereotactic radiosurgery  staging  staging of melanoma  stamceltransplantatie  STAMPEDE  STAMPEDE study  STAMPEDE trial  standard therapies  standard-dose versus low-dose  standard-of care axi-cel  standard-risk B-cell ALL  standard-risk medulloblastoma  standard-risk NDMM  standardized uptake value  stappenteller  STAR trial  STARGLO trial  STARS trial  START  START-FIT phase 2 trial  STATICE trial  statin use  statin use and incidence of CRC expressing SMAD4  statin use and liver cancer risk among heart failure patients  statin use and risk of breast cancer  statin use and survival  statines  statins  statins and lethal prostate cancer  statins and response to ICB  statistieken 2012  statistische genezing  STEAM study  STELLAR study  stem cell transplantation  stemmingsaandoeningen  stereotactic ablative body radiotherapy for oligometastatic cancers  stereotactic ablative radiotherapy  stereotactic ablative radiotherapy for oligometastasis  stereotactic body radiation therapy  stereotactic body radiation therapy plus systemic therapy  stereotactic body radiotherapy  stereotactic body radiotherapy versus conventional palliative radiotherapy  stereotactic or conformal radiotherapy  stereotactic radiation  stereotactic radiosurgery  stereotactic radiosurgery before resection of brain metastases  stereotactic radiosurgery versus whole-brain radiation therapy  stereotactic reirradiation  stereotactic reirradiation and temozolomide  stereotactic RT versus WBRT for cystic or solid brain metastases  stereotactic versus external beam radiotherapy  stereotactische lichaamsradiotherapie  stereotactische radiochirurgie  stereotactische radiotherapie  sterfte aan kanker  steroid refractory GVHD in children  steroid-refractory acute graft-versus-host disease  steroid-refractory immune-related hepatitis  steroid-refractory or steroid-dependent chronic GVHD  steroid-refractory PD-(L)1 pneumonitis  steroid-refractory resistant ICI related pneumonitis  steroid-resistant acute graft-versus-host disease  STHLM3 study  STHLM3-MRI trial  STHLM3AS study  STIC CTC study  sTILs  STO-3 trial long-term follow-up  STO-5 trial  Stockholm III  Stockholm Tamoxifen Randomized Clinical Trial secondary follow-up  Stockholm tamoxifen trials  stoma  stomach and esophagus cancer  stomach cancer pooling project  stomatitis  stool butyrate  Stop & Go study  STOP IMAPED study  STOP trial  stopping imatinib  Stopping of TKIs for CML  STORM study  STORM Study part 2  straling  stratification by cytology and HPV genotype  stratification of risk of distant metastasis and death  STREAM-studie  STRESS-LUNG study cohort 1  stroke at young age  stroma-gerichte therapie  stromal tumor-infiltrating lymphocytes  stromale tumor-infiltrerende lymfocyten  strongly HR-positive and HER2-negative breast cancer  STS  STS in chemotherapy-ineligible patients  STS liver metastases  STS of extremity  STS of the extremities  STSs  Studie-uitval  Study 111 KEYNOTE-146  Study 120  Study 19  Study G200802  study using electronic health records  Sturgeon  STYLE trial  STZ 5-FU  SU2C-SARC032  subcutaan trastuzumab  subcutaneous administration of daratumumab  subcutaneous trastuzumab  subcutaneous versus intravenous daratumumab  subcutaneous versus intravenous PF-06801591  subcutaneous versus intravenous trastuzumab  subependymal giant cell astrocytoma  subgroep-analyse van METEOR-studie  subgroepanalyse ALEX-studie  subgroepanalyse GREEN study  subgroepanalyse MONALEESA-2 studie  subgroepanalyse van FIRE-3 studie  subgroepanalyses LUX-Lung studies  subgroepenanalyses CAIRO3  subgroup analyses of ASPIRE and ENDEAVOR studies  sublobar resection  subsequent cancer diagnoses  subsequent CRC risk  subsequent female breast cancer  subsequent malignant neoplasms  subsequent neoplasms  subsequent neoplasms after a primary tumor  subsequent primary lymphoma  subsequent primary neoplasms  subsequent risk of cervical cancer  subsequent risk of CSCC  subsequent risk of DM  subsequent therapies after olaparib maintenance  substance use and mental health burden in HNC survivors  substratification  substudie ALTTO  substudie van TRYPHAENA  subtotal resection  subtype  subtype-based first-line treatment  subtype-specific CBC  subtypen  subtypen HER2-positieve borstkanker  subtypes  subtypes maagcarcinoom  subtypes mammacarcinoom  SUCCESS A  SUCCESS A study  SUCCESS A trial  SUCCESS-C study  sugar-sweetened beverage intake  sugary drink consumption and risk of cancer  sugemalimab  suicidality among adult survivors of childhood cancer  suïcide  suicide attempts and suicide deaths  suicide risk and mortality among patients with cancer  suicide risk following a new cancer diagnosis in veterans receiving VHA care  sulfur microbial diet  SUMMIT basket trial  sun exposure  suncreen use  sunitinib  sunitinib dose and schedule optimization  sunitinib for RCC  SUNLIGHT trial  SUNNIFORECAST trial  SUNSHINE trial  sunvozertinib  superficial basal-cell carcinoma  superior vena cava syndrome  supplemental CEM screening in women with elevated breast cancer risk  supplemental MRI  supplemental surgery  suppressie ovariumfunctie  supraglottische-larynxcarcinoom  SUPREMO trial  surgeon-patient sex concordance  surgery  surgery and PRT  surgery for AA  surgery for cancer  surgery for cancer in older adults  surgery for CRC in geriatric patients  surgery for head and neck cancer  surgery for LAPC in The Netherlands  surgery for malignant pleural mesothelioma after radiotherapy  surgery for MPNSTs  surgery for non-palpable breast lesions  surgery for prostate cancer  surgery versus active surveillance  surgery versus chemotherapy  surgery versus radiotherapy  surgery versus SBRT  surgical and oncologic outcomes  surgical complications  surgical deescalation  surgical delay and pathological outcomes  surgical excision  surgical excision margin  surgical QMs adherence  surgical removal of tonsils and adenoids  surgical resection of bone and soft tissue sarcoma of the extremities  surgical resection versus biopsy  surgical skill and perioperative outcomes  surgical treatment  surgical utilization and outcomes  surgical-site infections  surgically treated ACC  surgically treated brain metastases  surgically treated intrahepatic cholangiocarcinoma  surival  surivors of childhood AML  SURPASSe01 study  surrogate end points  SURTIME trial  surufatinib  SurVaxM  SURVAYA study  surveillance  surveillance after resection of breast cancer  surveillance as alternative to prophylactic surgery  surveillance colonoscopy after advanced adenoma removal  surveillance endoscopy  surveillance for relapse  survival  survival adjusted for comorbidity and socioeconomic status  survival after BCT vs mastectomy in breast cancer patients with or without the BRCA1 2 variant  survival after cancer diagnosis  survival after development of contralateral breast cancer  survival after first-mammogram detected cancer  survival after laparoscopic versus open surgery for rectal cancer  survival after radical prostatectomy  survival after radiotherapy  survival after recurrence  survival after resection  survival after treatment according to ESMO recommendations  survival and cardiovascular outcomes  survival and new prognosticator  survival and prognostication  survival and QOL  survival before and after CDK4 6-inhibitors  survival benefit associated with participation in clinical trials of anticancer drugs  survival benefit of increasing number of active drugs  survival benefit with primary tumor surgery  survival by age  survival by race ethinicity  survival during the COVID-19 pandemic  survival impact  survival impact of anti-GD2 antibody response  survival impact of number of adjuvant chemotherapy cycles for GC  survival impact of obesity  survival impact of physical activity before and after diagnosis  survival impact of sex  survival impact of time to diagnosis and time to treatment  survival impact of type and sequencing of therapies  survival in breast cancer  survival in breast cancer patients  survival in male breast cancer  survival less than 90 days  survival of advanced NSCLC  survival of breast cancer  survival of childhood cancer  survival of early-onset CRC  survival of lung cancer  survival of lymphoid neoplasms  survival of multiple myeloma and AL amyloidosis  survival of ovarian cancer  survival of patients with brain metastases  survival outcomes  survival outcomes for cancer in adolescents and young adults  survival outcomes with CPM  survival past five years  survival patterns  survival trend  survival trend in The Netherlands  survival trends  survival trends in The Netherlands  survival with chemotherapy  survival with HCC screening in patients with cirrhosis after HCC cure with DAA therapies  survival with new systemic therapies  survival with nivolumab for previously treated aNSCLC  survivin dendritic cell vaccine  survivin-expressie  survivors AYA cancer  survivors childhood ALL  survivors childhood and AYA cancer  survivors of adolescent and young adult cancer  survivors of adult-onset cancers  survivors of breast cancer  survivors of breast or prostate or colorectal cancer  survivors of childhood and adolescent cancer  survivors of childhood and AYA cancer  survivors of childhood cancer  survivors of childhood Hodgkin lymphoma  survivors of childhood or adolescence CNS tumors  survivors of colorectal cancer  survivors of early-adolescent and young adult cancers  survivors of HPV-associated cancers  survivors of NB diagnosed in infancy  survivors of non-central nervous system tumors in childhood  survivors of pediatric CNS tumors  survivors of testicular cancer  SurvMark-2 study  SURVSARC study  susceptibility gene mutations  suspected mNSCLC  sustained minimal residual disease negativity  sustained weight loss  SVCS  SVT  SWAN-studie  Swedish Breast Cancer Group 91 Radiotherapy studie  Swedish children treated for acute lymphoblastic leukemia  Swedish Multicenter Cohort Study  Swedish Obese Subjects study  Swedish pediatric ALL patients  sweetened beverages  SWISH-studie  SWITCH  switch maintenance endocrine therapy  switch-maintenance  switching pembrolizumab from 200 mg Q3W to 400 mg Q6W  SWOG 0777  SWOG 1200-studie  SWOG 1318  SWOG 1406  SWOG 1500 study  SWOG 1609 cohort 48  SWOG 80405  SWOG 9313 trial  SWOG S0120  SWOG S0221 study  SWOG S0337-studie  SWOG S0518  SWOG S0622  SWOG S0800  SWOG S0905  SWOG S1105 study  SWOG S1202-studie  SWOG S1403 analysis  SWOG S1406 study  SWOG S1616  SWOG-S0016  SWORD-studie  Sym004  SYMPATICO study  symptomatic breast cancer patients  symptomatic necrosis  symptomatic osteonecrosis  symptomatic skeletal-related events  symptoms of children undergoing cancer treatment  symptoms preceding acute care in patients with cancer  SYNCHRONOUS and CCRe-IV pooled analysis  synchronous and lifetime brain metastases  synchronous bilateral breast cancer  synchronous bilateral breast cancer in young women  synchronous brain metastasis  synchronous metastatic colorectal cancer  synchronous neoplasia  synchronous oligometastatic NSCLC  synchronous or metachronous metastases  synchronous stage IV anal canal squamous cell carcinoma  synoviaal sarcoom  synovial sarcoma  synovial sarcoma in children and AYAs  synoviosarcoom  systematic review  systemic anticoagulation  systemic chemotherapy  systemic light chain amyloidosis  systemic mastocytosis  systemic therapy  systemic therapy after resection  systemic therapy with or without local treatment  systemic treatment  systemic treatment options  systemic treatment versus PTR followed by systemic treatment  systemische lupus erythematosus  systemische mastocytose  SystHER study  T cell malignancies after CAR T cell therapy  T Cell Project  T-ALL  T-ALL and T-LL  t-APL  T-cadherin  T-cel acute lymfoblastische leukemie  T-cel lymfoom  T-cell acute lymphoblastic leukemia or lymphoma  T-cell ALL  T-cell expression profiles  T-cell lymphoblastic lymphoma  T-cell lymphomas  T-cell-replete haploidentical transplantation for ALL  T-cellymfoom  T-DM1  T-DM1 for HER2-positive MBC with brain metastases  T-DM1 plus neratinib  T-DM1 versus TH  T-Duo  T-DXd  T-DXd for mBC with active brain metastases  T-DXd versus chemotherapy  T-DXd versus T-DM1  t-MNs after aPBSCT for HL NHL  T-SAR trial  T-SCLC  T-VEC  T-VEC for melanoma  T-VEC plus imiquimod  T-VEC plus pembrolizumab  T1 bladder cancer  T1-T2 OPSCC  T1-T2 OSCC  T1-T2 RCC  T1a melanoma at critical structures  T1a-bN0M0 NSCLC  T1D  T1N0M0 TNBC  T2212 study  T2D  T2D risk  T2DM  T3 and T4 colon cancer  T790M-positive NSCLC after failure of first-line EGFR-TKI  T790M-positive NSCLC refractory to osimertinib  TAA-Ts  TABAsCO trial  TABEA  TAC  TACE  TACE followed by pembrolizumab  TACE plus RFA as initial treatment  TACE plus sunitinib versus sunitinib alone  TACT study  TACTOPS study  TAD after NST  tafasitamab plus lenalidomide  tagraxofusp  TAGS study  TAILOR trial  tailored immunotherapy approach  TAILORx analysis  TAILORx secondary analysis  TAILORx study  TAILORx-studie  Taiwanese breast cancer patients  TALAPRO-1 study  TALAPRO-2 trial  TaLaR trial  talazoparib  talazoparib plus avelumab  talazoparib plus enzalutamide  TALENT trial  taletrectinib  talk-pleurodesie  tall cell papillary thyroid cancer  talquetamab  TAM-01 trial 10-year follow-up  tamilogene laherparepvec  tAML  tamoxifen  tamoxifen for premenopausal breast cancer  tandem autologous stem cell transplant  tandem CD19 CD20 CAR T cell therapy  TAPS  TAPUR phase 2 basket trial  TAPUR study  TAPUR trial  TARDOX study  TARE combined with second-line chemotherapy  TARGET-TP trial  targeted agents  targeted alpha therapy  targeted BRAF inhibion  targeted exome next-generation sequencing  targeted immunotherapy for pediatric high-risk neuroblastoma  targeted intraoperative molecular imaging  targeted intraoperative radiotherapy  targeted therapies  targeted therapy  targeted therapy and survival in clinical practice  targeted therapy for advanced melanoma  targeted versus nontargeted therapy  targeting long-term non-attenders  TARGIT-A trial  tarlatamab  TAS-102  TAS-102 Gastric Study subgroup analysis  TAS-102 plus ramucirumab  TAS-114  taselisib  taste function  TASUKI-52 study  TASUKI-52 trial 3-year follow-up  TATTON study  tattoos  TAUTEM study  Taxaan resistentie  taxane chemotherapy  taxane with versus without anthracycline  taxane-based chemotherapy  taxane-based chemotherapy for breast cancer  taxane-induced nail changes and peripheral neuropathy  taxane-induced neuropathy  taxane-related patient-reported outcomes  taxanes  taxanes maintenance  TAXIS study  TAXYNERGY-studie  TAZ  tazemetostat  TBCRC 002 study  TBCRC 022 study  TBCRC 043 trial  TBCRC023 study  TBCRC026 study  TBCRC026 trial  TBCRC041  TBD genotypes  TBI after blood or marrow transplantation  TBI versus chemotherapy conditioning  TBI- versus CT-based myeloablative condition; impact on outcomes of transplantation for AML  TBISI  TC  TCF3-HLF positief ALL  TCH  TCIs for atopic dermatitis  TCP plus ATRA  TCR gene rearrangement  TD-FOREKNOW trial  TDs  TDT  TE or GEJ cancer  tea intake  TEAL study  TEAM IIB  TEAM-studie  TEAMM study  tebentafusp  tebotelimab  TEC  TECHNO and PREPARE trials  technology-enabled monitoring of toxic effects linked to ICIs for GU cancers  teclistamab  Teenage and Young Adult Cancer Survivor Study  TEKT4 germline variations  telaglenastat plus azacytidine  telaglenastat plus everolimus  tele-oncologie  telemedicine  telephone counseling  televisiekijken  teliso-V  telisotuzumab vedotin  telisotuzumab vedotin plus erlotinib  TELMA trial  telomeerlengte  telomeerziekten  telomerase-activiteit  telomerase-positive CTCs  temozolomide  temozolomide-based CRT  temporal changes  temporal changes in cause-specific death  temporal changes in incidence of relapse and outcome after relapse  temporal changes in survival  temporal glioblastoma surgery  temporal muscle thickness  temporal trend  temporal trends  temporal trends in active surveillance and watchful waiting  temporal trends in ALL outcomes in the USA  temporal trends in overall survival from 2000-2020  temporal trends in survival  temporal trends in testing and treatment  temporary cessation versus continuation of first-line TKI  temsirolimus  ten-year distant-recurrence risk  ten-year follow-up of FAST  ten-year incidence of mood disorder  ten-year outcomes  ten-year results  ten-year update  ten-year update of CALGB 49907  tenofovir  tenofovir versus entecavir after resection  tenosynovial giant cell tumor  tenosynovial giant-cell tumor  tepotinib  teratoma  TERAVOLT registry  terbinafine  teriparatide  TERRA-studie  TERT-mutatie  tertiary lymphoid structures  tesetaxel plus reduced dose of capecitabine  testicular cancer  testicular cancer in children and young adults  testicular cancer in the cisplatin era  testicular germ cell tumors  testikelkanker  testing for EGFR variants in pleural and pericardial effusion cfDNA  testing of PVs in BC susceptibility genes  testiscarcinoom  testosterone therapy  TETs  textbook outcomes of curative-intent resection  textbook surgical outcomes  TFAP2C  TFHL  tFL  TFS with first-line ICI therapies  TG01 vaccine  TG4010  TGCT  TGCTs  TGF-βRII  TGM95 study  TH-302  TH3RESA  thalidomide  The Multiethnic Cohort  thee  TheraP  TheraP study  therapeutic options  therapeutic value of SLNB  therapeutische vaccins  therapietrouw orale hormonale behandelingen  therapy-related AML  therapy-related cardiac risk  therapy-related myeloid neoplasms  thermal ablation  thermal ablation versus nephrectomy  thermal ablation versus surgical resection  thermale ablatie  thick melanoma  thin cutaneous melanoma  Thinking and Living With Cancer Study  thiopurine  thiotepa-busulfan-fludarabine conditioning  third or later line apatinib plus vinorelbine  third-line irinotecan plus cetuximab rechallenge  third-party BKV-HC  THOR Cohort 1 trial  thoracic radiotherapy  thorax-radiotherapie  three versus six months of adjuvant CAPOX or FOLFOX  three versus six months oxaliplatin-based adjuvant chemotherapy  three-year follow-up  three-year follow-up of TRAIN-2 trial  thrombocytosis and cancer risk  thromboembolism  thromboprofylaxis  thrombosis  thrombotic events  THRα2  thymic carcinoma  thymogolublin  thymoom  thymus removal in adults  thymuscarcinoom  thyorid cancer surgery  thyroid cancer  thyroid cancer detection in childhood cancer and BMT survivors  thyroid cancer risk  thyroid immune related adverse events  thyroid nodules  thyroid radiation dose and thyroid dysfunction  Tian  TIC  TIL therapy  TIL therapy versus ipilimumab  TIL versus ipilimumab  TILs  time between positive gFOBT and colonoscopy  time for CRC surgery and start of adjuvant chemotherapy  time from diagnosis to treatment  time from neoadjuvant chemotherapy to surgery  time interval between NAT and resection  time interval to biochemical failure  time of day of RT and durvalumab  time series analysis  time to death  time to first distant recurrence  time to first treatment  time to metastasis  time to surgery  time to systemic treatment  time to treatment failure  time trends  time trends and predictors of survival  time trends in survival  time trends of invasive recurrence  time without symptoms or toxicity  time-to-surgery  TIMELY trial  timing of adjuvant chemotherapy  timing of adjuvant hormone therapy  timing of adjuvant radiotherapy  timing of adjuvant therapy  timing of aspirin use  timing of corticosteroid initiation  timing of HPV16-E6 antibody seroconversion  timing of initiation of adjuvant chemotherapy  timing of local therapy  timing of MRD-negativity  timing of onset of irAEs  timing of palliative care  timing of postoperative radiotherapy  timing of postoperative SRS  timing of presentation and outcomes  timing of stereotactic radiosurgery and immunotherapy  timing of surgery  timing of surgery after neoadjuvant chemotherapy  timing of trastuzumab  tinzaparine  TIP  tipifarnib  TIPN  tirabrutinib  tiragolumab  tiragolumab plus atezolizumab  tiragolumab with or without atezolizumab  tirbanibulin ointment  tirlateraal retinoblastoom  tisa-cel  tisagenlecleucel  tislelizumab  tislelizumab plus chemotherapy  tislelizumab plus zanubrutinib  tisotumab vedotin  TITAN and SPARTAN studies  TITAN study  TITAN-RCC trial  TITAN-studie  TITAN-TCC study  TITAN-TCC trial  TIVO-3 study  tivozanib  TJMUCH-GI-001 trial  TKI  TKI discontinuation  TKI dose reduction without loss of MMR  TKI-refractory LUAD  TKIs  TKIs for cancer  TKIs for EGFR-mutant aNSCLC  TKIs for NSCLC  TKIs with versus without metformin  TL  TLP trial  TLSs  TMB  TMB and outcomes  TMB and response to CPI  TMC  tMDS  TMNs  TMW  TMZ  TMZ plus RT versus RT alone  TMZ with or without capecitabine  TN or HER2-positive ILC  TN-ILC  tnAcity-studie  TNBC  TNBC in older women  TNBC in postmenopausal women  TNBC risk genes  TNBC with residual disease after neoadjuvant chemotherapy  TNFi  TNFα-remmers  TNT  TNT-studie  TOAD-studie  TOCILAM study  tociluzimab  ToDA  tolerability  tolerability and efficacy of palbociclib  tomaten  tomosynthese  tomosynthesi  tomotherapy  tongbasiscarcinomen  tonsil SCC  tonsilcarcinoom  tonsillaire  tonsillar cancer  TOPARP-B trial  TOPAZ-1 phase 3 trial  TOPAZ-1 trial  TOPCS  topical calcitriol  topical diclofenac  topical histone deacytelase inhibition  topical hypericin photodynamic therapy  topical imiquimod versus surgery  topical pimecrolimus  topical remetinostat gel  topical submicron particle paclitaxel  topical TCA for CIN  topisch fluorouracil  topotecan with or without berzosertib  TORCH  TORCH trial  TORCHLIGHT trial  TORG160 trial  toripalimab  toripalimab plus axitinib  toripalimab plus chemoradiotherapy  toripalimab plus definitive CRT  toripalimab plus HBM4003  toripalimab plus IMRT  toripalimab plus nab-paclitaxel  TORS  TOSCA trial subgroup analysis  totaal lichaamsbestraling  totaal-vet  total neoadjuvant therapy  total neoadjuvant therapy vs standard therapy  total nodal basin  total versus cortical-sparing adenalectomy  totale lichaamsbestraling  totale mesorectale excisie  totale mortaliteit  totale overleving  TOTEM study  TOURMALINE-MM3 study  TOURMALINE-MM4 trial  tovorafenib  toxic effects and survival  toxiciteiten van oncologische behandelingen  toxicities  toxicities of immune checkpoint inhibition  toxicity  toxicity of chemotherapy  toxicity of PBT versus IMRT  toxicity profiles of systemic therapies  toxicity-related chemotherapy modifcation  Toxoplasma gondii infection  TP53  TP53 and KEAP1 mutations  TP53 co-mutation  TP53 genomic abnormalities  TP53 GOF and non-GOF mutations  TP53 mutation status  TP53- and RAS-mutant metastatic colorectal cancer  TP53-mutant AML MDS  TP53-mutant MDS  TP53-mutated acute myeloid leukemia  TP53-mutated AML  TP53-mutated MDS and AML  TP53-mutaties  TP53-veranderingen  TP53wt EC  TPK cohort  TPP  TQB2450  traankliertumoren  trabectedin  trabectedin plus doxorubicin  trabectedin plus radiotherapy  trabectedine plus durvalumab for pretreated advanced STS and OC  TRACERx  TRACERx study  traditional Chinese medicine plus chemotherapy  TRAEs  trajectories of alcohol consumption during life  trametinib  trametinib plus neoadjuvant chemoradiation  trametinib with or without dabrafenib  TRAMUNE study  tranexamic acid  tranplantation-ineligible MCL patients  transanal versus laparoscopic total mesorectal excision  transarterial chemoembolization  transarterial hepatic chemoembolization  transarterial radioembolization  transarteriële chemo-embolisatie  TRANSCEND CLL 004 trial  TRANSCEND NHL 001 study  transcriptomic signature predicts adjuvant gemcitabine sensitivity  transcriptomic signatures  transdermaal fentanyl  transdermal estradiol  transdermale toediening  TRANSFORM trial  transformation  transformation to SCLC  TRANSFORMER study  transfusion dependent lower-risk myelodysplastic syndromes  transgender people  transgenders  TRANSLATE trial  TransMet trial  TransMYME trial  transoral robotic surgery  transoral surgery and low-dose IMRT  transorale robotische chirurgie  transplant-associated immunosuppression  transplant-eligible MCL  transplant-eligible MCL patients  transplant-free approach  transplant-ineligible multiple myeloma  transplant-ineligible R R DLBCL  transplantation for myeloid malignancies  transplantation for older leukemia patients  transplantation from unrelated donors  transplantation-eligible NDMM  transverse colon cancer  TRAP study  TRASTS study  trastuzumab  trastuzumab deruxtecan  trastuzumab deruxtecan versus physician’s choice  trastuzumab deruxtecan versus trastuzumab emtansine  trastuzumab duocarmazine  trastuzumab emtansine  trastuzumab emtansine with or without atezolizumab  trastuzumab for breast cancer  trastuzumab plus FOLFOX  trastuzumab plus gemcitabine and cisplatin  trastuzumab plus paclitaxel  trastuzumab rezetecan  trastuzumab-pertuzumab-docetaxel  trastuzumab-related cardiotoxicity  trastuzumab-resistant HER2-positive ABC  trastuzumab-resistant HER2-positive breast cancer  TRBC1-directed CAR T cell therapy  TRC102 plus TMZ  treatment  treatment adherence and outcomes  treatment and outcome in Germany  treatment and outcomes  treatment at specialized cancer centers  treatment benefit  treatment beyond progression  treatment characteristics and outcomes  Treatment Efficacy Score  treatment facility characteristics and OS  treatment failure  treatment in Europe  treatment interruption  treatment modalities for breast cancer  treatment of anal HSILs to prevent anal cancer  treatment outcomes and clinical characteritics  treatment patterns  treatment patterns and outcomes  treatment patterns and survival  treatment recommendations  treatment response  treatment selection  treatment-emergent small-cell neuroendocrine prostate cancer  treatment-free remission  treatment-free remission after nilotinib for chronic phase CML  treatment-free survival  treatment-naïve metastatic uveal melanoma  treatment-related adverse events  treatment-related cardiotoxicity  treatment-related incidence of diseases of the circulatory system  treatment-related side effects  treatment-related thoracic STS  treatment-related toxicity  treatments  treatments after progression on osimertinib  treatments after T-DXd  treatments and outcomes after progression on crizotinib  treatments for advanced NSCLC  treatments for cancer of abdomen or pelvis  treatments for MaBC  trebananib  TREM study  tremelimumab  tremelimumab after platinum  tremelimumab and durvalumab  tremelimumab plus durvalumab  trend in outcomes 1998-2009  trend of toxicity and response in phase 1 trials for solid tumors over time  TREnd-studie  trends  trends 2005-2015  trends 2008-2014  trends and projections  trends and projections of incidence in The Netherlands  trends and variations in treatment in The Netherlands  trends from 1935 to 2015  trends in cancer incidence and mortality in the UK  trends in cancer incidence by socioeconomic deprivation  trends in cardiac events  trends in epidemiology in the US  trends in grade 5 toxicity and response  trends in incdence and outcomes  trends in incidence  trends in incidence among US adults  trends in incidence and survival  trends in incidence in the US  trends in late mortality  trends in late mortality and life expectancy  trends in morbidity and mortality in survivors of childhood ALL  trends in omission of ALND  trends in OS since 2011  trends in outcomes from 2000 to 2019  trends in primary treatment and survival  trends in second primary cancers in survivors of metastatic melanoma  trends in subtype-specific mortality  trends in survival rates in South Korea  trends in use and perceptions in The Netherlands  trends in use of metastasectomy  trends of cancer in children and adolescents  trends over five decades in Sweden  treosulfan-fludarabine conditioning  trial effect  TRIANGLE trial  TRIAS study  TRIBE  TRIBE and TRIBE2 pooled analysis  TRIBE2 study  TRICIN trial  TRICOLORE-studie  TRICOTEL study  TRIDENT-1  trifluridine tipiracil plus bevacizumab  trifluridine tipiracil with or without bevacizumab  trifluridine-tipiracil  trifluridine-tipiracil with or without bevacizumab  trilaciclib  trimodal therapy  trimodality therapy for MIBC  trimodality therapy for stage 2-3 rectal cancer  TRINITI-1 study  TRINOVA-1  triple negatieve borstkanker  triple negative and luminal breast cancer  triple negative borstkanker  triple negative breast cancer  triple negative mammacarcinoom  triple-class exposed patients with relapse or refractory multiple myeloma  triple-class refractory multiple myeloma  triple-negatief mammacarcinoom  triple-negative borstkanker  triple-negative breast cancer  triple-negative breast cancer. TNBC-DX genomic test  triple-negative mammacarcinoom  TripletBev  Triplex vaccine  triptorelin  TRITON3 trial  TRK fusion sarcomas  TRK fusion-positive lung cancer  TRK fusion-positive primary CNS tumors  TRK fusion-positive solid tumors  TRK inhibitor therapy  TROG 03.01-studie  TROG 99.03 study  TROIKA study  trombo-embolie  trombocyt lymfocyt ratio  TROPHIMMUN trial  TROPHY-U-01  TROPHY-U-01 Cohort 2  TROPHY-U-01 cohort 3  TROPHY-U-01 study  TROPiCS-02 OS analysis  TROPiCS-03 advanced endometrial cancer cohort  TROPION-Breast01 trial  TROPION-Lung01 study  TROPION-Lung05 study  TROPION-PanTumor01  TROPION-PanTumor01 Study  TRT  TRU-D trial  TRUST-I  TRUST-I study  TRUST-II  tryptophan-kynurenine pathway metabolites  TSC  TSCC  Tsjernobyl  TSP-1  TSR  TSR predicts survival  TT  TTAC  TTC  TTC after T-DXd  TTD of QOL or PF as a surrogate of OS  TTF  TTFields  TTI-003 for advanced solid tumors  TTI-621  TTP  tubaligatie  Tubo-ovarian high-grade serous carcinoma  tubulysines  tucatinib  tucatinib plus trastuzumab  tucidinostat  TULIP trial  tumor budding  tumor burden  tumor cell heterogeneity  tumor characteristics  tumor deposits in non-metastatic CRC  tumor expression of HGF and CXCL12  tumor genomic profiling in rare cancers  tumor hypoxia in FMISO PET  tumor inflitraing lymphocytes therapy  tumor mutation burden  tumor mutational burden  tumor mutational burdne  tumor necrosis  tumor organoids  tumor PD-L1 expression  tumor phenotype and concordance  tumor regrowth between surgery and radiotherapy  tumor response dynamics during first-line pembrolizumab therapy  tumor spread through air spaces  tumor stroma-immune interactions  tumor subtypes and survival  tumor suppressor  tumor treating fields therapy  tumor-DNA  tumor-geassocieerde neutrofielen  tumor-immuuntolerantie  tumor-infiltrating lymphocytes  tumor-only genomic profiling  tumor-stroma ratio  tumor-to-breast volume ratio  TUMORAPA study  tumorgraad  tumorgrootte  tumorinfiltrerende lymfocyten  tumoronderdrukkers  tumorpredispositiesyndroom  tumorsubtypen  TUXEDO-1 trial  TV  tv kijken  TV versus TLD  TVU  tweede kanker  tweede maligne neoplasmen  tweede maligniteit  tweede mammacarcinoom  tweede primaire maligniteit  tweejaaars-overleving  tweevoudige HER2-blokkade  twelve-year trend of textbook outcomes  twice versus once daily radiotherapy for SCLC  twice-daily thoracic radiotherapy  two cycles carboplatin-olaparib followed by olaparib monotherapy  two weeks on  two-step versus three-step approach of the WHO analgesic ladder in cancer patients  TXA  type 1-diabetes  type 2 diabetes  type 2 diabetes and glycemic control  type and timing of menopausal hormone therapy  type of ADT  type of breast cancer surgery  type of first-line therapy  tyrosine kinase inhibitors  tyrosinekinaseremmers  tyrosyl-DNA fosfodiësterase 1  U M HCC  U.S. papillary thyroid cancer incidence trends  UADT-carcinomen  UATD-kanker  UBC  UC  UC-CRC  UCB  UCC  UDCA for gallstone prevention after gastectomy for gastric cancer  UDON  UGN-101  UGT1A! genotype dependent dosed gFOLFIRINOX  UGT1A1 genotype  uHCC  UIP-ADC  UK ANZ DCIS randomized trial analysis  UK Biobank  UK Flexible Sigmoidoscopy Screening Trial  UK IMPORT LOW studie  UK Million Women Study  UK MRC OE05-studie  UK RAPID trial  UK Sloane Project  UK TRACC Part B  UKALL14 trial  ulocuplumab  ultra-deep genomic testing  ultra-fast CNS tumor classification during surgery  ultra-processed food consumption  ultra-processed foods  ULTRAPANC study  ultraprocessed food  ultrasonografie  ultrasonography  ultrasonography findings  ultrasound  ultrasound versus palpation  UM liver metastases  umbralisib  umbrella protocol  umbrella review of meta-analyses  UMRD  uncommon histology advanced non-small cell lung cancer  underestimation of invasive breast cancer  undetectable MRD as treatment endpoint in high-risk MM  undifferentiated pleomorphic sarcoma  undifferentiated pruritus  unesbulin plus dacarbazine  unexpected uterine cancer  unexpected weight loss in primary care  unfavorable-risk prostate cancer  UNICANCER HypoG-01  UNICANCER-PRODIGE 23  UNICANCER-PRODIGE 23 trial  UNICIT trial  UNICORN trial  unilateral retinoblastoma  unilateral RT  unilateral TNBC  uniportal VATS in The Netherlands  United Kingdom Women’s Cohort Study  UNITY-NHL study  UNITY-NHL trial  universal genetic testing versus guideline-based testing  universal germline genetic testing  universal screening for hereditary colorectal cancer  UNIVERSAL trial  unknown primary lesions  unmet needs  unnecerssary adjuvant chemotherapy in breast cancer  unplanned 30-day readmission  unplanned reoperation  unrelated donor hematopoietic cell transplant  unrelated donor hematopoïetische celtransplantatie  unresectable advanced RCC  unresectable advanced STS  unresectable CLM  unresectable colorectal liver metastases  unresectable CSCC  unresectable early stage HCC  unresectable esophageal squamous cell carcinoma in older adults  unresectable gastric or gastroesophageal junction cancer  unresectable HCC  unresectable hepatocellular carcinoma  unresectable intrahepatic cholangiocarcinoma  unresectable locally advanced ESCC  unresectable malignant pleural mesothelioma  unresectable metastatic colorectal cancer  unresectable NRAS-mutated cutaneous melanoma  unresectable or metastatic BTC  unresectable or metastatic hepatocellular carcinoma  unresectable or metastatic HER2-positive breast cancer  unresectable or recurrent craniopharyngioma  unresectable pleural mesothelioma  unresectable refractory melanoma  unresectable stage 3 NSCLC  unresectable stage III non-small cell lung cancer  unresectable stage III NSCLC  unresectable stage IIIA B NSCLC  unresectable stage IIIC or IV melanoma  unresectable TC  unselected TNBC  untreated advanced melanoma  untreated AML in patients unfit for intensive chemotherapy  untreated Burkitt lymphoma  untreated CIN2  untreated CLL SLL  untreated early unfavorable and advanced stage classical Hodgkin lymphoma  untreated mCRC in intensive therapy-ineligible patients  untreated multiple myeloma  untreated stage IIIB IV NSCLC  uPAR  update MONALEESA-2  Update WECARE-studie  updated analysis KEYNOTE-024  updated GPA  updated results  updated survival outcomes  upfront bortezomib  upfront doxorubicin-dcarbazine-nivolumab  upfront radiosurgery versus wait-and-scan  upper gastrointestinal cancer mortality  upper tract urothelial cancer  upper tract urothelial carcinoma  upper-tract urothelial carcinoma  uprosertib  uptake of and survival with ICIs  uptake of FIT-screening  urbanisatiegraad  uribiome-based metagenomic signature  urinaire bijwerkingen  urinary biomarkers  urinary cytokine profile to predict response  urinary PENK methylation test for BC diagnosis  urinary protein signature  urinary tract infections  urine DNA hypermethylation signatures  urine tumor DNA  urinetest  urineweginfectie  UROCCR Study 82  urotheelcarcinoom  urotheelcarcinoom van de blaas  urotheliaal blaascarcinoom  urotheliaal carcinoom  urothelial bladder carcinoma  urothelial cancer diagnosis  urothelial carcinoma  urothelial carcinoma of the upper urinary tract  URS  US cancer patients  US cancer population  US CRC mortality trends  US Medicare population aged 65 years and older  US men and women aged 15-39 years  US patients with metastatic cancer  US prostate cancer incidence after UPSTF recomeendations against screening  US skin cancer survivors  US survivors of adolescent and you adult cancer  US trends 1996-2019  USC  use of adjuvant capecitabine  use of BRCA-testing  use of cancer-directed therapy  use of cannabis  use of fertility drugs  use of new prostate cancer risk stratification technologies  use of oral complementary and alternative medication  use of social media for recuitment of patients for cancer trials  USPSTF recommendation  uterine brachytherapy  uterine cancer  uterine cancer with distant organ metastasis  uterine corpus cancer incidence and survival trends  uterine leiomyosarcoma  uterine sarcoma  uterine-confined and node-negative cervical cancer  uteruscarcinoom  utidelone plus capecitabine  utilization and outcomes  utomilumab plus rituximab  UTUC  UV radiation exposure  UVEA-Brig study  uveaal melanoom  uveaalmelanoom  uveal melanoma  uveal melanoma and metastases  uveal melanoma with liver metastasis  V-REX trial  V600E V600K BRAF-mutant melanoma  V600E-BRAF mutated metastatic colorectal cancer  VA Health Care System  VA patients with cancer  vaccin  vaccin mammacarcinoom  vaccinatie  vaginal brachytherapy plus chemotherapy  vaginal laser treatment  VAIN  Val600 BRAF-mutant melanoom  VALDAC trial  valemetostat  VALENTINE-PTCL01  valganciclovir  validation  validation of RTOG-0129 identified risk groups  validation study  validity as surrogate trial end point for OS  VALOR-studie  valproaat  valproate and retinoic acid in combination with decitabine  vals positieve uitslag  value of 21-gene RS  value of eHealth interventions  value of OR as predictor of OS  value of pCR as surrogate end point  value of screening lower endoscopy in adults older than 75 years  value of systemic chemotherapy  Van Nuys Prognostic Index  VANCE trial  VANDA-blinatumomab  vandetanib  variables associated with benefit  variant allele frequency in circulating tumor DNA  variant histology  VARIANZ study  variation in surgery for DTC  varicella zoster virus vaccine  various BRCA mutation types  various first-line chemotherapies  various treatments for localized prostate cancer  various types of advanced solid tumors  varying test positivity thresholds  Vasaloppet  vascular aging  vasectomie  vasectomy  vasomotor symptoms  VATS L-MLND  VATS versus open resection  VCE  VE-BASKET study  vebreltinib  vedolizumab compared with infliximab  veeleisende patiënten  vegetarische voeding  VEGF  VEGF-behandeling  VEGFR-remmer  VEGFR-TKI  VEGFR-TKIs  VEGFRI-induced hypertension  VELIA GOG-3005 study  veliparib  veliparib plus CRT  veliparib with carboplatin and paclitaxel  VELO trial  VELVET  VELVET cohort 2  vemurafenib  vemurafenib and cometinib for BRAF-mutant melanoma  vemurafenib plus everolimus  vemurafenib plus rituximab  vemurafenib priming before T-cell therapy  Ven-Obi versus Clb-Obi for previously untreated CLL  venetoclax  venetoclax plus azacitidine  venetoclax plus cytarabine with or without idarubicin  venetoclax plus FLAG-IDA  venetoclax plus gilteritinib  venetoclax plus intensive chemotherapy  venetoclax plus intensive induction chemotherapy  venetoclax plus LDAC  venetoclax plus low dose cytarabin  venetoclax plus low-dose cytarabine  venetoclax plus rituximab  venetoclax plus rituximab continuous or limited-duration therapy  venetoclax-azacitidine-homoharringtonine  venetoclax-BR  venetoclax-daratumumab-dexamethasone with or without bortezomib  venetoxlax plus ibrutinib  veneuze trombo-embolie  VENICE-1  venous and arterial thrombosis  venous thromboembolism  ventrico-peritoneal shunt related ascites  verbal memory  verf  verhoogd bloedglucose  VeriStrat test  vermoeidheid  verpleegkundigen  vertebral fractures  verteerbaar koolhydraat  vertrouwen  very early recurrence after liver resection  very high-risk prostate cancer  verzadigd vet  vessel co-option  vestibular dysfunction and survival  vestibular schwannoma  vestibular schwannomas  Veterans Affairs System  vetinname  vetrijke voeding  vetzuren  VGX-3100  VHL disease-associated pancreatic lesions  VHL disease-associated renal cell carcinoma  VIALE-A study  VIALE-A trial  VICTOR-6 study  VICTORI study  VICTORIA trial  VidazaAllo Study  video-assisted thoracoscopic surgery  Vigil maintenance  Vigil vaccine maintenance  vimseltinib  VIN  vincristine  vincristine-irinotecan with or without temozolomide  vinorelbine  VIOLA study  VIOLET trial  virotherapy  virtual prostatectomy  virtual reality for symptom control and well-being in oncology  virtual reality videos  viscerale adipositas  visconsumptie  VISION study  VISION trial  vismodegib plus RT  vistusertib plus anastrozole  visual outcome  VITAL study  VITAL-studie  vitamin A  vitamin and garlic supplementation  vitamin C intake  vitamin D  vitamin D binding protein  vitamin D deficiency  vitamin D intake  vitamin D level  vitamin D levels  vitamin D supplement use  vitamin D supplementation  vitamin D to attenuate bone loss  vitamin D3  vitamin D3 supplements and advanced cancer  vitamin E  vitamin K antagonists  vitamin supplements  vitamine B3  vitamine B6  vitamine D  vitamine D-spiegel  vitamine-inname  vitamins  vitiligo  Vivio  VIVROVAIRE I study  VLADI-studie  Vlagtwegge-Vlaardingen cohort  VLD  vlees  vleesconsumptie  vliegend personeel  VLL  vluchtige organische verbindingen  VMS  VOCs  vodobatinib  voeding  voeding tijdens zwangerschap  voedingsgewoonten  voedingskwaliteit  voedingssupplementen  voedingsvezel  voice abnormalities  volasertib  volatile organic compounds  VOLFI study  VOLFI-studie  Volume Pledge criteria  volume-based CT screening  von gunten  von hippel-lindau  Von Hippel-Lindau syndrome-associated CNS hemangioblastoma  Von Willebrand Disease  von-Hippel Lindau disease  voorspelling recidief  voorspelling ziektevrije overleving  vorasidenib  vorasidenib or ivosidenib  voriconazole in lung transplant recipients  vosaroxine  VR consolidation  VRD as induction prior to autoSCT  vroeg mammacarcinoom  vroege detectie  vroege detectie MBC  vroege menopauze  vroege resultaten COMPASS-studie  VS  VS in patients aged 70 years or older  VSCC  VTD versus TD  VTE  VTE events in last year of life of cancer patients  VTE risk  VTE risk despite thromboprofylaxis  VTEs  VTP  vulvacarcinoom  vulvaire intra-epitheliale neoplasie  vulvaire intraepitheliale neoplasie  vulvaire lichen sclerosus  vulvar cancer with SN metastases  vulvar cancers cohort  vulvar high-grade intraepithelial lesions  vulvar squamous cell carcinoma  vulvovaginal atrophy in breast cancer patients  Vvax001  VWF  W&W  wachttijd  Waldenström macroglobulinemia  Waldenstrom's macroglobulinemie  Waldenström’s macroglobulinemie  warfarine  WARMTH Act study  warren  watch and wait  watch-and-wait  watchful waiting  WBI  WBM  WBRT  WBRT with hippocampal avoidance  WBRT with or without Rh-endostatin  WBV  WD DDLS  WDTC  wearable device-based intervention  web-based symptom monitoring vs routine surveillance  WECARE-studie  weefseltype-agnostische gerichte therapie  weekend effect  weekly carboplatin and paclitaxel  weekly cisplatin  weekly dose-dense chemotherapy  weekly KMP  weekly paclitaxel  weekly paclitaxel with or without alisertib  weight change  weight cycling  weight loss  weight stability can mask sarcopenia or myosteatosis  weight tracking as prognostic marker after pancreatectomy  weight trajectories  wekedelensarcoom  wekedelensarcoom. STS  well-being of cancer survivors  werkloosheid  werkzaamheid placebo  Werkzaamheid van tweede- of laterelijns immuuncheckpointremmer voor sarcomatoïd carcinoom van de long  WES  Western dietary pattern  wetenschappelijk wangedrag  WGS as an alternative to cytogenetic analysis  WHI  WHI randomized clinical trials  WHI randomized trial long-term follow up  WHI-CaD studie  WHI-DM  WHO grade 2-3 meningioma  WHO grade II-III meningioma  whole brain radiation  whole brain radiotherapy  whole genome sequencing  whole grains  whole-body MRI  whole-brain radiation therapy  whole-genome sequencing  WHR  WID-EC test  wigresectie  wild-type advanced NSCLC  wildfire exposure while recovering from lung cancer surgery  Wilms tumor  Wilms tumor survivors  Wilms' tumor  Wilms’ tumor  WINDOW-1 trial  withdrawal of antiepileptics  WJOG5810G  WM  women with BRCA1 2 PVs  women with family history of breast cancer  women's health initiative  Women's Health Initiative-Observational Study  Women’s Health Initiative  Women’s Health Initiative Observational Study  Women’s Health Initiative randomized trials  worldwide trends in survival of young leukemia patients  WP-RT versus BO-RT  WPRT  WSG-ADAPT studie  WSG-ADAPT-HR+ HER2- trial  WSG-KEYRICHED-1 trial  WSG-TP-II trial  WT  WTB-HRM  WTC rescue and recovery workers  WTC-responders  WU-KONG6 trial  WW  XELAVIRI study  XELOX FOLFOX vs LV 5-FU  xerostomia  xevinapant  XRT plus ADT  Y90 plus durvalumab  Y90-radioembolization followed by nivolumab  YACPRIME study  YAP  YKL-40  YL201  YM155  yoga  yogurt consumption  young adult ALL patients  young adult body mass index  young adult survivors of pediatric cancer  young BRCA carriers  young breast cancer survivors  young children with relapsed medulloblastoma after initial CSI-sparing approaches  young Norwegian breast cancer patients  Young Women’s Breast Cancer Study  Young Women’s Health History Study  young-adult childhood cancer survivors  young-onset cholangiocarcinoma  young-onset digestive tract cancers  young-onset esophageal adenocarcinoma  young-onset mCRC  Young-PEARL randomized phase 2 trial  younger versus older adults  yttrium-90 conjugated mAb for solid tumors  YY-20394  zandelisib plus zanubrutinib  zanidatamab  zanidatamab-palbociclib-fulvestrant  zanubrutinib  zanubrutinib plus R-CHOP  zanubrutinib versus ibrutinib  ZAP-studie  zegelringcelcarcinoom  zelf-gerapporteerde vermoeidheid  zelf-onderzoek huid  zelf-test  ZENITH20 study cohort 2  ZENITH20-4  zenocutuzumab  ZETA trial  ziekenhuisvolume  Ziekte van Castleman  Ziektevrije-overlevingsanalyse van ABCSG-18 studie  ziftomenib  zilovertamab plus paclitaxel  zilovertamab vedotin  zinc-α2-glycoprotein  zipalertinib  zittende leefstijl  ziv-aflibercept  zolbetuximab  zoldonrasib  zoledronic acid for bone metastases  zoledroninezuur  zongertinib  zonlicht  ZUMA-1 studie  ZUMA-1 trial  ZUMA-12 trial  ZUMA-5 study  ZUMA-5 trial  ZUMA-7 trial  ZUMA-studie  ZW25  zwangerschap  zwangerschaps-geassocieerd mammacarcinoom  zwangerschapsuitkomsten  α-FAtE  γ-glutamyltransferase